


STAY  
UP TO DATE!

 [facebook.com/IASLC](https://www.facebook.com/IASLC)

 @IASLC

 IASLC

 IASLC

 [iaslungcancer](https://www.instagram.com/iaslungcancer)

 IASLC

IASLC



2023 World Conference  
on Lung Cancer

SEPTEMBER 9-12, 2023 | SINGAPORE

WCLC 2023

PROGRAM BOOK

[wclc2023.iaslc.org](https://wclc2023.iaslc.org) | #WCLC23

When EGFR-TKI resistance leads to progression in EGFRm mNSCLC<sup>1,a</sup>



FOLLOW A  
NEW LINE OF  
THINKING

 New strategies are currently under investigation

SEE THE LATEST THINKING AT **BOOTH B105**

DAIICHI SANKYO IS COMMITTED TO FINDING AN INNOVATIVE LINE OF THINKING TO ADDRESS PROGRESSION

<sup>a</sup>EGFR mutations include exon 19 del or exon 21 L858R.<sup>2</sup>

EGFRm, epidermal growth factor receptor mutant; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; exon 19 del, exon 19 deletions; exon 21 L858R, exon 21 leucine at amino acid 858; mNSCLC, metastatic non-small cell lung cancer.

**References:** 1. Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. *Nat Cancer*. 2021;2(4):377-391. 2. Jänne PA, Baik C, Su W-C, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. *Cancer Discov*. 2022;12(1):74-89.

# TABLE OF CONTENTS

IASLC 2023 World Conference on Lung Cancer

<b>01 Overview</b>	<b>07</b>
Welcome Messages	08
Important Information	10
IASLC Staff & WCLC Committees	15
IASLC & Conference Awards	26
Program at a Glance	35
<b>02 Scientific Program - Saturday, September 9</b>	<b>42</b>
<b>03 Scientific Program - Sunday, September 10</b>	<b>52</b>
<b>04 Scientific Program - Monday, September 11</b>	<b>76</b>
<b>05 Scientific Program - Tuesday, September 12</b>	<b>100</b>
<b>06 Posters</b>	<b>120</b>
Posters – Sunday, September 10	120
Posters – Monday, September 11	136
ePosters	156
<b>07 General Information</b>	<b>205</b>
Exhibit and Supporter Information	208
CME Satellite and Industry Sponsored Symposia	222
Conference Information	238
Venue Floor Plans	242

## CONFERENCE SECRETARIAT

International Conference Services Ltd. (ICS)  
Suite 710, 1201 West Pender Street,  
Vancouver, BC, Canada, V6E 2V2

Phone: +1 604 681 2153  
[www.icsevents.com](http://www.icsevents.com)



## GLOBAL OFFICES

Vancouver, Toronto, Vienna,  
London, Texas, Tokyo, Singapore

# IASLC 2023-2024

## MEETINGS SCHEDULE

**IASLC 2023 Hot Topic in  
Translational Science:  
Resistance to IO in NSCLC**  
November 10-12, 2023  
Brussels, Belgium | #IO23

**IASLC 2023 North America  
Conference on Lung Cancer**  
December 1-3, 2023  
Chicago, IL | #NACL23

**2024 Targeted Therapies  
of Lung Cancer**  
February 21-24, 2024  
Santa Monica, CA | #TTLC24

**IASLC 2024 World  
Conference on Lung Cancer**  
September 7-10, 2024  
San Diego, CA | #WCLC24

**2024 Latin America  
Conference on Lung Cancer**  
November 14-16, 2024  
Bogotá, Colombia | #LALCA24



\* Location and dates subject to change

CONNECT  
WITH US

@IASLC

facebook.com/IASLC

@iaslungcancer

linkedin.com/IASLC

IASLC

IASLC

## A Bold Frontier Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With **TROP2-Targeting ADCs** and Rational Combinations

**Saturday, September 9, 2023**

**11:45-12:00:** Check-In & Lunch  
**12:00-13:00:** In-Person & Virtual Symposium

Suntec Singapore Convention & Exhibition Centre  
Room 405A, Level Four



**CHAIR & PRESENTER**

**Stephen V. Liu, MD**  
Lombardi Comprehensive  
Cancer Center  
Georgetown University  
Washington, District of Columbia

Stephen V. Liu, MD, will be joined by other expert faculty members as presenters for this educational activity.

[PeerView.com/23TROP2-Live](https://www.peerview.com/23TROP2-Live)

This program was approved by the IASLC 2023 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2023 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program. This CME activity is provided by PVL, PeerView Institute for Medical Education. This program has been supported by an independent educational grant from Gilead Sciences, Inc.

PeerView  
Live

## Taking Aim With the Next Wave of **Antibody-Drug Conjugates in NSCLC**

*Rational Strategies for Addressing the Unmet Needs of Diverse Patient Populations  
With TROP2- and HER3-Targeting Therapies and Other ADC-Based Regimens*

**Tuesday, September 12, 2023**

**13:00-13:15:** Check-In & Lunch  
**13:15-14:15:** In-Person & Virtual Symposium

Suntec Singapore Convention & Exhibition Centre  
Room 406, Level Four



**CHAIR & PRESENTER**

**Melissa L. Johnson, MD**  
Sarah Cannon Research Institute  
Nashville, Tennessee



**PRESENTER**

**Enriqueta Felip, MD, PhD**  
Vall d'Hebron University Hospital  
Vall d'Hebron Institute of Oncology (VHIO)  
Universitat de Vic - Universitat Central de Catalunya  
Barcelona, Spain



**PRESENTER**

**Prof. Hidetoshi Hayashi, MD, PhD**  
Kindai University Faculty of Medicine  
Osakasayama City, Osaka, Japan

[PeerView.com/23ADC-Live](https://www.peerview.com/23ADC-Live)

This program was approved by the IASLC 2023 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2023 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program. This CME activity is provided by PVL, PeerView Institute for Medical Education. This activity is supported by an educational grant from Daiichi Sankyo, Inc.


PeerView  
Live

# DID YOU KNOW...

The **Early Lung Imaging Confederation** is an international alliance developing a globally distributed, privacy-secured, lung cancer imaging database and computational analysis environment.

**Detect lung cancer and discriminate benign and malignant nodules using:**

- › Deep learning methods
- › Artificial intelligence approaches



1

**CONFERENCE**  
OVERVIEW

**01 CONFERENCE OVERVIEW****Welcome Message from the WCLC 2023 Conference Chairs**

Dear Colleagues from around the World,

On behalf of the International Association for the Study of Lung Cancer (IASLC) it is our great pleasure to welcome you to the IASLC 2023 World Conference on Lung Cancer (#WCLC23) in Singapore.

From September 9 to 12, WCLC 2023 will offer four days of ground-breaking scientific activity bringing together more than 6,000 delegates globally from all fields in basic and clinical sciences related to thoracic malignancies. We are proud to have received more than 1,800 abstracts which will be presented in oral, mini-oral, and poster sessions. More than 350 invited lectures, 150 oral and mini-oral presentations as well as over 1,500 posters and ePosters will contribute to the exchange of new information among delegates.

To facilitate discussions and networking opportunities, we offer a virtual platform available on desktop and mobile devices that will allow delegates to ask questions and chat with other participants during the sessions.

We encourage you to participate actively in the discussions but also take some time to enjoy the beauty of Singapore. It is a melting pot of ethnicities, culture and cuisine. A cosmopolitan country that is rapidly evolving and constantly reinventing itself. A gateway to Asia with its share of attractions that must not be missed.

We also would like to extend our gratitude and thanks to all sponsors and exhibitors for their continued support to WCLC and IASLC. Without them, this Conference would not be possible.

Thank you for joining us in Singapore or also online. We wish all delegates an enjoyable and productive Conference.

Yours sincerely,



**Fiona Hegi-Johnson,  
MD**

Conference Co-Chair



**Pyng Lee,  
Professor**

Conference Co-Chair



**Chee Lee,  
MD**

Conference Co-Chair

**01 CONFERENCE OVERVIEW****Welcome Message from the IASLC President and CEO**

Dear WCLC Participants,

As the President and the CEO of the IASLC, we are thrilled to welcome you to the IASLC 2023 World Conference on Lung Cancer (#WCLC23) in beautiful Singapore. We are honored that you have chosen to join us for what is sure to be a rigorous, fascinating, and collaborative meeting.

This year marks the 24th WCLC, serving as a unique moment to pause and reflect on how this meeting and the thoracic oncology field have evolved over the past four decades. During that time, we've seen extraordinary progress in the field of lung cancer diagnosis and treatment, with the discovery of new biomarkers, new screening techniques, and the rise of precision medicine leading to improvements in overall mortality and quality of life for patients.

Throughout its long history, the WCLC has played a strong role in facilitating that progress – providing a platform for sharing cutting-edge research, creating space for new collaborations and partnerships, connecting established researchers with young investigators, and serving as a foundational meeting for healthcare professionals (representing the full spectrum of the multidisciplinary team), patients and advocates who have dedicated their lives to conquering these challenging diseases. This enduring importance is illustrated in how the WCLC has evolved over time – growing from a gathering of approximately 100 colleagues in the late-1970s to an expansive conference that regularly attracts over 7,500 international participants. Such growth in size, impact, and relevance did not happen by accident. We are grateful to our previous WCLC conference presidents, organizers, and participants. Additionally, we want to honor our past and current board members, as well as former CEOs Heine H. Hansen, Paul A. Bunn Jr. and Fred R. Hirsch for their leadership of the IASLC – from its formative years to the present day.

But while the story of the WCLC is well-established, we know that we must always be looking to the future if we are to continue making inroads in the treatment of thoracic cancers. That is why for WCLC 2023, we are proud to announce that the conference organizers have put together an incredible scientific program. We want to thank them for their hard work and we are especially grateful for the dedication and leadership of our Conference Chairs: Drs. Fiona Hegi-Johnson, Chee Lee, and Pyng Lee. We have no doubt that you will find WCLC 2023 to be an exceptional educational experience.

Thank you for attending WCLC 2023, and thank you for your engagement with the IASLC. We hope you enjoy the meeting; have the opportunity to explore Singapore; find opportunities to develop new relationships and collaborations; and, finally gain novel skills and insights that can be applied to improving the lives of thoracic cancer patients – both in your local communities and worldwide. Like so much of what the IASLC does, the success of the WCLC hinges on the passion, commitment, and engagement of those who attend it. In short, your participation is one of the main reasons for why the event has remained the world's leading thoracic cancer conference for almost 50 years. We appreciate you being a part of our ongoing story.



**Heather Wakelee, MD**

President  
International Association for the  
Study of Lung Cancer (IASLC)



**Karen Kelly, MD**

Chief Executive Officer  
International Association for the  
Study of Lung Cancer (IASLC)

**01 CONFERENCE OVERVIEW**

Important Information

**WIFI DETAILS**

Please join the network below to access free wifi for the duration of the Conference. No password required.

**WCLC23\_FREE\_WiFi@SuntecSingapore**

**DISCLAIMER**

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources.

Although every effort has been made to ensure the accuracy, currency, and reliability of the content, the organizers accept no responsibility in that regard.

**FOLLOW IASLC ON SOCIAL MEDIA**

 facebook.com/IASLC

 @IASLC

 IASLC

 IASLC

 iaslungcancer

 IASLC

**IASLC WCLC 2023 VIRTUAL PLATFORM**

All sessions will be audio recorded and made available on the Virtual Platform within 24 hours. The Virtual Platform also includes presentation slides, abstracts and posters.

Log-in details were sent to your registered email. If you need assistance, visit the Virtual Platform Help Desk located at Level 3 Concourse or send an email to [wclc2023-registration@icsevents.com](mailto:wclc2023-registration@icsevents.com).

**WCLC 2023 VIRTUAL PLATFORM:**  
[MEETINGSAPP.IASLC.ORG/EVENT/WCLC2023](https://meetingsapp.iaslc.org/event/wclc2023)

**VIRTUAL PLATFORM FEATURES:**

- Full Scientific Schedule
- Abstract Book, Program Book
- Venue and Exhibit Floor Plan
- Presentation Slides and Recordings (Within 24 Hours)
- ePosters (Online View During the Conference) and Downloadable PDFs for all Traditional Posters and ePosters after the Conference
- Opportunity to Create Personalized Calendar
- Networking Features to Connect with Delegates and Faculty
- Notification Alerts



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

**The Race is On!  
Vote Now!**



# A M A Z I N G C A S E R A C E

The 2023 IASLC Academy class is going to be part of the 1st Amazing Case Race! Every member of the 2023 Academy has produced one case summary based on real-life patients and using the testing and treatment options available in their countries and using protocols for their institutions. As a WCLC attendee, you will vote on your favorite case summaries.

At the end of the meeting, the top 5 cases will be included in the IASLC 1st case-based simulation course. So, don't forget to vote for your favorites and take the course to see who won the Amazing Case Race!





**2023 World Conference  
on Lung Cancer**

**SEPTEMBER 9-12, 2023 | SINGAPORE**

**Attend the special plenary session  
TNM for Lung, Mesothelioma and Thymic Cancers –  
Update on the Proposals for the  
9th Edition of TNM Staging to preview  
the new 9th edition recommendations.**

**Monday, September 11, 17:00 Singapore Time**

**Help change the landscape  
of lung cancer treatment  
for future patients!**

- New clinical and molecular elements have been added
- International participation is crucial to the project's success
- 10th edition lung cancer staging project launching in 2024



**Scan the QR code  
for more information**



# STRONGER TOGETHER

Research and patient advocates are an integral part of the IASLC. Their contributions reflect the reality of what research is aiming for — **HOPE.**

**Please visit the Patient Advocacy Lounge  
to find resources and to network.**

**01 CONFERENCE OVERVIEW**




IASLC and WCLC Committees

**International Association for the Study of Lung Cancer (IASLC)**

The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association's membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines and more than 100 countries.

By hosting global conferences, funding cutting-edge research, and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families, and communities.

**The IASLC mission is:**

-  To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies
-  To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public
-  To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world



999 17th Street, Suite 200 - Denver, Colorado 80202-2725

**Phone:** 1-855-GO-IASLC (1-855-464-2752)**IASLC BOARD OF DIRECTORS  
2021 – 2023****President:** Heather Wakelee, USA**Past President:** Tetsuya Mitsudomi, Japan**President-Elect:** Paul Van Schil, Belgium**Secretary:** Andrea Bezjak, Canada**Treasurer:** Erik Thunnissen, Netherlands**Chief Executive Officer:** Karen Kelly, USA**BOARD MEMBERS**

Joachim Aerts, Netherlands

Carlos Gil Moreira Ferreira, Brazil

Jhanelle Gray, USA

Roy Herbst, USA

Young Tae Kim, Republic of Korea

Morten Quist, Denmark

Lecia Sequist, USA

Ming-Sound Tsao, Canada

Paula Ugalde, USA

Caicun Zhou, China

**01 CONFERENCE OVERVIEW**

IASLC and WCLC Committees

**IASLC Staff****Karen Kelly**  
Chief Executive Officer**J. Michael Hoehn**  
Chief Operating Officer**John Skadow**  
Chief Financial Officer**Matt Yeingst**  
Chief Development Officer**Tessa Baxter**  
Development Program Manager**Becky Bunn**  
Director Strategic Initiatives**Mya Burns**  
Associate Director, Conferences**Casey Connolly**  
Project Manager**Bailey Creamer**  
Editorial Assistant**Kathy Doherty**  
Director, Human Resources**Cherie Dusek**  
Executive Assistant**Wanda Folsom**  
Education Manager**Rory Graham**  
Web Content Administrator**Ken Harrell**  
Database Administrator**Kelsey Hecker**  
Conference Coordinator**Kelly Heemsbergen**  
Conference Manager**O'Ryan Jackson**  
Development Specialist**Sara Lindsey Patton**  
Patient Advocacy Specialist**Katie Maher**  
Member Experience Specialist**Sunhee Malinowski**  
Controller**Jan Mazotti**  
Associate Director, Marketing and Communications**Kahri Nestingen**  
Sponsorship and Exhibits Coordinator**Kelly Nevins**  
Associate Director, Education**Rodrigo Sagastegui**  
Marketing Specialist**Savannah Spakes**  
Membership Coordinator**Alexander Watson**  
Business Services Lead**Kelsey Wood**  
Associate Director, Member Experience**Laura Woodruff**  
Education Specialist**Murry Wynes**  
Senior Advisor, Scientific Affairs**Kexin Yu**  
Accountant**Flavia Zarcula**  
Development Manager

Accelerating the pace of thoracic malignancy research and funding the next generation of lung cancer luminaries. The IASLC Foundation, LLC (IASLC Foundation) inspires hope through research.

For more information visit: <https://www.iaslc.org/foundation>



**01 CONFERENCE OVERVIEW**

IASLC and WCLC Committees

**Program Committee****Risk Factors, Risk Reduction & Tobacco Control**

Carolyn Dresler, Chair, USA  
 Emily Stone, Co-Chair, Australia  
 Csaba Degi, Romania  
 Joelle Fathi, USA  
 Jacek Jassem, Poland  
 Manfred Neuberger, Austria  
 Jamie Ostroff, USA  
 Pan-Chyr Yang, Taiwan

**Tumor Biology - Preclinical Biology**

Anne-Marie Baird, Chair, Ireland  
 Trevor Bivona, Co-Chair, USA  
 Alfredo Addeo, Switzerland  
 Marie-Liesse Asselin Labat, Australia  
 Alice Berger, USA  
 Magnus Dillon, UK  
 Katerina Politi, USA  
 Karin Schelch, Austria

**Tumor Biology - Translational Biology**

Daniel Tan, Chair, Singapore  
 Pasi A. Jänne, Co-Chair, USA  
 Esra Akbay, USA  
 Nicolaus Andratschke, Switzerland  
 Christine Lovly, USA  
 Ken O'Byrne, Australia  
 Jonathan Ostrem, USA  
 Robert Rintoul, UK  
 Kate Sutherland, Australia

**Screening & Early Detection**

Monica Castro, Chair, Argentina  
 Gerard Silvestri, Co-Chair, USA  
 Christine Berg, USA  
 Terri Byrne, Australia  
 Debra Dyer, USA  
 Wentao Fang, China  
 Anna Kerpel-Fronius, Hungary  
 Annette McWilliams, Australia

**Pulmonology & Staging**

Anne Hsu, Chair, Singapore  
 Douglas Arenberg, Co-Chair, USA  
 John Edwards, UK  
 David Fellerkopman, USA  
 Carla Lamb, USA  
 Edith Marom, Israel  
 Takahiro Nakajima, Japan  
 Daniel Serman, USA

**Pathology & Biomarkers**

Wendy Cooper, Chair, Australia  
 Keith Kerr, Co-Chair, UK  
 Sabina Berowzowska, Switzerland  
 Teh-Ying Chou, Taiwan  
 Anjali Saqi, USA  
 Lynette Sholl, USA  
 Jan Von Der Thusen, Netherlands  
 Yasushi Yatabe, Japan

**01 CONFERENCE OVERVIEW**

IASLC and WCLC Committees

**Early-Stage Non-small Cell Lung Cancer**

Kristin Higgins, Chair, USA  
 Jazmin Eckhaus, Co-Chair, Australia  
 Delphine Antoni, France  
 Jamie Chaft, USA  
 Aneez Ahmed Dokeu, Singapore  
 Mariano Provencio, Spain  
 Brendon Stiles, USA  
 Ricardo Terra, Brazil

**Local-Regional Non-small Cell Lung Cancer**

Jarushka Naidoo, Chair, Ireland  
 Michael MacManus, Co-Chair, Australia  
 Christine Bestvina, USA  
 Seamus Cotter, Ireland  
 Yeur-Hur Lai, Taiwan  
 Alan Sihoe, Hong Kong  
 Akif Turna, Turkey  
 Sue Yom, USA

**Metastatic Non-small Cell Lung Cancer - Local Therapies**

Yu Yang Soon, Chair, Singapore  
 Elizabeth David, Co-Chair, USA  
 Raid Aljumally, USA  
 Mara Antonoff, USA  
 Sze Wai Chan, South Africa  
 Cassandra Dickens, Australia  
 Francoise Mornex, France  
 Carol Ridge, UK  
 Anil Tibdewal, India

**Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy**

Nick Pavlakis, Chair, Australia  
 Kirsty Lee, Co-Chair, Hong Kong  
 Michael Boyer, Australia  
 Lisa Briggs, Australia  
 Gerard Hanna, Ireland  
 Melissa Johnson, USA  
 Natasha Leighl, Canada  
 Herbert Loong, Hong Kong  
 Egbert Smit, Netherlands

**Metastatic Non-small Cell Lung Cancer - Immunotherapy**

Tom John, Chair, Australia  
 Ross Soo, Co-Chair, Singapore  
 Clarissa Baldotto, Brazil  
 Puey Ling Chia, Singapore  
 Mary Duffy, Australia  
 Marina Garassino, USA  
 Pilar Garrido, Spain  
 Luciana Holtz, Brazil  
 Alexander Louie, Canada  
 Sanjay Popat, UK

**01 CONFERENCE OVERVIEW**

## IASLC and WCLC Committees

**Metastatic Non-small Cell Lung Cancer - Targeted Therapy**

Benjamin Solomon, Chair, Australia  
 Helena Yu, Co-Chair, USA  
 Paula De Vega, Australia  
 Ivy Elkins, USA  
 Bob Li, USA  
 Fiona McDonald, UK  
 Antony Mersiades, Australia  
 David Planchard, France  
 Qing Zhou, China

**Small Cell Lung Cancer & Neuroendocrine Tumors**

Stephen Liu, Chair, USA  
 Aaron Tan, Co-Chair, Singapore  
 Upal Basu Roy, USA  
 Corinne Favire-Finn, UK  
 Lynnette Fernandez-Cuestra, France  
 Julie George, Germany  
 Miyako Satouchi, Japan  
 Misty Shields, USA  
 Sumitra Thongprasert, Thailand

**Mesothelioma, Thymoma & Other Thoracic Tumors**

Stephen Kao, Chair, Australia  
 Yasushi Goto, Co-Chair, Japan  
 Yuki Katsuya, Japan  
 Sonja Klebe, Australia  
 Aaron Mansfield, USA  
 Isabelle Opitz, Switzerland  
 Andreas Rimner, USA  
 Rachel Thomas, UK

**Multidisciplinary Care: Nursing, Allied Health & Palliative Care**

Michael Franco, Chair, Australia  
 Anne Fraser, Co-Chair, New Zealand  
 Elizabeth Ivimey, Co-Chair, Australia  
 Andreas Charalambous, Cyprus  
 Polly Dufton, Australia  
 Simon Dunne, Ireland  
 Maria Ftanou, Australia  
 Laura Petrillo, USA  
 Ewelina Szmytko, Germany  
 Felicia Zhang, Canada

**Patient Advocacy**

Lillian Leigh, Chair, Australia  
 Jill Feldman, Co-Chair, USA  
 Andrew Ciupek, USA  
 Dusty Donaldson, USA  
 Caleb Egwuenu, Nigeria  
 Angeline Low, Australia  
 Stefania Vallone, Spain

**Global Health, Health Services & Health Economics**

Yiqing Huang, Chair, Singapore  
 Shalini Vinod, Co-Chair, Australia  
 Pedro Aguiar, Brazil  
 Paolo Boffetta, USA  
 Anne Fraser, New Zealand  
 Wee Yao Koh, Singapore  
 Gilberto Lopes, USA  
 Melody Qu, Canada

**01 CONFERENCE OVERVIEW**

## IASLC and WCLC Committees

**International Abstract Review Committee**

Prasad Adusumilli, USA  
 Joachim Aerts, Netherlands  
 Pedro Aguiar Jr, Brazil  
 Hiroaki Akamatsu, Japan  
 Esra Akbay, USA  
 Mihaela Aldea, France  
 Raid Aljumaily, USA  
 Ihsan Alloubi, Morocco  
 Mehmet Altan, USA  
 Chiara Ambrogio, Italy  
 Sita Andarini, Indonesia  
 Nicolaus Andratschke, Switzerland  
 Delphine Antoni, France  
 António Araújo, Portugal  
 Douglas Arenberg, USA  
 Marie-Liesse Asselin-Labat, Australia  
 Paul Baas, Netherlands  
 Leah Backhus, USA  
 Shahed Badiyan, USA  
 Anne-Marie Baird, Ireland  
 Haval Balata, UK  
 Clarissa Baldotto, Brazil  
 Andrew Bang, Canada  
 Upal Basu Roy, USA  
 Lyudmila Bazhenova, USA  
 Mary Beth Beasley, USA  
 Deepti Behl, USA  
 Sabina Berezowska, Switzerland  
 Christine Berg, USA  
 Eric Bernicker, USA  
 Christine Bestvina, USA  
 Paolo Boffetta, USA  
 Alain Charles Borczuk, USA  
 Hossein Borghaei, USA  
 Andrea K. Borondy-Kitts, USA  
 Michael Boyer, Australia  
 Luka Brcic, Austria  
 Caitlin Broderick, Australia  
 Odd Terje Brustugun, Norway  
 Lukas Bubendorf, Switzerland  
 Jennifer Carlisle, USA

Tina Cascone, USA  
 Mónica Castro, Argentina  
 Milena Cavic, Serbia  
 Jamie Chافت, USA  
 Sze Wai Chan, South Africa  
 Andreas Charalambous, Cyprus  
 Puey Ling Chia, Singapore  
 Teh-Ying Chou, Taiwan  
 Kevin Chua, Singapore  
 Stephen Chun, USA  
 Jin-Haeng Chung, Republic of Korea  
 Andrew Ciupek, USA  
 Wendy Cooper, Australia  
 Jose Corona-Cruz, Mexico  
 Seamus Cotter, Ireland  
 Melissa Culligan, USA  
 Sanja Dacic, USA  
 Roselle De Guzman, Philippines  
 Marc De Perrot, Canada  
 Paula De Vega, Australia  
 Aakash Desai, USA  
 Cassandra Dickens, Australia  
 Magnus Dillon, UK  
 Dusty Donaldson, USA  
 Carolyn Dresler, USA  
 Elizabeth Dudnik, Israel  
 Mary Duffy, Australia  
 Debra Dyer, USA  
 Jazmin Eckhaus, Australia  
 Martin Edelman, USA  
 John Edwards, UK  
 Caleb Egwuenu, Nigeria  
 Ivy Elkins, USA  
 Lawson Eng, Canada  
 Vinicius Ernani, USA  
 Bill Evans, Canada  
 Corinne Faivre-Finn, UK  
 Wentao Fang, China  
 Nick Faris, USA  
 Babalola Faseru, USA  
 Joelle Fathi, USA

**01 CONFERENCE OVERVIEW**

## IASLC and WCLC Committees

Jill Feldman, USA  
 Emanuela Felley-Bosco, Switzerland  
 Lynnette Fernandez-Cuesta, France  
 Carlos Gil Ferreira, Brazil  
 Mary Jo Fidler, USA  
 John Field, UK  
 Narjust Florez (Duma), USA  
 Kwun Fong, Australia  
 Anne Fraser, New Zealand  
 Jacqui Frowen, Australia  
 Maria Ftanou, Australia  
 Shirish Gadgeel, USA  
 Justin Gainor, USA  
 Francoise Galateau-Salle, France  
 Apar Kishor Ganti, USA  
 Pilar Garrido, Spain  
 Ioannis Gkiozos, Greece  
 Sarah Goldberg, USA  
 Maciej Goniewicz, USA  
 Yasushi Goto, Japan  
 Balazs Halmos, USA  
 Yuchen Han, China  
 Gerard Hanna, UK  
 Desiree Hao, Canada  
 Ken Harada, Japan  
 Matthew Hatton, USA  
 Hidetoshi Hayashi, Japan  
 Fiona Hegi-Johnson, Australia  
 Rebecca Heist, USA  
 Kristin Higgins, USA  
 Fred R. Hirsch, USA  
 Paul Hofman, France  
 Luciana Holtz, Brazil  
 Hidehito Horinouchi, Japan  
 Stefanie Houseknecht, USA  
 Anne Hsu, Singapore  
 Yiqing Huang, Singapore  
 Rudolf Huber, Germany  
 David Hwang, Canada  
 Deepali Jain, India  
 Seung Hun Jang, Republic of Korea  
 Jacek Jassem, Poland  
 James R. Jett, USA

Long Jiang, China  
 Sabita Jiwnani, India  
 Tom John, Australia  
 Melissa Johnson, USA  
 Philippe Joubert, Canada  
 Govind Babu Kanakasetty, India  
 Steven Kao, Australia  
 Yuki Katsuya, Japan  
 Ayten Kayi Cangir, Turkey  
 Karen Kelly, USA  
 Hirotsugu Kenmotsu, Japan  
 Anna Kerpel-Fronius, Hungary  
 Jamal Khader, Jordan  
 Chul Kim, USA  
 Hyojin Kim, Republic of Korea  
 Yeol Kim, Republic of Korea  
 Young Tae Kim, Republic of Korea  
 Nicole Kiss, Australia  
 Wee-Yao Koh, Singapore  
 Feng-Ming Kong, Hong Kong  
 Robert Kratzke, USA  
 Amit Kulkarni, USA  
 Yeur-Hur Lai, Taiwan  
 Stephen Lam, Canada  
 Sylvie Lantuejoul, France  
 John Le Quesne, UK  
 Chee Lee, Australia  
 Kirsty Lee, Hong Kong  
 Pyng Lee, Singapore  
 Lillian Leigh, Australia  
 Natasha Leighl, Canada  
 Whitney Lewis, USA  
 Bob Li, USA  
 Zhongxing Liao, USA  
 Stephen Liu, USA  
 Herbert Ho-fung Loong, Hong Kong  
 Gilberto Lopes, USA  
 Fernando Lopez-Rios, Spain  
 Alexander Louie, Canada  
 Christine Lovly, USA  
 Michael MacManus, Australia  
 Rami Manochakian, USA  
 Aaron Mansfield, USA

**01 CONFERENCE OVERVIEW**

## IASLC and WCLC Committees

Edith Marom, Israel  
 Thomas Marron, USA  
 Clarissa Mathias, Brazil  
 Annette McWilliams, Australia  
 Antony Mersiades, Australia  
 Andrzej Milewski, Poland  
 Yuko Minami, Japan  
 Mari Mino-Kenudson, USA  
 Deebya Raj Mishra, Nepal  
 Tetsuya Mitsudomi, Japan  
 Satoru Miura, Japan  
 James Mulshine, USA  
 Sudish Murthy, USA  
 Misako Nagasaka, USA  
 Yasushi Nagata, Japan  
 Jarushka Naidoo, Ireland  
 Takahiro Nakajima, Japan  
 Joel Neal, USA  
 Manfred Neuberger, Austria  
 Calvin SH Ng, Hong Kong  
 Andrew Nicholson, UK  
 Kim Norris, USA  
 Anna Katherine Nowak, Australia  
 Kenneth O'Byrne, Australia  
 Emma O'Dowd, UK  
 Isabelle Opitz, Switzerland  
 Raymond Osarogiagbon, USA  
 Dwight Owen, USA  
 Mauro Papotti, Italy  
 Seong Yong Park, Republic of Korea  
 Jyoti Patel, USA  
 Manish Patel, USA  
 Sandip Patel, USA  
 Nick Pavlakis, Australia  
 Tobias Peikert, USA  
 Nir Peled, Israel  
 Laura Petrilo, USA  
 Zofia Piotrowska, USA  
 David Planchard, France  
 Claudia Poleri, Argentina  
 Katerina Politi, USA  
 Sanjay Papat, UK  
 Mariano Provencio, Spain

Daniel Przybysz, USA  
 Paul Martin Putora, Switzerland  
 Melody Qu, Canada  
 Morten Quist, Denmark  
 Ahmed M. Rabea, Egypt  
 Luis Raez, MD, FACP, USA  
 Karen Reckamp, USA  
 Noemí Reguart, Spain  
 Natasha Rekhman, USA  
 Joshua Reuss, USA  
 Carole Ridge, UK  
 Maureen Rigney, USA  
 Andreas Rimner, USA  
 Robert Rintoul, UK  
 Anja Roden, USA  
 Christian Rolfo, USA  
 John Ruckdeschel, USA  
 Witold Rzyman, Poland  
 Ricardo Sales Santos, Brazil  
 Rachel Sanborn, USA  
 Jacob Sands, USA  
 Beth Sandy, USA  
 Edgardo Santos, USA  
 Anjali Saqi, USA  
 Takaaki Sasaki, Japan  
 Miyako Satouchi, Japan  
 Charles Sauer, Austria  
 Toshiyuki Sawa, Japan  
 Marco Scarci, UK  
 Karin Schelch, Austria  
 Yoshitaka Sekido, Japan  
 Lecia Sequist, USA  
 Abhishek Shankar, India  
 Misty Shields, USA  
 Shani Shilo, Israel  
 Hyo Sup Shim, Republic of Korea  
 Lynette Sholl, USA  
 Elaine Shum, USA  
 Alan Sihoe, China  
 Gerard Silvestri, USA  
 Navneet Singh, India  
 Christina Sit, Canada  
 Shankar Siva, Australia

## 01 CONFERENCE OVERVIEW

### IASLC and WCLC Committees

Matthew Smeltzer, USA  
Egbert Smit, Netherlands  
Junichi Soh, Japan  
Benjamin Solomon, Australia  
Ross Soo, Singapore  
Yu Yang Soon, Singapore  
Matthew Steliga, USA  
Brendon Stiles, USA  
Emily Stone, Australia  
Francisco Suarez, Chile  
Kenichi Suda, Japan  
Jennifer Suga, USA  
Kate Sutherland, Australia  
Aaron Tan, Singapore  
Erik Thunnissen, Netherlands  
Anil Tibdewal, India  
Betty Tong, USA  
William Travis, USA  
Ming Tsao, Canada  
Yasuhiro Tsutani, Japan  
Akif Turna, Turkey  
Michelle Turner, USA  
Paula Ugalde Figueroa, USA  
Dipesh Uprety, USA  
Stefania Vallone, Italy

Vamsidhar Velcheti, USA  
Luigi Ventura, UK  
Shalini Vinod, Australia  
Lucia Viola, Colombia  
Jan von der Thüsen, Netherlands  
Heather Wakelee, USA  
Stefan Watzka, Austria  
Meng Welliver, USA  
Paul Wheatley-Price, Canada  
Ignacio Wistuba, USA  
Sharlene Wong, Singapore  
Antoinette Wozniak, USA  
Chi-Fu Jeffrey Yang, USA  
Dawei Yang, China  
Pan-Chyr Yang, Taiwan  
David Yankelevitz, USA  
Yasushi Yatabe, Japan  
Sue Yom, USA  
Helena Yu, USA  
Alona Zer, Israel  
Felicia Zhang, Canada  
Caicun Zhou, China  
Qing Zhou, China  
Javier J. Zulueta, USA

**Walk, Run, Rest, Repeat!**

**Eat, Sleep, Stretch, Repeat!**

**Step, Scan, Play, Compete!**

**Join #WCLC23Well and move your feet!**



# STEP IT UP FOR RESEARCH

IASLC WELLNESS CHALLENGE 2023 • *Singapore*



Register for the  
IASLC 2023 Wellness  
Challenge and support  
lung cancer research.

Sponsored by  
**REGENERON®**



# 2024 Targeted Therapies of Lung Cancer Meeting

FEBRUARY 21-24, 2024  SANTA MONICA, CALIFORNIA



# SAVE THE DATE

## #TTLC24



## Visit the IASLC Membership Booth and Join Today!

**WCLC SPECIAL OFFER**  
New Members  
Join During WCLC  
for a Special Rate!

Scan the QR code & enter  
WCLCNewMember2023



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

Staging		
Patient Advocacy		
Publications		
Podcasts		
Networking		
Scientific Expertise		
ILCN		
IASLC Meeting Discounts		
Grant Opportunities		
Membership		
IASLC Journals		
Committees		

**01 CONFERENCE OVERVIEW**

IASLC and Conference Awards

**IASLC Distinguished Service Awards**

The IASLC Distinguished Service Awards will be presented during the **Opening Plenary Session 1 on Saturday, September 9 (18:15 – 20:00)**.

**Mary J. Matthews Pathology/Translational Research Award****Fernando Lopez-Rios**

Spain

Fernando Lopez-Rios has recently joined the Department of Pathology at “12 de Octubre” University Hospital (Madrid) as the Chief of the Molecular Diagnostics Service. He received his medical degree and PhD from the Faculty of Medicine at Autonoma University and Complutense University respectively and completed his residency in Pathology at “12 de Octubre” University Hospital (Madrid). Dr Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at “HM Hospitales” and a visiting researcher at Memorial Sloan Kettering Cancer Center (New York). His main clinical and research expertise is in cancer biomarker testing, with a special interest in lung cancer and mesothelioma. He is currently a member of the IASLC Pathology Committee.

**01 CONFERENCE OVERVIEW**

IASLC and Conference Awards

**IASLC Distinguished Service Awards**

The IASLC Distinguished Service Awards will be presented during the **Opening Plenary Session 1 on Saturday, September 9 (18:15 – 20:00)**.

**Paul A. Bunn, Jr. Scientific Award****Suresh Ramalingam**

USA

Suresh S. Ramalingam is the Executive Director of the Winship Cancer Institute of Emory University (Atlanta, USA). He serves as Professor and the Roberto C. Goizueta Chair for Cancer Research at the Emory University School of Medicine. Dr. Ramalingam's research is focused on the development of novel treatment approaches for patients with lung cancer. Specifically, his group has developed novel treatment options for lung cancer patients harboring an EGFR mutation, resulting in FDA approval of third generation inhibitors for metastatic NSCLC. He also leads clinical and translational investigations of novel immunotherapy approaches for the treatment of lung cancer. He has published more than 400 peer reviewed publications, with over 36,000 citations and a H-index of 80. His research has been published in leading journals including the NEJM, Lancet, Science, Nature, PNAS, JCI, JCO and JTO. He serves as the principal investigator for the Emory University Lung Cancer SPORE award from the NCI. Dr. Ramalingam serves as Deputy Chair for Therapeutics Programs at ECOG-ACRIN, and is a former chair of the ECOG-ACRIN Thoracic Malignancies Committee. He is the Editor-in-chief for ‘Cancer’ journal (American Cancer Society). Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence at Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award (2013), and the NCI ‘Clinical Investigators Team Leadership Award’ (2010-12). Dr. Ramalingam served as a member of the board of directors for the International Association for the Study of Lung Cancer (IASLC) (2017-21) and as a member of the NCI Thoracic Malignancies Steering Committee (2012-2021). He is past president of the Georgia Society of Oncology and a former member of the Emory Healthcare board of directors.

**01 CONFERENCE OVERVIEW**

IASLC and Conference Awards

**IASLC Distinguished Service Awards**

The IASLC Distinguished Service Awards will be presented during the **Opening Plenary Session 1 on Saturday, September 9 (18:15 – 20:00)**.

**Adi F. Gazdar IASLC Merit Award****Myung-Ju Ahn**

Republic of Korea

Myung-Ju Ahn is Professor of Hemato-Oncology at the Department of Medicine, Sungkyunkwan University School of Medicine, Seoul. She is a member of numerous research associations and societies, including the IASLC, AACR, and ASCO and is currently Chief of the Executive Committee and Chairperson of Lung Cancer Disease Committee of the KCSG. She is the current president of the KSMO and was chairperson of the multidisciplinary Immuno-oncology Study Group (2017–2018). She is a board member for the KCA, KSMO and KALC, and is on the editorial board of Journal of Thoracic Oncology. Prof Ahn received her medical and doctoral degrees from Hanyang University College of Medicine, Seoul and completed her residency training at Hanyang University Hospital. She has held numerous research fellowships, including a postdoctoral research fellowship at the Memorial Sloan-Kettering Cancer Center, New York, and has authored over 250 cancer research publications. Her research interests include the development of predictive and prognostic markers for personalised lung cancer therapy. She has recently focused on early clinical trials for the development of drug discovery and repositioning of targeted drugs and the development of a NSCLC genome atlas. Her accolades for her dedication to cancer research include Best Researcher Award, KMWA (2003); Best Researcher Award, KACO (2015); Boryoung Scientific Award, Korean Cancer Research Foundation (2018), and Highly Cited Researcher, Clavirate analytics (2019); Daniel C. Ihde Lectureship Award for Medical Oncology (IASLC, 2020).

**01 CONFERENCE OVERVIEW**

IASLC and Conference Awards

**IASLC Distinguished Service Awards**

The IASLC Distinguished Service Awards will be presented during the **Opening Plenary Session 1 on Saturday, September 9 (18:15 – 20:00)**.

**Joseph W. Cullen Prevention/Early Detection Award****William Evans**

Canada

William Evans' interest in thoracic oncology developed in his early career (1975-1985) working at the Toronto General Hospital with an impressive group of thoracic surgeons. Dr. Evans participated with them in the adjuvant clinical trials of North American Lung Cancer Study Group, in NIH funded studies of nutritional support in lung cancer and numerous trials of systemic therapy for NSCLC and SCLC. He initiated the first trials of etoposide-cisplatin in SCLC and made the first presentation on this regimen at WCLC. In 1985, he became the Head of Medical Oncology and in 1988, the CEO of the Ottawa Regional Cancer Centre. His administrative role enabled collaboration with Statistics Canada on modelling of lung cancer and determination of costs of care; leading to the concept of diagnostic assessment units for lung and other cancers. Eventually, Dr. Evans implemented lung DAUs for more efficient diagnostic work up across the province of Ontario. In 2010, he promoted the need for smoking cessation in regional cancer centers to improve the clinical outcomes of cancer patients, and he led the Cancer Care Ontario Steering Committee to create and implement a framework for smoking cessation (SC) within the 14 regional cancer centres in Ontario. This led to pan-Canadian efforts through the Canadian Partnership Against Cancer (CPAC) to implement SC in provincial cancer centres. Dr. Evans participated in the launch of the CPAC initiative and spoke at numerous cancer centers across Canada. Over 90% of cancer centres now have SC programs. Additionally, he collaborated with Statistics Canada and CPAC to model lung cancer, including LDCT screening with and without SC, influencing design of the Ontario Screening Pilot. Currently, Dr. Evans is the Clinical Lead for Smoking Cessation at Ontario Health (CCO) and continues to drive change: extension of SC to screening programs, DAUs, inpatient oncology and to enhance data capture on smoking status over patients' clinical journey. Dr. Evans has over 300 peer-reviewed publications, 20 specifically focused on screening and aspects of SC since 2014.

**01 CONFERENCE OVERVIEW**

IASLC and Conference Awards

**IASLC Lectureship Awards**

The IASLC Lectureship Awards will be presented during the **IASLC Lectureship Award Presentations Plenary Session on Sunday, September 10 (08:30 – 10:30)**.

**Clifton F. Mountain Lectureship Award for Staging**

**NAVNEET SINGH, INDIA**

**Daniel C. Ihde Lectureship Award for Medical Oncology**

**D. ROSS CAMIDGE, USA**

**Heine H. Hansen Lectureship Award for Small Cell Lung Cancer**

**JIE WANG, CHINA**

**IASLC Lectureship Award for Tobacco Control and Smoking Cessation**

**SILVIA NOVELLO, ITALY**

**Fred R. Hirsch Lectureship Award for Translational Research**

**WENDY COOPER, AUSTRALIA**

**Robert J. Ginsberg Lectureship Award for Surgery**

**JESSICA DONINGTON, USA**

**Tsuguo Naruke Lectureship Award for Surgery**

**ALAN SIHOE, HONG KONG**

**IASLC Lectureship Award for Nurses and Allied Health Professionals (NAHP)**

**MELISSA CULLIGAN, UK**

**James D. Cox Lectureship Award for Radiation Oncology**

**RAFAL DZIADZIUSZKO, POLAND**

**01 CONFERENCE OVERVIEW**

IASLC and Conference Awards

**WCLC 2023 Education Awards****DEVELOPING NATIONS**

All WCLC 2023 Education Award Winners will be presented with their award during the **IASLC Award Ceremony on Saturday, September 9 (17:00 – 18:00)**.

**NOUR AL-BZOUR, JORDAN**

MA20.10: A 9-Gene Inflammation Signature Predicts Survival and Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

**JIA-YI DENG, CHINA**

P2.05-16: Immune Suppressive Microenvironment in Liver Metastases Contributes to Organ-Specific Response of Immunotherapy

**MUHAMMED ELFAITURI, LIBYA**

P1.01-09: Assessing the Relationship Between Frailty and Lung Cancer Survival: A Systematic Review and Meta-Analysis

**CHINMAY SATISH HARIDAS, INDIA**

MA18.06: Reassessing Sublobar vs. Lobar Resection for Early-stage Small Cell Lung Cancer in the Wake of CALGB 140503

**YANG-SI LI, CHINA**

P1.09-02: Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR Mutant NSCLC

**YIN LI, CHINA**

P1.09-04: Characterization of the Immunosuppressive Function of UPP1high Tumor Cells In Lung Adenocarcinoma and Its Association with Immunotherapy

**SI-CONG MA, CHINA**

OA19.06: CRTAM Acts as a Checkpoint of Immune-related Adverse Events Uncoupling Efficacy and Toxicity During Immunotherapy

**ZHENBIN QIU, CHINA**

P1.03-01: Dynamic Transcriptomic Characterization Changes of Early Stage Lung Adenocarcinoma as per the Incrassation of Consolidation Tumor Ratio

**DUO XU, CHINA**

MA17.08: Whole-Genome CRISPR Screening Reveals Genetic Vulnerabilities and Therapeutic Targets in Malignant Pleural Mesothelioma

**CHAO ZHANG, CHINA**

P1.27-03: Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis



**01 CONFERENCE OVERVIEW**

IASLC and Conference Awards

**WCLC 2023 Education Awards**  
**EARLY CAREER RESEARCHERS****JACQUELINE AREDO, USA**

MA02.06: Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening

**XIAOSHUANG FENG, FRANCE**

MA19.05: Performance of Risk Prediction Models to Select Individuals for Lung Cancer Screening in the European Population

**PATRICK GOODLEY, UK**

OA07.03: Performance of PLCOm2012-based Screening Eligibility in the Manchester Lung Health Check Pilot Cohort after 6 Years

**ADAM GRIPPIN, USA**

MA15.04: Timing of Pre-biopsy COVID-mRNA Vaccination and PD-L1 Expression in Advanced Non-small Cell Lung Cancer

**ILIAS HOUDA, NETHERLANDS**

OA06.03: An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer

**MATTHEW LEE, USA**

P2.09-04: Treatment Adherence Disparities and Clinical Outcomes of Osimertinib Among Ethnic-Minority Patients with EGFR-mutated NSCLC

**ANLIN LI, CHINA**

OA09.03: STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy in NSCLC: Results From Three Randomized Trials

**SESHIRU NAKAZAWA, USA**

OA19.05: Activating MET Tyrosine Kinase Domain Mutations as De Novo Oncogenic Drivers in Non-small Cell Lung Cancer

**PRIYANKA SENTHIL, USA**

MA10.08: The Disparate Burden of COVID-19 Lung Cancer Patients During Periods of High Transmission of SARS-CoV-2

**NEIL WALLACE, AUSTRALIA**

MA03.03: Does Smoking Status Affect Survival After Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer?

**01 CONFERENCE OVERVIEW**

IASLC and Conference Awards

**WCLC 2023 Education Awards**  
**NURSING AND ALLIED HEALTH PROFESSIONALS****Early Career Researcher****JENNY TURCOTT, MEXICO**

EPI0.01-15: Sarcopenia as a Predictive Factor of Carboplatin Toxicity in Patients with Advanced Non-small Cell Lung Cancer

**Developing Nations****SHANKH PAL, INDIA**

P2.26-01: Managing Pain Lung Cancer Patients – Contribution of Oncology Nurses

**WCLC 2023 Education Awards**  
**TOBACCO CONTROL****Early Career Researcher****XINAN WANG, USA**

MA03.04: Pre-diagnosis Smoking Cessation and Overall Survival Among Non-small Cell Lung Cancer Patients: Results From a Large Lung Cancer Survivor Cohort

**Developing Nations****ZHUANGZHUANG LIU, CHINA**

P1.01-10: Peptic Ulcer and Long-Term Risk of Lung Cancer: A Prospective Cohort Study from UK Biobank

**WCLC 2023 Education Awards**  
**PATIENT ADVOCATES****ADITYA MANNA, INDIA**

MAS Clinic and Hospital

**YVONNE DIAZ, UK**

ALK+ International

**ANNABELLE GURWITCH, USA****GRAHAM HALL, AUSTRALIA****JOSEPH ISAAC, NIGERIA**

Move Against Cancer Africa

**MIRYANA PÉREZ VELA, MEXICO**

Fundación Rebecca de Alba, A.C.

# 01 CONFERENCE OVERVIEW

IASLC and Conference Awards



## WCLC 2023 International Mentorship Program

The International Mentorship Program participants will be acknowledged during the **IASLC Award Ceremony on Saturday, September 9 (17:00 - 18:00).**

### RUI FU, CHINA

P2.03-05: Clinical Impact of Genomic Characterization in Induced Oligometastatic Non-small Cell Lung Cancer

### EDWIN NUGROHO NJOTO, INDONESIA

P1.22-12: Nomogram Prediction for the Detection of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma Patients in Indonesia

### JAYSON PARAGAS, PHILIPPINES

P2.02-05: Comprehensive Pneumonitis Assessment Among Inoperable Stage III NSCLC Patients Treated with Chemoradiotherapy-Immunotherapy Regimen

### RAGHDA TALEB, EGYPT

EP06.06-05: Circular RNA hsa\_circ\_0067705 Expression as a Potential Diagnostic Biomarker for Malignant Pleural Effusion

### YANG WO, CHINA

EP07.05-01: Postoperative Recurrence Pattern and the Role of Adjuvant Therapy in Radiological Solid-Predominant Part-Solid Lung Adenocarcinoma


### MEIMEI ZHENG, CHINA

P1.23-09: Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study

# 01 CONFERENCE OVERVIEW

Program at a Glance

## Saturday, September 9, 2023




- In-Person Only
- Live-Streamed
- Ticketed Event
- ACCME Accredited by IASLC
- Refreshments Provided
- Lunch Provided
- Breakfast & Refreshments Provided
- Lunch & Refreshments Provided

# 01 CONFERENCE OVERVIEW

Program at a Glance

## Sunday, September 10, 2023




In-Person Only
 Live-Streamed
 Ticketed Event
 ACCME Accredited by IASLC

Refreshments Provided
 Lunch Provided
 Breakfast & Refreshments Provided
 Lunch & Refreshments Provided

# 01 CONFERENCE OVERVIEW

Program at a Glance

## Monday, September 11, 2023



In-Person Only
 Live-Streamed
 Ticketed Event
 ACCME Accredited by IASLC

Refreshments Provided
 Lunch Provided
 Breakfast & Refreshments Provided
 Lunch & Refreshments Provided

# 01 CONFERENCE OVERVIEW

Program at a Glance

## Tuesday, September 12, 2023

07:30	Concurrent Meet the Expert (MTE) Sessions 07:30 - 08:15			07:30
08:00	Plenary Session 5: Transforming Discovery Into Treatments in Lower Middle Income Regions 08:30 - 10:00			08:00
08:30				08:30
09:00				09:00
09:30				09:30
10:00	Coffee Break 10:00 - 10:45	IASLC Business Meeting 10:00 - 10:45	Press Conference 10:05 - 11:00	10:00
10:30				10:30
11:00	Concurrent Oral Abstract Sessions 10:45 - 11:45	Concurrent Mini Oral Abstract Sessions 10:45 - 11:45	Concurrent Education Sessions 10:45 - 11:45	11:00
11:30				11:30
12:00	Concurrent Oral Abstract Sessions 12:00 - 13:00	Concurrent Mini Oral Abstract Sessions 12:00 - 13:00	Concurrent Education Sessions 12:00 - 13:00	12:00
12:30				12:30
13:00				13:00
13:30	Lunch Break 13:15 - 14:15	Satellite CME Symposium 13:15 - 14:15		13:30
14:00				14:00
14:30	Concurrent Oral Abstract Sessions 14:30 - 15:30	Concurrent Mini Oral Abstract Sessions 14:30 - 15:30	Concurrent Education Sessions 14:30 - 15:30	14:30
15:00				15:00
15:30				15:30
16:00	Closing Plenary 6: Advances in Lung Cancer Pathology 15:45 - 16:45			16:00
16:30				16:30
17:00				17:00

In-Person Only

Live-Streamed

Ticketed Event

ACCME Accredited by IASLC

Refreshments Provided

Lunch Provided

Breakfast & Refreshments Provided

Lunch & Refreshments Provided

Download the free official WCLC 2023 virtual platform available for desktop and mobile devices for a convenient way to stay up-to-date on the latest Conference information. View the full scientific schedule, abstracts, exhibit information, and general Conference and venue information on our easy-to-use platform!



# 01 CONFERENCE OVERVIEW

Program at a Glance - Industry Sponsored Symposia

## Saturday, September 9, 2023

10:45 - 11:45	Industry Sponsored Symposium by Abbvie: The Expanding Role of Precision Medicine with Antibody Drug Conjugates in NSCLC	
13:15 - 14:15	Industry Sponsored Symposium by Sanofi: Hitting the Mark: Emerging Biomarkers in Advanced NSCLC	
14:30 - 15:30	Industry Sponsored Symposium by Boehringer Ingelheim: Past, Present, and Future of Personalized Care in Lung Cancer: HER2 and DLL3 Targeted Therapies In Focus	Industry Sponsored Symposium by Janssen: Academy for Cancer Education (ACE) Asia Pacific Lung Cancer Symposium: Emerging Strategies in EGFR Driver Mutation-based Management of Advanced Non-small Cell Lung Cancer (NSCLC)
15:45 - 16:45	Industry Sponsored Symposium by Pfizer: Maximising the Potential in ALK+ NSCLC: Enhancing Outcomes and Improving Patient Care	

## Sunday, September 10, 2023

13:45 - 14:45	Industry Sponsored Symposium by AstraZeneca: The Road Ahead: Navigating Opportunities in Resectable NSCLC	Industry Sponsored Symposium by Amgen: Transforming Care for Patients with Advanced Lung Cancer
18:30 - 19:30	Industry Sponsored Symposium by MSD: Reaching New Heights: Building on the Foundation of Immuno-Oncology	Industry Sponsored Symposium by Novocure: A Spotlight on Tumor Treating Fields in Thoracic Oncology

## Monday, September 11, 2023

13:15 - 14:15	Industry Sponsored Symposium by Daiichi Sankyo: ADCs in Lung Cancer: Where We Are and Where We Are Going	Industry Sponsored Symposium by AstraZeneca: Tailoring Treatment in Metastatic NSCLC: Advances in Targeted Therapy and Post-progression Treatment Options	Industry Sponsored Symposium by Regeneron and Sanofi: The Path to Optimizing Immunotherapy in Advanced NSCLC
19:00 - 20:00	Industry Sponsored Symposium by Daiichi-Sankyo and AstraZeneca: Taking Aim at HER2-Driven NSCLC	Industry Sponsored Symposium by GSK: Tackling Unmet Needs for Patients with NSCLC: Latest Scientific Advances and Investigational Approaches	

## 01 CONFERENCE OVERVIEW


Program at a Glance - Satellite CME Symposia

### Saturday, September 9, 2023

**12:00 - 13:00** Satellite CME Symposium by PeerView Institute for Medical Education, Supported by Gilead - A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations 

**15:45 - 16:45** Satellite CME Symposium by Medscape Oncology Global, Supported by Lilly: Unlocking the Power of Genomic Testing in NSCLC: Implementing Personalized Therapy to Impact Outcomes 

### Sunday, September 10, 2023

**13:45 - 14:45** Satellite CME Symposium by PeerVoice, Supported by Daiichi Sankyo: Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next? 

**18:30 - 19:30** Satellite CME Symposium by AGILE, Supported by Merck KGaA: MET Inhibition in Metastatic NSCLC "In the Spotlight" 


### Monday, September 11, 2023

**19:00 - 20:00** Satellite CME Symposium by Med Learning Group, Supported by Regeneron Pharmaceuticals: Applying Multidisciplinary Expertise and Heterogeneous Skills in Clinical Practice: Transforming Non-Small Cell Lung Cancer Treatment with Immunotherapy 

### Tuesday, September 12, 2023

**13:15 - 14:15** Satellite CME Symposium by PVI, PeerView Institute for Medical Education, Supported by Daiichi Sankyo, Inc.: Taking Aim With the Next Wave of Antibody-Drug Conjugates in NSCLC: Rational Strategies for Addressing the Unmet Needs of Diverse Patient Populations With TROP2- and HER3-Targeting Therapies and Other ADC-Based Regimens 

 ACCME Accredited by Other Provider

LC |  2023 World Conference on Lung Cancer  
SEPTEMBER 9-12, 2023 | SINGAPORE

Join us in Singapore for  
**NCLC 2023!**

IASLC  


INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER  
Conquering Thoracic Cancers Worldwide



**2** PROGRAM  
SATURDAY

**02 WCLC 2023 FULL PROGRAM**

Saturday, September 9, 2023

**Saturday, September 9, 2023****08:00 – 09:00 Social Media & Communications Workshop**

ROOM: 327, LEVEL 3

Not for CME Credit

- 08:00 Welcome**
- 08:02 Promoting Health Equity in Science Communication**  
*Narjust Florez (Duma), USA*
- 08:10 How to Give a Great Presentation: Demystifying the Data, Figures and Message**  
*Jarushka Naidoo, Ireland*
- 08:18 Simplifying Stats & Methods in Science Communication**  
*Matthew Smeltzer, USA*
- 08:26 Scholarly Communication: Tips & Tracks for Manuscript Reviewing, Reviewer Responses & the Editorial Process**  
*Martin Edelman, USA*
- 08:34 Scientific Communication with the Press: Do's & Don'ts**  
*Brendon Stiles, USA*
- 08:42 Science Through Social Media: Communications 2.0**  
*Stephen V. Liu, USA*
- 08:50 Panel Discussion**

**08:00 - 11:30 WS01: Early Career & First Time Attendee Workshop**

ROOM: NICOLL 2, LEVEL 3

Breakfast and Refreshments Provided

Not for CME Credit

Chairs: Chee Lee, Australia &amp; Fiona Hegi-Johnson, Australia

Recommended for Early Career Researchers

- 08:00 Welcome & Introduction**  
*Chee Lee, Australia & Fiona Hegi-Johnson, Australia*
- 08:02 WS01.03: Making the Most of WCLC: A Guide for First Time Attendees**  
*Jarushka Naidoo, Ireland*
- 08:17 WS01.04: Early Career Researcher Experience - Opportunities and Challenges**  
*Aaron Tan, Singapore*
- 08:32 WS01.05: Engaging with the Pharmaceutical Industry**  
*James Chih-Hsin Yang, Taiwan*
- 08:47 WS01.06: How to Set up an Investigator Initiated Trial**  
*Myung-Ju Ahn, Republic of Korea*
- 09:02 WS01.07: Seeking and Preparing a Successful Grant Application**  
*Narjust Florez (Duma), USA*
- 09:17 Networking Break**

- 09:45 WS01.08: Tips of Getting Your Paper Published**  
*Young Tae Kim, Republic of Korea*
- 10:00 WS01.09: How to Deliver an Engaging Presentation**  
*Tony Mok, China*
- 10:15 WS01.10: Role of IASLC in Developing Countries**  
*Clarissa Mathias, Brazil*
- 10:30 WS01.11: Benefits of Joining IASLC as an Early Career Physician/Researcher**  
*Karen Kelly, USA*
- 10:45 Q&A**
- 11:00 Networking with Faculty and Other Early Career Researchers**

**08:00 - 12:00 WS02: Joint IASLC-CSCO-CAALC Session - Innovation Drives Lung Cancer Management**

ROOM: SUMMIT 1, LEVEL 3

Recommended for Early Career Researchers

Not for CME Credit

Chairs: Yi-Long Wu, China &amp; Chun-Xue Bai, China &amp; Caicun Zhou, China &amp; Karen Kelly, USA

Breakfast and Refreshments Provided

- 08:00 WS02.05: Welcome**  
*Karen Kelly, USA*
- 08:10 WS02.06: Artificial Intelligence in Early Detection for Lung Cancer - Chinese Perspective**  
*Chun-Xue Bai, China*
- 08:30 WS02.07: Beyond Checkmate 816: What Is the Future in Perioperative Immune-Oncology (IO) Treatment - European Perspective**  
*Solange Peters, Switzerland*
- 08:50 WS02.08: New IO Drug (Beyond PD-1/L1) Development in China - Chinese Perspective**  
*Fei Zhou, China*
- 09:10 WS02.09: How to Successfully Conduct Clinical Trials for Patients with Uncommon Driver Mutation Positive Tumors - North American Perspective**  
*Thomas Stinchcombe, USA*
- 09:30 Networking and Poster Viewing**
- 10:30 WS02.11: HRA00129-C004, a Novel c-Met ADC with Promising Preclinical Anti-tumor Activity and Expanded Therapeutic Window**  
*Yunan Tian, China*
- 10:40 WS02.12: Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS)**  
*Hua Lin Chen, China*
- 10:50 WS02.13: PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)**  
*Si-Yang Liu, China*
- 11:00 WS02.14: Oral Abstracts Discussant (WS02.11 – WS02.13)**  
*Daniel Tan, Singapore*
- 11:15 WS02.21: Poster Discussant (WS02.15 – WS02.20)**  
*Jie Hu, China*
- Discussing the following Posters:**
- WS02.15: Effect of Gut Microbiome on Metastasis of Non-small Cell Lung Cancer**  
*Chen-Guang Liu, China*

**WS02.16: Proteomics-based Predictive Model for the Increased Brain Metastasis Risk in Resected Lung Adenocarcinoma with EGFR Mutation***Haihong Yang, China***WS02.17: A Novel Blood-Based DNAMethylation Panel for Detection of Lung Cancer at Very Early Stage***Rongxi Yang, China***WS02.18: Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study***Mei-Mei Zheng, China***WS02.19: Comparison of NGS and FISH Platforms to Test MET Amplification in Chinese Lung Cancer Patients: A Prospective Study***Xue Lin, China***WS02.20: Upregulation of HLA-I/II and Pro-inflammatory Cells in PBMCs Indicated Efficacy of Neoadjuvant Chemo-immunotherapy in Locally Advanced NSCLC***Hui Kang Xie, China***11:30** **WS02.22: Concluding Remarks****08:00 - 11:00 WS03: Radiation Oncology Workshop****ROOM: SUMMIT 2, LEVEL 3** **Not for CME Credit***Chairs: Kristin Higgins, USA & Fiona McDonald, UK***08:00** **Welcome & Introduction***Kristin Higgins, USA & Fiona McDonald, UK* **Recommended for Early Career Researchers****08:02** **WS03.03: SBRT Lung with a Focus on OARs (Brachial Plexus, Central Structures, Bronchial Tree, Chest Wall)***Anil Tibdewal, India***08:42** **WS03.04: Locally Advanced Stage IIIC or IIIB NSCLC with a Focus on Defining GTV***Nonette Cupino, Philippines***09:22** **WS03.05: SBRT for Oligoprogression in the Lung on Systemic Therapy***Connie Yip, Singapore***10:02** **WS03.06: Stage II-III Unresectable NSCLC with Associated Lung Collapse***Ivy Ng, Singapore***10:42** **Q&A****09:00 - 15:40 WS04: 2023 IASLC CT Screening Symposium****ROOM: NICOLL 3, LEVEL 3** **Ticketed Session** **Not for CME Credit****9:00** **Chairs Welcome** **Lunch and Refreshments Provided****TOPIC 1: WHO SHOULD BE SCREENED****9:10** **WS04.01: Welcome***Pyng Lee, Singapore***9:15** **WS04.02: Lung Cancer Screening - Asian Perspective***Haiquan Chen, China***9:25** **WS04.03: Pro: Never and Light Smokers Should Be Screened***Stephen Lam, Canada***9:30** **WS04.04: Con: Never and Light Smokers Should Not Be Screened**  
*Hilary Robbins, France***9:35** **WS04.05: Pro: Never and Light Smokers Should Be Screened**  
*Pan Chyr Yang, Taiwan***9:40** **WS04.06: Con: Never and Light Smokers Should Not Be Screened**  
*Jin Mo Goo, Republic of Korea***9:45** **Pro/Con Debate + Q&A****10:20** **WS04.08: Conclusion**  
*Raymond Osarogiagbon, USA***10:25** **Break****TOPIC 2: LUNG CANCER RISK ASSESSMENT****10:40** **WS04.10: Welcome**  
*Stephen Lam, Canada***10:45** **WS04.11: Environmental Factors**  
*Renelle Myers, Canada***10:55** **WS04.12: Tumor Biology Based Biomarkers**  
*Rayjean Hung, Canada***11:05** **WS04.13: Next Generation Lung Cancer Risk Prediction Model**  
*Chao A Hsiung, Taiwan***11:15** **WS04.14: Modifying Lung Cancer Risk (e.g. Smoking Cessation, Radon Exposure)**  
*Rachael Murray, UK***11:25** **Panel Discussion + Q&A****11:50** **WS04.16: Conclusion**  
*Rafael Meza, USA***11:55** **Lunch Break****TOPIC 3: DIAGNOSTIC STRATEGY****12:55** **WS04.18: Welcome**  
*Marjolein Heuvelmans, Netherlands***13:00** **WS04.19: Bronchoscopic Diagnosis**  
*Carla Lamb, USA***13:10** **WS04.20: CT Guided Lung Biopsy**  
*Peter Goh, Singapore***13:20** **WS04.21: Management of Multiple Lung Nodules**  
*Thirugnanam Agasthian, Singapore***13:30** **WS04.22: 4-In-The-Lung-Run Trial**  
*Matthijs Oudkerk, Netherlands***13:40** **WS04.23: Watch the Spot Trial**  
*Michael Gould, USA***13:50** **Panel Discussion + Q&A****14:05** **WS04.25: Conclusion**  
*Annette McWilliams, Australia***14:10** **Break****TOPIC 4: APPLICATION OF AI IN LUNG SCREENING****14:20** **WS04.27: Welcome**  
*Chi-Fu Yang, USA*

## SCIENTIFIC PROGRAM - SATURDAY, SEPTEMBER 9, 2023

- 14:25** **WS04.28: Predicting Lung Cancer Risk from a Single Chest CT**  
*Lecia Sequist, USA*
- 14:35** **WS04.29: Optimizing Workflow Using AI**  
*Marjolein Heuvelmans, Netherlands*
- 14:45** **WS04.30: Clinical Impact of Identifying Additional (Incidental) Findings on Screening LDCT**  
*David Yankelevitz, USA*
- 14:55** **WS40.31: Towards Developing Universal Quality Indicators To Measure Performance of Screening Program**  
*Ella Kazerooni, USA*
- 15:05** **Panel Discussion + Q&A**
- 15:25** **WS04.33: Session Conclusion**  
*Ella Kazerooni, USA*
- 15:30** **WS04.34: Workshop Summary/Conclusion**  
*John Field, UK*

**10:45 – 11:45 Industry Sponsored Symposium**

FOR FURTHER INFORMATION, PLEASE SEE PAGE 222.

**12:00 – 13:00 Satellite CME Symposium**

FOR FURTHER INFORMATION, PLEASE SEE PAGE 226.

**12:00 - 16:30 WS05: Preceptorship Workshop**

ROOM: SUMMIT 2, LEVEL 3



Refreshments Provided



Not for CME Credit

Chair: Nick Pavlakis, Australia

- 12:00** **WS05.01: Welcome & Introduction**  
*Nick Pavlakis, Australia*
- 12:15** **WS05.02: Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening - NLST**  
*Jamie Feng, Canada*
- 12:25** **WS05.03: Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial - NELSON Trial**  
*Monica Chen, USA*
- 13:00** **WS05.04: Mentor: Lung Cancer Screening**  
*Emily Stone, Australia*
- 13:00** **WS05.05: Stereotactic Ablative Radiotherapy versus Standard Radiotherapy in Stage 1 Non-small-Cell Lung Cancer (TROG 09.02 CHISEL): A Phase 3, Open-Label, Randomised Controlled Trial**  
*Diane Lim, Australia*
- 13:10** **WS05.06: Postoperative Radiotherapy versus No Postoperative Radiotherapy in Patients with Completely Resected Non-small-Cell Lung Cancer and Proven Mediastinal N2 Involvement (Lung ART): An Open-Label, Randomised, Phase 3 Trial**  
*Philippa Johnstone, Australia*
- 13:20** **WS05.07: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer - PACIFIC Trial**  
*Joe Wei, Australia*

## SCIENTIFIC PROGRAM - SATURDAY, SEPTEMBER 9, 2023

- 13:30** **WS05.08: Mentor: Early-Stage NSCLC - Radiotherapy**  
*Dasantha Jayamanne, Australia*
- 13:30** **WS05.09: Mentor: Early-Stage NSCLC - Radiotherapy**  
*Aaron Tan, Singapore*
- 13:55** **WS05.10: Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma- IPASS Trial**  
*Rajat Rai, Australia*
- 14:05** **WS05.11: Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer - FLAURA Trial**  
*Deborah Zhou, Australia*
- 14:15** **WS05.12: Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer - ADAURA Trial**  
*Arianna Marinello, France*
- 14:25** **WS05.13: Mentor: Sensitizing EGFR Mutations - Advanced to Early NSCLC**  
*Tom John, Australia*
- 14:25** **WS05.14: Mentor: Sensitizing EGFR Mutations - Advanced to Early NSCLC**  
*Kirsty Lee, Hong Kong*
- 14:50** **Break**
- 15:20** **WS05.16: Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer - Keynote-189 Trial &#38; Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer - Keynote 024 Trial**  
*Shalini Subramaniam, Australia*
- 15:30** **WS05.17: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer - Checkmate 816 Trial**  
*Lauren Brown, Australia*
- 15:40** **WS05.18: Adjuvant Atezolizumab after Adjuvant Chemotherapy in Resected Stage IB-IIIa Non-small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial**  
*Nicholas McNamee, Australia*
- 15:50** **WS05.19: Mentor: Immunotherapy - Advanced to Early NSCLC**  
*Melissa Moore, Australia*
- 15:50** **WS05.20: Mentor: Immunotherapy - Advanced to Early NSCLC**  
*Malinda Itchins, Australia*
- 16:15** **WS05.21: Closing Remarks**  
*Nick Pavlakis, Australia*

**12:00 - 15:00 WS06: IASLC/iMig Workshop**

ROOM: NICOLL 2, LEVEL 3



Not for CME Credit

Chairs: Paul Baas, Netherlands

- 12:00** **Welcome & Introduction**  
*Paul Baas, Netherlands & Kenneth O'Byrne, Australia*
- 12:05** **WS06.02: History of MPM Subgroups: Is It Useful?**  
*Sanja Dacic, USA*
- 12:30** **WS06.03: Can Blood and Fluid Biomarkers Make a Difference in Diagnosis or Therapy**  
*Jenette Creaney, Australia*
- 12:55** **WS06.04: Genomics of Cancer: Deep Sequencing and Treatment Options in MPM**  
*Thomas Marron, USA*
- 13:20** **Break**



- 13:25** **WS06.06: What Does the IO System Sees in MPM and How It Can Be Used in Treatments**  
*Bruce Robinson, Australia*
- 13:50** **WS06.07: Novel Targets: Catastrophic Chromosomal Events in Mesothelioma**  
*Aaron Mansfield, USA*
- 14:15** **WS06.08: Novel Targets: BAP1 as an Evolving Target**  
*Michele Carbone, USA*
- 14:40** **WS06.09: Summary and Closing Remarks**  
*Kenneth O'Byrne, Australia*

**12:30 - 17:00 WS07: Nurse & AHP + ITONF Workshop**

ROOM: SUMMIT 1, LEVEL 3



Lunch Provided



Not for CME Credit

Chairs: *Mary Duffy, Australia & Caitlin Broderick, Australia*

- 12:30** **WS07.01: ITONF AGM for ITONF Members**  
*Mary Duffy, Australia & Caitlin Broderick, Australia*

**12:50 Lunch & Networking****SESSION 1: TREATMENT UPDATES FOR NURSES & AHPS**

- 13:20** **Welcome to the IASLC & ITONF Nursing & Allied Health Professionals Workshop**  
*Mary Duffy, Australia & Maria Ftanou, Australia*
- 13:25** **WS07.06: Introduction - Session 1: Treatment Updates for Nurses & AHPS**  
*Caitlin Broderick, Australia*
- 13:30** **WS07.07: Oncology Nursing in China: How It Evolved and What Does the Future Hold?**  
*Xiao Li, China*
- 13:45** **WS07.08: What Are the Latest Thoracic Oncology Treatments for Nurses & AHPS: Hot Off the Press**  
*Mel Laan, Australia*
- 14:05** **WS07.09: Highlights from iMig From a Nursing & AHP Perspective: What You Need to Know**  
*Leah Taylor, UK*

**14:20 Q&A****14:25 Refreshment Break & Networking****SESSION 2: HUMANITY IN THORACIC ONCOLOGY CARE**

- 14:45** **WS07.12: Moderator - Session 2: Humanity in Thoracic Oncology Care**  
*Maria Ftanou, Australia*
- 14:50** **WS07.13: Introduction - Session 2: Humanity in Thoracic Oncology Care**  
*Whitney Lewis, USA*
- 14:55** **WS07.14: The Humanitarian Crisis of Cancer**  
*Gary Rodin, Canada*
- 15:15** **WS07.15: Addressing Inequities in Lung Cancer Care**  
*Gail Garvey, Australia*

**15:35 Q&A****15:45 Networking Break****SESSION 3: NURSING & AHP DRIVEN RESEARCH IN THORACIC ONCOLOGY CARE**

- 15:55** **WS07.18: Introduction - Session 3: Nursing & AHP Driven Research in Thoracic Oncology Care**  
*Jacqui Frowen, Australia*

- 16:00** **WS07.19: Managing Cancer & Living Meaningfully (CALM) - An Australian Nurse Perspective**  
*Mary Duffy, Australia*
- 16:10** **WS07.20: Perceptions and Measurements of Dyspnea and Quality of Life Experienced by Malignant Pleural Mesothelioma Patients before and after Lung-Sparing Surgery: A Pilot Mixed Methods Study**  
*Melissa Culligan, USA*
- 16:20** **WS07.21: How Do We Integrate Cancer Services?**  
*Anne Fraser, New Zealand*
- 16:30** **WS07.22: Breaking Barriers to Facilitate Participation in Pulmonary Rehabilitation in Patients Following Lung Resection for Non-small Cell Lung Cancer: Is It Physical Activity Coaching?**  
*Sarah Haesevoets, Belgium*
- 16:40** **WS07.23: Successfully Navigating the WCLC Program, Summary & Close**  
*Morten Quist, Denmark*

**13:00 - 14:00 PC01: Press Conference**

ROOM: 327, LEVEL 3



Not for CME Credit

**13:15 - 14:15 Industry Sponsored Symposium**

FOR FURTHER INFORMATION, PLEASE SEE PAGE 222.

**14:30 - 15:30 Concurrent Industry Sponsored Symposia**

FOR FURTHER INFORMATION, PLEASE SEE PAGE 223.

**15:30 - 17:00 WS08: LATAM Workshop**

ROOM: NICOLL 2, LEVEL 3



Not for CME Credit

Chairs: *Ticiana Leal, USA & Clarissa Mathias, Brazil*

- 15:30** **Welcome & Introduction**  
*Ticiana Leal, USA & Clarissa Mathias, Brazil*
- 15:32** **WS08.03: How We Can Do Immunotherapy and Targeted Therapy Research in Latin America**  
*Oscar Arrieta, Mexico*
- 15:42** **WS08.04: Establishing Lung Cancer Screening and Incidental Pulmonary Nodule Programs in the Region**  
*Lucia Viola, Colombia*
- 15:52** **WS08.05: Looking for Equity in Access to Genomic Testing and Targeted Therapy Among Hispanics Living in the US and Latin America**  
*Luis Raez, USA*
- 16:02** **WS08.06: The LungTrust Methodology**  
*Andrés Cardona, Colombia*
- 16:12** **WS08.07: Evaluation of a Risk-sharing Agreement for Atezolizumab Treatment in NSCLC Patients: A Strategy to Improve Access in Low Income Countries**  
*Oscar Arrieta, Mexico*

SCIENTIFIC PROGRAM - SATURDAY, SEPTEMBER 9, 2023

- 16:22 WS08.08: Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes**  
*Norma Hernandez Pedro, Mexico*
- 16:32 WS08.09: Discussant (WS08.06 - WS08.08)**  
*Andres Cardona, Colombia*
- 16:42 Q&A**

**15:45 – 16:45 Concurrent Industry Sponsored and CME Satellite Symposia**

FOR FURTHER INFORMATION, PLEASE SEE PAGES 224 & 226.

**17:00 - 18:00 IASLC Award Ceremony**

ROOM: 405B, LEVEL 4

 Refreshments Provided  Not for CME Credit

 Live-Streamed  Recommended for Early Career Researchers

Join us for the IASLC Award Ceremony as we celebrate our early career researchers and award winners.

**18:15 - 20:00 PL01: Opening Plenary Session 1 (with IASLC Distinguished Service Award Presentations): Equity and Access to Appropriate Clinical Care in Lung Cancer – Pathway Towards Effective Global Implementation**

ROOM: 406, LEVEL 4

 Live-Streamed  Not for CME Credit

*Chairs: Jill Feldman, USA & Fiona Hegi-Johnson, Australia*

 Recommended for Early Career Researchers

- 18:15 Welcome Remarks**
- 18:35 IASLC Distinguished Service Award Presentations**
- 18:55 PL01.09: Lung Cancer Treatment Divide - Breathtaking Inequity**  
*Her Royal Highness Princess Dina Mired, Jordan*
- 19:20 PL01.10: The Humanitarian Crisis in Cancer: Challenges and Solutions**  
*Gary Rodin, Canada*
- 19:45 Q&A**

**20:00 – 21:30 Welcome Reception**

ROOM: EXHIBIT HALL, LEVEL 4

 Refreshments Provided  Not for CME Credit



**3 PROGRAM SUNDAY**

**03 WCLC 2023 FULL PROGRAM**

Sunday, September 10, 2023

**Sunday, September 10, 2023****07:30 - 08:15 MTE01: Lung Cancer Risk Reduction in Asia - People Who Smoke Versus Those Who Haven't**

Track: Risk Factors, Risk Reduction &amp; Tobacco Control

ACCME Accredited By IASLC

ROOM: 405B, LEVEL 4

Light Breakfast Provided

In-Person Only (NOT RECORDED)

Ticketed Session

**07:30 MTE01.01: Lung Cancer in Asians Who Do Not Have a Smoking History: Epidemiology & Biology**  
Hsiu-Hsi Chen, Taiwan

**07:45 MTE01.02: Women, Smoking and Lung Cancer**  
Emma O'Dowd, UK

**08:00 Q&A****07:30 - 08:15 MTE02: Oncogene Driven Lung Cancer - From Target Identification to Clinic to Community - Open Panel Discussion**

Track: Tumor Biology - Preclinical Biology

Ticketed Session

ACCME Accredited By IASLC

ROOM: SUMMIT 1, LEVEL 3

Light Breakfast Provided

In-Person Only (NOT RECORDED)

Recommended for Early Career Researchers

**07:30 MTE02.01: From Target Identification to Clinic**  
Zofia Piotrowska, USA

**07:45 MTE02.02: Real World Impact of Targeted Therapy**  
Lillian Leigh, Australia

**08:00 Q&A****07:30 - 08:15 MTE03: Screening for Lung Cancer in Individuals with No Smoking History**

Track: Screening and Early Detection

Ticketed Session

ACCME Accredited By IASLC

ROOM: SUMMIT 2, LEVEL 3

Light Breakfast Provided

In-Person Only (NOT RECORDED)

**07:30 MTE03.01: How to Implement CT Screening Program for Person Who Does Not Smoke/ With No History of Smoking**  
Pan-Chyr Yang, Taiwan

**07:45 MTE03.02: IASLC Early Detection and Screening Committee View**  
Ella Kazerooni, USA

**08:00 Q&A****07:30 - 08:15 MTE04: Molecular Biomarker Testing for Targeted Therapy in Lung Cancer - All You Need to Know in One Atlas**

Track: Pathology and Biomarkers

Ticketed Session

ACCME Accredited By IASLC

ROOM: 405C, LEVEL 4

Light Breakfast Provided

In-Person Only (NOT RECORDED)

Recommended for Early Career Researchers

Chair: Daniel Tan, Singapore

**07:30 Welcome & Introduction**  
Daniel Tan, Singapore

**07:32 MTE04.02: Molecular Biomarker Testing for Targeted Therapy in Lung Cancer - All You Need to Know in One Atlas**  
Wendy Cooper, Australia

**07:47 MTE04.03: Molecular Biomarker Testing for Targeted Therapy in Lung Cancer - All You Need to Know in One Atlas**  
Ming-Sound Tsao, Canada

**08:02 Q&A****07:30 - 08:15 MTE05: Challenges in the Management of Recurrent Brain Metastases Previously Treated with Radiation Therapy in Non-small Cell Lung Cancer**

Track: Metastatic Non-small Cell Lung Cancer - Local Therapies

In-Person Only (NOT RECORDED)

ROOM: NICOLL 2, LEVEL 3

Ticketed Session

ACCME Accredited By IASLC

Light Breakfast Provided

**07:30 MTE05.01: Treatment Approaches for Recurrent Brain Metastases Previously Treated with Radiation Therapy in Non-small Cell Lung Cancer**  
Nicolaus Andratschke, Switzerland

**07:45 MTE05.02: Challenges in the Diagnosis and Management of Radiation Necrosis in the Brain**  
Wee-Yao Koh, Singapore

**08:00 Q&A****07:30 - 08:15 MTE06: Equity in Lung Cancer Care - Indigenous Health, Digital Health, Access to Treatments/Diagnostics**

Track: Multidisciplinary Care: Nursing, Allied Health &amp; Palliative Care

Light Breakfast Provided

ROOM: NICOLL 3, LEVEL 3

Ticketed Session

ACCME Accredited By IASLC

In-Person Only (NOT RECORDED)

**07:30 MTE06.01: Equity in Indigenous Health**  
Gail Garvey, Australia

**07:45 MTE06.02: Equity in Lung Cancer Care - Access to Approved Therapies and Clinical Trials**  
Abhijit Pal, Australia

**08:00 Q&A**

**07:30 - 08:15 MTE07: Biology of Individuals without a Smoking History****Track: Tumor Biology – Translational Biology**

Ticketed Session

ACCME Accredited By IASLC

**ROOM: NICOLL 1, LEVEL 3**

Light Breakfast Provided

In-Person Only (NOT RECORDED)

**07:30 MTE07.01: Biology of Individuals without a Smoking History***Charles Swanton, UK***07:50 Q&A****08:30 - 10:30 PL02: Plenary Session 2: IASLC Lectureship Award Presentations****ROOM: 406, LEVEL 4**

Live-Streamed

ACCME Accredited By IASLC

*Chairs: Karen Kelly, USA & Heather Wakelee, USA*

Recommended for Early Career Researchers

**08:30 Welcome & Introduction***Karen Kelly, USA & Heather Wakelee, USA***08:32 PL02.03: IASLC Lectureship Award for Tobacco Control and Smoking Cessation***Silvia Novello, Italy***08:45 PL02.04: Tsuguo Naruke Lectureship Award for Surgery***Alan Sihoe, China***08:58 PL02.05: Daniel C. Ihde Lectureship Award for Medical Oncology***D. Ross Camidge, USA***09:11 PL02.06: Robert J. Ginsberg Lectureship Award for Surgery***Jessica Donington, USA***09:24 PL02.07: James D. Cox Lectureship Award for Radiation Oncology***Rafal Dziadziuszko, Poland***09:37 PL02.08: Heine H. Hansen Lectureship Award for Small Cell Lung Cancer***Jie Wang, China***09:50 PL02.09: Fred R. Hirsch Lectureship Award for Translational Research***Wendy Cooper, Australia***10:03 PL02.10: IASLC Lectureship Award for Nurses and Allied Health Professionals (NAHP)***Melissa Culligan, USA***10:16 PL02.11: Clifton F. Mountain Lectureship Award for Staging***Navneet Singh, India***10:30 - 11:15 Meet Her Royal Highness Princess Dina Mired, Jordan****IASLC BOOTH IN THE EXHIBIT HALL****10:30 - 11:15 Coffee Break****ROOM: EXHIBIT HALL, LEVEL 4**

Refreshments Provided

**10:35 - 11:30 PC02: Press Conference****ROOM: 327, LEVEL 3**

Not for CME Credit

**10:40 - 11:10 IASLC01: IASLC Board Office Hours****ROOM: EXHIBIT HALL, COLLABORATIVE MEETING LOUNGE**

Not for CME Credit

Join select IASLC Board Members and ask them anything you want to know about the IASLC and its activities, being a member, being a board or committee member or anything else you have always wanted to know!

**11:15 - 12:15 ES01: Smoking Cessation Is a Necessary Intervention****Track: Risk Factors, Risk Reduction & Tobacco Control**

ACCME Accredited By IASLC

**ROOM: NICOLL 1, LEVEL 3**

Recommended for Early Career Researchers

*Chairs: Kwun Fong, Australia & Joelle Fathi, USA***11:15 Welcome & Introduction***Kwun Fong, Australia & Joelle Fathi, USA***11:17 ES01.03: How to Incorporate Smoking Cessation to CT Screening Program***Rachael Murray, UK***11:32 ES01.04: How to Introduce Smoking Cessation to Clinic: Pharmacological and Non-pharmacological Aids***Sita Andarini, Indonesia***11:47 ES01.05: End of the Lung Cancer Epidemic from Tobacco***Janet Hoek, New Zealand***12:02 Q&A****11:15 - 12:15 ES02: Adaptive Mechanisms of Drug Resistance in the Tumour Microenvironment****Track: Tumor Biology – Preclinical Biology**

ACCME Accredited By IASLC

**ROOM: NICOLL 3, LEVEL 3***Chairs: Eliza Fong, Singapore & Trever Bivona, USA***11:15 Welcome & Introduction***Eliza Fong, Singapore & Trever Bivona, USA***11:17 ES02.03: The Evolution of Tumour Cells and Targeted Therapy Resistance***Caicun Zhou, China***11:29 ES02.04: Tumour Immune Microenvironment and Immunotherapy Resistance***Ping Chih Ho, Switzerland***11:41 ES02.05: Exploiting the TME For Novel Therapeutic Development***Katey Enfield, UK***11:53 ES02.06: Mediators of Radiotherapy Resistance in the TME***Magnus Dillon, UK***12:05 Q&A**

**11:15 - 12:15 ES03: Personalising LCS: A Global Perspective of Barriers, Opportunities and Challenges for Improving Equity in Screening****Track: Screening and Early Detection** ACCME Accredited By IASLC**ROOM: 405A, LEVEL 4**

Chairs: Christine Argento, USA &amp; WenTao Fang, China

**11:15 Welcome & Introduction**

Christine Argento, USA &amp; WenTao Fang, China

**11:17 ES03.03: Modelling the Benefits of Screening to Better Include Women and the Underserved**

Rafael Meza, USA

**11:29 ES03.04: The Need for Expanding LC Screening in Women: Balance Between Harms and Benefits**

Monica Castro, Argentina

**11:41 ES03.05: Improving the Uptake of Screening for Lung Cancer Among Women and Minorities: The Search Continues**

Narjust Florez (Duma), USA

**11:53 ES03.06: Early Detection in Indigenous/First Population: Breaking Down Barriers**

Sue Crengle, New Zealand

**12:05 Q&A****11:15 - 12:15 ES04: Updates on Staging of Lung Cancer****Track: Pulmonology and Staging** ACCME Accredited By IASLC**ROOM: SUMMIT 1, LEVEL 3** Recommended for Early Career Researchers

Chairs: Chunxue Bai, China &amp; Tetsuya Mitsudomi, Japan

**11:15 Welcome & Introduction**

Chunxue Bai, China &amp; Tetsuya Mitsudomi, Japan

**11:17 ES04.03: Pitfalls of Clinical Lung Cancer Staging**

Florian Fintelmann, USA

**11:29 ES04.04: CT Deep Learning for Survival Prediction**

Jin Mo Goo, Republic of Korea

**11:41 ES04.05: Approach to Multistation Lymph Node Staging and Multifocal NSCLC**

Kazuhiro Yasufuku, Canada

**11:53 ES04.06: N0/1 Staging for Limited Resection and Resectable N2 NSCLC**

Kenichi Suda, Japan

**12:05 Q&A****11:15 - 12:15 ES05: Improving Outcomes for Lung Cancer Patients****Track: Patient Advocacy** ACCME Accredited By IASLC**ROOM: NICOLL 2, LEVEL 3**

Chairs: Christina Sit, Canada &amp; Satoko Yamaoka, Japan

**11:15 Welcome & Introduction**

Christina Sit, Canada &amp; Satoko Yamaoka, Japan

**11:17 ES05.03: Global State of Lung Cancer Research**

Richard Sullivan, UK

**11:29 ES05.04: Lung Cancer Screening. Focus on Information for Participants**

Maureen Rigney, USA

**11:41 ES05.05: Global Consumer Polling on Lung Cancer Issues. What Does the General Public Think?**

Carolyn Aldige, USA

**11:53 ES05.06: Implementing Lung Cancer Screening - The Challenge for Africa**

Lauren Pretorius, South Africa

**12:05 Q&A****11:15 - 12:15 MA01: Holistic Patient Care: Advances in Symptom Management and Supportive Care****Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care** Not for CME Credit**ROOM: 405C, LEVEL 4**

Chairs: Felicia Zhang, Canada &amp; Mary Duffy, Australia

**11:15 Welcome & Introduction**

Felicia Zhang, Canada &amp; Mary Duffy, Australia

**11:17 MA01.03: Thromboprophylaxis for Lung Cancer Patients: Combined Results from GMaT and ACT4CAT Studies**

Nikolaos Tsoukalas, Greece

**11:22 MA01.04: Randomized Phase II Study of Zoledronate Dosing Every 4 Versus 8 Weeks in Patients With Bone Metastasis From Lung Cancer (Hanshin Cancer Group 0312)**

Akito Hata, Japan

**11:32 MA01.06: Retrospective Analysis of Intrapleural Administration of Hypotonic Cisplatin for Malignant Pleural Effusions with Non-Expandable Lung**

Wataru Mori, Japan

**11:37 Q&A****11:45 MA01.08: Effect of Ayurvedic Rasayan Therapy on Outcome of Quality of Life in Advanced-Stage Geriatric Lung Cancer Patients**

Anand Rao Patil, India

**11:50 MA01.09: A Novel Advanced Nurse Practitioner Virtual Clinic for Patients with Low Probability of Lung Cancer**

Kirstie Woods, UK

## SCIENTIFIC PROGRAM - SUNDAY, SEPTEMBER 10, 2023

**11:55** MA01.10: A Smartphone App Assisting Rehabilitation and Symptom Management After VATS Lobectomy of Lung Cancer: A Prospective Randomized Controlled Trial  
*Chao Lv, China*

**12:00** MA01.11: Assessment of Baseline Nutritional Status in Patients with Advanced Lung Cancer in the Lung Cancer Pathway, and Patient Satisfaction  
*Rafael Lopez-Castro, Spain*

**12:05** Q&A

### 11:15 - 12:15 OA01: Advancing Immunotherapy in ES-SCLC

Track: Small Cell Lung Cancer and Neuroendocrine Tumors



ROOM: 406, LEVEL 4

Chairs: Michael Boyer, Australia & Chunxia Su, China

**11:15** Welcome & Introduction  
*Michael Boyer, Australia & Chunxia Su, China*

**11:17** OA01.03: Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial  
*Ying Cheng, China*

**11:27** OA01.04: Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results  
*Stephen Liu, USA*

**11:37** OA01.05: Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 in Patients with DLL3+ Tumors: Focus on SCLC  
*Martin Wermke, Germany*

**11:47** OA01.06: First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study  
*Ying Cheng, China*

**11:57** OA01.07: Discussant  
*Noemí Reguart, Spain*

**11:57** Q&A

### 11:15 - 12:15 OA02: Evolving Landscape in Mesothelioma

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors



ROOM: SUMMIT 2, LEVEL 3

Chairs: Ayten Kayi Cangir, Turkey & Surein Arulananda, Australia

**11:15** Welcome & Introduction  
*Ayten Kayi Cangir, Turkey & Surein Arulananda, Australia*

**11:17** OA02.03: Variance in Pathologists Grading of Pleural Mesothelioma  
*Sarita Prabhakaran, Australia*

**11:27** OA02.04: Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma - NCT03126630  
*Aaron Mansfield, USA*

## SCIENTIFIC PROGRAM - SUNDAY, SEPTEMBER 10, 2023

**11:37** OA02.05: Dendritic Cell Immunotherapy Versus Best Supportive Care as Maintenance Treatment in Patients with Pleural Mesothelioma  
*Joachim Aerts, Netherlands*

**11:47** OA02.06: No Significant Difference in Survival Between Radical Surgery and Visceral-Sparing Approach for Malignant Mesothelioma  
*Melissa Culligan, USA*

**11:57** OA02.07: Discussant  
*Nobukazu Fujimoto, Japan*

**12:07** Q&A

### 12:30 - 13:30 ES06: Perioperative Therapies in Early Stage NSCLC

Track: Early-Stage Non-small Cell Lung Cancer



ROOM: 405A, LEVEL 4

Chairs: Jazmin Eckhaus, Australia & Jamie Chافت, USA

**12:30** Welcome & Introduction  
*Jazmin Eckhaus, Australia & Jamie Chافت, USA*

**12:32** ES06.03: Adjuvant Therapies in Resected NSCLC  
*Dolores Isla, Spain*

**12:44** ES06.04: Neoadjuvant Therapies in Resectable NSCLC  
*Tina Cascone, USA*

**12:56** ES06.05: Targeted Therapies in Resected NSCLC  
*Haiquan Chen, China*

**13:08** ES06.06: Predictive Biomarker Testing in Early Stage NSCLC  
*Atocha Romero, Spain*

**13:20** Q&A

### 12:30 - 13:30 ES07: Challenging Therapeutic Targets in Lung Cancer

Track: Tumor Biology - Translational Biology



ROOM: SUMMIT 1, LEVEL 3

Chairs: Junko Tanizaki, Japan & Jii Bum (Joy) Lee, Republic of Korea

**12:30** Welcome & Introduction  
*Junko Tanizaki, Japan & Jii Bum (Joy) Lee, Republic of Korea*

**12:32** ES07.03: Targeting DNA Repair Pathways in Lung Cancer  
*Timothy Yap, USA*

**12:44** ES07.04: Targeting Drug Tolerant Persisters  
*Trever Bivona, USA*

**12:56** ES07.05: Treatment of Clonally Heterogeneous Lung Cancers  
*Antonio Passaro, Italy*

**13:08** ES07.06: Exploiting Metabolic Dependencies in Lung Cancer for Therapeutic Interventions  
*Wai Leong Tam, Singapore*

**13:20** Q&A

**12:30 - 13:30 ES08: Advances in the Management of Bone Metastases in De Novo Oligometastatic Non-small Cell Lung Cancer**

Track: Metastatic Non-small Cell Lung Cancer – Local Therapies

**ROOM: NICOLL 2, LEVEL 3**

Chairs: Anil Tibdewal, India &amp; Po Yee Yip, Australia

**12:30 Welcome & Introduction**

Anil Tibdewal, India &amp; Po Yee Yip, Australia

**12:32 ES08.03: Role and Timing of Surgery for Bone Metastases**

Mark Puhaindran, Singapore

**12:44 ES08.04: Role and Timing of Radiation Therapy for Bone Metastases**

Jing Zeng, USA

**12:56 ES08.05: Role and Timing of Interventional Radiology Treatments for Bone Metastases**

Amgad Moussa, USA

**13:08 ES08.06: Integration of Systemic Therapies with Bone Metastases Directed Local Therapies**

Yasir Elamin, USA

**13:20 Q&A****12:30 - 13:30 ES09: The Role of Biomarkers and Pathology for Optimal Neoadjuvant/Adjuvant Therapy in Early Stage Lung Cancer**

Track: Pathology and Biomarkers

**ROOM: SUMMIT 2, LEVEL 3**

Chairs: Sanja Dacic, USA &amp; Sylvie Lantuejoul, France

**12:30 Welcome & Introduction**

Sanja Dacic, USA &amp; Sylvie Lantuejoul, France

**12:32 ES09.03: Neo-Adjuvant Trials in NSCLC? What Does It Mean for Pathological Assessment (CPR/MPR)**

Anjali Saqi, USA

**12:44 ES09.04: Neo-Adjuvant Trials in NSCLC? What Does It Mean for Biomarker Assessment**

Stephen Fox, Australia

**12:56 ES09.05: Adjuvant Trials in NSCLC? What Does This Mean for Pathology/Biomarkers**

Yasushi Yatabe, Japan

**13:08 ES09.06: Prognostic Factors in NSCLC: Potential Role in Selecting Patients for Neoadj and Adjuvant Therapy Eg Tumour Grade**

John Le Quesne, UK

**13:20 Q&A****12:30 - 13:30 MA02: Real World Initiatives for Lung Cancer Screening**

Track: Screening and Early Detection

**ROOM: 405B, LEVEL 4**

Chairs: John Field, UK &amp; Ella Kazerooni, USA

**12:30 Welcome & Introduction**

John Field, UK &amp; Ella Kazerooni, USA

**12:32 MA02.03: Incidentally-Detected Lung Cancer in Individuals Who Smoked v Never Smoked in a US Cohort**

Matthew Smeltzer, USA

**12:37 MA02.04: Does the Evidence Support Years-Since-Quit Smoking as a Factor in Lung Cancer Screening Eligibility**

Robert Smith, USA

**12:42 MA02.05: Long-Term Follow-up of Screening Detected Pure Ground-Glass Nodules Stable for 10 Years**

Sang-Won Um, Republic of Korea

**12:47 MA02.06: Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening**

Jacqueline Aredo, USA

**12:52 Q&A****13:00 MA02.08: Pack-Year Smoking History is an Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility**

Alexandra Potter, USA

**13:05 MA02.09: Effectiveness of Screening with Concurrent Smoking Cessation for the Netherlands**

Koen de Nijs, Netherlands

**13:10 MA02.10: A Strategic Plan to Accelerate Lung Cancer Screening - An American Cancer Society National Lung Cancer Roundtable Initiative**

Lauren Rosenthal, USA

**13:15 MA02.11: Population-Based Implementation of Lung Cancer Screening: Coupling Model Parsimony and Performance to Determine Screening Eligibility**

Thomas Callender, UK

**13:20 Q&A****12:30 - 13:30 MA03: Empowering Your Patients: Strategies for Risk Reduction and Prevention of Lung Cancer**

Track: Risk Factors, Risk Reduction &amp; Tobacco Control

**ROOM: 405C, LEVEL 4**

Chairs: Lawson Eng, Canada &amp; Douglas Arenberg, USA

**12:30 Welcome & Introduction**

Lawson Eng, Canada &amp; Douglas Arenberg, USA

## SCIENTIFIC PROGRAM - SUNDAY, SEPTEMBER 10, 2023

- 12:32 MA03.03: Does Smoking Status Affect Survival After Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer?**  
*Neil Wallace, Australia*
- 12:37 MA03.04: Pre-diagnosis Smoking Cessation and Overall Survival Among Non-small Cell Lung Cancer Patients: Results from a Large Lung Cancer Survivor Cohort**  
*Xinan Wang, USA*
- 12:42 MA03.05: Factors Associated with Smoking Cessation of Participants in National Lung Cancer Screening Program in Korea**  
*Na-Young Yoon, Republic of Korea*
- 12:47 MA03.06: Respiratory Tract Malignancy-associated Mortality Attributable to Particulate Matter in South Asia from the Global Burden of Disease**  
*Karl D'Silva, USA*
- 12:52 Q&A**
- 13:00 MA03.08: Regular Use of Pharmaceutical Opioids and Subsequent Risk of Lung Cancer**  
*Mahdi Sheikh, France*
- 13:05 MA03.09: Embedding Smoking Cessation into a Potential Lung Cancer Screening Program: Australian Tobacco Control Expert Perspectives**  
*Nathan Harrison, Australia*
- 13:10 MA03.10: The Interim Analysis of Can-Prevent-Lung Trial: Canakinumab for The Prevention of Lung Cancer**  
*JianJun Zhang, China*
- 13:15 MA03.11: Big Data and Artificial Intelligence for Exploring the Role of Genetic Risk. Family History of Cancer and Lung Cancer. Results from CLARIFY**  
*Virginia Calvo, Spain*
- 13:20 Q&A**

**12:30 - 13:30 OA03: Newer Generation Treatments for EGFR, ALK and ROS1**

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

**ROOM: 406, LEVEL 4**Chairs: *Pei Ni Ding, Australia & Fiona Blackhall, UK*

- 12:30 Welcome & Introduction**  
*Pei Ni Ding, Australia & Fiona Blackhall, UK*
- 12:32 OA03.03: Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study**  
*Jing Chen, China*
- 12:42 OA03.04: A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions**  
*Baohui Han, China*
- 12:52 OA03.05: A Randomized, Phase 3 Study of Iruplinalkib (WX-0593) vs Crizotinib in Locally Advanced or Metastatic ALK+ Non-small Cell Lung Cancer (NSCLC)**  
*Runxiang Yang, China*
- 13:02 OA03.06: Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial**  
*Byoung Chul Cho, Republic of Korea*

## SCIENTIFIC PROGRAM - SUNDAY, SEPTEMBER 10, 2023

- 13:12 OA03.07: Discussant**  
*Hiroaki Akamatsu, Japan*
- 13:22 Q&A**

**12:30 - 13:30 OA04: Lung Cancer Management - Research to Reality**

Track: Global Health, Health Services, and Health Economics

**ROOM: NICOLL 3, LEVEL 3**Chairs: *Marjolein Heuvelmans, Netherlands & Hirotsugu Kenmotsu, Japan*

- 12:30 Welcome & Introduction**  
*Marjolein Heuvelmans, Netherlands & Hirotsugu Kenmotsu, Japan*
- 12:32 OA04.03: Australian Registry and Biobank of Thoracic Cancers (AURORA) - A Multi-Site Research Platform and Longitudinal Cohort Study**  
*Jennifer Rogers, Australia*
- 12:42 OA04.04: The Registry of Genetic Alterations of Taiwan NSCLC by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study - TCOG T1521 Study**  
*Bin-Chi Liao, Taiwan*
- 12:52 OA04.05: To Treat or Not to Treat: Factors Impacting Treatment Decisions in Octogenarians with Non-Small Cell Lung Cancer (NSCLC)**  
*Wan Hsiang Chen, USA*
- 13:02 OA04.06: The Global Landscape of Lung Squamous Cell Carcinoma, Lung Adenocarcinoma, Small Cell Lung Cancer Incidence in 2020**  
*Jia Wang, China*
- 13:12 OA04.07: Discussant**  
*Fabio Ynoe de Moraes, Canada*
- 13:22 Q&A**

**13:45 - 14:45 Lunch Break****ROOM: EXHIBIT HALL, LEVEL 4****13:45 - 14:45 Concurrent Industry Sponsored and Satellite CME Symposia**

FOR FURTHER INFORMATION, PLEASE SEE PAGES 228 &amp; 230.

**13:45 - 14:45 GE01: Gender Equity in Thoracic Oncology****ROOM: NICOLL 1, LEVEL 3**Chairs: *Narjust Florez (Duma), USA & Heather Wakelee, USA*

- 13:45 Welcome & Introduction**  
*Narjust Florez (Duma), USA & Heather Wakelee, USA*
- 13:47 Listen to Interesting and Inspiring Personal Stories**  
*Her Royal Highness Princess Dina Mired, Jordan*  
*Mei Ling Yap, Australia*  
*Pyng Lee, Singapore*  
*Paula Ugalde Figueroa, USA*





**14:27 Panel Discussion**  
*Shalini Vinod, Australia*  
*Helena Linardou, Greece*  
*Karen Kelly, USA*  
*Lucia Viola, Colombia*

**14:35 Round Table Discussions – What Can IASLC Do to Help Achieve Gender Equity?**

**15:00 - 16:00 ES10: Optimal Surgical Approaches in Early Stage NSCLC**

**Track: Early-Stage Non-small Cell Lung Cancer**

ACCME Accredited By IASLC

**ROOM: 405A, LEVEL 4**

Recommended for Early Career Researchers

*Chairs: Brendon Stiles, USA & Alan Sihoe, China*

**15:00 Welcome & Introduction**  
*Brendon Stiles, USA & Alan Sihoe, China*

**15:02 ES10.03: Surgical Techniques: The Global Perspective**  
*Aneez Ahmed Dokeu, Singapore*

**15:14 ES10.04: When and Why Wedge Resection is Good Enough**  
*Alejandra Romero, Spain*

**15:26 ES10.05: Lobectomy Reigns Supreme**  
*Eric Lim, UK*

**15:38 ES10.06: Surgery and Shared Decision Making: The Patient Perspective**  
*Upal Roy, USA*

**15:50 Q&A**

**15:00 - 16:00 ES11: Tailored Therapies for KRAS Mutant Lung Cancers**

**Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy**

ACCME Accredited By IASLC

**ROOM: SUMMIT 2, LEVEL 3**

Recommended for Early Career Researchers

*Chairs: Julia Rotow, USA & Hiroaki Akamatsu, Japan*

**15:00 Welcome & Introduction**  
*Julia Rotow, USA & Hiroaki Akamatsu, Japan*

**15:02 ES11.03: Mechanisms of Resistance to KRAS G12C Inhibitors**  
*Biagio Ricciuti, USA*

**15:14 ES11.04: New Combinations Therapies and Moving beyond Current KRAS G12C Inhibitors**  
*Pasi Janne, USA*

**15:26 ES11.05: Novel Therapies for Non G12C KRAS-Mutant Lung Cancers**  
*Kathryn Arbour, USA*

**15:38 ES11.06: Sequencing Treatments for KRAS-Mutant Lung Cancers and Role for KRAS Inhibitors as First-Line Treatment and Adjuvant Treatment**  
*Enriqueta Felip, Spain*

**15:50 Q&A**

**15:00 - 16:00 ES12: Early Palliative Care for Lung Cancer: Where Are We in 2023?**

**Track: Multidisciplinary Care: Nursing, Allied Health & Palliative Care**

ACCME Accredited By IASLC

**ROOM: NICOLL 2, LEVEL 3**

Recommended for Early Career Researchers

*Chairs: Michael Franco, Australia & Anne Fraser, New Zealand*

**15:00 Welcome & Introduction**  
*Michael Franco, Australia & Anne Fraser, New Zealand*

**15:02 ES12.03: Review of Evidence: Positive Studies**  
*Andreas Charalambous, Cyprus*

**15:14 ES12.04: Review of Evidence: Negative or Equivocal**  
*Jaclyn Yoong, Australia*

**15:26 ES12.05: Components of Successful Early Referral/Screening Tools/Who to Refer**  
*David Hui, USA*

**15:38 ES12.06: Early Lung Cancer Referral: Implementation Challenges/Models of Care**  
*Peter Poon, Australia*

**15:50 ES12.07: Q&A**

**15:00 - 16:00 ES13: Pleural Malignancy, Old Problems and New Solutions**

**Track: Pulmonology and Staging**

ACCME Accredited By IASLC

**ROOM: NICOLL 3, LEVEL 3**

*Chairs: Yvonne Ang, Singapore & Harish Mithiran, Singapore*

**15:00 Welcome & Introduction**  
*Yvonne Ang, Singapore & Harish Mithiran, Singapore*

**15:02 ES13.03: Realtime Ultrasound Guided Interventions in Pleural Disease**  
*Christine Argento, USA*

**15:14 ES13.04: Tumor Markers in Diagnosis & Treatment of Malignant Pleural Effusion**  
*Carla Lamb, USA*

**15:26 ES13.05: Pleural Effusion Control - Where Have We Come From and Going?**  
*YC Gary Lee, Australia*

**15:38 ES13.06: Surgical Intervention for Malignant Pleural Disease**  
*Takahiro Nakajima, Japan*

**15:50 Q&A**

**15:00 - 16:00 MA04: Novel Targets and Overcoming Drug Resistance**

**Track: Tumor Biology – Translational Biology**

Not for CME Credit

**ROOM: 405B, LEVEL 4**

*Chairs: Jonathan Ostrem, USA & Regina Hoo, Singapore*

**15:00 Welcome & Introduction**  
*Jonathan Ostrem, USA Regina Hoo, Singapore*

## SCIENTIFIC PROGRAM - SUNDAY, SEPTEMBER 10, 2023

- 15:02 MA04.03: Osimertinib-induced Epigenetic and Transcriptional Reprogramming Drives a BRD4-POUF-PDGFRB-YAP-EMT Axis of Resistance in NSCLC**  
*Antja-Voy Hartley, USA*
- 15:07 MA04.04: A Novel Anti-EGFR/CD3 Bispecific Antibody Exhibits Potent Efficacy for Osimertinib-resistant NSCLC**  
*Haoyue Guo, China*
- 15:12 MA04.05: Transcriptomic Features as Determinant of Therapy Response in Neuroendocrine-Transformed Adenocarcinomas Following TKI**  
*Ming Tsao, Canada*
- 15:17 MA04.06: Epigenomic Drug Effect on Osimertinib-Induced Drug Tolerant Persister in a Lung Cancer Patient-Derived Xenograft Model**  
*Yoshiaki Inoue, Japan*
- 15:22 Q&A**
- 15:30 MA04.08: Identifying Early and Late Hallmarks of Plasticity in Neuroendocrine Transformation of Lung Cancer at Single-Cell Level**  
*Joseph Chan, USA*
- 15:35 MA04.09: The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)**  
*Rafael Rosell, Spain*
- 15:40 MA04.10: Molecular Characteristics of Non-Small Cell Lung Cancer with MET Fusions**  
*Chul Kim, USA*
- 15:50 Q&A**

**15:00 - 16:00 MA05: Patient Experience in Treatment and Research**

Track: Patient Advocacy

**ROOM: 405C, LEVEL 4***Chairs: Yi Lin Teh, Singapore & Janet Freeman-Daily, USA*

- 15:00 Welcome & Introduction**  
*Yi Lin Teh, Singapore & Janet Freeman-Daily, USA*
- 15:02 MA05.03: Questionnaire Survey on the Experience and Awareness of Personalized Medicine in Patients with Lung Cancer**  
*Kazuo Hasegawa, Japan*
- 15:07 MA05.04: Role of QoL in Treatment Decisions for Patients with ALK+ NSCLC**  
*Heather Law, USA*
- 15:12 MA05.05: Patient Reported Rxprience as a Baseline for 4R Care Sequence Implementation at 8 Cancer Centers**  
*Kevin Prescott, USA*
- 15:17 MA05.06: Lung Cancer Patients' Preferred Method of Contact with Their Treatment Team in Different Situations: Insights From a Global Experience Survey**  
*Jackie Fenemore, UK*
- 15:22 Q&A**

## SCIENTIFIC PROGRAM - SUNDAY, SEPTEMBER 10, 2023

- 15:30 MA05.08: LungMATCH - The Impact of Direct to Patient Clinical Trial Navigation on Engagement In the Lung Cancer Trial Process**  
*Andrew Ciupek, USA*
- 15:35 MA05.09: Neutrophil Count In African American Patients with Lung Cancer: Implications for Inclusion in Clinical Trials**  
*Haiying Cheng, USA*
- 15:40 MA05.10: Patient-Initiated a Phase II study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutated T790M-Negative NSCLC**  
*Kazuo Hasegawa, Japan*
- 15:45 MA05.11: Predictive Utility of Patient-Reported Outcomes for Survival in 1st-Line Treated Patients with aNSCLC in EMPower-Lung 1 and 3**  
*David R. Gandara, USA*
- 15:50 Q&A**

**15:00 - 16:00 OA05: Antibody Drug Conjugates: The Next Tsunami**

Track: Small Cell Lung Cancer and Neuroendocrine Tumors

**ROOM: 406, LEVEL 4***Chairs: Melissa Moore, Australia & Aliyah Pabani, USA*

- 15:00 Welcome & Introduction**  
*Melissa Moore, Australia & Aliyah Pabani, USA*
- 15:02 OA05.03: Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01**  
*Helena Yu, USA*
- 15:12 OA05.04: Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study**  
*Byoung Chul Cho, Republic of Korea*
- 15:22 OA05.05: Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study**  
*Melissa Johnson, USA*
- 15:32 OA05.06: Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04**  
*Saiama Waqar, USA*
- 15:42 OA05.07: Discussant**  
*Helena Linardou, Greece*
- 15:42 Q&A**

**15:00 - 16:00 OA06: To Resect or Not to Resect (In Stage III NSCLC)? That Is the Question**

Track: Local-Regional Non-small Cell Lung Cancer

**ROOM: SUMMIT 1, LEVEL 3***Chairs: Leah Backhus, USA & Sabina Berezowska, Switzerland*

- 15:00 Welcome & Introduction**  
*Leah Backhus, USA & Sabina Berezowska, Switzerland*

## SCIENTIFIC PROGRAM - SUNDAY, SEPTEMBER 10, 2023

- 15:02** **OA06.03: An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer**  
*Ilias Houda, Netherlands*
- 15:12** **OA06.04: Surgery after Neoadjuvant Immuno-Chemoradiotherapy in (Borderline) Resectable NSCLC: Results from the INCREASE Trial**  
*Chris Dickhoff, Netherlands*
- 15:22** **OA06.05: Consensual Definition of Stage III NSCLC Resectability: EORTC-Lung Cancer Group Initiative with Other Scientific Societies**  
*Mariana Brandao, Netherlands*
- 15:32** **OA06.06: A Novel Multiparameter Biomarker of Pathological Response for NSCLC Receiving Neoadjuvant Immunotherapy: A Real-world Study**  
*Shaowei Wu, China*
- 15:42** **OA06.07: Discussant**  
*Sandip Patel, USA*
- 15:52** **Q&A**

**16:15 - 17:15 ES14: Assessment for Curative Intent-Therapy in LR NSCLC**

Track: Local-Regional Non-small Cell Lung Cancer

ACCME Accredited By IASLC

ROOM: SUMMIT 1, LEVEL 3

Recommended for Early Career Researchers

Chairs: Sze Wai Chan, South Africa &amp; Rina Hui, Hong Kong

- 16:15** **Welcome & Introduction**  
*Sze Wai Chan, South Africa & Rina Hui, Hong Kong*
- 16:17** **ES14.03: Tobacco Moment: Impact of Smoking on Clinical Outcomes in Radiotherapy**  
*Jacek Jassem, Poland*
- 16:22** **ES14.04: Staging for Radiation Therapy in Locally Resectable NSCLC**  
*Michael MacManus, Australia*
- 16:34** **ES14.05: Assessment for Surgery in Locally Resectable NSCLC**  
*Akif Turna, Turkey*
- 16:46** **ES14.06: Assessment for Systemic Therapy in Locally Resectable NSCLC**  
*Christine Bestvina, USA*
- 16:58** **ES14.07: Preparing the Patient for Treatment in Locally Resectable NSCLC**  
*Mary Duffy, Australia*
- 17:10** **Q&A**

**16:15 - 17:15 ES15: How Are Antibody Drug Conjugates (ADCs) Being Strategized to Revolutionize NSCLC Treatment?**

Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

ACCME Accredited By IASLC

ROOM: 406, LEVEL 4

Recommended for Early Career Researchers

Chairs: Egbert Smit, Netherlands &amp; Melissa Johnson, USA

- 16:15** **Welcome & Introduction**  
*Egbert Smit, Netherlands & Melissa Johnson, USA*

## SCIENTIFIC PROGRAM - SUNDAY, SEPTEMBER 10, 2023

- 16:17** **ES15.03: Pharmacology of ADC Classes**  
*Pamela Abdayem, France*
- 16:29** **ES15.04: Current ADC Development in NSCLC**  
*William Nassib Williams, Brazil*
- 16:41** **ES15.05: Management of ADC Associated Toxicities**  
*Sun Min Lim, Republic of Korea*
- 16:53** **ES15.06: Are Biomarkers Necessary for ADCs?**  
*Aakash Desai, USA*
- 17:05** **Q&A**

**16:15 - 17:15 ES16: Early Mesothelioma**

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors

ACCME Accredited By IASLC

ROOM: SUMMIT 2, LEVEL 3

Recommended for Early Career Researchers

Chairs: Steven Kao, Australia &amp; Shalini Subramaniam, Australia

- 16:15** **Welcome & Introduction**  
*Steven Kao, Australia & Shalini Subramaniam, Australia*
- 16:17** **ES16.03: Biomarkers for Early Detection**  
*Haining Yang, USA*
- 16:29** **ES16.04: What Is Mesothelioma Insitu? Diagnostic and Treatment Implications**  
*Sonja Klebe, Australia*
- 16:41** **ES16.05: Surgical Management of Pleural Mesothelioma**  
*Seiki Hasegawa, Japan*
- 16:53** **ES16.06: Radiation as Part of Multimodality Therapy**  
*Andreas Rimner, USA*
- 17:05** **Q&A**

**16:15 - 17:15 ES17: Hot Topics in Lung Cancer Biomarkers**

Track: Pathology and Biomarkers

ACCME Accredited By IASLC

ROOM: NICOLL 2, LEVEL 3

Chairs: Angela Takano, Singapore &amp; Wendy Cooper, Australia

- 16:15** **Welcome & Introduction**  
*Angela Takano, Singapore & Wendy Cooper, Australia*
- 16:17** **ES17.03: Biomarkers for Antibody/Drug Conjugates - Lessons from PD-L1**  
*Mary Beth Beasley, USA*
- 16:29** **ES17.04: Liquid vs Tissue? Which and When Is the Issue for Clinical Utility**  
*Umberto Malapelle, Italy*
- 16:41** **ES17.05: Refining Prediction of Response to IO in NSCLC Eg CD8+, Spatial Immune Variability**  
*Kosuke Tanaka, Japan*
- 16:53** **ES17.06: Emerging Biomarkers for IO Therapy in Small Cell Lung Cancer**  
*Navin Mahadevan, USA*
- 17:05** **Q&A**

**16:15 - 17:15 MA06: Targeted Therapy: KRAS and Beyond**

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Not for CME Credit

**ROOM: 405B, LEVEL 4**

Chairs: Sukhmani Padda, USA &amp; Thanyanan Baisamut (Reungwetwattana), Thailand

- 16:15 Welcome & Introduction**  
Sukhmani Padda, USA & Thanyanan Baisamut (Reungwetwattana), Thailand
- 16:17 MA06.03: KontraST-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors**  
Marcelo Negrao, USA
- 16:22 MA06.04: KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC**  
Shirish Gadgeel, USA
- 16:27 MA06.05: CodeBreak 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC.**  
Jeffrey Clarke, USA
- 16:32 MA06.06: A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J**  
Gary Middleton, UK
- 16:37 Q&A**
- 16:45 MA06.08: Real-World Landscape Analysis of Activating ERBB2/ERBB3 Alterations in 107,561 Tissue and Plasma Samples from Patients with NSCLC**  
Dazhi Liu, USA
- 16:55 MA06.10: Discovery of Potent Degradors of KRASG12D Based on a Novel KRAS Binder**  
Dongzhou Liu, China
- 17:00 MA06.11: Lorlatinib for Previously Treated ALK-positive Advanced NSCLC: Updated Efficacy and Safety Data from a Phase 2 Study in China**  
Shun Lu, China
- 17:05 Q&A**

**16:15 - 17:15 MA07: Barriers and Benefits**

Track: Patient Advocacy

Not for CME Credit

**ROOM: 405C, LEVEL 4**

Chairs: Dave Bjork, USA &amp; Ewelina Szymtyke, Poland

- 16:15 Welcome & Introduction**  
Dave Bjork, USA & Ewelina Szymtyke, Poland
- 16:17 MA07.03: Analyzing and Understanding the Unmet Needs of Lung Cancer Patients and Their Loved Ones**  
Brittney Nichols, USA
- 16:22 MA07.04: Barriers to Lung Cancer Care in Europe**  
Anne-Marie Baird, Ireland

- 16:27 MA07.05: Canadian Lung Cancer Patient-Reported Fear and Anxiety: Current State and Ongoing Needs**  
Angus Pratt, Canada
- 16:32 MA07.06: Media Training Equips Advocates to Increase Awareness About Lung Cancer Issues**  
Dusty Donaldson, USA
- 16:37 Q&A**
- 16:45 MA07.08: Patient Involvement in Decision-Making Around Their Treatment and Care: Findings from a Global Patient Experience Survey**  
Jackie Fenemore, UK
- 16:50 MA07.09: Adapted Physical Activity (AMAti) Program for Lung Cancer Patients Realized by WALCE (Women Against Lung Cancer in Europe)**  
Stefania Vallone, Italy
- 16:55 MA07.10: Co-Design and Implementation of A Digital Care Pathway for Patients with Lung Cancer**  
Katharine See, Australia
- 17:00 MA07.11: An International Survey Assessing the Unmet Needs of Family Caregivers of People with Lung Cancer: Preliminary Findings**  
Heather Law, USA
- 17:05 Q&A**

**16:15 - 17:15 OA07: Refining Risk Prediction Models for Lung Cancer Screening**

Track: Screening and Early Detection

ACCME Accredited By IASLC

**ROOM: 405A, LEVEL 4**

Chairs: Ricardo Sales Santos, Brazil &amp; Lucia Viola, Colombia

- 16:15 Welcome & Introduction**  
Ricardo Sales Santos, Brazil & Lucia Viola, Colombia
- 16:17 OA07.03: Performance of PLCOm2012-Based Screening Eligibility in the Manchester Lung Health Check Pilot Cohort after 6 years**  
Patrick Goodley, UK
- 16:27 OA07.04: Effectiveness of NELSON versus PLCOm2012 Lung Cancer Screening Eligibility Criteria: First Results from the German HANSE Study**  
Jens Vogel-Claussen, Germany
- 16:37 OA07.05: Pre-Recruitment as a Strategy to Address “Near-Miss” Cases in Risk-Based Lung Cancer Screening Selection: An Analysis of ILST Data**  
Chellan Kumarasamy, Australia
- 16:47 OA07.06: Development and Validation of a Protein-Based Lung Cancer Risk Prediction Model - Initial Results from the Lung Cancer Cohort Consortium (LC3)**  
Hana Zahed, France
- 16:57 OA07.07: Discussant**  
Antoni Rosell, Spain
- 17:07 Q&A**

**16:15 - 17:15** **OA08: Thriving not Surviving: Advances in Lung Cancer Rehabilitation and Lung Cancer in Older Adults**

**Track:** Multidisciplinary Care: Nursing, Allied Health & Palliative Care **ACCME Accredited By IASLC**

**ROOM: NICOLL 3, LEVEL 3**

*Chairs: Morten Quist, Denmark & Maria Ftanou, Australia*

**16:15** **Welcome & Introduction**

*Morten Quist, Denmark & Maria Ftanou, Australia*

**16:17** **OA08.03: Do Enhanced Recovery after Lung Cancer Surgery Programs Risk Putting Primacy of Caring at Stake?**

*Malene Missel, Denmark*

**16:27** **OA08.04: Exploring Survivorship Care Needs for Low-Income Older Adults with Lung Cancer in a Safety-Net Setting: A Qualitative Study**

*Ana Velazquez, USA*

**16:37** **OA08.05: Implementation and Evaluation of a Geriatric Oncology Model of Care for Older Patients with Lung Cancer**

*Shalini Vinod, Australia*

**16:47** **OA08.06: Development of a Lung Cancer Rehabilitation Core Outcome Set: An International Delphi Study (UNITE)**

*Lara Edbrooke, Australia*

**16:57** **OA08.07: Discussant**

*David Hui, USA*

**17:07** **Q&A**

**17:30 - 19:30** **Poster Viewing Networking Reception (Poster Session 1: P1) with Presenters in Attendance**

**ROOM: EXHIBIT HALL, LEVEL 4**

**Refreshments Provided**

**18:00 - 18:30** **JTO and JTO CRR Editorial Reception (By Invitation Only)**

**ROOM: CONCOURSE 1/REGISTRATION, LEVEL 3**

**Not for CME Credit**

**18:30 - 19:30** **Concurrent Industry Sponsored and Satellite CME Symposia**

**FOR FURTHER INFORMATION, PLEASE SEE PAGES 229 & 230.**

**20:00 - 23:00** **Faculty Dinner (By Invitation Only)**



**4** **PROGRAM**  
**MONDAY**

# The Journal of Thoracic Oncology 2022 Impact Factor has risen to

# 20.4

# #13

OF 241  
ONCOLOGY  
JOURNALS

# #4

OF 65  
RESPIRATORY  
SYSTEM JOURNALS

THE  
HIGHEST  
YET!



# LUNG CANCER CONSIDERED



with Dr. Stephen Liu and Dr. Narjust Florez  
an IASLC Podcast

In 2023, the podcast was ranked in the Top 5% of  
Global Podcasts by Listen Notes.



2022 w3 Gold Award for  
Creative Excellence

Join us in listening to our award winning content  
on your favorite app.



Find new  
podcast episodes  
here.



Lung Cancer Considered  
is funded in part by:  
AstraZeneca, Daiichi-Sankyo,  
Genentech, and Takeda


# 04 WCLC 2023 FULL PROGRAM

Monday, September 11, 2023

## Monday, September 11, 2023

### 07:30 - 08:15 HOD01: Highlights of the Day - Sunday Abstracts


ROOM: 405A, LEVEL 4  

- 07:30 **HOD01.01: Radiation Oncology**  
*Feng-Ming Kong, Hong Kong* 
- 07:40 **HOD01.02: Pulmonology**  
*Kwun Fong, Australia*
- 07:50 **HOD01.03: Medical Oncology**  
*Rami Manochakian, USA*
- 08:00 **Q&A**

### 07:30 - 08:15 MTE08: Liquid Biopsies - Current Technologies and Clinical Applications

Track: Tumor Biology - Translational Biology  

ROOM: 405C, LEVEL 4  

- 07:30 **MTE08.01: New and Novel Technologies for Liquid Biopsies**  
*Maximilian Diehn, USA* 
- 07:45 **MTE08.02: Current and Future Clinical Applications of Liquid Biopsies**  
*Se-Hoon Lee, Republic of Korea*
- 08:00 **Q&A**


### 07:30 - 8:15 MTE09: Patient Centered Grand Rounds in Local Regional NSCLC: Single Mediastinal Station Stage IIIA

Track: Local-Regional Non-small Cell Lung Cancer  

ROOM: SUMMIT 1, LEVEL 3  

- 07:30 **MTE09.01: Surgery Perspective**  
*Simon Knight, Australia* 
- 07:40 **MTE09.02: Rad Onc Perspective**  
*Shalini Vinod, Australia*
- 07:50 **MTE09.03: Med Onc Perspective**  
*Jamie Chافت, USA*
- 08:00 **MTE09.04: Patient Response**  
*Jill Feldman, USA*
- 08:07 **MTE09.05: Patient Response**  
*Seamus Cotter, Ireland*

### 07:30 - 08:15 Systemic Therapy Combinations in EGFR-mutated NSCLC

Track: Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy 

ROOM: NICOLL 2, LEVEL 3   



- 07:30 **MTE10.01: Chemotherapy after Targeted Therapy - What is the Best Strategy?**  
*Laura Mezquita, Spain*
- 07:45 **MTE10.02: Choosing the Best Chemotherapy Regimen for NSCLC Subpopulations**  
*Rina Hui, Hong Kong*
- 08:00 **Q&A**

### 07:30 - 08:15 MTE11: Optimizing First-Line Targeted Therapy Treatment

Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy 

ROOM: NICOLL 3, LEVEL 3  

- 07:30 **MTE11.01: First Line-Combination Therapies to Eradicate Persister Cells**  
*James Chih-Hsin Yang, Taiwan*
- 07:45 **MTE11.02: Risk Adaptive First-Line Treatments: Use of ctDNA, Comutations or Clinical Factors to Risk Stratify**  
*Helena Yu, USA*
- 08:00 **Q&A**

### 07:30 - 08:15 MTE12: Debate: Upfront NGS Testing Should Be the Standard of Care in Advanced NSCLC

Track: Global Health, Health Services, and Health Economics 

ROOM: SUMMIT 2, LEVEL 3  



- 07:30 **MTE12.01: For the Proposition**  
*Natasha Leigh, Canada*
- 07:45 **MTE12.02: Against the Proposition**  
*Herbert Loong, Hong Kong*
- 08:00 **MTE12.03: Q&A**  
*Luis Raez, USA*

### 07:30 - 08:15 MTE13: Controversy in Staging: Nodes vs Nodule

Track: Pulmonology and Staging  

ROOM: NICOLL 1, LEVEL 3  

- 07:30 **MTE13.01: Prioritizing Staging vs Nodule Diagnosis. Case Illustration**  
*Douglas Arenberg, USA*
- 07:50 **MTE13.02: Robotic Navigational Bronchoscopy and Ablative Therapy**  
*Calvin Ng, Hong Kong*
- 08:10 **Q&A**

**08:30 - 10:00 PLO3: Plenary Session 3: Presidential Symposium****ROOM: 406, LEVEL 4***Chairs: Heather Wakelee, USA & Paul Van Schil, Belgium***08:30 PLO3.02: President's Address***Heather Wakelee, USA***08:36 PLO3.03: Incoming President's Address***Paul Van Schil, Belgium***08:46 PLO3.04: The Taiwan National Lung Cancer Screening Program***Chi-Yen Huang, Taiwan***08:53 PLO3.05: Discussant***Gerard Silvestri, USA***09:01 Q&A****09:03 PLO3.07: Invasion or No Invasion, That's the Question. A Large Reproducibility Study in Pulmonary Adenocarcinoma, Supporting a Modified Classification***Erik Thunnissen, Netherlands***09:10 PLO3.08: Discussant***Mari Mino-Kenudson, USA***09:18 Q&A****09:20 PLO3.10: MARS 2: A Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus No Radical Surgery for Mesothelioma***Eric Lim, UK***09:30 PLO3.11: Discussant***Paula Ugalde Figueroa, USA***09:38 Q&A****09:40 PLO3.13: Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)***Pasi Janne, USA***09:50 PLO3.14: Discussant***Yi-Long Wu, China***09:58 Q&A****10:00 - 10:45 Meet the IASLC Committees****IASLC MEMBERSHIP LOUNGE IN THE EXHIBIT HALL**

IASLC Members - Visit the Committee Corner within the IASLC Membership Lounge for a chance to connect with Committee Members and to learn more about IASLC Committee initiatives.

**10:00 - 10:45 Coffee Break****ROOM: EXHIBIT HALL, LEVEL 4****10:05 - 11:00 PC03: Press Conference****ROOM: 327, LEVEL 3****10:10 - 10:40 IASLC02: IASLC Board Office Hours****ROOM: EXHIBIT HALL, COLLABORATIVE MEETING LOUNGE**

Join select IASLC Board Members and ask them anything you want to know about the IASLC and its activities, being a member, being a board or committee member or anything else you have always wanted to know!

**10:45 - 11:45 ES18: Preclinical Modeling and Drug Development****Track: Tumor Biology - Translational Biology****ROOM: NICOLL 2, LEVEL 3***Chairs: Pasi Janne, USA & Dean Fennell, UK***10:45 Welcome & Introduction***Pasi Janne, USA & Dean Fennell, UK***10:47 ES18.03: Mouse Models of Squamous Cell Lung Cancer***Kwok Kin Wong, USA***10:59 ES18.04: Derivation and Characterization of Pleural Mesothelioma Organoid Models***Robert Rintoul, UK***11:11 ES18.05: Patient-Derived Tumor Explant Models for Personalized Drug Testing***Eliza Fong, Singapore***11:23 ES18.06: Tumor Organotypic Spheroids for Preclinical Studies on Immunotherapies***David Barbie, USA***11:35 Q&A****10:45 - 11:45 ES19: Curative Intent Therapy in Patients with LR NSCLC with Special Characteristics****Track: Local-Regional Non-small Cell Lung Cancer****ROOM: SUMMIT 1, LEVEL 3***Chairs: Yu Yang Soon, Singapore & Monica Castro, Argentina***10:45 Welcome & Introduction***Yu Yang Soon, Singapore & Monica Castro, Argentina***10:47 ES19.03: Surgery in Patients with Adverse Prognostic Factors***Jazmin Eckhaus, Australia***10:59 ES19.04: Radiation Therapy in Patients with Adverse Prognostic Factors***Sue Yom, USA***11:11 ES19.05: Systemic Therapy in Patients with Adverse Prognostic Factors***Jarushka Naidoo, Ireland***11:23 ES19.06: Special Patient Needs in LR NSCLC***Sue McCullough, Australia***11:35 Q&A**



**10:45 - 11:45 ES20: Defining and Managing Oligoprogression in Metastatic Non-small Cell Lung Cancer**Track: Metastatic Non-small Cell Lung Cancer – Local Therapies 

ROOM: NICOLL 1, LEVEL 3



Chairs: Mark Berry, USA &amp; Connie Yip, Singapore

**10:45 Welcome & Introduction**

Mark Berry, USA &amp; Connie Yip, Singapore

**10:47 ES20.03: Defining Oligoprogression during Systemic Treatment**

Yolande Lievens, Belgium

**10:59 ES20.04: Considerations for Surgery for Oligoprogression**

Mara Antonoff, USA

**11:11 ES20.05: Considerations for Radiation Therapy for Oligoprogression**

Kevin Chua, Singapore

**11:23 ES20.06: Strategies for Empowering Patients and Personalizing Treatment Recommendations for Oligoprogression: Patient's Perspectives**

Fan Yang, Australia

**11:35 Q&A****10:45 - 11:45 ES21: Risk Reduction and Tobacco Control**Track: Risk Factors, Risk Reduction & Tobacco Control 

ROOM: 405A, LEVEL 4

Chairs: Yvonne Ang, Singapore &amp; Feng Ming Kong, Hong Kong

**10:45 Welcome & Introduction**

Yvonne Ang, Singapore &amp; Feng Ming Kong, Hong Kong

**10:47 ES21.03: Evidence of Harm from Newer Non-combusted Tobacco Products (ENDS & HTP)**

Emily Stone, Australia

**11:02 ES21.04: Air Pollution and Lung Cancer - Public Health Perspectives**

Michelle Turner, Spain

**11:17 ES21.05: Pathologic and Molecular Features of Lung Adenocarcinoma in People Who Smoke and People Who Do Not Smoke**

Guoping Cai, USA

**11:32 Q&A****10:45 - 11:45 MA08: Mediastinal Lumps and Bumps**Track: Mesothelioma, Thymoma, and Other Thoracic Tumors 

ROOM: 405C, LEVEL 4

Chair: Andrea Bezjak, Canada &amp; Michael Boyer, Australia

**10:45 Welcome & Introduction**

Andrea Bezjak, Canada &amp; Michael Boyer, Australia

**10:47 MA08.03: Too Early to be Different? A Multi-Institutional Study for Early Stage Thymoma with 30-Year Follow-up**  
Yi-Ting Yen, Taiwan**10:52 MA08.04: Assessment of the Quality of the Surgical Procedure and the Operative Report Based on Nationwide French Registry: A RYTHMIC study**  
Jose Benitez, France**10:57 MA08.05: Combining SBRT with GM-CSF and Peg-IFN $\alpha$  to Induce Abscopal Effects in Previously Treated Patients with Stage IV Thymic Tumors**  
Min Fan, China**11:07 Q&A****11:15 MA08.08: First-line PD-1 Inhibitor plus Chemotherapy versus Platinum-based Chemotherapy for Patients with Advanced Thymic Carcinoma**  
Xue Hou, China**11:20 MA08.09: SMARCA4 deficient Thoracic Tumors: Clinicopathological, Molecular Characteristics and Optimal Therapeutics Methods**  
Lanlan Pang, China**11:25 MA08.10: The Novel Algorithm for Diagnosis of Mediastinal Tumours**  
Oleg Pikin, Russian Federation**11:30 MA08.11: Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma**  
Jia Luo, USA**11:35 Q&A****10:45 - 11:45 OA09: Immunotherapy for Advanced NSCLC**Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy 

ROOM: 406, LEVEL 4

Chairs: Benjamin Solomon, Australia &amp; Ana Gelatti, Brazil

**10:45 Welcome & Introduction**

Benjamin Solomon, Australia &amp; Ana Gelatti, Brazil

**10:47 OA09.03: STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy in NSCLC: Results From Three Randomized Trials**  
Anlin Li, China**10:57 OA09.04: ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors**  
Chee Lee, Australia**11:07 OA09.05: A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004)**  
Caicun Zhou, China**11:17 OA09.06: IMpower151: Phase III Study of Atezolizumab + Bevacizumab + Chemotherapy in 1L Metastatic Nonsquamous NSCLC**  
Caicun Zhou, China**11:27 OA09.07: Discussant**  
Justin Gainor, USA**11:17 Q&A**

**10:45 - 11:45 OA10: Precision Language in Thoracic Oncology**

Track: Patient Advocacy

ACCME Accredited By IASLC

ROOM: SUMMIT 2, LEVEL 3

Recommended for Early Career Researchers

Chairs: Upal Basu Roy, USA &amp; Cecilia Pompili, Italy

- 10:45 Welcome & Introduction**  
Upal Basu Roy, USA & Cecilia Pompili, Italy
- 10:47 OA10.03: Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective**  
Eric Singhi, USA
- 10:57 OA10.04: A Systems Approach to Improving Clinical Trial Informed Consent Forms in Lung Cancer Clinical Trials**  
Bellinda King-Kallimanis, USA
- 11:07 OA10.05: Patient-Facing Biomarker Testing Reports: Views and Preferences of People with Lung Cancer and Caregivers**  
Andrew Ciupek, USA
- 11:17 OA10.06: Recognizing Early Adopters of Non Stigmatizing Language at IASLC WCLC 2022**  
Jill Feldman, USA
- 11:27 OA10.07: Discussant**  
Lawrence Feldman, USA
- 11:37 Q&A**

**10:45 - 11:45 OA11: Make It Mini: Minimal and Increasingly Minimally Invasive Approaches in Early Stage Lung Cancer**

Track: Early-Stage Non-small Cell Lung Cancer

ACCME Accredited By IASLC

ROOM: NICOLL 3, LEVEL 3

Chairs: Eldsamira Mascarenhas, Brazil &amp; Erin Gillaspie, USA

- 10:45 Welcome & Introduction**  
Eldsamira Mascarenhas, Brazil & Erin Gillaspie, USA
- 10:47 OA11.03: Prognostic Impact of Ground Glass Opacity Component and Consolidation Size After Sublobar Resection: A Quantitative Analysis**  
Ji Yong Kim, Republic of Korea
- 10:57 OA11.04: Which Lymph Nodes Should be Evaluated with Priority in Segmentectomy for Lung Cancer?**  
Junji Ichinose, Japan
- 11:07 OA11.05: A Propensity-Matched Comparison between Minimally Invasive Surgery and Stereotactic Radiotherapy in the Treatment of Clinical Stage I NSCLC**  
Andrea Billè, Italy
- 11:17 OA11.06: Sublobar Resection vs. Lobectomy for Non-Small-Cell Lung Cancers 2cm or Less in Size with High-Risk Features**  
Camille Mathey-Andrews, USA
- 11:27 OA11.07: Discussant**  
Aneez Ahmed Dokeu, Singapore
- 11:37 Q&A**

**12:00 - 13:00 ES22: Pushing the Limit- Novel Solutions to Challenges Related to Pulmonary Malignancy**

Track: Pulmonology and Staging

ACCME Accredited By IASLC

ROOM: NICOLL 3, LEVEL 3

Chairs: Navneet Singh, India &amp; John Tam, Singapore

- 12:00 Welcome & Introduction**  
Navneet Singh, India & John Tam, Singapore
- 12:02 ES22.03: Virtual Image-Based Biopsy of Lung Metastases: Promise of Radiomics**  
Ritu Gill, USA
- 12:14 ES22.04: Therapeutic Bronchoscopic Interventions for Modification of Primary Tumor and Nodal Microenvironment**  
Daniel Serman, USA
- 12:26 ES22.05: Bronchoscopy for Malignant Central Airway Obstruction and Fistula**  
Anne Hsu, Singapore
- 12:38 ES22.06: Robotic Surgery for Locally Advanced and Oligometastatic NSCLC**  
Seong-Yong Park, Republic of Korea
- 12:50 Q&A**

**12:00 - 13:00 ES23: Supporting Smoking Cessation in the Clinic - The Complete Toolbox for Doctors**

Track: Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy

ACCME Accredited By IASLC

ROOM: SUMMIT 2, LEVEL 3

Chairs: Emily Stone, Australia &amp; Alvin Lo, Singapore

- 12:00 Welcome & Introduction**  
Emily Stone, Australia & Alvin Lo, Singapore
- 12:02 ES23.03: The Effect of Smoking on Survival in NSCLC - Is It Too Late to Quit?**  
Matthew Steliga, USA
- 12:14 ES23.04: Smoking Cessation in Different Patient Groups - Is There a Personalised Strategy?**  
Magdalena Cedzynska, Poland
- 12:26 ES23.05: Building Trust and Supporting Quitting - What Not to Do**  
Matthew Evison, USA
- 12:38 ES23.06: Taking the Pain out of Discussing Quitting in the Clinic - An Effective Approach**  
Henry Marshall, Australia
- 12:50 Q&A**

**12:00 - 13:00 ES24: Forward Progress in Oncogene-Addicted NSCLC**

Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy

ACCME Accredited By IASLC

ROOM: 405A, LEVEL 4

Chairs: Byoung Chul Cho, Republic of Korea &amp; Jhanelle Gray, USA

- 12:00 Welcome & Introduction**  
Byoung Chul Cho, Republic of Korea & Jhanelle Gray, USA

- 12:02 ES24.03: How to Incorporate Liquid Biopsies into Treatment beyond Diagnosis - Consider Role in Early Stage Setting, Minimal Residual Disease and in the Resistance Setting Prior to Radiographic Changes**  
*Jordi Remon, France*
- 12:14 ES24.04: Mechanisms of Resistance to Targeted Therapy - Common Themes and Treatments to Target**  
*Sanjay Papat, UK*
- 12:26 ES24.05: Addressing the Problem of CNS Mets**  
*Yu Yang Soon, Singapore*
- 12:38 ES24.06: Second Line and beyond Treatments for Advanced/Metastatic EGFR-Mutant NSCLC**  
*Tae Min Kim, Republic of Korea*
- 12:50 Q&A**

**12:00 - 13:00 ES25: Hot Topics in Lung Cancer Pathology**

Track: Pathology and Biomarkers

**ROOM: NICOLL 2, LEVEL 3**

Chairs: Lukas Bubendorf, Switzerland &amp; Xin Min Cheng, Singapore

- 12:00 Welcome & Introduction**  
*Lukas Bubendorf, Switzerland & Xin Min Cheng, Singapore*
- 12:02 ES25.03: Grading of Lung Cancers and the Clinical Significance - ADC, SCC Prognostic Factors Being Considered for Grading Scheme**  
*Mari Mino-Kenudson, USA*
- 12:14 ES25.04: Assessment of Invasion in Lung Adenocarcinoma**  
*Akihiko Yoshizawa, Japan*
- 12:26 ES25.05: Lessons from Challenging Lung Cases**  
*Edwina Duhig, Australia*
- 12:38 ES25.06: AI Applications in Lung Cancer Pathology - Diagnosis, Classification, MPR Assessment**  
*Jan von der Thusen, Netherlands*
- 12:50 Q&A**

**12:00 - 13:00 MA09: Deciphering the Tumor Microenvironment**

Track: Tumor Biology – Translational Biology

**ROOM: 405C, LEVEL 4**

Chairs: Shengxiang Ren, China &amp; Mihaela Aldea, France

- 12:00 Welcome & Introduction**  
*Shengxiang Ren, China & Mihaela Aldea, France*
- 12:02 MA09.03: High-Dimensional Profiling of the Tumour Microenvironment of Non-small Cell Lung Cancer**  
*Arutha Kulasinghe, Australia*

- 12:07 MA09.04: Genome-wide Analysis Identifies Nuclear Factor IC as a Novel Transcription Factor and Potential Therapeutic Target in SCLC**  
*Haitao Wang, USA*
- 12:12 MA09.05: Tumoral ATF4-Mediated Fatty Acid Metabolism Disorder Fuels MDSC Reprogramming in LKB1-Mutant Lung Cancer**  
*Zejin Guo, China*
- 12:17 MA09.06: NSCLC Oncogenotypes as Biomarkers and Regulators of Cachexia Development**  
*Puneeth Iyengar, USA*
- 12:22 Q&A**
- 12:30 MA09.08: Single-cell Analysis Revealed an Immunosuppressive Subtype of Senescent Tumor Cells in Lung Adenocarcinoma**  
*Guangyu Fan, China*
- 12:35 MA09.09: CASPASE1 Modulates CD8+ T Cell Infiltration through IL-18 Secretion in Tumor Immune Microenvironment of EGFR-TKI-Resistant NSCLC**  
*Yajie Cheng, China*
- 12:40 MA09.10: Paired Specimens Elucidate the Role of Tumor Microenvironment Reprogramming in the Efficacy of Neoadjuvant Chemoimmunotherapy in NSCLC**  
*Yang Xia, China*
- 12:45 MA09.11: Acetaminophen Reduces Neoadjuvant Chemo-Immunotherapy Efficacy in NSCLC Patients by Promoting Neutrophil Extracellular Traps Formation**  
*Junqi Wu, China*
- 12:50 Q&A**

**12:00 - 13:00 MA10: Challenges in Lung Cancer Care: Costs, Accessibility, Pathways and Impact of COVID-19**

Track: Global Health, Health Services, and Health Economics

**ROOM: 405B, LEVEL 4**

Chairs: Roselle De Guzman, Philippines &amp; Haval Balata, UK

- 12:00 Welcome & Introduction**  
*Roselle De Guzman, Philippines & Haval Balata, UK*
- 12:02 MA10.03: A Cost-Effectiveness Analysis of Actionable Genomic Alteration (AGA) Testing Strategies in Non-Small Cell Lung Cancer (NSCLC)**  
*Yvonne Ang, Singapore*
- 12:07 MA10.04: Evaluation of a Risk-Sharing Agreement for Atezolizumab Treatment in NSCLC Patients: A Strategy to Improve Access in Low Income Countries**  
*Oscar Arrieta, Mexico*
- 12:12 MA10.05: Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review**  
*Kelly Needham, UK*
- 12:17 MA10.06: CARMA-BROS: Cancers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study**  
*Faisal Al Agha, Canada*
- 12:22 Q&A**

- 12:30** **MA10.08: The Disparate Burden of COVID-19 Lung Cancer Patients During Periods of High Transmission of SARS-CoV-2**  
*Priyanka Senthil, USA*
- 12:35** **MA10.09: The Impact of the COVID-19 Pandemic on Diagnosis, Treatment, and Survival of Lung Cancer Patients in Thailand from 2019 - 2021**  
*Khemruthai Chaiwipassatorn, Thailand*
- 12:40** **MA10.10: A Review of the Routes into the Lung Cancer Pathway for Patients Diagnosed with Lung Cancer in Wales**  
*Lydia Guhaniyogi, UK*
- 12:45** **MA10.11: Exploration of Side Effects and Patient-Reported Outcomes in First Line Compared to Late Line Chemotherapy and Targeted Therapies**  
*Upal Basu Roy, USA*
- 12:50** **Q&A**

**12:00 - 13:00** **OA12: Pushing the Boundaries: Adjuvant and Neoadjuvant Approaches in Early Stage Non-small Cell Lung Cancer**

Track: Early-Stage Non-small Cell Lung Cancer



ROOM: NICOLL 1, LEVEL 3

Chairs: Tina Cascone, USA & Gavin Wright, Australia

- 12:00** **Welcome & Introduction**  
*Tina Cascone, USA & Gavin Wright, Australia*
- 12:02** **OA12.03: An Analysis of the Rate of Second Primary Lung Cancer from CALGB (Alliance) 140503 Trial of Lobar versus Sub-Lobar Resection for T1aNO NSCLC**  
*Thomas Stinchcombe, USA*
- 12:12** **OA12.04: Nivolumab After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial**  
*Joe Chang, USA*
- 12:22** **OA12.05: Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN)**  
*Tetsuya Mitsudomi, Japan*
- 12:32** **OA12.06: Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)**  
*David Harpole, USA*
- 12:42** **OA12.07: Discussant**  
*Solange Peters, Switzerland*
- 12:52** **Q&A**

**12:00 - 13:00** **OA13: Lung Cancer Prevention in the New Millennium**

Track: Risk Factors, Risk Reduction & Tobacco Control



ROOM: SUMMIT 1, LEVEL 3

Chairs: Renelle Myers, Canada & William Evans, Canada

- 12:00** **Welcome & Introduction**  
*Renelle Myers, Canada & William Evans, Canada*

- 12:02** **OA13.03: Associations Between Sex Specific Reproductive Factors and Risk of New Onset Lung Cancer Among Women**  
*Yan Zhang, China*
- 12:12** **OA13.04: Profile of Reactive Estrogen Species in Women with EGFR-Mutated Non-small Cell Lung Cancer (NSCLC)**  
*J. Nicholas Bodor, USA*
- 12:22** **OA13.05: Strategies to Increase Acceptance of Referral to Smoking Cessation at an Ontario Regional Cancer Centre**  
*Bill Evans, Canada*
- 12:32** **OA13.06: The Epidemiology of Young Lung Cancer: Interim Analysis of Risk Factors and Genetic Mutations**  
*Marisa Bittoni, USA*
- 12:42** **OA13.07: Discussant**  
*Jacek Jassem, Poland*
- 12:52** **Q&A**

**13:15 - 14:15** **Lunch Break**

ROOM: EXHIBIT HALL, LEVEL 4



**13:15 - 14:15** **HW01: Creating Workplace Well-being for Yourself and Others**

ROOM: SUMMIT 1, LEVEL 3



Chair: Carlos Gil Ferreira, Brazil

- 13:15** **Welcome & Introduction**  
*Carlos Gil Ferreira, Brazil*
- 13:20** **HW01.02: Expanding the Wellness Paradigm: Beyond Personal Resilience to Building a Comprehensive Academic Center Wellness Program**  
*Anne Tsao, USA*
- 13:35** **HW01.03: Empowering Self-Care: Nurturing Wellness and Personal Growth in Everyday Life**  
*Maria Ftanou, Australia*
- 13:50** **Q&A**

**13:15 - 14:15** **Concurrent Industry Sponsored Symposia**

FOR FURTHER INFORMATION, PLEASE SEE PAGES 232 & 233.

**14:00 - 15:00** **Meet the Editor**

ROOM: 327, LEVEL 3



**14:30 - 15:30 ES26: Rethinking the Scope of LCS: What Will Screening Look Like in 20 Years?**

Track: Screening and Early Detection

**ROOM: SUMMIT 2, LEVEL 3**

Chairs: Kirsty Lee, Hong Kong &amp; Edith Marom, Israel

- 14:30 Welcome & Introduction**  
Kirsty Lee, Hong Kong & Edith Marom, Israel
- 14:32 ES26.03: Incorporating Biomarkers into Lung Cancer Screening: Who Benefits?**  
Hillary Robbins, France
- 14:44 ES26.04: Artificial Intelligence in Lung Cancer Screening: Current and Future Perspectives**  
Lecia Sequist, USA
- 14:56 ES26.05: To Screen or Not to Screen: Decisions at the Patient Level**  
David Baldwin, UK
- 15:08 ES26.06: Quality Criteria for Future Initiatives on LCS**  
Monica Perez-Rios, Spain
- 15:20 Q&A**

**14:30 - 15:30 ES27: Disrupting the Landscape in Oncogene-Addicted NSCLC**

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

**ROOM: NICOLL 1, LEVEL 3**

Chairs: Caicun Zhou, China &amp; Mark Kris, USA

- 14:30 Welcome & Introduction**  
Caicun Zhou, China & Mark Kris, USA
- 14:32 ES27.03: EGFR TKI-Based Combination Therapies and Novel Targeted Therapies After Initial EGFR TKI**  
Sehhoon Park, Republic of Korea
- 14:44 ES27.04: What's New in EGFR Exon 20 Positive Lung Cancers**  
Joop de Langren, Netherlands
- 14:56 ES27.05: New Data from ALK, ROS1 and RET**  
Jessica Lin, USA
- 15:08 ES27.06: New Data for MET and HER2**  
Xiuning Le, USA
- 15:20 Q&A**

**14:30 - 15:30 ES28: State-of-the-Art Management of LR NSCLC**

Track: Local-Regional Non-small Cell Lung Cancer

**ROOM: SUMMIT 1, LEVEL 3**

Chairs: Stephanie Saw, Singapore &amp; Gerard Hanna, UK

- 14:30 Welcome & Introduction**  
Stephanie Saw, Singapore & Gerard Hanna, UK

- 14:32 ES28.03: State of the Art in LR NSCLC: Systemic Therapy**  
Tom John, Australia
- 14:44 ES28.04: State of the Art in NSCLC: Radiation Therapy**  
Kristin Higgins, USA
- 14:56 ES28.05: State of the Art in LR NSCLC: Surgery**  
Isabelle Opitz, Switzerland
- 15:08 ES28.06: State of the Art: Supportive Care**  
Paul Glare, Australia
- 15:20 Q&A**

**14:30 - 15:30 ES29: Interactive Case Study: Holistic, Multidisciplinary Management of Thoracic Cancers in 2023**

Track: Multidisciplinary Care: Nursing, Allied Health &amp; Palliative Care

**ROOM: NICOLL 3, LEVEL 3**

Chairs: Michael Franco, Australia &amp; Yiqing Huang, Singapore

- 14:30 Welcome & Introduction**  
Michael Franco, Australia & Yiqing Huang, Singapore
- 14:32 ES29.03: Nursing**  
Melissa Culligan, USA
- 14:44 ES29.04: Psychology**  
Simon Dunne, Ireland
- 14:56 ES29.05: Physiotherapy/Other Allied Health**  
Nicole Kiss, Australia
- 15:08 ES29.06: Patient/Consumer**  
Ewelina Szmytko, Poland
- 15:20 Q&A**

**14:30 - 15:30 MA11: New Technology and Innovations in Early Stage Lung Cancer**

Track: Early-Stage Non-small Cell Lung Cancer

**ROOM: 405C, LEVEL 4**

Chairs: Mara Antonoff, USA &amp; Ivan Tham, Singapore

- 14:30 Welcome & Introduction**  
Mara Antonoff, USA & Ivan Tham, Singapore
- 14:32 MA11.03: First in Human Prospective Validation of Intraoperative Artificial Intelligence Guided Diagnosis of Indeterminate Lung Nodules**  
Feredun Azari, USA
- 14:37 MA11.04: Video-Based Artificial Intelligence in Thoracoscopic Lobectomy for Lung Cancer: Surgical Structures Segmentation and Phase Recognition**  
Hengrui Liang, China
- 14:42 MA11.05: Identification of Bio-Immune Markers that Differentiate Long-Term Survivors from Relapse in Patients with Early-Stage Lung Adenocarcinomas**  
Yanyan Lou, USA

- 14:47** MA11.06: Results from a Phase II trial of a Tumor-Activated Fluorescent Molecule for the Intra-Operative Identification of Lung Cancer  
*Gavin Wright, Australia*
- 14:52** Q&A
- 15:00** MA11.08: IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC  
*Enriqueta Felip, Spain*
- 15:05** MA11.09: SAKK 16/18: Neoadjuvant Chemotherapy, Durvalumab and Immune-Modulatory RT in Stage III(N2) NSCLC. Surgical Interim Analysis  
*Patrick Dorn, Switzerland*
- 15:10** MA11.10: Intravenous Indocyanine Green Administration Provides Sufficient Margins in Pulmonary Segmentectomy  
*Takahiro Ochi, Japan*
- 15:15** MA11.11: Drug Tolerant Persister Cells to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer Harboring EGFR Mutations (NORA)  
*Jii Bum Lee, Republic of Korea*
- 15:20** Q&A

**14:30 - 15:30 MA12: Big Data & New Technologies**

Track: Tumor Biology – Translational Biology

**ROOM: 405B, LEVEL 4**

Chairs: Vamsidhar Velcheti, USA &amp; Harriet Gee, Australia

- 14:30** Welcome & Introduction  
*Vamsidhar Velcheti, USA & Harriet Gee, Australia*
- 14:32** MA12.03: New Data from the LungNENomics Project Provide Insights on the Supra-Carcinoid Emerging Variant of Lung Neuroendocrine Tumors  
*Lynnette Fernandez-Cuesta, France*
- 14:37** MA12.04: Evolutionary Proteogenomic Landscape from Pre-invasive to Invasive Lung Adenocarcinoma  
*Yang Zhang, China*
- 14:42** MA12.05: The Patterns & Prognostic Value of Clonal Seeding in Lung Cancer Metastasis  
*Chao Zhang, China*
- 14:47** MA12.06: Integrative Multi-Omics Analyses Reveal Molecular Subtypes with Distinct Prognosis of Early-Stage High-Grade Lung Adenocarcinoma  
*Nan Wu, China*
- 14:52** Q&A
- 15:00** MA12.08: Growth Pattern Evolution of Lung Adenocarcinoma from Primary Tumour to Metastasis in TRACERx  
*Takahiro Karasaki, Japan*
- 15:05** MA12.09: Identification of Tumor-Specific Single-Nucleotide Variants and Intratumor Heterogeneity in LUADs by Full Length ScRNAseq  
*Paola Marignani, Canada*

- 15:10** MA12.10: Three Subsets of Lung Cancer-associated Fibroblasts Define Tumor Progression, Therapy Resistance and Patient Prognosis  
*Xu Weijiao, China*
- 15:15** MA12.11: A Novel 89Zr-anti-PD1 immunoPET-CT May Predict Response to PD-1 Inhibitors in a Lung Cancer Murine Model Receiving Immunotherapy  
*Ignacio Gil-Bazo, Spain*
- 15:20** Q&A

**14:30 - 15:30 OA14: Immune Checkpoint Therapy: Long Term Follow Up**

Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy

**ROOM: 405A, LEVEL 4**

Chairs: Puey Ling Chia, Singapore &amp; Elizabeth Dudnik, Israel

- 14:30** Welcome & Introduction  
*Puey Ling Chia, Singapore & Elizabeth Dudnik, Israel*
- 14:32** OA14.03: Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227  
*Solange Peters, Switzerland*
- 14:42** OA14.04: Three-Year Outcomes with First-Line Pembrolizumab, in Patients with Non-small Cell Lung Cancer and A PD-L1 Tumor Proportion Score >90%  
*Biagio Ricciuti, USA*
- 14:52** OA14.05: 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC with PD-L1 Tumor Proportion Score <1%  
*Shirish Gadgeel, USA*
- 15:02** OA14.06: Reported Cardiovascular Events in Lung Cancer Patients After Immune-Checkpoint Inhibitor Therapy  
*Sai-Ching Yeung, USA*
- 15:12** OA14.07: Discussant  
*Ferdinandos Skoulidis, USA*
- 15:22** Q&A

**14:30 - 15:30 OA15: Pathological Biomarkers for Immunotherapy**

Track: Pathology and Biomarkers

**ROOM: NICOLL 2, LEVEL 3**

Chairs: Deepali Jain, India &amp; Dongmei Lin, China

- 14:30** Welcome & Introduction  
*Deepali Jain, India & Dongmei Lin, China*
- 14:32** OA15.03: Evaluation of Pathological Tumor and Nodal Responses Following Neoadjuvant Chemoimmunotherapy in NSCLC Patients  
*Shujie Huang, China*
- 14:42** OA15.04: Comparison of Digital Vs Manual PD-L1 Tumour Cell Scoring on SP263-Stained Whole Imaging Slides from IMpower110  
*Roy S. Herbst, USA*

## SCIENTIFIC PROGRAM - MONDAY, SEPTEMBER 11, 2023

**14:52** **OA15.05: Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC**  
*Matthieu Roulleaux Dugage, France*

**15:02** **OA15.06: Differences in Pathologic Assessment by MPR Calculation Methods for Multiple Slides of Tumor Bed in SQUAT Trial (WJOG12119L)**  
*Jumpei Kashima, Japan*

**15:12** **OA15.07: Discussant**  
*Annikka Weissferdt, USA*

**15:22** **Q&A**

### 15:45 - 16:45 ES30: Non-invasive Approaches for Early Stage NSCLC

**Track: Early-Stage Non-small Cell Lung Cancer**

 ACCME Accredited By IASLC

**ROOM: NICOLL 2, LEVEL 3**

 Recommended for Early Career Researchers

*Chairs: Jane Ludbrook, Australia & Kristin Higgins, USA*

**15:45** **Welcome & Introduction**  
*Jane Ludbrook, Australia & Kristin Higgins, USA*

**15:47** **ES30.03: SBRT and IO Combinations**  
*Harriet Gee, Australia*

**15:59** **ES30.04: SBRT in the Operable Patient**  
*Megan Daly, USA*

**16:11** **ES30.05: High-Risk SBRT Scenarios**  
*Delphine Antoni, France*

**16:23** **ES30.06: Tobacco Moment: The Role of the Surgeon in a Patient's Smoking Cessation**  
*Matthew Steliga, USA*

**16:35** **Q&A**

### 15:45 - 16:45 ES31: The Future of Biomarkers in Immunotherapy

**Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy**

 ACCME Accredited By IASLC

**ROOM: NICOLL 1, LEVEL 3**

*Chairs: Clarissa Baldotto, Brazil & Yasushi Yatabe, Japan*

**15:45** **Welcome & Introduction**  
*Clarissa Baldotto, Brazil & Yasushi Yatabe, Japan*

**15:47** **ES31.03: Tumor Biomarkers**  
*Biagio Ricciuti, USA*

**15:59** **ES31.04: ctDNA for Checkpoint Inhibitor Monitoring**  
*Christian Rolfo, USA*

**16:11** **ES31.05: Biomarkers Beyond PDL1**  
*Yoon La Choi, Republic of Korea*

**16:23** **ES31.06: Integration of Biomarkers with Artificial Intelligence**  
*Arsela Prelaj, Italy*

**16:35** **Q&A**

## SCIENTIFIC PROGRAM - MONDAY, SEPTEMBER 11, 2023

### 15:45 - 16:45 ES32: Limited-Stage SCLC & Thoracic NETs

**Track: Small Cell Lung Cancer and Neuroendocrine Tumors**

 ACCME Accredited By IASLC

**ROOM: SUMMIT 1, LEVEL 3**

*Chairs: Sukhmani Padda, USA & Aaron Tan, Singapore*

**15:45** **Welcome & Introduction**  
*Sukhmani Padda, USA & Aaron Tan, Singapore*

**15:47** **ES32.03: Recent Insights into the Biology of Lung Neuroendocrine Neoplasms**  
*Lynette Fernandez Cuesta,*

**15:59** **ES32.04: Surgical Management of Thoracic NETs**  
*Leanne Ashrafian, UK*

**16:11** **ES32.05: Optimising the Use of Radiation Therapy in LS-SCLC**  
*Bjorn Henning Gronberg, Norway*

**16:23** **ES32.06: Systemic Therapy for Thoracic Carcinoids**  
*Nick Pavlakis, Australia*

**16:35** **Q&A**

### 15:45 - 16:45 ES33: Access to Lung Cancer Care for All

**Track: Patient Advocacy**

 ACCME Accredited By IASLC

**ROOM: NICOLL 3, LEVEL 3**

 Recommended for Early Career Researchers

*Chairs: Ewelina Szymtke, Poland & Angeline Low, Australia*

**15:45** **Welcome & Introduction**  
*Ewelina Szymtke, Poland & Angeline Low, Australia*

**15:47** **ES33.03: Empowering Underserved Communities in Lung Cancer Screening and Treatment**  
*Monica Baskin, USA*

**15:59** **ES33.04: Lung Cancer Experiences: A Pathway for Improvement in Europe**  
*Merel Hennink, Netherlands*

**16:11** **ES33.05: Gendered Lenses in Lung Cancer Screening and Treatment**  
*Maria Calibo Sales, Australia*

**16:23** **ES33.06: Gendered Lenses in Lung Cancer Screening and Treatment**  
*Angeline Low, Australia*

**16:35** **Q&A**

### 15:45 - 16:45 MA13: Targeted Therapy: EGFR and HER2

**Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy**

 Not for CME Credit

**ROOM: 405B, LEVEL 4**

*Chairs: David R. Gandara, USA & Marina Garassino, USA*

**15:45** **Welcome & Introduction**  
*David R. Gandara, USA & Marina Garassino, USA*

- 15:47** MA13.03: BBT-176, a 4th Generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: Updated Report from a Phase 1 Study  
*Sun Min Lim, Republic of Korea*
- 15:52** MA13.04: Final Overall Survival Analysis of Osimertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations (KCSG-LU15-09)  
*Jang Ho Cho, Republic of Korea*
- 15:57** MA13.05: Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study  
*Min Yu, China*
- 16:02** MA13.06: Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2  
*Se-Hoon Lee, Republic of Korea*
- 16:07** Q&A
- 16:15** MA13.08: Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations  
*Noboru Yamamoto, Japan*
- 16:20** MA13.09: Efficacy and Safety of Pozitotinib in HER2 Exon 20 Insertion NSCLC Patients Who Received at Least 2 Previous Systemic Therapies  
*Xiuning Le, USA*
- 16:25** MA13.10: Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-small Cell Lung Cancer: Primary Results of DESTINY-Lung02  
*Pasi Janne, USA*
- 16:30** MA13.11: Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial  
*Sehhoon Park, Republic of Korea*
- 16:35** Q&A

**15:45 - 16:45 MA14: Genetic Biomarkers for NSCLC**

Track: Pathology and Biomarkers

**ROOM: 405C, LEVEL 4***Chairs: Kurt Schalper, USA & Angela Takano, Singapore*

- 15:45** Welcome & Introduction  
*Kurt Schalper, USA & Angela Takano, Singapore*
- 15:47** MA14.03: Targetable Driver Alterations in Non-adenocarcinoma NSCLC: Population-Based Prevalence Data from the National Swedish Lung Cancer Registry  
*Johan Isaksson, Sweden*
- 15:52** MA14.04: Prospective Trial of an EMR-based Nudge to Increase Molecular Genotyping in Newly Diagnosed Metastatic Non-squamous NSCLC  
*Melina Marmarelis, USA*
- 15:57** MA14.05: Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib  
*Mengzhao Wang, China*

- 16:02** MA14.06: Clinicopathologic Characteristics of Stage IV NRG1 Fusion-Positive Lung Cancer  
*Hyo Sup Shim, Republic of Korea*
- 16:07** Q&A
- 16:15** MA14.08: Pathogenic Germline Variants in Patients with Non-small Cell Lung Cancer (NSCLC) Detected by Tissue Comprehensive Genomic Profiling  
*Laura Mezquita, Spain*
- 16:20** MA14.09: Development of a Clinico-Proteo-Metagenomic Classifier for Risk Stratification of Incidentally-Detected Pulmonary Nodules  
*Harvey Pass, USA*
- 16:25** MA14.10: Spatiotemporal Heterogeneity of Genomic and Transcriptomic Landscape of Multiple Lung Cancer by a Novel Multi-omics Algorithm  
*Yijun Song, China*
- 16:30** MA14.11: Genomic Mutational Discordances and Heterogeneous PD-L1 Expression and Immune Infiltrates of Non-small Cell Lung Cancer Metastasis  
*Jianghua Wu, China*
- 16:35** Q&A

**15:45 - 16:45 OA16: Expanding the Scope of Lung Cancer Screening Initiatives Worldwide**

Track: Screening and Early Detection

**ROOM: 405A, LEVEL 4***Chairs: Raymond Osarogiagbon, USA & Witold Rzyman, Poland*

- 15:45** Welcome & Introduction  
*Raymond Osarogiagbon, USA & Witold Rzyman, Poland*
- 15:47** OA16.03: Taking A Health Systems Approach to Low-Dose CT Lung Cancer Screening: A Bespoke Framework to Support Implementation  
*Stephen C. Lam, Canada*
- 15:57** OA16.04: Preliminary Results from the Female Asian Nonsmoker Screening Study (FANSS)  
*Elaine Shum, USA*
- 16:07** OA16.05: Assessing the Impact of Increasing Lung Screening Eligibility by Relaxing the Maximum Years Since Quit Threshold. A Simulation Modeling Study  
*Rafael Meza, USA*
- 16:17** OA16.06: Trends of Positive Rates of Initial Screening And Repeated Screening in National Organized Population-Based Lung Cancer Screening in Korea  
*Nayoung Lee, Republic of Korea*
- 16:27** OA16.07: Discussant  
*Milena Cavic, Serbia*
- 16:27** Q&A



**15:45 - 16:45 OA17: Next Steps in Locally Advanced NSCLC: Optimizing Techniques and Choosing Populations That Benefit**

Track: Local-Regional Non-small Cell Lung Cancer

ACCME Accredited By IASLC

**ROOM: SUMMIT 2, LEVEL 3**Chairs: *Christine Bestvina, USA & Elisangela Carvalho, Brazil***15:45 Welcome & Introduction***Christine Bestvina, USA & Elisangela Carvalho, Brazil***15:47 OA17.03: Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R)***Solange Peters, Switzerland***15:57 OA17.04: Long-Term Outcomes by Radiation Technique for Locally-Advanced Non-small Lung Cancer: A Secondary Analysis of NRG Oncology-RTOG 0617 at 5-years***Stephen Chun, USA***16:07 OA17.05: Association Between Pre-Treatment Circulating Immune Biomarkers and Survival in Stage III NSCLC: A Translational Analysis From NRG-RTOG 0617***Mitchell Machtay, USA***16:17 OA17.06: The Predictive Value of PD-L1 levels on Circulating Stromal Cells in Unresectable Stage 3 NSCLC Treated with Chemoradiation***Steven Lin, USA***16:27 OA17.07: Discussant***Matthew Hatton, UK***16:37 Q&A****17:00 - 18:00 PLO4: Special Plenary Session 4: TNM for Lung, Mesothelioma and Thymic Cancers - Update on the Proposals for the 9th Edition of TNM Staging****ROOM: 406, LEVEL 4**

Live-Streamed

ACCME Accredited By IASLC

Chairs: *Ramon Rami-Porta, Spain & Paul van Schil, Belgium*

Recommended for Early Career Researchers

**17:00 Welcome & Introduction***Ramon Rami-Porta, Spain & Paul van Schil, Belgium***17:02 PLO4.03: 9th Edition TNM Staging Classification: Lung Cancer***Hisao Asamura, Japan***17:32 PLO4.04: 9th Edition TNM Staging Classification: Mesothelioma***Valerie Rusch, USA***17:42 PLO4.05: 9th Edition TNM Staging Classification: Thymic***Enrico Ruffini, Italy***17:52 Q&A****18:00 - 20:00 Poster Viewing Networking Reception (Poster Session 2: P2) with Presenters in Attendance****ROOM: EXHIBIT HALL, LEVEL 4**

Refreshments Provided

**19:00 - 20:00 Concurrent Industry Sponsored and Satellite CME Symposia****FOR FURTHER INFORMATION, PLEASE SEE PAGES 233 & 234.****20:30 - 24:00 IASLC Benefit Supporting Early Career Researchers**


Ticketed Event

# JTO CLINICAL AND RESEARCH REPORTS


**Editor-in-Chief:** Emily Stone, MBBS, PhD, FRACP,  
St. Vincent's Hospital, Sydney and School of Clinical  
Medicine, UNSW, Sydney, Australia.

*JTO Clinical and Research Reports* is the official  
open access journal of the International Association  
for the Study of Lung Cancer. It aims to complement  
the *Journal of Thoracic Oncology* by offering authors  
a gold open access publication option and publishing  
of the following article types in particular:

- Phase I trials
- Well-performed single-arm phase II trials
- Small to moderate-sized randomized  
phase II trials
- Subset analyses of published trials
- Impactful retrospective studies
- Database and registry analysis
- Large institutional series
- High-quality case reports
- Region-specific clinical trials
- Subspecialty specific thoracic  
oncology studies
- Selected high-quality meeting reports



**Now indexed in  
PubMed Central!**



[jtocrr.org](http://jtocrr.org)



**5 PROGRAM  
TUESDAY**

**05 WCLC 2023 FULL PROGRAM**

Tuesday, September 12, 2023

**Tuesday, September 12, 2023****07:30 - 08:15 HOD02: Highlights of the Day - Monday Abstracts****ROOM: 405A, LEVEL 4**

Light Breakfast Provided

ACCME Accredited By IASLC

**07:30 HOD02.01: Radiation Oncology**

Gerard Hanna, UK

Recommended for Early Career Researchers

**07:40 HOD02.02: Surgery**

John Tam, Singapore

**07:50 HOD02.03: Pulmonology**

Stephen Lam, Canada

**08:00 HOD02.04: Medical Oncology**

Kirsty Lee, Hong Kong

**08:10 Q&A****07:30 - 08:15 MTE14: Real World Challenges in Integrating Immunotherapy in Our Clinical Practice****Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy**

Recommended for Early Career Researchers

**ROOM: 405C, LEVEL 4**

Light Breakfast Provided

In-Person Only (NOT RECORDED)

**07:30 MTE14.01: What Is the Role of Immune Checkpoint Inhibition in a Patient with an Autoimmune Disease?**

Yuko Oya, Japan

ACCME Accredited By IASLC

Ticketed Session

**07:45 MTE14.02: IO Use in Patient with Active Infection Such as COVID-19, TB, HIV**

Lizza Hendriks, Netherlands

**08:00 Q&A****07:30 - 08:15 MTE15: Extensive Stage Small Cell Lung Cancer (ES-SCLC) After Chemo-Immunotherapy****Track: Small Cell Lung Cancer and Neuroendocrine Tumors**

Recommended for Early Career Researchers

**ROOM: SUMMIT 1, LEVEL 3**

Light Breakfast Provided

In-Person Only (NOT RECORDED)

**07:30 MTE15.01: What is the Role for PCI and Thoracic RT in ES-SCLC?**

Suresh Senan, Netherlands

ACCME Accredited By IASLC

Ticketed Session

**07:45 MTE15.02: How Do We Select Second-Line Systemic Therapy in ES-SCLC?**

Ticiana Leal, USA

**08:00 Q&A****07:30 - 08:15 MTE16: Optimal First Line Therapy in Pleural Mesothelioma****Track: Mesothelioma, Thymoma, and Other Thoracic Tumors**

ACCME Accredited By IASLC

**ROOM: NICOLL 1, LEVEL 3**

Light Breakfast Provided

In-Person Only (NOT RECORDED)

**07:30 MTE16.01: Pro Chemotherapy**

Steven Kao, Australia

Ticketed Session

**07:45 MTE16.02: Pro Immunotherapy**

Paul Baas, Netherlands

**08:00 MTE16.03: Moderator/Chair for the Debate**

Federica Grosso, Italy

**07:30 - 08:15 MTE17: Advocating for Equity in Lung Cancer****Track: Patient Advocacy**

Recommended for Early Career Researchers

ACCME Accredited By IASLC

**ROOM: NICOLL 3, LEVEL 3**

Light Breakfast Provided

In-Person Only (NOT RECORDED)

**07:30 MTE17.01: The Importance of Promoting Equity in Lung Cancer**

Kim Norris, USA

Ticketed Session

**07:45 MTE17.02: A Social Science Framework to Improve Equity in Lung Cancer Care**

Ambreen Sayani, Canada

**08:00 Q&A**

Christina Sit, Canada

**07:30 - 08:15 MTE18: Surgery versus SBRT in the Borderline Operable Candidate****Track: Early-Stage Non-small Cell Lung Cancer**

Ticketed Session

ACCME Accredited By IASLC

**ROOM: SUMMIT 2, LEVEL 3**

Light Breakfast Provided

In-Person Only (NOT RECORDED)

**07:30 MTE18.01: Surgeon's Perspective**

David Harpole, USA

**07:45 MTE18.02: Radiation Oncologist's Perspective**

Alexander Sun, Canada

**08:00 Q&A**

**08:30 - 10:00 PL05: Plenary Session 5: Transforming Discovery into Treatments in Lower Middle Income Regions****ROOM: 406, LEVEL 4**

Chairs: Daniel Tan, Singapore &amp; Pyng Lee, Singapore

**08:30 Welcome & Introduction**

Daniel Tan, Singapore &amp; Pyng Lee, Singapore

**08:32 PL05.03: Insights into Lung Cancer Evolution from the TRACERx and PEACE Studies**

Mariam Jamal-Hanjani, UK

**08:47 PL05.04: State of the Art Management of Early Stage Disease**

Alan Sihoe, China

**09:02 PL05.05: Precision Management of Oligometastatic Disease**

Jai Prakash Agarwal, India

**09:17 PL05.06: Access to Novel Treatments and Clinical Trials**

Ross Soo, Singapore

**09:32 Q&A****10:00 - 10:45 Coffee Break****ROOM: EXHIBIT HALL, LEVEL 4****10:00 - 10:45 IASLC Business Meeting****ROOM: NICOLL 2, LEVEL 3****10:05 - 11:00 PC04: Press Conference****ROOM: 327, LEVEL 3****10:45 - 11:45 ES34: Implementing Lung Cancer Screening in Your Country: Taking Screening from the Trials to the Public****Track: Screening and Early Detection****ROOM: 406, LEVEL 4**

Chairs: Claudia Henschke, USA &amp; Pan-Chyr Yang, Taiwan

**10:45 Welcome & Introduction**

Claudia Henschke, USA &amp; Pan-Chyr Yang, Taiwan

**10:47 ES34.03: The First Million Screens in U.S.: What Does It Tell Us**

Gerard Silvestri, USA

**10:59 ES34.04: Lung Cancer Screening in Europe: What Have We Learnt?**

John Field, UK

**11:11 ES34.05: Implementing Screening in Australia: The Challenges of a Diverse Landscape**

Annette McWilliams, Australia

**11:23 ES34.06: Lung Cancer Screening in Asia Unique Challenges and Opportunities**

Pyng Lee, Singapore

**11:35 Q&A****10:45 - 11:45 ES35: Who, When and How to Give Chemotherapy in the Era of Immunotherapy for NSCLC All-Comers?****Track: Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy****ROOM: 405C, LEVEL 4**

Chairs: Fiona McDonald, UK &amp; Nandini Menon, India

**10:45 Welcome & Introduction**

Fiona McDonald, UK &amp; Nandini Menon, India

**10:47 ES35.03: The Case for Combination Chemo-Immunotherapy Over Sequential Treatment in Advanced NSCLC**

Cheryl Ho, Canada

**10:59 ES35.04: The Case for Immunotherapy First Followed by Chemotherapy in Advanced NSCLC**

Myung-Ju Ahn, Republic of Korea

**11:11 ES35.05: Chemotherapy After Immunotherapy Failure - What is the Best Strategy?**

Clarissa Baldotto, Brazil

**11:23 ES35.06: Integrating Radiotherapy with Chemotherapy in Metastatic NSCLC**

Alexander Louie, Canada

**11:35 Q&A****10:45 - 11:45 ES36: Extensive-Stage SCLC****Track: Small Cell Lung Cancer and Neuroendocrine Tumors****ROOM: 405B, LEVEL 4**

Chairs: Stephen Liu, USA &amp; Hidehito Horinouchi, Japan

**10:45 Welcome & Introduction**

Stephen Liu, USA &amp; Hidehito Horinouchi, Japan

**10:47 ES36.03: Latest Updates for Upfront Systemic Therapy in ES-SCLC**

Misty Shields, USA

**10:59 ES36.04: Smoking Cessation Data in Oncology Clinical Trials - What Are We Missing?**

Bill Evans, Canada

**11:11 ES36.05: State of the Art in Novel Agents for SCLC**

Byoung Chul Cho, Republic of Korea

**11:23 ES36.06: Applying Emerging Biomarkers in SCLC**

Triparna Sen, USA

**11:35 Q&A**

**10:45 - 11:45 ES37: Actions Towards Equity****Track: Patient Advocacy****ROOM: NICOLL 3, LEVEL 3***Chairs: Lillian Leigh, Australia & Stefania Vallone, Italy*

- 10:45 Welcome & Introduction**  
*Lillian Leigh, Australia & Stefania Vallone, Italy*
- 10:47 ES37.03: Tobacco Moment: The Role of the Oncologist in a Cancer Patient's Smoking Cessation**  
*Lawson Eng, Canada*
- 10:52 ES37.04: Actions from Africa in Addressing Unmet Needs in Lung Cancer**  
*Caleb Egwuenu, Nigeria*
- 11:04 ES37.05: Actions from Latin America in Addressing Unmet Needs in Lung Cancer**  
*Luis Corrales, Costa Rica*
- 11:16 ES37.06: Improving Radiotherapy Access in Countries with Limited Resources**  
*Shekinah Elmore, USA*
- 11:28 ES37.07: Importance of Implementation Science to Promote Health Equity in Lung Cancer Screening**  
*Nicole Rankin, Australia*
- 11:40 Q&A**

**10:45 - 11:45 MA15: Bringing New Discoveries into Early Phase Clinical Trials****Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy****ROOM: 405A, LEVEL 4***Chairs: Junko Tanizaki, Japan & Roy S. Herbst, USA*

- 10:45 Welcome & Introduction**  
*Junko Tanizaki, Japan & Roy S. Herbst, USA*
- 10:47 MA15.03: Harnessing Cornification and Tumor Microenvironment for Evaluation of Immunotherapy Efficacy in Squamous Cell Lung Carcinoma**  
*Minlin Jiang, China*
- 10:52 MA15.04: Timing of Pre-Biopsy COVID-mRNA Vaccination and PD-L1 Expression in Advanced Non-Small Cell Lung Cancer**  
*Adam Grippin, USA*
- 11:02 MA15.06: Association of Pathomics-based MHC-II Assessment with NSCLC Immunotherapy Efficacy**  
*Jiaqing Liu, China*
- 11:07 Q&A**
- 11:10 MA15.07: NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC**  
*Roy Herbst, USA*
- 11:15 MA15.08: Multicenter Phase II Trial of LN-145 TIL Cell Therapy plus Pembrolizumab in Patients with ICI-Naïve Metastatic NSCLC**  
*Adam Schoenfeld, USA*

- 11:20 MA15.09: Ph 2 Trial of IO102-IO103 Vaccine Plus Pembrolizumab: Preliminary Results for the First-line Treatment of Lung Adenocarcinoma**  
*Jonathan Riess, USA*
- 11:25 MA15.10: Phase II Study of Nivolumab Plus Ipilimumab with Chemotherapy for Advanced NSCLC with Untreated Brain Metastases: Nike Trial (LOGiK2004)**  
*Yuko Tsuchiya-Kawano, Japan*
- 11:30 MA15.11: A Phase I/II Study of TQ-B2450 plus Anlotinib in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies:Phase II Results Updates**  
*Meiqi Shi, China*
- 11:35 Q&A**

**10:45 - 11:45 MA16: Innovations in the Treatment of Stage III NSCLC****Track: Local-Regional Non-small Cell Lung Cancer****ROOM: SUMMIT 1, LEVEL 3***Chairs: Christine Bestvina, USA & Sue Yom, USA*

- 10:45 Welcome & Introduction**  
*Christine Bestvina, USA & Sue Yom, USA*
- 10:47 MA16.03: Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial**  
*Michiel Smeenk, Netherlands*
- 10:52 MA16.04: Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used**  
*Roberto Serna Blasco, Spain*
- 10:57 MA16.05: Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC**  
*Juan Li, China*
- 11:02 MA16.06: Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study**  
*Cheryl Ho, Canada*
- 11:07 Q&A**
- 11:16 MA16.08: The Efficacy of MR-Guided Hypo-Fractionated Radiotherapy and Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer**  
*Pengxin Zhang, China*
- 11:21 MA16.09: Evaluation of the Diagnostic Performance of AI Accompanied by CT Images in the Differentiation of Malignant or Benign MLN in NSCLC**  
*Yusuf Kahya, Turkey*
- 11:26 MA16.10: An Update 5 Years of Randomized Phase 2 Study (PRoT-BM Trial)**  
*Oscar Arrieta, Mexico*
- 11:31 MA16.11: Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI) vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC**  
*Amin Nassar, USA*
- 11:36 Q&A**

**10:45 - 11:45 MA17: Current Standards and Future Directions in Mesothelioma****Track: Mesothelioma, Thymoma, and Other Thoracic Tumors****ROOM: NICOLL 1, LEVEL 3**

Chairs: Joachim Aerts, Netherlands &amp; Wendy Cooper, Australia

- 10:45 Welcome & Introduction**  
Joachim Aerts, Netherlands & Wendy Cooper, Australia
- 10:47 MA17.03: Determining the Clinical Utility of a Breath Test to Screen Asbestos-Exposed Persons for Pleural Mesothelioma.**  
Kevin Lamote, Belgium
- 10:52 MA17.04: The IASLC Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma**  
Andrea Wolf, USA
- 10:57 MA17.05: Real World Outcomes of Immunotherapy (IO) for Pleural MESOthelioma in Australia - RIOMeso**  
Nicholas McNamee, Australia
- 11:02 MA17.06: Surgical Results of EORTC 1205, a Randomized Phase II Study of Surgery for Mesothelioma Preceded or Followed by Chemotherapy**  
Paul Van Schil, Belgium
- 11:07 Q&A**
- 11:07 MA17.08: Whole-Genome CRISPR Screening Reveals Genetic Vulnerabilities and Therapeutic Targets in Malignant Pleural Mesothelioma**  
Duo Xu, China
- 11:12 MA17.09: BAP1 Deficiency Inflames the TME & is a Candidate Biomarker for Improved Immunotherapy in Malignant Pleural Mesothelioma**  
Yongqian Shu, Switzerland
- 11:17 MA17.10: miRNA Signatures In Mesothelioma and their Associations with Outcomes with Immune Checkpoint Inhibitors**  
Farhad Kosari, USA
- 11:22 MA17.11: Spatial Transformation in Mesothelioma Involves a Hypoxia-TGF Beta-EMT Axis That is Reversible via PRX3 Inhibition**  
Dean Fennell, UK
- 11:35 Q&A**

**10:45 - 11:45 OA18: Targeting Molecular Drivers of Tumour Immunity****Track: Tumor Biology – Preclinical Biology****ROOM: SUMMIT 2, LEVEL 3**

Chairs: Nir Peled, Israel &amp; Arutha Kulasinghe, Australia

- 10:45 Welcome & Introduction**  
Nir Peled, Israel & Arutha Kulasinghe, Australia
- 10:47 OA18.03: Surfaceome of TP53-Mutant NSCLC Reveals a Distinct Subtype with Immunotherapy Vulnerability, Characterized by Co-occurring PTPRD Mutant**  
Xiaoting Cai, China

- 10:57 OA18.04: Tumor-Derived Complement C3 as a Therapeutic Target in STK11 Mutant Non-small Cell Lung Cancer**  
Edwin Yau, USA
- 11:07 OA18.05: Tumor Immune Microenvironment Profiling in Oligometastatic Non-small Cell Lung Cancer with Brain Metastases**  
Raphael Werner, Switzerland
- 11:17 OA18.06: SOX9 Drives KRAS-Induced Lung Adenocarcinoma Progression Through Suppression of Anti-Tumor Immunity**  
Sharon Pine, USA
- 11:27 OA18.07: Discussant**  
Maija Kohonen-Corish, Australia
- 11:37 Q&A**

**12:00 - 13:00 ES38: Cost and Accessibility of Oncology Treatments for Lung Cancer****Track: Global Health, Health Services, and Health Economics****ROOM: NICOLL 3, LEVEL 3**

Chairs: Yiqing Huang, Singapore &amp; Wee-Yao Koh, Singapore

- 12:00 Welcome & Introduction**  
Yiqing Huang, Singapore & Wee-Yao Koh, Singapore
- 12:02 ES38.03: Access to Radiotherapy in the Management of Lung Cancer**  
Mei-Ling Yap, Australia
- 12:14 ES38.04: The Development of Fast Followers for Cancer Care: Opportunities & Challenges**  
Gilberto Lopes, USA
- 12:26 ES38.05: Access to Systemic Therapies in Developing Nations - Challenges and Opportunities**  
Nandini Menon, India
- 12:38 ES38.06: Cost-Effectiveness of Immunotherapy in NSCLC**  
Pedro Aguiar, Brazil
- 12:50 Q&A**

**12:00 - 13:00 ES39: Next Generation Immunotherapies: Are We There Yet?****Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy****ROOM: 406, LEVEL 4**

Chairs: Tom John, Australia &amp; Julie Brahmer, USA

- 12:00 ES39.01: Chair**  
Tom John, Australia & Julie Brahmer, USA
- 12:02 ES39.03: Emerging Strategies Eg Combinations with Newer Immune Checkpoint Targets-TIGIT, LAG3, TIM3**  
Puey Ling Chia, Singapore

- 12:14 ES39.04: Immunotherapy Beyond Immune Checkpoints (Vaccines, Cytokines Etc)**  
*Edward Garon, USA*
- 12:26 ES39.05: Cellular Therapy in NSCLC: Challenges and Opportunities**  
*Melissa Johnson, USA*
- 12:38 ES39.06: Integrating RT into the Immunotherapy Treatment Paradigm in Advanced Disease**  
*Fiona McDonald, UK*
- 12:50 Q&A**

**12:00 - 13:00 ES40: Unresectable Mesothelioma**

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors

ACCME Accredited By IASLC

ROOM: 405C, LEVEL 4

Recommended for Early Career Researchers

Chairs: Aaron Mansfield, USA &amp; Yukari Tsubata, Japan

- 12:00 Welcome & Introduction**  
*Aaron Mansfield, USA & Yukari Tsubata, Japan*
- 12:02 ES40.03: Current Systemic Therapy Options**  
*Maria Disselhorst, Netherlands*
- 12:14 ES40.04: Future Biomarker Driven Treatment**  
*Dean Fennell, UK*
- 12:26 ES40.05: Role of Radiation in Mesothelioma**  
*Nicholas Bucknell, Australia*
- 12:38 ES40.06: Supportive Care during Treatment**  
*Rachel Thomas, UK*
- 12:50 Q&A**

**12:00 - 13:00 ES41: Joint IASLC-ESTRO Session**

ROOM: NICOLL 2, LEVEL 3

ACCME Accredited By IASLC

Chairs: Nicolaus Andratschke, Switzerland &amp; Andrea Bezjak, Canada

- 12:00 Welcome & Introduction**  
*Nicolaus Andratschke, Switzerland & Andrea Bezjak, Canada*
- 12:02 ES41.03: New Neoadjuvant/Adjuvant Strategies for Resectable Disease**  
*Malinda Itchins, Australia*
- 12:14 ES41.04: New Strategies for Unresectable Disease**  
*Ken Harada, Japan*
- 12:26 ES41.05: The Challenge of Equipoise When Comparing Surgical vs. Non-surgical Strategies in Stage III NSCLC**  
*Erin Gillaspie, USA*
- 12:32 ES41.06: The Challenge of Equipoise When Comparing Surgical vs. Non-surgical Strategies in Stage III NSCLC**  
*Alexander Louie, Canada*
- 12:38 ES41.07: Biomarkers for Patient Selection and Monitoring**  
*Gerard Hanna, UK*
- 12:50 Q&A**

**12:00 - 13:00 MA18: Refining Practice and Redefining Standards in SCLC**

Track: Small Cell Lung Cancer and Neuroendocrine Tumors

Not for CME Credit

ROOM: 405A, LEVEL 4

Chairs: Margot Lehman, Australia &amp; Bin-Chi Liao, Taiwan

- 12:00 Welcome & Introduction**  
*Margot Lehman, Australia & Bin-Chi Liao, Taiwan*
- 12:02 MA18.03: Preliminary Safety and Treatment Data of A Phase 3 Trial: Hypofractionated Versus Conventional Fractionated Concurrent Chemoradiation for LS-SCLC**  
*Nan Bi, China*
- 12:07 MA18.04: Prognostic Factors in Limited-Stage Small Cell Lung Cancer (LSCLC): Secondary Analysis of CALGB 30610 (Alliance)/RTOG 0538**  
*Michael Farris, USA*
- 12:12 MA18.05: Biomarkers for Brain Metastases Risk and Survival Benefit of Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer**  
*Li Li, China*
- 12:17 MA18.06: Reassessing Sublobar vs. Lobar Resection for Early-stage Small Cell Lung Cancer in the Wake of CALGB 140503**  
*Chinmay Haridas, USA*
- 12:22 Q&A**
- 12:30 MA18.08: A Phase 2 Study of Carboplatin, Etoposide and Nintedanib for Unresectable Small-Cell Lung Cancer with Idiopathic Pulmonary Fibrosis**  
*Yoko Agemi, Japan*
- 12:35 MA18.09: Carboplatin, Etoposide, Bevacizumab, and Atezolizumab in Patients with Extensive-Stage SCLC - GOIRC-01-2019 CeLEBrATE Trial**  
*Giuseppe Lamberti, Italy*
- 12:40 MA18.10: Phase 2 Multicohort Study of CC-90011, a LSD1 Inhibitor, in Combination with Nivolumab in Patients with Advanced Lung Cancer**  
*Enric Carcereny, USA*
- 12:45 MA18.11: A Phase Ib/II Study of Senaparib in Combination with Low-dose Temozolomide: Updated Results in Relapsed ES-SCLC Patients**  
*Min Hee Hong, Republic of Korea*
- 12:50 Q&A**

**12:00 - 13:00 MA19: Emerging Technologies in Lung Cancer Screening**

Track: Screening and Early Detection

Not for CME Credit

ROOM: SUMMIT 1, LEVEL 3

Chairs: Helmut Prosch, Austria &amp; Claudia Henschke, USA

- 12:00 Welcome & Introduction**  
*Helmut Prosch, Austria & Claudia Henschke, USA*
- 12:02 MA19.03: Sex Differences in the Prediction of Future Lung Cancer Risk Based on a Single Low-Dose Chest Computed Tomography Scan**  
*Florian Fintelmann, USA*

- 12:07** **MA19.04: Impact of Radiomic Features and Software Algorithm on Pulmonary Nodule Measurement Uncertainty**  
*Artit Jirapatnakul, USA*
- 12:12** **MA19.05: Performance of Risk Prediction Models to Select Individuals for Lung Cancer Screening in the European Population**  
*Xiaoshuang Feng, France*
- 12:17** **MA19.06: Artificial Intelligence as Concurrent Reader in Prospective European Lung Cancer Screening (4-IN-THE-LUNG-RUN) Trial**  
*Matthijs Oudkerk, Netherlands*
- 12:22** **Q&A**
- 12:30** **MA19.08: AI Can Greatly Reduce Radiologist Workload if Used as a First Read Filter to Rule-Out Negative Cases in Lung Cancer Screening**  
*Harriet Lancaster, Netherlands*
- 12:35** **MA19.09: AI-Based Early Detection and Subtyping of Non-Small Cell Lung Cancer from Blood Samples Using Orphan Noncoding RNAs**  
*Mehran Karimzadeh, USA*
- 12:40** **MA19.10: Saliva Metabolic Profiling for Benign and Malignant Pulmonary Nodules Distinguish and Early Lung Cancer Detection**  
*Jianmin Wu, China*
- 12:45** **MA19.11: Predicting Future Lung Cancer Risk with Low-Dose Screening CT Using an Artificial Intelligence Model**  
*Ren Yuan, Canada*
- 12:50** **Q&A**

**12:00 - 13:00 OA19: Novel Targets and Biomarkers****Track: Tumor Biology – Translational Biology****ROOM: 405B, LEVEL 4***Chairs: Kenneth O'Byrne, Australia & Esra Akbay, USA*

- 12:00** **Welcome & Introduction**  
*Kenneth O'Byrne, Australia & Esra Akbay, USA*
- 12:02** **OA19.03: Exportin 1 Inhibition Constraints Lineage Plasticity and Histological Transformation through Downregulation of SOX2**  
*Alvaro Quintanal-Villalonga, USA*
- 12:12** **OA19.04: MEF2Dhigh Pericytes Orchestrate an Immunosuppressive Perivascular Niche and Curtail Immunotherapy Efficacy of Lung Cancer**  
*Bai Xue, China*
- 12:22** **OA19.05: Activating MET Tyrosine Kinase Domain Mutations as de Novo Oncogenic Drivers in Non-small Cell Lung Cancer**  
*Seshiru Nakazawa, USA*
- 12:32** **OA19.06: CRTAM Acts as a Checkpoint of Immune-related Adverse Events Uncoupling Efficacy and Toxicity During Immunotherapy**  
*Si-Cong Ma, China*
- 12:42** **OA19.07: Discussant**  
*Dominic Rothwell, UK*
- 12:52** **Q&A**

**12:00 - 13:00 OA20: Assessing Invasion and Tumour Grade in NSCLC****Track: Pathology and Biomarkers****ROOM: SUMMIT 2, LEVEL 3***Chairs: Teh-Ying Chou, Taiwan & Jan von der Thusen, Netherlands*

- 12:00** **Welcome & Introduction**  
*Teh-Ying Chou, Taiwan & Jan von der Thusen, Netherlands*
- 12:02** **OA20.03: Spatially Resolved Transcriptomic Characterisation of High-Risk Morphologies in Lung Adenocarcinoma**  
*John Le Quesne, UK*
- 12:12** **OA20.04: Clinical Significance of IASLC Proposed Pathologic Criteria for Invasion in Resected Non-mucinous Lung Adenocarcinoma**  
*Tae Hee Hong, Republic of Korea*
- 12:22** **OA20.05: The International Association for the Study of Lung Cancer Grading System for Recurrence and Lung Cancer-Specific Survival**  
*Kay See Tan, USA*
- 12:32** **OA20.06: Quantification of Pathologically Assessed Lymph Node Area in Lung Cancer Resection Using Deep Learning**  
*André Lametti, Canada*
- 12:42** **OA20.07: Discussant**  
*Marina Baine, USA*
- 12:52** **Q&A**

**13:15 - 14:15 Lunch Break****ROOM: EXHIBIT HALL, LEVEL 4****13:15 - 14:15 Satellite CME Symposium****FOR FURTHER INFORMATION, PLEASE SEE PAGE 235.****14:30 - 15:30 ES42: Models to Improve Lung Cancer Care****Track: Global Health, Health Services, and Health Economics****ROOM: NICOLL 3, LEVEL 3***Chairs: Shalini Vinod, Australia & Melody Qu, Canada*

- 14:30** **Welcome & Introduction**  
*Shalini Vinod, Australia & Melody Qu, Canada*
- 14:32** **ES42.03: Quality Models to Improve Cancer Care and Find Value-Based Propositions for High/Middle/Low Income Countries**  
*Vedner Guerrier, USA*
- 14:44** **ES42.04: Diversity in Clinical Trials - How Do We Ensure a Safe Space and Access**  
*Anne-Marie Baird, Ireland*
- 14:56** **ES42.05: Real World Data and Value Driven Outcomes - Opportunities and Limitations**  
*Susan Harden, Australia*



**15:08 ES42.06: Models of Nursing Care in Lung Cancer***Anne Fraser, New Zealand***15:20 Q&A****14:30 - 15:30 ES43: Integrating Immunotherapy in Metastatic NSCLC Patients****Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy** ACCME Accredited By IASLC**ROOM: 405B, LEVEL 4**

Recommended for Early Career Researchers

*Chairs: Malinda Itchens, Australia & Jordi Remon, France***14:30 Welcome & Introduction***Malinda Itchens, Australia & Jordi Remon, France***14:32 ES43.03: Checkpoint Inhibition for Concogene-Addicted Disease (EGFR, ALK, ROS1)***Hidetoshi Hayashi, Japan***14:44 ES43.04: Best Sequencing Strategies for Patients with KRAS Mutations - When to Use Chemo IO vs KRAS Inhibitors***Pilar Garrido, Spain***14:56 ES43.05: Selecting a Patient for CTLA4 Inhibition***Maurice Perol, France***15:08 ES43.06: Duration of Immune Checkpoint Inhibitor: Stop or Continue After 2 Years?***Marina Garassino, USA***15:20 Q&A****14:30 - 15:30 ES44: Thymic Epithelial Tumour****Track: Mesothelioma, Thymoma, and Other Thoracic Tumors** ACCME Accredited By IASLC**ROOM: SUMMIT 2, LEVEL 3***Chairs: Yuki Katsuya, Japan & Bin-Chi Liao, Taiwan***14:30 Welcome & Introduction***Yuki Katsuya, Japan & Bin-Chi Liao, Taiwan***14:32 ES44.03: From Diagnosis to Surgery***Harish Mithiran, Singapore***14:44 ES44.04: Developments and Challenges in the Pathology of Thymic Epithelial Tumors***Anja Roden, USA***14:56 ES44.05: The Role of Radiation Therapy in Localized Thymic Epithelial Tumours***Annemarie Shepherd, USA***15:08 ES44.06: Systemic Therapy for Advanced Thymic Epithelial Tumors***Yusuke Okuma, Japan***15:20 Q&A****14:30 - 15:30 ES45: Data-Driven Approaches to Drug Development****Track: Tumor Biology – Preclinical Biology**

ACCME Accredited By IASLC

**ROOM: 405C, LEVEL 4***Chairs: Marie-Liesse Asselin-Labat, Australia & Alfredo Addeo, Switzerland***14:30 Welcome & Introduction***Marie-Liesse Asselin-Labat, Australia & Alfredo Addeo, Switzerland***14:32 ES45.03: Big Data and Bioinformatics for Biomarker Discovery***Yu Shyr, USA***14:44 ES45.04: Computational Models for Novel Biomarker Identification***Anders Jacobsen Skanderup, Singapore***14:56 ES45.05: Improving Personalised Medicine through Tissue Spatial ‘Omics’ Approaches***Jinmiao Chen, Singapore***15:08 ES45.06: Integration of Multi-Omics Data Using AI for Novel Target Identification***Chiara Loeffler, Germany***15:20 Q&A****14:30 - 15:30 MA20: Prognostic and Predictive Biomarkers in NSCLC****Track: Pathology and Biomarkers**

Not for CME Credit

**ROOM: SUMMIT 1, LEVEL 3***Chairs: Yuko Minami, Japan & Hyo Sup Shim, Republic of Korea***14:30 Welcome & Introduction***Yuko Minami, Japan & Hyo Sup Shim, Republic of Korea***14:32 MA20.03: The Value of Lepidic and Invasion Pattern NEW Diagnostic Criteria for the Differential Diagnosis of in AIS, MIA from Invasive Adenocarcinoma***Huikang Xie, China***14:37 MA20.04: Predicting Tumor Spread Through Air Space in the Pulmonary Adenocarcinoma Slides Using Deep Learning Model***Sejoon Lee, Republic of Korea***14:42 MA20.05: The IASLC Grading System as a Predictor For EGFR-TKI Therapy in EGFR-Mutant Lung Adenocarcinoma***Chaoqiang Deng, China***14:47 MA20.06: Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma***Alessandro Di Federico, USA***14:52 Q&A****15:00 MA20.08: Prediction of Immune-Related Adverse Events Based on Th17 Cell Differentiation Pathway***Dongchen Sun, China***15:05 MA20.09: Baseline PD-L1+ Neutrophils and Monocytes Predict Radiological Response to Anti-PD-(L)1 Therapy in Patients with Advanced NSCLC***Margarita Majem, Spain*

- 15:10** MA20.10: A 9-Genes Inflammation Signature Predicts Survival and Immune Checkpoint Blockade in Non-small Cell Lung Cancer  
*Nour Al-Bzour, Jordan*
- 15:15** MA20.11: Noninvasive Diagnosis of Pulmonary Nodules Using a Circulating TsRNAs-Based Nomogram  
*Qixing Mao, China*
- 15:20** Q&A

**14:30 - 15:30 MA21: The Continuous Reshaping of Lung Cancer Staging**

Track: Pulmonology and Staging



ROOM: NICOLL 2, LEVEL 3

Chairs: John Tam, Singapore & Jazmin Eckhaus, Australia

- 14:30** Welcome & Introduction  
*John Tam, Singapore & Jazmin Eckhaus, Australia*
- 14:32** MA21.03: Preoperative Assessment of N2 Mediastinal Lymph Nodes in Non-small Cell Lung Cancer Using Ga-68 FAPI PET/CT: A Prospective Pilot Study  
*Kwon Joong Na, Republic of Korea*
- 14:37** MA21.04: Novel Classification with Number or Zones of Involved Lymph Nodal Stations in Patients with Resected Non-Small Cell Lung Cancer  
*Atsushi Kamigaichi, Japan*
- 14:42** MA21.05: What Is the Proper T Category for the Tumor with Additional Nodules in Different Lobes of Ipsilateral Lung?  
*Jing-Sheng Cai, China*
- 14:47** Q&A
- 14:47** MA21.07: Validation of The Proposal in the IASLC R Classification to Upgrade Extracapsular Extension of Tumor in Nodes from R0 to Incomplete Resection  
*Chenyang Dai, China*
- 14:52** MA21.08: Usefulness of Bronchoscopic Cytology Pellets for Next Generation Sequencing  
*Chihiro Mimura, Japan*
- 14:57** MA21.09: More Accurate Staging of Stage IV Lung Cancer Through EUS B of the Left Adrenal Gland  
*Filiz Oezkan, Germany*
- 15:15** Q&A

**14:30 - 15:30 OA21: MET Matters in NSCLC**

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy



ROOM: 406, LEVEL 4



Chairs: Nandini Menon, India & Rafael Rosell, Spain

- 14:30** Welcome & Introduction  
*Nandini Menon, India & Rafael Rosell, Spain*
- 14:32** OA21.03: A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation  
*Shun Lu, China*

- 14:42** OA21.04: Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study  
*Natasha Leigh, Canada*
- 14:52** OA21.05: Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis  
*Tae Min Kim, UK*
- 15:02** OA21.06: ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial  
*Xiuning Le, UK*
- 15:12** OA21.07: Discussant  
*Alexander Drilon, USA*
- 15:22** Q&A

**14:30 - 15:30 OA22: Integration of Local Therapies with Modern Immune Checkpoint Inhibitors and Targeted Therapies in Metastatic NSCLC: When and How?**

Track: Metastatic Non-small Cell Lung Cancer – Local Therapies



ROOM: 405A, LEVEL 4

Chairs: Nan Bi, China & Steven Kao, Australia

- 14:30** Welcome & Introduction  
*Nan Bi, China & Steven Kao, Australia*
- 14:32** OA22.03: The Addition of Multisite SBRT to Ipilimumab and Nivolumab in First Line Metastatic NSCLC: The COSINR Trial  
*Aditya Juloori, USA*
- 14:42** OA22.04: BRIGHTSTAR Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC  
*Yasir Elamin, USA*
- 14:52** OA22.05: TTFIELDS and Immune-Checkpoint Inhibitor in Metastatic Non-small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study  
*Ticiana Leal, USA*
- 15:02** OA22.06: Changes in Cognition after Osimertinib, with or without SRS, in EGFRm NSCLC with Brain Metastases: a Pooled Analysis of RCTs  
*Yu Yang Soon, Singapore*
- 15:12** OA22.07: Discussant  
*Daniel Gomez, USA*
- 15:22** Q&A

15:45 - 16:45 **PL06: Closing Plenary Session 6: Advances in Lung Cancer Pathology**

**ROOM: 406, LEVEL 4**

📺 Live-Streamed

🏆 ACCME Accredited By IASLC

*Chairs: Chee Lee, Australia & Ignacio Wistuba, USA*

👍 Recommended for Early Career Researchers

**15:45 Welcome & Introduction**

*Chee Lee, Australia & Ignacio Wistuba, USA*

**15:47 PL06.03: NeoPathology? The Role of Pathology in the Setting of Neoadjuvant Treatment for NSCLC**

*Keith Kerr, UK*

**16:07 PL06.04: Assessment of Pathological Response to Neoadjuvant Therapy? Results of the IASLC Interobserver Study**

*Sanja Dacic, USA*

**16:27 Q&A**

**16:30 Closing Remarks and Invitation to WCLC 2024 San Diego, USA**

**On Demand HOD03: Highlights of the Day - Tuesday Abstracts**

**HOD03.01: Radiation Oncology**

*Ken Harada, Japan*

👍 Recommended for Early Career Researchers

**HOD03.02: Medical Oncology**

*Deborah Zhou, Australia*

🏆 ACCME Accredited By IASLC

**HOD03.03: Medical Oncology**

*Aaron Tan, Singapore*



**6 POSTER INFORMATION**


**Now Available!**

## IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer.

The IASLC's latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results, from both a diagnostic and clinical perspective.

The IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer is a useful reference for anyone involved in treating lung cancer patients, from allied health professionals to surgeons. All pathologists and medical oncologists should have access to these best practices.

Visit the IASLC booth for a free hard copy or scan the QR code to order online.



THE IASLC EXPERIENCE

CONNECT WITH US



@IASLC



facebook.com/IASLC



@iaslungcancer



linkedin.com/IASLC



IASLC

## RENEW YOUR MEMBERSHIP TODAY!



EXPERIENCE collaboration with global thoracic oncology thought leaders across all disciplines.



EXPERIENCE access to the *Journal of Thoracic Oncology* and discount publication fees to the *JTO Clinical and Research Reports (JTO CRR)*.



EXPERIENCE discounts to meetings and the annual IASLC World Conference on Lung Cancer.



IASLC.org/membership

**06 WCLC 2023 POSTER SESSIONS**

Poster Session 1: P1

Display Time: **Sunday, September 10, 2023 – 10:00 – 19:30**Presenters in Attendance: **Sunday, September 10, 2023 – 17:30 – 19:30****POSTER SESSION 1: P1****P1.01 Track: Risk Factors, Risk Reduction & Tobacco Control**

- P1.01-01** Frequency of Germline Mutations in Patients with Non-small Cell Lung Cancer (NSCLC) Harboring Actionable DRIVER Alterations (G-DRIVER)  
*Ernest Nadal, Spain*
- P1.01-02** Diabetes as Prognostic and Predictive Factors in Resected Non-small Cell Lung Cancer, from a Large Chinese Cohort  
*Yifan Guo, China*
- P1.01-03** Novel Anoikis-Related Prognostic Signatures of NSCLC Based on mRNA-IncRNA Analysis and Primary Validation in CRISPR Screening  
*Anlin Li, China*
- P1.01-04** Clinical and Genetic Characteristics in Younger vs Older Lung Cancer Patients  
*Cristina Candal-Pedreira, Spain*
- P1.01-05** A Predictive Model for Postoperative Recurrence of Lung Cancer Based on Multi-omic Machine Learning  
*Zihao Chen, China*
- P1.01-06** A Phase IB Trial Of Nivolumab for Immunoprevention of Bronchial Dysplasia Progression in High-risk Current and Former Smokers  
*Hui Yu, USA*
- P1.01-07** Asbestos Exposure and Small Cell Lung Cancer. Systematic Review and Meta-Analysis  
*Julia Rey Brandariz, Spain*
- P1.01-08** A Content Analysis E-cigarette Retailer Websites and Nicotine Addiction Among E-cigarette Users - Mixed Methods Study from Malaysia  
*Chandrashekhar Sreerramareddy, Malaysia*
- P1.01-09** Assessing the Relationship Between Frailty and Lung Cancer Survival: A Systematic Review and Meta-Analysis  
*Muhammed Elfaituri, Libyan Arab Jamahiriya*
- P1.01-10** Peptic Ulcer and Long-Term Risk of Lung Cancer: A Prospective Cohort Study from UK Biobank  
*Zhuangzhuang Liu, China*
- P1.01-11** Lung Cancer Risk Prediction Model Incorporating Liver Function Markers: a Prospective Cohort Study from the UK Biobank  
*Xiang Yu Sun, China*
- P1.01-12** "A Core Part of the Whole Thing...": Stakeholder Views on Offering Smoking Cessation Support in Lung Cancer Screening  
*Nathan Harrison, Australia*
- P1.01-13** Amelioration of the Toll of Air Pollution on Lung Cancer  
*Renelle Myers, Canada*

**P1.02 Track: Tumor Biology – Preclinical Biology – Molecular Therapeutic Targets**

- P1.02-01** HRA00129-C004, a Novel c-Met ADC with Promising Preclinical Anti-tumor Activity and Expanded Therapeutic Window  
*Yunan Tian, China*
- P1.02-02** Co-inhibition of MEK/RTKs Pathways via Trametinib Plus Anlotinib for KRAS-Mutant NSCLC  
*Baohui Han, China*
- P1.02-03** Identifying Biomarkers of Response to Ensartinib, Lorlatinib, and Alectinib in an ALK+ Non-Small Cell Lung Cancer Preclinical Model (ResCu)  
*Christopher Bulow, USA*
- P1.02-04** Targeting ATP7A by Elesclomol-Copper Derived Endoplasmic Reticulum Stress to Mediate Cuproptosis in KRAS-G12 Mutant LUAD  
*Zeyi Liu, China*
- P1.02-05** METTL3-mediated m6A Modification of SRPK1 Promotes Lung Adenocarcinoma Through Aerobic Glycolysis  
*Zeyi Liu, China*
- P1.02-06** Glucose Deprivation Promotes Pseudo-Hypoxia and De-differentiation in Lung Adenocarcinoma  
*Claudio Scafoglio, USA*

**P1.03 Track: Tumor Biology – Preclinical Biology – Omics Approaches**

- P1.03-01** Dynamic Transcriptomic Characterization Changes of Early Stage Lung Adenocarcinoma as per the Incrassation of Consolidation Tumor Ratio  
*Zhen-bin Qiu, China*
- P1.03-02** Combination of Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment  
*Yuanliu Nie, China*

**P1.04 Track: Tumor Biology – Preclinical Biology – Radiobiology**

- P1.04-01** CDK4/6 Inhibitor Improves Radioimmunotherapy Efficacy via Inducing PD-L1 Transcription through Increased c-Jun Activation in NSCLC  
*Yan Gong, China*
- P1.04-02** Ablative Radiation Induces Distinct Sequential Waves of Mitotic and Innate Immune Death Regulated through DNA Repair Pathways  
*Harriet Gee, Australia*

**P1.05 Track: Tumor Biology – Preclinical Biology – Regulatory Mechanisms**

- P1.05-01** Research on Specific DNA Methylation Regulatory Mechanism Based on Pan-Cancer Analysis  
*Yvan Guo, China*

**P1.06 Track: Tumor Biology – Preclinical Biology – Tumor Immunity**

- P1.06-01** NIR-II Mediates Non-small Cell Lung Cancer Nanovaccines for Targeted Lymph Node Delivery and Anti-tumor Immune Activation  
*Haiyu Zhou, China*

## POSTER SESSION 1: P1 - SUNDAY, SEPTEMBER 10, 2023

**P1.06-02** Trametinib Plus ANTI-PD-1 Immunotherapy Impairs Tumor Growth and Increases Survival of Lung Cancer Through ID1 Downregulation

*Ignacio Gil-Bazo, Spain*

**P1.06-03** Effect and Mechanism of ASNS Remodeling the Metastatic Lymph Node Immune Microenvironment in Lung Cancer

*Min Li, China*

**P1.06-04** Phenotype Mapping of Patient-Derived Small Cell Lung Cancer Organoids Illuminate Subtype-Specific Therapeutic Vulnerability

*Takahiro Fukushima, Japan*

### **P1.07 Track: Tumor Biology – Translational Biology – Disease Modeling**

**P1.07-01** Collective Lung Cancer Migration Using a 3D Model

*Helmut Popper, Austria*

**P1.07-02** Patient-Derived Xenografts from Thoracic Malignancies as Promising Preclinical Models

*Kosuke Fujino, Japan*

### **P1.08 Track: Tumor Biology – Translational Biology - Drug Resistance**

**P1.08-01** CoxMoE: A Deep Learning Model Predicts Survival and Response in T790M Positive NSCLC Patients Treated with Third-Generation EGFR-TKI

*Ning Lou, China*

**P1.08-02** Exploring Autophagy Flux-Related Molecules for Overcoming EGFR TKI Resistance

*Jin-Hyoung Kang, Republic of Korea*

**P1.08-03** Hyper-Interferon Sensitive Influenza Virus Induces Immune Activation and Overcomes Resistance to Anti-PD-1 in Murine NSCLC

*Ramin Salehi-rad, USA*

**P1.08-04** Delivery of ATRA and Gefitinib by Polyphenylalanine Nanosystem to Overcome EGFR-TKI Resistance in Lung Adenocarcinoma

*Bin Xu, China*

**P1.08-05** On-Target Acquired Resistance to Mobocertinib and Strategy to Overcome It - In Vitro Study Using EGFR Ex20 Insertion Models

*Akira Hamada, Japan*

**P1.08-06** Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes

*Norma Hernandez Pedro, Mexico*

### **P1.09 Track: Tumor Biology – Translational Biology - IO**

**P1.09-01** Anti-Cancer Immune Activation Post Bronchoscopic Thermal Ablation in Non-small Cell Lung Cancer

*Kanishka Rangamuwa, Australia*

**P1.09-02** Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR mutant NSCLC

*Yang-Si Li, China*

**P1.09-03** Clinical Relevance of Serum Lipids in Increasing NK Cell Anti-tumor Activity Within NSCLC Tumor Microenvironment

*Ying Yang, China*

## POSTER SESSION 1: P1 - SUNDAY, SEPTEMBER 10, 2023

**P1.09-04** Characterization of the Immunosuppressive Function of UPP1high Tumor Cells in Lung Adenocarcinoma and Its Association with Immunotherapy

*Yin Li, China*

**P1.09-05** SFRP2+ CAFs Hinder Abscopal Effect from Combined Radiotherapy and Immunotherapy by Forming a Hostile Perivascular Niche

*Zhang Yanpei, China*

**P1.09-06** SRSF9 Fuels PD-1+ Regulatory T Cells and Cancer Oncogenic Pathway to Drive Hyperprogression Under Immunotherapy

*Zhong-Yi Dong, China*

**P1.09-07** Obesity Promotes Lung Carcinogenesis Through T-cell Immune Dysfunction

*Sai Yendamuri, USA*

**P1.09-08** Characterization of the Expression of BTN1A1 Exclusive to PD-L1/PD-1 Axis in Small Cell Lung Cancer Using Spatial Biology Approach

*Stephen Yoo, USA*

**P1.09-09** DCBLD2 Impacts Tumor Immune-Vascular Microenvironment of Lung Cancer by Inducing Pro-angiogenic Macrophages

*Bai Xue, China*

### **P1.10 Track: Tumor Biology – Translational Biology – Novel Targets**

**P1.10-01** Enrichment of FA/HR Aberrations in ATM/ATR-mutated NSCLC was Accompanied by Distinct Molecular Features and Poor Prognosis

*Yang Shao, China*

### **P1.11 Track: Tumor Biology – Translational Biology - Omics and New Technologies**

**P1.11-01** Utility of ctDNA Monitoring During Surveillance in Surgically Resected NSCLC Patients

*Shuta Ohara, Japan*

**P1.11-02** DYNAMALK: Dynamic ctDNA Profiling in ALK+ NSCLC. A Study of the Australian Registry and Biobank of Thoracic Cancers AURORA

*Malinda Itchins, Australia*

**P1.11-03** Proteomics-based Predictive Model for the Increased Brain Metastasis Risk in Resected Lung Adenocarcinoma with EGFR Mutation

*Haihong Yang, China*

**P1.11-04** Clinical Implication of Multi-Genomic Analysis about Compound and Uncommon EGFR Mutations in the Non-small Cell Lung Cancer

*Jaekyeong Lee, Republic of Korea*

**P1.11-05** Application of the CRISPR/Cas9-based Gene Editing Technology for the Treatment of NUT Carcinoma

*Juyoung Choi, Republic of Korea*

### **P1.12 Track: Tumor Biology – Translational Biology - Translational Therapeutics**

**P1.12-01** CD66c Activates EGFR Signalling Pathway and Promotes EMT in Lung Adenocarcinoma

*Yushi Li, Hong Kong*

**P1.12-02** Mechanism of Osteopontin Mediating Targeted Therapy Induced Interstitial Lung Disease Through Integrin  $\alpha$ V $\beta$ 3/Prostaglandin E2

*Zeyi Liu, China*

## POSTER SESSION 1: P1 - SUNDAY, SEPTEMBER 10, 2023

- P1.12-03** LP-184, a Tumor Site Activated Small Molecule Acylfulvene, is Effective Preclinically in Subsets of Lung Cancer  
*Reginald Ewesuedo, USA*
- P1.12-04** In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a Broad Panel of NSCLC Patient-Derived Xenograft Models  
*Lara McGrath, USA*
- P1.12-05** Combining Anti-HER3 Antibody, HMBD-001, with EGFR Inhibition and Chemotherapy May Improve Treatment Outcomes in SqNSCLC  
*Dipti Thakkar, Singapore*
- P1.12-06** BiFeO<sub>3</sub>@PANI Sensitizes LKB1-Deficient LUAD to Radiotherapy via Induction of Tumoral Lipid Oxidation and Ferroptosis  
*Zejin Guo, China*
- P1.12-07** Ferroptosis-induction Therapy Combined with Super-enhancers Inhibitors Selectively Target NRF2-activated Lung Cancer  
*Ke Xu, China*
- P1.12-08** Characterization of MET Exon 14 Skipping Analog (Y1003) in Non-small Cell Lung Cancer (NSCLC)  
*So Yeon Kim, USA*
- P1.12-09** APC-1, A Novel Aptamer-Cisplatin Conjugate, Exhibits Promising Anti-tumor Effect in Lung Cancer  
*Emily Lin, Taiwan*
- P1.12-10** Sensitization of Cancer Cells to Tumor Treating Fields (TTFields) via Inhibition of the PI3K/AKT Signaling Pathway  
*Moshe Giladi, Israel*

**P1.13 Track: Screening and Early Detection - Biomarkers/Imaging Technology**

- P1.13-01** A Proteomics-Annotated Risk Model to Predict Recurrence in Stage I Non-small Cell Lung Cancer  
*Ying Huang, China*
- P1.13-02** Deep Multi-omic Blood-Based Biomarker Discovery in People with Smoking History Demonstrates High Early Detection of Nsclc  
*Brian Koh, USA*
- P1.13-03** Proof-of-mechanism for a Diagnostic Probe Generating D5-Ethanol Asan On-Breath Reporter Molecule for Lung Cancer - Evolution Phase 1.  
*Marc Schee, UK*
- P1.13-04** The LuCID Study: Detection of Lung Cancer Breath Biomarkers via Breath Biopsy in a Multi-Centre Trial  
*Marc Schee, UK*
- P1.13-05** Targeting SGLT2 for Early Diagnosis of Lung Adenocarcinoma  
*Claudio Scafoglio, USA*
- P1.13-06** Plasma Cell-free RNA Sequencing Enables Sensitive Detection of Lung Cancer  
*Yee Fang Hum, Singapore*
- P1.13-07** A Novel Blood-Based DNAMethylation Panel for Detection of Lung Cancer at Very Early Stage  
*Rongxi Yang, China*

## POSTER SESSION 1: P1 - SUNDAY, SEPTEMBER 10, 2023

- P1.13-08** Detection of Lung Cancer in People Without a Smoking History Using Exhaled Breath as an Exogenous Probe  
*Renelle Myers, Canada*
- P1.13-09** A Multi-Stage Imaging-Based Deep Learning Classifier for EGFR-TKI Response Prediction in EGFR mutant Non-small Cell Lung Cancer  
*Yang Xia, China*

**P1.14 Track: Screening and Early Detection - Implementation**

- P1.14-01** Strengthening the Screening of Lung Cancer in Europe (SOLACE) Project  
*Hans-Ulrich Kauczor, Germany*
- P1.14-02** Validation of Lung Cancer Risk Prediction Models in an Asbestos Exposed Population  
*Chellan Kumarasamy, Australia*
- P1.14-03** How Do Patients with Screening-Detected Pulmonary Nodules, Experience and React to Being under Surveillance?  
*Evangelos Katsampouris, UK*
- P1.14-04** European Lung Cancer Screening Implementation: 4-IN-THE-LUNG-RUN trial  
*Matthijs Oudkerk, Netherlands*

**P1.15 Track: Screening and Early Detection - Maximising Screening Benefits**

- P1.15-01** Optimised Lung Cancer Screening to Prevent Cardiovascular and Pulmonary Diseases Coupled with Primary Prevention: Results of the Baseline Round  
*Piergiorgio Muriana, Italy*
- P1.15-02** Cardiovascular Implications of Lung Cancer Screening Program: The Smokers Health Multiple Actions (SMAC) study  
*Piergiorgio Muriana, Italy*
- P1.15-03** Dedicated Cardiovascular Screening in Lung Cancer Screening: Preliminary Results from the European 4-IN-THE-LUNG-RUN Trial  
*Matthijs Oudkerk, Netherlands*
- P1.15-04** Awareness, Understanding, and Follow Up of Women with Dense Breasts Identified on Low-Dose CT Screening for Lung Cancer  
*Rowena Yip, USA*

**P1.16 Track: Screening and Early Detection - Nodule Management**

- P1.16-01** Artificial Intelligence-Assisted Quantitative CT parameters in Predicting the Degree of Risk of Solitary Pulmonary Nodules  
*Long Jiang, China*
- P1.16-02** Three Dimensional Volumetric Analysis Is Useful to Improve Diagnostic Accuracy in Early-Stage Lung Adenocarcinoma.  
*Shinji Kaneda, Japan*
- P1.16-03** Transbronchial Cryobiopsy Using 1.1 mm-Diameter Cryoprobe for the Diagnosis of Early Stage Lung Cancer  
*Jung Seop Eom, Republic of Korea*
- P1.16-04** Differences in Incidentally Detected Versus Screening Detected Stage I Lung Cancer Surgery Patients  
*Shubham Gulati, USA*

- P1.16-05 **Quality Initiative to Improve Timeliness of Care in a Rapid Assessment Lung Cancer Clinic**  
*Shakti Dabholkar, Australia*

### P1.17 Track: Screening and Early Detection - Program Design

- P1.17-01 **Lung Cancer Screening in Low- and Middle-income Countries - Report on Status, Challenges and Perspectives from WCLC2022 and LALCA2023**  
*Milena Covic, Serbia*
- P1.17-02 **Interval of Computed Tomography after Lung Cancer Surgery Follow-Ups Did Not Affect Survival**  
*Natsumi Maru, Japan*
- P1.17-03 **Cost-effectiveness of Low-dose Computerized Tomography Lung Cancer Screening in High-risk Non-smokers and Smokers in Hong Kong**  
*Herbert Loong, Hong Kong*
- P1.17-04 **Lung-Cancer Screening: Is It Worth Investing? Evidence from a Population-Based Markov Study in Italy**  
*Pierluigi Novellis, Italy*
- P1.17-05 **Cost-Effectiveness of LDCT Screening in Never Smokers at High Lung-Cancer Risk**  
*Szu-Chun Yang, Taiwan*
- P1.17-06 **Integrated TB and Lung Cancer Screening in Viet Nam**  
*Thang Dao, Viet Nam*
- P1.17-07 **Impact of Lung Cancer Screening with Low-Dose Chest Computed Tomography Scan in an Elderly Population: A Retrospective Cohort Study**  
*Hyeong-Jun Noh, Republic of Korea*
- P1.17-08 **Program Factors Associated with the Psychosocial Outcomes of Lung Cancer Screening: A Systematic Review**  
*Kathleen McFadden, Australia*

### P1.18 Track: Screening and Early Detection - Recruitment + Screening Uptake

- P1.18-01 **Association between Cognitive Impairment & Lung Cancer Screening Use among People with Significant Smoking History: Population-Based Study**  
*Hermine Poghosyan, USA*
- P1.18-02 **Coordinating Lung Cancer Screening with Screening Mammography: The CALM Study**  
*Robert Smith, USA*
- P1.18-03 **Patients with Smoking-Associated Atherosclerotic Cardiovascular Diseases: Does Prevalung Refines Eligibility for Screening?**  
*David Boulate, France*
- P1.18-04 **First Annual Lung Cancer Screening Day in the United States Saturday November 12 2022**  
*Ella Kazerooni, USA*
- P1.18-05 **Te Oranga Pūkahu: Developing an Indigenous Māori Led Approach to Lung Cancer Screening**  
*Kate Parker, New Zealand*
- P1.18-06 **Barriers to Completing Low Dose CT Scan for Lung Cancer Screening**  
*Lye-Yeng Wong, USA*

- P1.18-07 **Systematic Enrolment Ensures High Participation Rate in Lung Cancer Screening - Results of Regional Pilot Study in Estonia**  
*Tanel Laisaar, Estonia*

### P1.19 Track: Pulmonology and Staging

- P1.19-01 **Pleural Invasion of Primary Lung Cancer With Interstitial Lung Disease Treated by Surgical Resection**  
*Takahisa Koizumi, Japan*
- P1.19-02 **Results of Comparing Seven Lymph Node Staging Systems in Completely Resected Non-small Cell Lung Cancer Patients**  
*Jing-Sheng Cai, China*
- P1.19-03 **External Validation of the T Category for the Patients with Bronchus Involvements: A Population-Based Study**  
*Jing-Sheng Cai, China*
- P1.19-04 **The Prognosis of the T2N0M0 Non-small Cell Lung Cancer with Visceral Pleural Invasion Is Dependent on Tumor Size**  
*Jing-Sheng Cai, China*

### P1.20 Track: Pathology and Biomarkers - Artificial Intelligence in Pathology

- P1.20-01 **Computed Tomography-based Deep Learning Model for Spread Through Air Spaces Prediction in Ground-Glass Predominant Lung Adenocarcinoma**  
*Mong-Wei Lin, Taiwan*
- P1.20-02 **Improved Diagnosis of Lung Neuroendocrine Tumors: Role of Proliferative Activity and Deep Learning**  
*Sylvie Lantuejoul, France*
- P1.20-03 **Solute Carrier Transporter-based Machine Learning Model Predicts Efficacy of Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer**  
*Mengting Shi, China*
- P1.20-04 **Predictability of Actionable Mutations in NSCLC using Attention-Based Multiple-Instance Learning on H&E Images**  
*Pierre Murchan, Ireland*
- P1.20-05 **Leveraging NLP to Identify Biomarker-Eligible Patients**  
*John Ruckdeschel, USA*
- P1.20-06 **Mapping the Histopathological Landscape of Lung Adenocarcinoma Using Self-Supervised Learning Artificial Intelligence**  
*John Le Quesne, UK*

### P1.21 Track: Pathology and Biomarkers - Biomarkers for Immuno-oncology

- P1.21-01 **Major Pathologic Response after Neoadjuvant Therapy in NSCLC: Predicting Better Outcomes with High Interobserver Agreement**  
*Sungjin Kim, Republic of Korea*
- P1.21-02 **Genetic Susceptibility to Immune Checkpoints Blockade Resistance**  
*Jose Benítez, Spain*
- P1.21-03 **Upregulation of HLA-I/II and Pro-inflammatory Cells in PBMCs Indicated Efficacy of Neoadjuvant Chemo-immunotherapy in Locally Advanced NSCLC**  
*Hui Kang Xie, China*



## POSTER SESSION 1: P1 - SUNDAY, SEPTEMBER 10, 2023

- P1.21-04 **Role of HLA-I as a Molecular Prognostic Factor for Long Term Responders in Non-small Cell Lung Cancer Patients Treated with Immunotherapy**  
*Enric Carcereny, Spain*
- P1.21-05 **The Upregulated Expression of IGF2BP2 Predicts Poor Prognosis in Lung Adenocarcinoma and Affects Immune Microenvironment and Drug Sensitivity**  
*Xuequan Wang, China*
- P1.21-06 **Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer**  
*Diego de Miguel Perez, USA*
- P1.21-07 **Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer**  
*Javier Baena, Spain*
- P1.21-08 **Eosinophil to Neutrophil Ratio Predicts Efficacy in Patients Receiving Immunotherapy in Metastatic Non-small Cell Lung Cancer (mNSCLC)**  
*Joe Wei, Australia*
- P1.21-09 **Radiomic Signature of Identifies Outcome and Prognosis to Immune Checkpoint Inhibitors (ICI) in PD-L1 Low Non-small Cell Lung Cancer (NSCLC)**  
*Nathaniel Braman, USA*
- P1.21-10 **PD-1 and Interleukin-10-Receptor Expression by T Lymphocytes in Malignant and Benign Pleural Effusions**  
*Berta Mosleh, Austria*
- P1.21-11 **Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS $\geq$ 50%**  
*Jennifer Suga, USA*
- P1.21-12 **Microsatellite Instability Defines a Subset of Lung Cancers with Smoking Exposure, High Tumor Mutational Burden and MLH1 Inactivation**  
*Soo-Ryum Yang, USA*
- P1.21-13 **Genomic Correlates of Response to PD-1 Blockade Plus Chemotherapy in Patients with Untreated Advanced NSCLC**  
*Tao Jiang, China*
- P1.21-14 **LPII-based Score Predicting OS Benefit for the Addition of Chemotherapy to Pembrolizumab in aNSCLC with PD-L1 TPS $\geq$ 50%**  
*Elizabeth Dudnik, Israel*
- P1.21-15 **Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab**  
*Mingjia Li, USA*
- P1.21-16 **NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy**  
*Dhruv Bansal, USA*
- P1.21-17 **DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-small Cell Lung Cancer**  
*Yang Shao, China*
- P1.21-18 **Potential Role of Serum Glycoproteomics in Predicting irAEs in NSCLC Patients Treated with Immunotherapy**  
*Young Kwang Chae, USA*
- P1.21-19 **Potential Utilization of Serum Glycoproteomics as a Biomarker to Predict Survival Outcomes and irAEs in Advanced NSCLC Treated with ICI**  
*Young Kwang Chae, USA*

## POSTER SESSION 1: P1 - SUNDAY, SEPTEMBER 10, 2023

- P1.21-20 **Tertiary Lymphoid Structures Assessed by an AI-powered Analysis of H&E Images is Correlated with Favorable Outcomes of Immunotherapy in NSCLC**  
*Young Kwang Chae, USA*
- P1.21-21 **PD-L1 Expression in Surgically Resected Lung Pleomorphic Carcinoma - One-centre Study of 107 Patients**  
*Renata Langfort, Poland*

**P1.22 Track: Pathology and Biomarkers - Genetic Biomarkers**

- P1.22-01 **Clinical Characteristics and Biomarkers in Lung Cancer: A Comparison Between Screened and Non-Screened Cohorts**  
*Mary Pasquinelli, USA*
- P1.22-02 **Whole Genome Sequencing Analysis of ALK-rearranged Non-small Cell Lung Cancer**  
*Yoon-La Choi, Republic of Korea*
- P1.22-03 **Ventana ALK (D5F3) Immunohistochemistry Improves the Accuracy of Pathologic Assessment after Neoadjuvant ALK-TKIs for ALK-Positive NSCLC**  
*Li-Xu Yan, China*
- P1.22-04 **Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study**  
*Natasha Leighl, Canada*
- P1.22-05 **Prevalence of KRAS Subtype Alterations in Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases**  
*Faran Polani, USA*
- P1.22-06 **Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey**  
*Jackie Fenemore, UK*
- P1.22-07 **Predictive Biomarkers of Response to REGN5093 to Guide Patient Selection in MET-Altered Advanced Non-small Cell Lung Cancer**  
*Petra Rietschel, USA*
- P1.22-08 **Biomarker Testing Trends from a Global Patient-Reported Outcomes Registry**  
*Heather Law, USA*
- P1.22-09 **Molecular Profiling Reveals Distinct Clinical and Genomic Features as Potential Therapeutic Targets in Pulmonary Spindle Cell Carcinoma**  
*Yang Shao, China*
- P1.22-10 **RET Fusion (RETfus+) Driven Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study with Histologic Correlation**  
*Alina Basnet, USA*
- P1.22-11 **Comparison of NGS and FISH Platforms to Test MET Amplification in Chinese Lung Cancer Patients: A Prospective Study**  
*Xue Lin, China*
- P1.22-12 **Nomogram Prediction for the Detection of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma Patients in Indonesia**  
*Edwin Njoto, Indonesia*
- P1.22-13 **Predominant Solid Patterns in Advanced EGFR Mutated Lung Adenocarcinoma Treated with TKI Is Associated with Worse Outcomes**  
*Oscar Arrieta, Mexico*

## POSTER SESSION 1: P1 - SUNDAY, SEPTEMBER 10, 2023

- P1.22-14** A Phase 3 Multicenter Study to Evaluate the Feasibility of a New NGS Panel Using Cytological Specimens for NSCLC  
*Kei Morikawa, Japan*
- P1.22-15** Identification of MIF as a Multiple Primary Lung Cancer Related Gene Based on RNA Sequencing Technology and Study of Its Function  
*Haoshuai Yang, China*
- P1.22-16** ERBB3 and BRAF Mutations as Potential Biomarkers in Non-small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments  
*Lucía Robado de Lope, Spain*
- P1.22-17** Addressing Lung Cancer Biomarker Testing Through the ECHO Model - Results from a 3-State Pilot in the United States  
*Lauren Rosenthal, USA*
- P1.22-18** Immediate Biomarkers Profiling of Actionable NSCLC Panel from a Digitized H&E Biopsy Image  
*Nurit Paz-Yaacov, Israel*
- P1.22-19** Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions  
*Arianna Marinello, France*
- P1.22-20** High Incidence of Ischemic Stroke in Patients with Non-small Cell Lung Cancer and RET Fusions  
*Mihaela Aldea, France*
- P1.22-21** Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations  
*Wei-Hsun Hsu, Taiwan*

**P1.23 Track: Pathology and Biomarkers - Liquid Based Biomarkers**

- P1.23-01** ctDNA Positivity Is a Clinical Prognosis Biomarker in Patients with EGFR ex20ins+ NSCLC  
*Sampurna Chatterjee, USA*
- P1.23-02** Circulating Tumour DNA as a Predictive Biomarker for Tumour Response and Prolonged Clinical Benefit with Nivolumab in NSCLC  
*Ullas Batra, India*
- P1.23-03** Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer  
*Richa Dawar, USA*
- P1.23-04** Extracellular Small Vesicle Phosphorylated PD-L1 Liquid Biopsy Levels Correlate with Tumour Proportion Score (TPS) in NSCLC  
*Kenneth O'Byrne, Australia*
- P1.23-05** Clinical Utility of Plasma-Based Comprehensive Genomic Profiling in Korean Non-small Cell Lung Cancer Patients  
*Jiwon Lee, Republic of Korea*
- P1.23-06** Liquid Biopsy Predicts Differential Benefit from First Line Pembrolizumab in Advanced Non-small Cell Lung Cancer  
*Laura Bonanno, Italy*
- P1.23-07** Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study  
*Marco Tagliamento, France*

## POSTER SESSION 1: P1 - SUNDAY, SEPTEMBER 10, 2023

- P1.23-08** Clinical Utility of Combined Plasma and Tissue NGS in Patients with Advanced, Treatment-Naïve, Non-small Cell Lung Cancer  
*Helena Bote de Cabo, Spain*
- P1.23-09** Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study  
*Mei-Mei Zheng, China*

**P1.24 Track: Pathology and Biomarkers - Pathology and Prognostic Markers**

- P1.24-01** Is It Possible to Predict STAS before Surgery in Non-small Cell Lung Cancer?  
*Yusuf Kahya, Turkey*
- P1.24-02** Mortality Benefit of a 4-Protein Blood-Based Biomarker Panel for Lung Cancer  
*Edwin Ostrin, USA*
- P1.24-03** TAT3 Predicts Favourable Prognosis in Advanced Non Small Cell Lung Cancer  
*Xuequan Wang, China*
- P1.24-04** A Comparative Analysis of Secreted MiRNAs Reveals Candidate Biomarkers for Pleural Mesothelioma Detection  
*Agnieszka Kraft, Switzerland*
- P1.24-05** The Association of Acinar Pattern with Clinicopathological, Molecular Features, and Prognosis in Lung Adenocarcinoma Patients  
*Hanie Abolfathi, Canada*
- P1.24-06** Prognostic Value of DNA Ploidy and Nucleotyping in Early-stage Non-small Cell Lung Cancer  
*Luning Mao, China*
- P1.24-07** Association between Whole Blood ACTB methylation and Lung Cancer: A Case-Control Study  
*Rongxi Yang, China*
- P1.24-08** Effect of Gut Microbiome on Metastasis of Non-small Cell Lung Cancer  
*Chen-Guang Liu, China*
- P1.24-09** Spatially Defined Immune Response Signatures in 5µm Tumor Section of Resected T1-2N0M0 Lung Cancer Predict Clinical Outcome  
*Ping Yang, USA*
- P1.24-10** Clinical Implication of Karyopherin a 2, Which Is a Nuclear Export Protein in Lung Adenocarcinoma  
*Seoree Kim, Republic of Korea*
- P1.24-11** Single-Cell Profiling Reveals the Trajectory of FOLR2+TAMs to Tregs in the Progression of Lung Adenocarcinoma  
*Yuchen Han, China*
- P1.24-12** Exploring the Stability of Gut Microbiome and Its Association with the Prognosis of NSCLC Treated with Chemoradiotherapy  
*FangJie Liu, China*
- P1.24-13** Role of EVs-miR-200b-5p Mediating Tgf- Signaling Pathway in Radiation Pneumonia  
*Wei Feng, China*
- P1.24-14** Clinicopathological Characteristics of Pulmonary Squamous Cell Carcinoma with KDM5D Copy Number Loss  
*Takuo Hayashi, Japan*
- P1.24-15** Prognostic Molecular and Genetic Factors in Early Stage Non-small Cell Lung Cancer  
*Gizem Özçibik Isik, Turkey*

## POSTER SESSION 1: P1 - SUNDAY, SEPTEMBER 10, 2023

P1.24-16 Discovery of Novel Biomarkers of Small Cell Lung Cancer Using Highly Sensitive Quantitative Proteomic Analysis

*Seung Hyeun Lee, Republic of Korea*

P1.24-17 The Paradoxical Behavior of Kappa When Quantifying Agreement in Histological Subtype Classification Among Thoracic Pathologists

*Kay See Tan, USA*

**P1.25 Track: Early-Stage Non-small Cell Lung Cancer - Pushing the Boundaries: Changing Paradigms and Outcomes**

P1.25-01 Real-World Data of Completely Resected Lung Adenocarcinoma Harboring Common EGFR Mutation in Japan (CReGYT-01 EGFR study)

*Shinya Katsumata, Japan*

P1.25-02 Complete Pathologic Response (pCR) as a Surrogate Endpoint in Neoadjuvant Immunotherapy Clinical Trials for NSCLC: A Meta-analysis

*Jacobi Hines, USA*

P1.25-03 Comparing Timeliness of Treatment for Surgery vs Radiation for Early-Stage Lung Cancer

*Jeffrey Zhu, USA*

P1.25-04 Days Alive and Out of Hospital After Thoracoscopic Surgery and Exploratory Study the Correlation on the PRO of First Discharge Day

*Wenwu Liu, China*

P1.25-05 Real-World Outcomes in Non-metastatic Non-small Cell Lung Cancer (NSCLC): An I-O Optimise Multi-Country Analysis

*Melinda Daumont, Belgium*

P1.25-06 Real-world Primary Treatment Patterns in Stages I-III Non-Small Cell Lung Cancer

*Jessica Donington, USA*

P1.25-07 Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of Early-EGFR

*Tu Dao, Viet Nam*

P1.25-08 Surgical Outcomes in Patients with Resected Node-negative Lung Adenocarcinoma of 2cm or Smaller

*Jung-Jyh Hung, Taiwan*

P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-III NSCLC

*Ross Soo, Singapore*

P1.25-10 Delays to Early-Stage Lung Cancer Surgery: Patient and Surgeon Perspectives

*Sydney Kantor, USA*

P1.25-11 Phase 2 Trial of Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable or Potentially Resectable NSCLC

*Haoran Xia, China*

P1.25-12 Adequacy of Mediastinal Lymph Node Dissection in the Setting of New NCCN Guidelines: Simplified Method From A Rural Hospital

*Kevin Kennedy, USA*

P1.25-13 Enhanced Assessment of Recurrence Risk of Stage I NSCLC By Combined Adenocarcinoma Grading System and Serum Proteomic Testing

*Harvey Pass, USA*

## POSTER SESSION 1: P1 - SUNDAY, SEPTEMBER 10, 2023

P1.25-14 Delayed Recovery Time of Percutaneous Oxygen Saturation After Stair-climbing as a Predictor of Postoperative Complications

*Kensuke Takei, Japan*

P1.25-15 Trends and Disparities in Curative-Intent Treatment for Early-Stage Non-small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT

*Estelamari Rodriguez, USA*

P1.25-16 Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study

*Carolyn Presley, USA*

P1.25-17 Stereotactic Ablative Body Radiotherapy for Early NSCLC: Changes in Pulmonary Function, Dyspnoea and Quality of Life

*Julie Ahn, Australia*

P1.25-18 Prognostic Impact of Exon20 Insertion in Surgically Resected Lung Adenocarcinoma Harboring Atypical EGFR Single Mutation

*Tao Chen, China*

P1.25-19 Patient-Reported Outcomes and Exercise Capacity in a Real-Life Setting in Non-small Cell Lung Cancer Patients Undergoing Radiotherapy

*Yolande Lievens, Belgium*

**P1.26 Track: Early-Stage Non-small Cell Lung Cancer - Getting Smaller: More Minimally Invasive Approaches**

P1.26-01 A Real World Study of Perioperative Outcomes after Minimally Invasive Segmentectomy Versus Lobectomy for Early-Stage Lung Cancer

*Yang Chen, China*

P1.26-02 Random Matrix Based Multiple Scattering Component Extraction Can Significantly Shorten the Time of Lung Segmentectomy

*Hua Liu, China*

P1.26-03 Retrospective Comparison of Robotic- and Video-assisted Thoracic Surgery after Neoadjuvant Therapy for Non-small Cell Lung Cancer

*Hong-Ji Li, China*

P1.26-04 Increased Risk of Death from Other Causes After Lobectomy Compared with Sublobar Resection in Lung Cancer Patients

*Masayuki Nakao, Japan*

P1.26-05 Sublobar Resection is Equivalent to Lobectomy for Stage IA Adenocarcinoma Presenting as Subsolid Nodule

*Sebron Harrison, USA*

P1.26-06 Harmonized Maximum Standardized Uptake Value as an Indicator for Sublobar Resection: A Multicenter Retrospective Study

*Masahiro Adachi, Japan*

P1.26-07 Trisegmentectomy is Indicated for Non-Small Cell Lung Cancer in the Left Upper Division

*Paula Ugalde Figueroa, USA*

P1.26-08 Usefulness and Safety of Chest Tube Removal Regardless of Drainage Volume of Pleural Effusion in Patients Who Underwent Pulmonary Resection

*Tomohiro Haruki, Japan*

P1.26-09 Wedge Resection vs. Segmentectomy for NSCLC Size  $\leq 2$  CM, Consolidation Tumor Ratio  $>0.25$ , cNO: A Multicenter Propensity-Score Matching Analysis

*Tetsuya Isaka, Japan*

**P1.26-10** Is Mediastinal Lymph Node Dissection Necessary in Segmentectomy for Peripheral Stage IA ( $\leq 2$  CM) Non-small-Cell Lung Cancer?  
*Hiroyuki Adachi, Japan*

**P1.27 Track: Early-Stage Non-small Cell Lung Cancer - Innovation and New Technology**

**P1.27-01** Comparison of Physical and Mental Load Between VATS and RATS Based on NASA-Task Load Index: A Prospective Cohort Study  
*Weijie Zhan, China*

**P1.27-02** Artificial Intelligence Analysis Predicts Highly Malignant Potential in Small-Sized Lung Adenocarcinoma  
*Yujin Kudo, Japan*

**P1.27-03** Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis  
*Chao Zhang, China*

**P1.27-04** Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung  
*Young Kwang Chae, USA*

**P1.27-05** Two- and Three-dimensional Radiomic Measurements for Clinical Stage IA Lung Adenocarcinoma: Less is More  
*Meng-Min Wang, China*

**P1.27-06** Construction of Postoperative Prediction Model Based on the New IASLC Grading System for Early Stage Lung Adenocarcinoma  
*Hong Jiang, China*

**P1.27-07** BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy  
*Lucia Robado de Lope, Spain*

**P1.27-08** Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials  
*Ben Ponvilawan, USA*

**P1.27-09** Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT)  
*Baohui Han, China*

**P1.27-10** NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-III B EGFR-mutant Lung Adenocarcinoma  
*Fang-Liang Lu, China*

**P1.28 Track: Local-Regional Non-small Cell Lung Cancer**

**P1.28-01** Adherence to Post-treatment Surveillance Guidelines in Non-small Cell Lung Cancer - A Veteran's Health Administration Cohort  
*Ryan Randle, USA*

**P1.28-02** EVs-miRNAs-Based Models in Predicting Radiosensitive Patients with Local Advanced-NSCLC Who Can Benefit from Adaptive Radiotherapy  
*Haihua Yang, China*

**P1.28-03** Adjuvant CCRT Does Not Improve Survival Outcomes in Patients with ECE Positive Pathologic Stage III-N2 NSCLC After Upfront Surgery  
*Jeonga Son S, Republic of Korea*

**P1.28-04** Should Older Patients with Stage Iii Non-small-Cell Lung Cancer Be Treated with Concurrent Chemoradiotherapy?  
*Neil Wallace, Australia*

**P1.28-05** Cessation of Marrow Proliferation on FLT-PET with Low RT Doses During ChemoRT for NSCLC Correlates with Lymphocyte Decline  
*Michael MacManus, Australia*

**P1.28-06** Treatment Strategies for Locally-advanced NSCLC with Invasive T4 Tumors: A SEER Analysis in the Era of Precision Medicine  
*Min Wang, China*

**P1.28-07** Dose-Response Relationship Between Radiotherapy and Loss in Lung Perfusion Determined From DECT and PET/CT in NSCLC  
*Mathieu Gaudreault, Australia*

**P1.28-08** Definition of Resectable Stage III Non-Small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group  
*Eleni Xenophontos, Belgium*

**P1.28-09** Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel  
*Mariana Brandao, Belgium*

**P1.28-10** Differential Kinetics of Blood and Immune Subpopulations for Cisplatin vs. Sensitizing Paclitaxel Radiotherapy in Locally Advanced Lung Cancer  
*Yuhchyan Chen, USA*

**P1.28-11** Recurrence Dynamics for Pathological N2 Non-small Cell Lung Cancer Depending on the IASLC Residual Tumor Descriptor  
*In Ha Kim, Republic of Korea*

**P1.28-12** Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy  
*Hyung-Joo Oh, Republic of Korea*

**06 WCLC 2023 POSTER SESSIONS**

POSTER SESSION 2: P2

Display Time: **Monday, September 11, 2023 – 10:00 – 20:00**Presenters in Attendance: **Monday, September 11, 2023 – 18:00 – 20:00****POSTER SESSION 2: P2****P2.01 Track: Local-Regional Non-small Cell Lung Cancer - Novel Therapies and Trials**

- P2.01-01** Initial Result of the ImmunoPET Phase I Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT  
*Fiona Hegi-Johnson, Australia*
- P2.01-02** Neoadjuvant Targeted Therapy for Resectable ALK-fusion Locally Advanced Non-small Cell Lung Cancer  
*Nan Wu, China*
- P2.01-03** Efficiency and Survival Data of Neoadjuvant PD-1 Inhibitor Combined With Chemotherapy in Potentially Resectable IIIA or IIIB NSCLC  
*Kewei Ma, China*
- P2.01-04** An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC  
*Ashley Horne, UK*
- P2.01-05** The Safety and Efficacy of Induction Chemoimmunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC  
*Min Tang, China*
- P2.01-06** NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC  
*Jay Lee, Usa*
- P2.01-07** Restoring Lymphocytes Using NKTR-255 after Chemoradiotherapy in Solid Tumors (RESCUE)  
*Steven Lin, USA*

**P2.02 Track: Local-Regional Non-small Cell Lung Cancer - Toxicities of Multimodality Therapy**

- P2.02-01** PROphylactic Pirfenidone for Prevention of Radiation Induced Pneumonitis in Patients with Lung Cancer (PROPeR study)  
*Naveen Mummudi, India*
- P2.02-02** Pneumonitis Rates Before Versus After Adoption of Immunotherapy Consolidation for Locally Advanced Non-Small Cell Lung Cancer  
*Nikhil Yegya-Raman, USA*
- P2.02-03** Association of irAEs with the Efficacy of PACIFIC Regimen in Patients with Unresectable Stage III NSCLC: WJOG11518L/SUBMARINE  
*Yukihiro Toi, Japan*

- P2.02-04** Neoadjuvant Immunotherapy Related Pneumonitis in Non-Small Cell Lung Cancer Patients: Incidence, Risk Factors, and Management  
*Long Jiang, China*
- P2.02-05** Comprehensive Pneumonitis Assessment Among Inoperable Stage III NSCLC Patients Treated with Chemoradiotherapy-Immunotherapy Regimen  
*Jayson Paragas, Philippines*

**P2.03 Track: Metastatic Non-small Cell Lung Cancer – Local Therapies**

- P2.03-01** Effectiveness and Safety of Combining Bevacizumab and Fractionated Stereotactic Radiotherapy for Brain Metastases in NSCLC Patients  
*Rui Zhou, China*
- P2.03-02** Hybrid Immuno-RT (EclipseRT) for Bulky Tumors: Low-Dose Radiotherapy with Partial Tumor SBRT in Mice and Patients  
*Ren Luo, China*
- P2.03-03** Upfront or Delayed Cranial RT in Oncogene Mutated NSCLC with Asymptomatic Brain Metastases: A Phase III Randomized Controlled Trial  
*Anil Tibdewal, India*
- P2.03-04** Predicting Risk of Distant Brain Failure with Radiosurgery and Systemic Therapy in a Diverse NSCLC Brain Metastasis Population  
*Rupesh Kotecha, USA*
- P2.03-05** Clinical Impact of Genomic Characterization in Induced Oligometastatic Non-small Cell Lung Cancer  
*Rui Fu, China*
- P2.03-06** Treatment-related Pneumonitis in Non-small Cell Lung Cancer Treated with Thoracic RT Plus TKI: A Systematic Review and Meta-Analysis  
*Yinnan Meng, China*

**P2.04 Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy**

- P2.04-01** HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade Plus Chemotherapy in Untreated Advanced NSCLC  
*Tao Jiang, China*
- P2.04-02** AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced/mNSCLC  
*Terufumi Kato, Japan*
- P2.04-03** EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 ± Anti-cancer Agents in Advanced Solid Tumours  
*Sally Lau, USA*

**P2.05 Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy - Biomarker**

- P2.05-01** Clinical impact of TTF-1 for Combined Chemoimmunotherapy Efficacy in Lung Adenocarcinoma: A Multicenter Prospective Study  
*Yuki Katayama, Japan*
- P2.05-02** MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial  
*Gabriele Minuti, Italy*

## POSTER SESSION 2: P2 - MONDAY, SEPTEMBER 11, 2023

- P2.05-03 Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort  
*Sarah Cook, Canada*
- P2.05-04 Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)  
*Petra Rietschel, USA*
- P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC  
*Yiqing Huang, Singapore*
- P2.05-06 An Artificial Neural Network System to Predict the Immune-related Adverse Events Based on the RNA Data of ORIENT-3 Study  
*Tongji Xie, China*
- P2.05-07 Roles of p53 and AXL Expressions on the Efficacy of ICI-Based Therapy in Patients with EGFR Mutated Lung Cancer after Osimertinib  
*Tadaaki Yamada, Japan*
- P2.05-08 Immunotherapy Prognostication with Thoracic CT Contrastive Self-Supervised Learning in Patients with Non-Small Cell Lung Cancer  
*Tafadzwa Chaunzwa, USA*
- P2.05-09 SIPS as a Prognostic Biomarker within Performance Status in Advanced Lung Cancer Patients Treated with Pembrolizumab  
*Samantha Low, UK*
- P2.05-10 The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes is Determined by Tumor Transcriptome  
*Anlin Li, China*
- P2.05-11 Serum Metabolomics to Determine Survival of Immunotherapy for Advanced Non-small Cell Lung Cancer: Metabolomic Analysis Based on Two Cohorts  
*Yun Fan, China*
- P2.05-12 Full Spectrum Flow Cytometry-powered Analysis of PBMC as Biomarkers for Immunotherapy in NSCLC with EGFR-TKI Resistance  
*Chunxia Su, China*
- P2.05-13 Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1  
*Daniel Tan, Singapore*
- P2.05-14 Understanding Genomic and Social Determinants of Cancer Immunotherapy Outcome Across Ancestry  
*Jian Carrot-Zhang, USA*
- P2.05-15 Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials  
*Yanguo Liu, China*
- P2.05-16 Immune Suppressive Microenvironment in Liver Metastases Contributes to Organ-Specific Response of Immunotherapy  
*Jia-Yi Deng, China*
- P2.05-17 A Novel Autoantibodies Panel Predicted the Prognosis of Advanced Non-Small Cell Lung Cancer Receiving Anti-PD1 Combined With Chemotherapy  
*Liyuan Dai, China*
- P2.05-18 A Seven-Lnc RNA Signature for Prognosis Prediction of Patients with Lung Squamous Cell Carcinoma through Tumor Immune Escape  
*Zhong Lin, China*

## POSTER SESSION 2: P2 - MONDAY, SEPTEMBER 11, 2023

- P2.05-19 Prediction of Durable Response to Immunotherapy by Early Dynamic in ctDNA and Peripheral Immune Features in NSCLC  
*Xinghao Ai, China*

### P2.06 Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy - Prospective

- P2.06-01 Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3  
*Ana Baramidze, Georgia*
- P2.06-02 DENosumab plus PD-1 Inhibitor for MAINTenance Therapy of Advanced KRAS-Mutant NSCLC - A Prospective, Single-Arm, Phase II Study (DEMAIN)  
*Yan Wang, China*
- P2.06-03 Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients  
*Banzhou Pan, China*
- P2.06-04 First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN  
*Xue Hou, China*
- P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of Patients with PFS ≥12 months in POSEIDON  
*Byoung Chul Cho, Republic of Korea*
- P2.06-06 Study Design to Assess Anti-TIGIT Mab Combination with Dostarlimab vs Pembrolizumab or Dostarlimab Monotherapy in NSCLC  
*Byoung Chul Cho, Republic of Korea*
- P2.06-07 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)  
*Si-Yang Liu, China*
- P2.06-08 Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab  
*Angel Qin, USA*
- P2.06-09 Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227  
*Julie Brahmer, USA*
- P2.06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1  
*Mahmut Gümüş, Turkey*
- P2.06-11 Camrelizumab Plus Apatinib as First-Line Treatment for Advanced Squamous Non-small Cell Lung Cancer: Updated Survival Results of a Phase 2 Trial  
*Jinliang Wang, China*
- P2.06-12 The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2  
*Khvaramze Shaverdashvili, USA*

### P2.07 Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy - Retrospective

- P2.07-01 Development of Postoperative Bronchopleural Fistula after Neoadjuvant Immunochemotherapy in Non-small Cell Lung Cancer: Case Reports  
*Kewei Ma, China*

## POSTER SESSION 2: P2 - MONDAY, SEPTEMBER 11, 2023

- P2.07-02** Association between OS and Subsequent ICI in Control Arm Patients of First Line ICI-based RCTs of Advanced/Metastatic NSCLC: FDA Analysis  
*Oladimeji Akinboro, USA*
- P2.07-03** Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer  
*Biagio Ricciuti, USA*
- P2.07-04** Genomic Subtypes of EGFR-Mutant NSCLC and Real-World Progression-Free Survival (rwPFS) with Immunotherapy (IO)  
*Joseph Bodor, USA*
- P2.07-05** Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry  
*Jordi Remon Masip, France*
- P2.07-06** Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics  
*Wallace Akerley, USA*
- P2.07-07** Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors  
*Lei Deng, USA*
- P2.07-08** Checkpoint Inhibitor Pneumonitis Model for NSCLC based on Preexisting Lung Ground Glass Opacities: Development and Validation  
*Xinyue Wang, China*
- P2.07-09** Stage 3 NSCLC Patients Progressing After Concurrent Chemo-Radiotherapy and Durvalumab- is There a Role for Another IO?  
*Jair Bar, Israel*

**P2.08 Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy - TIPS**

- P2.08-01** TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)  
*Caicun Zhou, China*
- P2.08-02** STAR-121: Phase 3 Study of DOM and ZIM plus Chemo vs Pembro plus Chemo in 1L mNSCLC with No Actionable Gene Alterations  
*Delvys Rodriguez-Abreu, Spain*
- P2.08-03** A Phase 2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab  
*Edwin Yau, USA*
- P2.08-04** A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab  
*Mariam Alexander, USA*
- P2.08-05** IMRPrinter: A Phase 1/1b Trial of IMU-201 (PD1-Vaxx) as Monotherapy or in Combination with Atezolizumab +/- Chemotherapy in NSCLC  
*Michael Boyer, Australia*
- P2.08-06** A Phase II Study of Subcutaneous (SC) Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model  
*Jorge Nieva, USA*
- P2.08-07** EDGE-Lung: A Phase 2 Open-Label Platform Study to Evaluate Immunotherapy-Based Combinations in Patients with Metastatic NSCLC  
*Melissa Johnson, USA*

## POSTER SESSION 2: P2 - MONDAY, SEPTEMBER 11, 2023

**P2.09 Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy - EGFR/HER2**

- P2.09-01** A Large Asian Real-World EGFR exon 20 Insertion Mutated NSCLC Dataset with Deep Genomic Characterization  
*Aaron Tan, Singapore*
- P2.09-02** Impact of Co-mutations on the Prognosis of Targeted Therapy in EGFR-Mutant Advanced NSCLC: A Result of Real-World Study  
*Sisi Pan, China*
- P2.09-03** Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis  
*Thanyanan Reungwetwattana, Thailand*
- P2.09-04** Treatment Adherence Disparities and Clinical Outcomes of Osimertinib Among Ethnic-Minority Patients with EGFR-Mutated NSCLC  
*Matthew Lee, USA*
- P2.09-05** Identification of Co-existing Genetic Alterations in Advanced Stage EGFR mutated NSCLC at Baseline and Disease Progression  
*Amber Rathor, India*
- P2.09-06** Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer  
*Jieran Long, China*
- P2.09-07** Safety and Efficacy of Aumolertinib in Patients with Advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated  
*Wen Fang, China*
- P2.09-08** Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial  
*Yoonsil Jang, Republic Of Korea*
- P2.09-09** A Phase 1, 2 Study to Evaluate the Safety and Anti-tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced NSCLC  
*Sun Min Lim, Republic of Korea*
- P2.09-10** Genomic Characteristics and Clonal Evolution of EGFR-mutated Lung Adenocarcinoma-Transformed Squamous Carcinoma after EGFR-TKIs Treatment  
*Jin Kang, China*
- P2.09-11** JIN-A04, Highly Effective and Brain-penetrant Tyrosine Kinase Inhibitor Targeting HER2 Exon20 Insertion Mutations in NSCLC  
*Mi Ra Yu, Republic of Korea*
- P2.09-12** Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations  
*Luan Pham, Viet Nam*
- P2.09-13** QT-interval Prolongation and Torsades de Pointes With EGFR TKIs in NSCLC: Targeted Literature Review  
*Bilal Khokhar, USA*
- P2.09-14** Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations  
*Jane Sui, USA*
- P2.09-15** Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer  
*Katherine Zhou, USA*

## POSTER SESSION 2: P2 - MONDAY, SEPTEMBER 11, 2023

- P2.09-16 **Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles**  
*Wei Wang, China*
- P2.09-17 **OSTARA: A Phase II Study of First-line Osimertinib Combined with Amivantamab in EGFRm Advanced Non-Small Cell Lung Cancer**  
*Daniel Tan, Singapore*
- P2.09-18 **FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions**  
*Alexander Spira, USA*
- P2.09-19 **Increased Dose of Aumolertinib Rechallenge in Advanced NSCLC with Gradual Progression**  
*Jun Li, China*
- P2.09-20 **Updated Data of Osimertinib Rechallenge after Pneumonitis; A Multicenter Retrospective Cohort Study**  
*Mihoko Imaji, Japan*
- P2.09-21 **VRN110755, A New Therapeutic Option for EGFR Mutation-Driven NSCLC with Brain Metastasis or 1st-line Osimertinib-Resistant EGFR Mutations**  
*Sunghwan Kim, Republic of Korea*
- P2.09-22 **Efficacy of Aumolertinib in EGFR T790M-negative or -unknown NSCLC with Brain Metastases Following Resistance to Prior EGFR-TKIs**  
*Cheng Han, China*
- P2.09-23 **A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study)**  
*Kageaki Watanabe, Japan*
- P2.09-24 **Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD**  
*Molly Li, Hong Kong*
- P2.09-25 **Inhibition of AXL and Mcl-1 Contributes to Eradicating Tolerance to EGFR-TKI Lazertinib in Lung Cancer Cells Expressing Mutant EGFR**  
*Yohei Matsui, Japan*
- P2.09-27 **Trials in Progress: Phase 1a/b study of ELVN-002, in Solid Tumors with HER2 Mutations, Amplification or Overexpression**  
*Samantha Bowyer, Australia*
- P2.09-28 **Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC)**  
*Jamie Feng, Canada*
- P2.09-29 **Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY)**  
*Laura Mezquita, Spain*
- P2.09-30 **Enhanced in Vivo Efficacy of Mobocertinib and Amivantamab Combination in EGFR ex20ins+ NSCLC PDX Models**  
*Sampurna Chatterjee, USA*
- P2.09-31 **Intracranial Efficacy of Afatinib as First-line Treatment in Common/Uncommon EGFR-Mutant Advanced Non-small Cell Lung Cancer Patients**  
*Ying Liang, China*
- P2.09-32 **Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS)**  
*Hua Lin Chen, China*

## POSTER SESSION 2: P2 - MONDAY, SEPTEMBER 11, 2023

- P2.09-33 **A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs**  
*Richeng Jiang, China*
- P2.09-34 **Design, Synthesis and Assessment of Novel Molecule Against Drug-Resistant Dual Mutant EGFR (T790M/L858R) to Treat NSCLC**  
*Vikas Kumar, India*
- P2.09-35 **Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China**  
*Shun Lu, China*
- P2.09-36 **Efficacy and Safety of Furmonertinib 160 mg as First-line Therapy for EGFR-mutated Advanced NSCLC Patients with CNS Metastases**  
*Xixi Zheng, China*
- P2.09-37 **Combined Multi-omics Explore the Resistance Mechanism of Third-generation EGFR-TKI BPI-7711**  
*Ruyun Gao, China*
- P2.09-38 **MRI Radiomics Approach to Predict the Intracranial Efficacy of the Third Generation EGFR-TKI Osimertinib in NSCLC Patients with Brain Metastases**  
*Xin Tang, China*
- P2.09-39 **Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers**  
*Shirish Gadgeel, USA*
- P2.09-40 **Efficacy of Anlotinib in T790M-positive NSCLC Patients with Osimertinib Resistance: A Retrospective and Exploratory Study**  
*Ya Chen, China*
- P2.09-41 **Phase I/II Study Exploring Safety and Efficacy of Apl-101 Plus Frontline Osimertinib in EGFR-mutated Metastatic Non-small Cell Lung Cancer**  
*Siddhartha Devarakonda, USA*
- P2.09-42 **Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy**  
*Li Li, China*

**P2.10 Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy - FUSIONS**

- P2.10-01 **ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK+ NSCLC and ALK-inhibitor Resistance**  
*Malinda Itchins, Australia*
- P2.10-02 **Liquid Biopsy-based Umbrella Trial for Advanced NSCLC: Results of Phase 2 Plasma A LK-positive Cohort (A-Liquid)**  
*Yuki Nakatani, Japan*
- P2.10-03 **Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study**  
*Aaron Tan, Singapore*
- P2.10-04 **Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors**  
*Per Hydbring, Sweden*
- P2.10-05 **Cost of Managing Brain Metastases in Patients with ALK+ aNSCLC with First-Line Tyrosine Kinase Inhibitors (TKIs) in the UK**  
*Hannah Le, USA*



## POSTER SESSION 2: P2 - MONDAY, SEPTEMBER 11, 2023

- P2.10-06 Brain Metastases in Patients with Fusion-Positive Lung Cancers**  
*Jane Sui, USA*
- P2.10-07 ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC Patients with Leptomeningeal Metastases**  
*Tijmen van der Wel, Netherlands*
- P2.10-08 A New Prognostic Tool for Predicting the Overall Survival of ALK Positive Non-small Cell Lung Cancer with Brain Metastasis**  
*Wei Feng, China*
- P2.10-09 Updated Survival Data in Advanced ALK-rearranged Non-small Cell Lung Cancer Treated with Alectinib and Bevacizumab in the ALEK-B Study**  
*Oscar Arrieta, Mexico*
- P2.10-10 Co-occurring Loss of CDKN2A/2B Associated with Worse Survival and Increase Risk of Brain Metastasis in ALK-Rearranged Non-small Cell Lung Cancer**  
*Oscar Arrieta, Mexico*
- P2.10-11 Comparative Effectiveness Analysis of Selpercatinib versus Standard Therapy in Patients with Non-small Cell Lung Cancer**  
*Daniel Tan, Singapore*
- P2.10-12 Loss of EPHA2 Induces Primary Lorlatinib Resistance Through Sustained MAPK Activation**  
*Anlin Li, China*
- P2.10-13 Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice**  
*Oscar Arrieta, Mexico*
- P2.10-14 First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs**  
*Sai-Hong Ignatius Ou, USA*
- P2.10-15 Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients with ALK+ NSCLC in ALTA-1L**  
*Rosario García-Campelo, Spain*

**P2.11 Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy - KRAS/ MET**

- P2.11-01 A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer**  
*Yaewon Yang, Republic of Korea*
- P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION**  
*Myung-Ju Ahn, Republic of Korea*
- P2.11-03 Synergistic Co-Targeting Of MYC And KRAS In Lung Cancer By Novel Ligand-Directed Inverted Chimeric RNAi Molecules**  
*Yogitha Chareddy, USA*
- P2.11-04 A Phase 1B Trial of Tarloxotinib and Sotorasib in Lung Cancer Patients with KRAS G12C Mutations**  
*Mariam Alexander, USA*
- P2.11-05 SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation**  
*Chee Lee, Australia*

## POSTER SESSION 2: P2 - MONDAY, SEPTEMBER 11, 2023

**P2.12 Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy - Other**

- P2.12-01 Tumor Microenvironment Remodeling Contributes to the Resistance to EGFR-TKI in EGFR-mutated Non-small Cell Lung Cancer**  
*Xinyu Song, China*
- P2.12-02 Beware: Tyrosine Kinase Inhibitors for Lung Cancers that Inhibit MATE-1 can Lead to “False” Decreases in Renal Function**  
*Monica Chen, USA*
- P2.12-03 COVALENT-102: A Phase 1/1b Study of BMF-219, A Menin Inhibitor in Patients with Unresectable, Metastatic NSCLC, PDAC, and CRC**  
*Sandip Patel, USA*
- P2.12-04 Cerebrospinal Fluid is an Alternative Medium of Liquid Biopsy for Patients with Brain Parenchymal Metastases from Non-Small Cell Lung Cancer**  
*Jianing Chen, China*
- P2.12-05 Real-World Data of Biomarker Diagnostics, Treatment Strategy, and Survival Outcome with Advanced or Recurrent NSCLC in Japan**  
*Takaaki Tokito, Japan*
- P2.12-06 Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib**  
*Sarah Goldberg, USA*
- P2.12-07 Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression**  
*Joseph Treat, USA*
- P2.12-08 Response to Emerging Targeted Therapies and Genomic Analysis for NSCLC with Leptomeningeal Metastases and Uncommon Mutations**  
*Guang-Ling Jie, China*
- P2.12-09 Targeted and Immunotherapy Associated Cardiotoxicity in Stage IV Lung Cancer Patients With and Without Cardiac Comorbidities**  
*Ping Yang, USA*

**P2.13 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Biomarkers and Radiomics**

- P2.13-01 Spatially Resolved Transcriptomics deciphers Inter- and Intra-Tumor Heterogeneity of Small Cell Lung Cancer**  
*Xujie Sun, China*
- P2.13-02 Molecular Subtyping of Small Cell Lung Carcinoma: An Attempt at Unravelling Its Biological Heterogeneity**  
*Arkadipta Mukherjee, India*
- P2.13-03 Genomic Associations of Chemoimmunotherapy Outcomes in a Real-World Cohort of Small Cell Lung Cancer (SCLC) Patients**  
*Ayman Ullah, USA*
- P2.13-04 Pathological Images Machine Learning Predicts Long Term Effects for Immunotherapy in Small-Cell Lung Cancer**  
*Ryota Shibaki, Japan*
- P2.13-05 Spatiotemporal Heterogeneity of Transcription Factor-Based Subtype Assignment in Small Cell Lung Carcinoma**  
*Mari Mino-Kenudson, USA*

- P2.13-06** A Novel Clinical Scoring System (EAST score) for the Prediction of Treatment Response in Limited-Stage Small-Cell Lung Cancer  
*Yu Ito, Japan*
- P2.13-07** Biomarkers for Predicting the Efficacy of PD-L1 Inhibitors Combined with Chemotherapy in ES-SCLC  
*Xinghao Ai, China*
- P2.13-08** Integrated Clinical and Radiomics Approach to Assess the Treatment Outcome of Combined Chemoimmunotherapy in Extensive-Stage SCLC  
*Yang Xia, China*

#### **P2.14 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - First Line Therapy**

- P2.14-01** Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC  
*Manuel Dómine Gómez, Spain*
- P2.14-02** First-Line Envafofimid plus Carboplatin-etoposide in Extensive-Stage Small-Cell Lung Cancer: a Single-Arm Phase II Study  
*Shengjie Sun, China*
- P2.14-03** Outcomes of Chemoimmunotherapy in Patients with ES-SCLC According to Liver Metastasis: A Multicenter Prospective Cohort Study  
*Yuhei Harutani, Japan*
- P2.14-04** Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study  
*Rosario García-Campelo, Spain*
- P2.14-05** A Phase II Study of Sintilimab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small Cell Lung Cancer: SINCE-01 Trial  
*Wei Huang, China*
- P2.14-06** A Phase II Trial Assessing the Safety and Efficacy of Tislelizumab Combined with Chemotherapy and Autologous NK Cells in Patients with ES-SCLC  
*Mingfang Zhao, China*
- P2.14-07** Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial  
*Shengxiang Ren, China*

#### **P2.15 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Preclinical**

- P2.15-01** Priming SCLC Vasculature to Facilitate NK Cell Attack  
*Navin Mahadevan, USA*
- P2.15-02** Distinct Tumor Microenvironment in SCLC as compared with NSCLC by Single Cell Analysis  
*Xuanhe Wang, China*

#### **P2.16 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Trials in Progress**

- P2.16-01** Sintilimab in Combination With Carboplatin/Cisplatin and Etoposide in the Treatment of Patients with Previously Untreated ES-SCLC  
*Mengqing Xie, China*
- P2.16-02** Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial  
*Noemí Reguart Aransay, Spain*
- P2.16-03** RYZ101 + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer  
*Claire Mulvey, USA*
- P2.16-04** Assessment of the Efficacy and Safety of Durvalumab Associated with Platinum-Etoposide in Previously Untreated ES-SCLC in Brazil  
*Mauro Zukin, Brazil*
- P2.16-05** Durvalumab+EP in Advanced Large-Cell Neuroendocrine Carcinoma of Lung (aLCNEC): A Pilot Phase II study  
*Elizabeth Dudnik, Israel*
- P2.16-06** A Phase 2 Study of Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Previously Treated ES-SCLC  
*Melissa Johnson, USA*

#### **P2.17 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Relapse and Salvage Therapy**

- P2.17-01** Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer  
*Hossein Borghaei, USA*
- P2.17-02** Effectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study  
*Apar Kishor Ganti, USA*
- P2.17-03** CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer  
*Ying Cheng, China*
- P2.17-04** Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC  
*Hui Zhu, China*
- P2.17-05** Characterizing Mechanisms of Treatment Resistance in SCLC  
*Siddhartha Devarakonda, USA*
- P2.17-06** Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial  
*Jose Antonio Lopez-Vilariño, Spain*
- P2.17-07** Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis  
*Balazs Halmos, USA*

**P2.18 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Clinical**

- P2.18-02** Successful Generation of Tumor-Infiltrating Lymphocytes (TIL) for Adoptive Cell Therapy from Mesothelioma  
*Dean Fennell, UK*
- P2.18-03** Impact of Inclusion of Immunotherapy in National Treatment Guidelines on Survival Outcomes in Malignant Pleural Mesothelioma  
*Logan Roof, USA*
- P2.18-04** Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso)  
*Edgar Aguirre, Argentina*
- P2.18-05** Impact of Evolving Treatment Paradigms on Survival Outcomes in Advanced Pleural Mesothelioma: A Real-World Analysis  
*Florence Wu, Canada*
- P2.18-06** Co-designing an Experience of Care and Quality of Life Survey for an Australian Mesothelioma Clinical Outcomes Registry  
*Dani Samankula, Australia*

**P2.19 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Clinical Trial in Progress**

- P2.19-01** First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced Mesothelioma  
*Timothy Yap, USA*
- P2.19-02** [DREAM] Double Lung Transplant Registry Aimed for Lung-Limited Malignancies - A Prospective Registry Study for Medically Refractory Cancers  
*Young Kwang Chae, USA*

**P2.20 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Thymic Malignancy**

- P2.20-01** A Precision Medicine Approach by Performing Comprehensive Cancer Genome Profiling of Thymomas and Recurrent Thymomas  
*Jessica Evangelista, Italy*
- P2.20-02** Thymomatous Myasthenia Gravis after Total Thymectomy at a Tertiary-Care Surgical Centre: a 20-Year Retrospective Review  
*Anna McGuire, Canada*
- P2.20-03** Clinical Outcome of Patients with Thymic Carcinoma Treated with Preoperative Induction Therapy Followed by Surgical Resection  
*Osamu Noritake, Japan*
- P2.20-04** Differential Expression of Genes in Type A and B3 Thymomas and Thymic Carcinomas  
*Anja Roden, USA*
- P2.20-05** The Impact of Preoperative Immunotherapy On Peri-Operative Outcomes After Thymectomy for Thymic Epithelial Tumors  
*Lye-Yeng Wong, USA*
- P2.20-06** Does Radical Thymectomy Influence the Neurological Outcome in Patients Aged over 65 with Thymoma and Myasthenia Gravis?  
*Filippo Lococo, Italy*

**P2.21 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Translational**

- P2.21-01** Inflammatory Biomarkers as Prognostic Factors for Malignant Pleural Mesothelioma  
*Keval Yerigeri, USA*
- P2.21-02** A Combination of PD-1 and TIGIT Checkpoint Blockade Elicits a Strong Antitumor Response in the Patient and Mouse Pleural Mesothelioma Model  
*Huaikai Shi, Australia*
- P2.21-03** Novel microRNAs are Associated with Presence of Pleural Mesothelioma and Response to Chemotherapy  
*Michaela Kirschner, Switzerland*
- P2.21-04** The Significance of BAP1 and MTAP/CDKN2A Expression in Well-Differentiated Papillary Mesothelial TUMour: A Series of 21 Cases  
*Sarita Prabhakaran, Australia*
- P2.21-05** CD47 as Biomarker of Prognosis in Patients with Malignant Pleural Mesothelioma  
*Oscar Arrieta, Mexico*
- P2.21-06** Characterization of the Genomic and Immune Landscape of Malignant Pleural Mesothelioma  
*Andrea Bille, UK*
- P2.21-07** A Novel Proteomic Technique Uncovers New Diagnostic Biomarkers for Malignant Pleural Mesothelioma  
*Kevin Lamote, Belgium*
- P2.21-08** Mutant NF2-Driven De Novo Pyrimidine Synthesis is a Metabolic Vulnerability in Malignant Pleural Mesothelioma  
*Duo Xu, China*
- P2.21-09** Single-Cell Dissection Reveals Mesothelial Heterogeneity and Dysfunctional Immunity in Malignant Pleural Mesothelioma  
*Duo Xu, China*

**P2.22 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Other Thoracic Malignancy**

- P2.22-01** Single-nuclei RNA Sequencing Reveals Heterogeneity and Malignancy in Pulmonary Sarcomatoid Carcinoma  
*Fei Zhou, China*
- P2.22-02** Long-term Survival in Patients with Primitive Neuroectodermal Tumors of Thorax: Does Size Matter?  
*Akif Turna, Turkey*
- P2.22-03** NUT Midline Carcinoma (NC) Deciphering the Standard of Care in an Ultra-rare Cancer  
*Maria Virginia Sanchez-Becerra, France*
- P2.22-04** Is the Modified Frailty Index (mFI) a Reliable Predictor of Complications after Transthoracic Esophagectomy?  
*Sabita Jiwnani, India*

**P2.23 Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Nursing and Allied Health**

- P2.23-01 An Untold Story About Living with Low Muscle Mass and its Impact Throughout Curative Radiotherapy Treatment for Lung Cancer  
*Nicole Kiss, Australia*
- P2.23-02 Prospective Observational Study of Cachexia and Its Effect on Systemic Therapy in Patients with Previously-Untreated Advanced NSCLC (NEJ050A)  
*Naoki Furuya, Japan*
- P2.23-03 The Role of The Mesothelioma UK Nurse Increases the Number of Patients Accessing Legal Representation, Financial Entitlement.  
*Louise Gilham, UK*
- P2.23-04 Changes in Physical Activity, Fatigue, and Six-Minute Walk Distance Among Lung Cancer Patients Before and After Chemotherapy  
*Pi-Hua Chang, Taiwan*
- P2.23-05 Counseling & Rehabilitation of Lung-Cancer Sufferers by Nursing Personnel  
*S Pal, India*
- P2.23-06 Evaluation/Analysis of Opinions of Oncology Nurses. What We Need to Do?  
*S Pal, India*
- P2.23-07 Crucial, Complex, Caring: A Professional Development Framework for Lung Cancer Nurse Specialists  
*Jackie Fenemore, UK*
- P2.23-08 Determination of the Best Cut-off Point To Establish the Performance of a Mexican Cohort with Non-small Cell Lung Cancer in the 6-Minute Walk Test  
*Oscar Arrieta, Mexico*

**P2.25 Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Supportive Care**

- P2.25-01 Geriatric Assessment in Lung Cancer Surgery Patients and Caregivers  
*Jae Kim, USA*
- P2.25-02 Resiliency among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT): A Novel Pilot Supportive Care Intervention Study  
*Carolyn Presley, USA*
- P2.25-03 Functional Independence of Older Adults after Lung Cancer Surgery: Final Analysis of a Prospective Observational Study  
*Tomonori Mizutani, Japan*
- P2.25-04 Unmet Social Needs and Spiritual Well-Being of Lung Cancer Surgery Patients and Family Caregivers from the United States  
*Dede Teteh, USA*

**P2.26 Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Symptom Management**

- P2.26-01 Managing Pain Lung Cancer Patients -- Contribution of Oncology Nurses  
*S Pal, India*
- P2.26-02 Patient-Reported Symptom Monitoring Improves 1-Year Quality of Life in Lung Cancer Patients; the SYMPRO-Lung Trial  
*Annemarie Becker-Commissaris, Netherlands*

**P2.27 Track: Patient Advocacy**

- P2.27-01 Does Patient Experience with Robotic Thoracic Surgery Influence Their Willingness to Pay for It?  
*Yogita S. Patel, Canada*
- P2.27-02 Stigma-Reducing Interventions for Lung Cancer and Other Smoking-Related Respiratory Diseases: A Systematic Review  
*Nathan Harrison, Australia*
- P2.27-03 Perception of Benefits and Risks of Treatments in Patients with Metastatic NSCLC with EGFRex20ins  
*Jun Zhang, USA*
- P2.27-04 Advocates Unite to Increase Lung Cancer Research Funding  
*Dusty Donaldson, USA*
- P2.27-05 Everywhere Is Local: Applying Lessons from the Community to Areas across the Globe  
*Maureen Rigney, USA*

**P2.28 Track: Global Health, Health Services, and Health Economics - COVID 19**

- P2.28-01 Lung Cancer Mortality in Brazil: Temporal Trends, Regional Disparities and the Impact of the COVID-19 Pandemic  
*Jean Henri Maselli-Schoueri, Brazil*
- P2.28-02 Impact of the Covid-19 Pandemic on Lung Cancer Diagnosis in a German Comprehensive Cancer Center. Are we Still Paying the Debt?  
*Jane Winantea, Germany*
- P2.28-03 Symptomatic vs. Asymptomatic SARS-CoV-2 Infection Rates in Lung Cancer: Longitudinal Nucleocapsid Antibody Analysis  
*Fred R. Hirsch, USA*

**P2.29 Track: Global Health, Health Services, and Health Economics - Digital Solutions**

- P2.29-01 Harnessing Artificial Intelligence to Expand Lung Cancer Clinical Trial Opportunities in Spain  
*Eduarne Arriola Aperribay, Spain*
- P2.29-02 The LungTrust Methodology  
*Andrés Cardona, Colombia*

**P2.30 Track: Global Health, Health Services, and Health Economics - Health Economics**

- P2.30-01 Cost Estimation of Radiotherapy for Local Control and Overall Survival Benefit of Lung Cancer in the Australian Population  
*Shalini Vinod, Australia*
- P2.30-02 Assessing the Impact of Using Disease-Specific Novel Value Elements on Cost-Effectiveness Results in Lung Cancer  
*Yong Yuan, USA*

**P2.31 Track: Global Health, Health Services, and Health Economics - Real World Data**

- P2.31-01** Characterization of Survival Disparities among Asian Pacific Islander (API) Subgroups in Stage IV NSCLC in California  
*Robert Hsu, USA*
- P2.31-02** Real-World Survival Outcomes in NSCLC in Adults Ages 50 and Younger at a Large Academic Institution  
*Robert Hsu, USA*
- P2.31-03** Lambert-Eaton Myasthenic Syndrome is Underrecognized in Small Cell Lung Cancer: An Analysis of Real-World Data  
*David Morrell, USA*
- P2.31-04** Implementation of a Novel Chart Rounds Application to Facilitate Lung Radiotherapy Plan Peer-Review in a Virtual Environment  
*Naba Ali, USA*
- P2.31-05** Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data  
*Melina Marmarelis, USA*
- P2.31-06** Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy  
*Shivani Mhatre, USA*
- P2.31-07** Incidence and Survival Outcomes of Lung Cancer Post-Double Lung Transplant and its Association with Graft Rejection  
*Hye Sung Kim, USA*
- P2.31-08** Disparities in Representation of Older Adults, Women, Racial/Ethnic Minorities in Lung Cancer Clinical Trials: Meta-analysis  
*Kaushal Parikh, USA*
- P2.31-09** Missed Opportunities for Lung Cancer Personalized Medicine in a Brazilian Public Healthcare Service  
*Pedro Aguiar Jr, Brazil*
- P2.31-10** Clinical Outcomes of Real-World Treatment for Metastatic EGFRm NSCLC after Osimertinib and Platinum-Based Chemotherapy  
*Jyoti Patel, USA*
- P2.31-11** Impact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia  
*Sanuki Tissera, Australia*
- P2.31-12** Sexual Dysfunction on Patients with Lung Cancer: Results from the CLARIFY Project  
*Aylen Ospina Serrano, Spain*


13977 0723

# Leading the way in lung screening

Low-dose CT and AI post processing by Siemens Healthineers



The clinical overlay is not that of the individual pictured. It was modified for better visualization.





2023 World Conference  
on Lung Cancer

SEPTEMBER 9-12, 2023 | SINGAPORE

# GET SOCIAL

Remember to use  
the official hashtag:

**#WCLC23**

 @IASLC

 facebook.com/IASLC

 @iaslungcancer

 linkedin.com/IASLC

 IASLC

 IASLC

# JOIN THE CONVERSATION



2022 Journal  
Impact Factor\*

**20.4**

\*Journal Citation Reports®  
(Clarivate Analytics, 2023)

A subscription to **JTO** is a benefit of membership  
in the IASLC. To join, visit [www.IASLC.org](http://www.IASLC.org)

**Official Journal of the International Association for the Study of Lung Cancer**

Editor-in-Chief: **Alex A. Adjei**, MD, PhD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

The **Journal of Thoracic Oncology (JTO)**, the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. JTO emphasizes a multidisciplinary approach, and includes original research (clinical trials, and translational or basic research), reviews, and opinion pieces. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.



[jto.org](http://jto.org)

## 06 WCLC 2023 POSTER SESSIONS

Electronic Posters

Display: During Exhibit Show Hours at the ePoster Stations in the Exhibit Hall

EP01	Track: Risk Factors, Risk Reduction & Tobacco Control
EP01.01-01	Adenocarcinoma and Small Cell Lung Cancer Risk Associated with Occupation in Women <i>Alberto Ruano Ravina, Spain</i>
EP01.01-02	Prognostic Analysis and Nomogram Establishment of Synchronous Dual Primary Lung Cancer: Based on Multicenter Data <i>Haoshuai Yang, China</i>
EP01.01-03	Postoperative Course of Completion Pneumonectomy May Be Better than Predicted <i>Kana Kinjo, Japan</i>
EP01.01-04	Postoperative Course of Surgically Resected Lung Cancer Patients in Preserved Ratio Impaired Spirometry <i>Hayato Konno, Japan</i>
EP01.01-05	Poor Sleep Quality in Lung Cancer Patients <i>Andika Putra, Indonesia</i>
EP01.01-06	Casual Effects of Some Chronic Respiratory Diseases on Squamous Cell Lung Cancer: A Mendelian Randomization Study <i>Xiaoxue Cheng, China</i>
EP01.01-07	Sex Difference Indicate Survival Disparity in Resected NSCLC, from a Large Chinese Cohort <i>Yifan Guo, China</i>
EP01.01-08	Histopathological Risk Factors Correlation in Patients with Non-small Cell Lung Cancer <i>Aldiesa Pritami, Indonesia</i>
EP01.01-09	Radiation Exposure in Intraoperative Navigation for Peripheral Small Pulmonary Nodule <i>Yuichi Saito, Japan</i>
EP01.01-10	Long-term Survivals Associated with High Levels of Na <sup>+</sup> and Ca <sup>2+</sup> in the Blood of Patients with Stage IV Lung Cancer <i>Feng-Ming (Spring) Kong, China</i>
EP01.01-11	Familial Aggregation in Non-small Cell Lung Cancer <i>Sindhura Durga Chitikela, India</i>
EP01.01-12	Binge-Watching Frequency and Tobacco Use in Adolescents: Data from "Blaam Smoke-Free Movie" Program <i>Daniela Bafunno, Italy</i>
EP01.01-13	Awareness and Perceptions of Compliance with the Nigerian Tobacco Control Law Among Young Adults in Lagos, Nigeria <i>Adebusayo Sipe, Nigeria</i>

EP01.01-14	Gender Differences in Clinical Course and Patient-Reported Outcomes Among Patients with Early-Stage Non-Small Cell Lung Cancer <i>Haiyu Zhou, China</i>
EP01.01-15	Study on Risk Prediction Model of PD1/PD-L1 Inhibitor-associated Pneumonia <i>Yan Zhang, China</i>
EP01.01-16	Osteoporotic Vertebral Fractures in Non-small Cell Lung Cancer: A Cracking Connection <i>Ghassen Soussi, France</i>
EP01.01-18	Genomic Alterations of Lung Cancer: Experience in Peru <i>George Oblitas, Peru</i>
EP01.01-19	Impact of Smoking on Survival in NSCLC Patients Treated with Hemoimmunotherapy or Chemotherapy: A Real-world Data Study <i>Ayah Bani Mostafa, Jordan</i>
EP01.01-20	Evaluation of Perioperative Nintedanib for Lung Cancer with Idiopathic Pulmonary Fibrosis <i>Ryusuke Sumiya, Japan</i>
EP01.01-21	Respirable Crystalline Silica Exposure and Lung Cancer Risk: A Review of Cut-off Points <i>Julia Rey Brandariz, Spain</i>
EP01.01-22	Risk Factors of Intraoperative Air Leakage in Anatomical Pulmonary Resection <i>Jotaro YUSA, Japan</i>
EP01.01-23	Provider Perspectives on a Navigational Pilot Study for Cancer Patients within a Tobacco Treatment Program <i>Carolyn Zawislak, USA</i>
EP01.01-24	Median Age at Lung Cancer Diagnosis in 60 Countries: An International Comparative Study <i>Hana Zahed, France</i>
EP01.01-25	Occupational Exposure and Lung Cancer Risk in Women: A Pooling Study <i>Cristina Candal-Pedreira, Spain</i>
EP01.01-26	Association between ACEI-Induced Cough and the Risk of Lung Cancer: A Mendelian Randomization Study <i>Zhenchao Wu, China</i>
EP01.01-27	Gender and Lung Cancer (LC): Preliminary Data from a Prospective, Woman-Centered Local Registry <i>Mónica Castro, Argentina</i>
<b>EP02.01</b>	<b>Track: Tumor Biology – Preclinical Biology - Molecular Therapeutic Targets</b>
EP02.01-01	Differing Cell Cycle Responses for Alectinib and SHP099 in Variant 1 and Variant 3 ALK+ Non-Small Cell Lung Cancer Cell Lines <i>Madeleine Berry, New Zealand</i>
EP02.01-02	Novel Therapeutic Vulnerabilities in SOX2-dependent Squamous Cell Lung Cancer <i>Daniel Kottmann, UK</i>
EP02.01-03	Suppression of Telomerase RNA Component Induces Autophagy and Ferroptosis in Lung Cancer via Regulation of AMP-activated Protein Kinase <i>Wenmei Su, China</i>

- EP02.01-04 **Androgen Receptor Suppresses Lung Cancer Invasion and Cisplatin Resistance via Decreasing TPD52 Expression**  
*Shiqing Liu, China*
- EP02.01-05 **Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases**  
*Joaquim Bosch-Barrera, Spain*
- EP02.01-06 **TP53 Mutation Has Significant Impact on Other Driver Genes in Lung Cancer**  
*Yaxian Yang, China*
- EP02.01-07 **DEPDC1 Expression and Mechanisms in Lung Adenocarcinoma : Insights into Proliferation and KIF2C Regulation**  
*Sisi He, China*
- EP02.01-08 **SOX2 Deregulated Squamous Carcinomas Are Vulnerable to AKT3 Inhibition**  
*Wenrui Guo, UK*
- EP02.01-09 **Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma**  
*Masaoki Ito, Japan*
- EP02.01-10 **Dysfunction of FBXL5-mediated Ferrous Iron Homeostasis Suppresses Lung Cancer Growth**  
*Hironori Hinokuma, Japan*
- EP02.01-11 **CSNK1D and CSNK1E Inhibition Regulates Autophagy by Promoting Autophagic Flux in Lung Cancer**  
*Vivian Weiwen Xue, China*
- EP02.01-12 **PEG2000-PLA-Based Nanoscale Polymeric Micellar Reduces Paclitaxel-Related Toxicity in Beagles**  
*Jun Lu, China*

**EP02.02 Track: Tumor Biology – Preclinical Biology – Omics Approaches**

- EP02.02-01 **Genomic Correlates with Ancestry in Lung Squamous Cell Carcinoma**  
*Alison Taylor, USA*
- EP02.02-02 **Transcriptomic Response to Tumor Treating Fields (TTFields) Across Tumor Types**  
*Moshe Giladi, Israel*
- EP02.02-03 **Combination of Radiotherapy and PD-L1 Blockade Induces Abscopal Responses in EGFR-mutated Lung Cancer**  
*Wuyan Xia, China*
- EP02.02-04 **Lysimachia Capillipes Capilliposide C Modulates the Irradiation-Sensitivity of Lung Cancer through Regulation of STAT3-ERRFI1 Axis in Vivo**  
*Kan Wu, China*
- EP02.02-05 **Microbiome in Lung Cancer: Culture-Based Analysis Using Transthoracic Needle Biopsy (TTNB)**  
*So-yun Kim, Republic of Korea*
- EP02.02-06 **Radiation-induced SERPINE2 Expression Inhibit Abscopal Effect in Non-small Cell Lung Cancer via Exosomes**  
*Lucheng Zhu, China*
- EP02.02-07 **Machine Learning for Multi-Omics Data Identifies Vulnerabilities in a Subset of Squamous Cell Lung Cancers**  
*Daniel Kottmann, UK*

- EP02.02-08 **Identification of COL5A2+ Cancer-Associated Fibroblast in Solid Subtype of LUAD by Integrated Analysis of WGCNA and Single Cell RNA-seq**  
*Zhaoxuan Wang, China*

**EP02.03 Track: Tumor Biology – Preclinical Biology - Regulatory Mechanisms**

- EP02.03-01 **ADAR1 Knockout Results in Loss of Tumorigenicity in a Syngeneic Murine Model of Non-small Cell Lung Cancer.**  
*Manish Patel, USA*
- EP02.03-02 **Defining Genetic Instability at Tetranucleotide Repeats (EMAST) in a Non-small Cell Lung Cancer**  
*Hannah Parker, Australia*
- EP02.03-03 **The Functional and Mechanistic Role of PA28 in Lung Cancer**  
*Satyendra Tripathi, India*
- EP02.03-04 **Silencing of Long Non-coding RNA LINC00265 Triggers Autophagy in Lung Cancer by Reducing Protein Stability of SIN3A Oncogene**  
*Wenmei Su, China*
- EP02.03-05 **Circular RNA-mediated ceRNA Network was Identified in Human Lung Adenocarcinoma by High-throughput Sequencing**  
*Wenmei Su, China*
- EP02.03-06 **Suppression of the Long Non-coding RNA LINC01279 Triggers Autophagy in Lung Cancer by Regulating SIN3A**  
*Wenmei Su, China*
- EP02.03-07 **LINC00629 Regulates Cell Proliferation, Migration, Invasion and Apoptosis of Lung Adenocarcinoma**  
*Sisi He, China*

**EP02.04 Track: Tumor Biology – Preclinical Biology - Tumor Immunity**

- EP02.04-01 **The Suppressed Peritumoral Immune Microenvironment Enhances the Progression of Primary Lung Cancer And Metastatic Liver Tumor**  
*KUAN-LI WU, Taiwan*
- EP02.04-02 **A Nanoplatfrom Based on an in Situ Tumor Vaccine and Activation of STING and TLR7/8 Pathways for Enhanced NSCLC Immunotherapy**  
*Haiyu Zhou, China*
- EP02.04-03 **Frequency of the Number of Myeloid Derived Suppressor Cells in Patients with Lung Cancer According to Tumor Pathohistological Type**  
*Jelena Vukovic, Serbia*
- EP02.04-04 **PHLPP2 Enhances Anti-tumor Immunity by Promoting M1 Polarization of Macrophages via STAT3-related Pathway in NSCLC**  
*Haihua Yang, China*
- EP02.04-05 **Xenotransplanted Lung Tumors Display Variable Pleomorphic Patterns in Immunosuppressed BALB/c Mice**  
*Maria Isabel Idolor, Philippines*
- EP02.04-06 **Integrative Single Cell RNA Sequencing Reveals New Insight in Lung Cancer Microenvironment**  
*Duk Ki Kim, Republic of Korea*



EP02.04-07 Metformin Enhances Immune Checkpoint Inhibitor Efficacy in an Obesity-Specific Manner  
*Sai Yendamuri, USA*

**EP03.01 Track: Tumor Biology – Translational Biology - Disease Modeling**

EP03.01-01 Genetic Alterations as Independent Prognostic Factors to Predict Organ- Metastases of Lung Cancer  
*Ann Valter, Estonia*

EP03.01-02 Molecular Characterization of Non-small Cell Lung Cancer in People Living with HIV or Solid Organ Transplants  
*Vanya Aggarwal, USA*

EP03.01-03 Differences in Glucose and Energy Metabolism between Lung Squamous Cell and Lung Adenocarcinoma  
*Shanshan Xiao, China*

EP03.01-04 The Role of Microenvironmental Biomechanics in Lung Cancer Development and Metastasis  
*Jian Gao, China*

**EP03.02 Track: Tumor Biology – Translational Biology - Drug Resistance**

EP03.02-01 EGFR T790M Detection Differences by Original Mutation Types and Detection Samples  
*Jian Ni, China*

EP03.02-02 miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in NSCLC Cells by Targeting USP37  
*Sei-hoon Yang, Republic of Korea*

EP03.02-03 High-Throughput Screening Reveals Ceritinib as a Sensitizer for Cafs-Induced Osimertinib Resistance in Non-small Cell Lung Cancer  
*Hongfang Zhang, China*

**EP03.03 Track: Tumor Biology – Translational Biology - IO**

EP03.03-01 IS1160 Transposon Mycobacterium Tuberculosis Detection in Lung Cancer - A Preliminary Study  
*Hana Faisal, Indonesia*

EP03.03-02 Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer  
*Sanad Alhushki, Jordan*

EP03.03-03 Comprehensive Analysis of Primary Immunotherapy-resistant Genes with Regard Immune Infiltration and Prognosis in Lung Adenocarcinoma  
*Jianxiang Deng, China*

EP03.03-04 Decoding the Immune Dysfunction of Cancer Cachexia in Lung Cancer Patients  
*Laila Roisman, Israel*

EP03.03-05 Immunological Profiling of PD-1-Treated Murine Model Reveals Meyloid-Enriched Phenotypes  
*Xiaoshen Zhang, China*

EP03.03-06 The Involvement of Tumor Endothelial Cells in the Regulation of PD-L1 and Tregs in the Immune Microenvironment of Early-stage Lung Adenocarcinoma  
*Dawei Yang, China*

EP03.03-07 T-Cell Receptor Repertoire Profiling as a Predictive Biomarker for Immunotherapy in Unresectable Stage III Non-small Cell Lung (NSCLC)  
*Narumol Trachu, Thailand*

EP03.03-08 Single-nucleus RNA Sequencing Dissecting the Tumor Microenvironment of Liver Metastasis of Non-small Cell Lung Cancer  
*Jie Huang, China*

EP03.03-09 Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS CoV2 Vaccination in Patients with Non Small Cell Lung Cancer  
*Norma Hernández Pedro, Mexico*

**EP03.04 Track: Tumor Biology – Translational Biology - Novel Targets**

EP03.04-01 Detection of Possible Targets in Aggressive Lung Cancer Using Molecular Abundances and Catalytic Action of Serine Hydrolases  
*Sven Hillinger, Switzerland*

EP03.04-02 Evaluation of Potential Therapeutic Targets with Experimental or FDA-approved Therapies in Thymic Tumor Microarrays  
*Fatemeh Ardeshir Larijani, USA*

**EP03.05 Track: Tumor Biology – Translational Biology - Omics and New Technologies**

EP03.05-01 Aberrant Methylation of ZNF577 As a Potential Prognostic Biomarker for Lung Adenocarcinoma  
*Batkhishig Munkhjargal, Japan*

EP03.05-02 Genomic Landscape Features of Minimally Invasive Adenocarcinoma and Invasive Lung Adenocarcinoma  
*Bo Liu, China*

EP03.05-03 Hollow-MnO<sub>2</sub> Nanofabricated Platform Equipped with Carbon Monoxide Gas Combined with SDT Enhanced ROS Generator for Lung Cancer Treatment  
*Yujia Fang, China*

EP03.05-04 RNA Sequencing to Characterize Pathways in Patients with EGFR-mutated Non-Small Cell Lung Cancer  
*Nicole Yun, USA*

EP03.05-05 Non-Small Cell Lung Cancer: Artificial Intelligence, Complex System Analysis and Computer Simulation for Best Management.  
*Oleg Kshivets, Russian Federation*

EP03.05-06 Identification of Oncogenic Non-coding Regions Inducing the ANKZF1 Expression in Lung Cancer by a Multi-omics Website Omics3D  
*Chen Lian, China*

**EP03.06 Track: Tumor Biology – Translational Biology - Translational Therapeutics**

EP03.06-01 Differential Anticancer Compound Response of Filipino Patient-derived Lung Adenocarcinoma Cells (GL01) Against A549 Cell Line  
*Kim Claudette Fernandez, Philippines*

EP03.06-02 Novel HDAC Inhibitor CG200745 Inhibit EMT and Induce Apoptosis in Lung Cancer Cells  
*Hak-Ryul Kim, Republic of Korea*

- EP03.06-03 The Landscape of NFI Alteration in Chinese Non-Small-Cell Lung Cancer Patients  
*Zhenliang Shi, China*
- EP03.06-04 Development of an Inhibitor for the Treatment of Lung Cancer  
*Amila Suraweera, Australia*
- EP03.06-05 Synthetic Lethality Targeting Programmed Cell Death Reverses the Osimertinib Resistance Induced by ARID1A Deficiency in LUAD  
*Dantong Sun, China*
- EP03.06-06 KRAS-B: Molecular Epidemiology and Clinical Outcomes of KRAS-Mutant Non-small Cell Lung Cancer (NSCLC) in Brazil  
*Pedro De Marchi, Brazil*

**EP04.01 Track: Screening and Early Detection - Biomarkers/Imaging Technology**

- EP04.01-01 The PneuVision Test Detects Both Lung Squamous Cell Carcinoma and Adenocarcinoma from Cells in Sputum  
*Michael Meyer, USA*
- EP04.01-02 Volatile Organic Compounds in Exhaled Breath as Biomarkers for Lung Cancer. A Screening-Based Study in High-Risk Participants  
*Annamaria Catino, Italy*
- EP04.01-03 Advancing Malignancy Risk Stratification for Early-Stage Cancers in Lung Nodules by Combined Imaging and Electrical Impedance Analysis  
*Dawei Yang, China*
- EP04.01-04 Detecting KRAS Mutations in Peripheral Blood Extracellular Vesicles in Non-small Cell Lung Cancer Using Digital Droplet PCR  
*Caeli Zahra, Australia*
- EP04.01-05 True Abnormal Cells in Normal Cases Detected by the PneuVision Test for Early-Stage Lung Cancer  
*Michael Meyer, USA*
- EP04.01-06 Double Blind Evaluation of Circulating Cancer Associated Macrophage Like (CAML) Cells for Detection of Cancer in Pulmonary Nodules  
*Martin Edelman, USA*
- EP04.01-07 Optimal Predictors for Lung Cancer Using High-Resolution CT  
*Hirotsugu Notsuda, Japan*
- EP04.01-08 Users' Satisfaction and Usefulness of Cloud-based Computer Aided Quality Control System Using in Korean National Lung Cancer Screening Program  
*Yeol Kim, Republic of Korea*
- EP04.01-09 The Combination of a Seven-Autoantibody Panel with Computed Tomography Scanning Can Enhance the Diagnostic Efficiency of Lung Cancer  
*Tianyu He, China*
- EP04.01-10 Metabolomic Biomarkers for Lung Cancer: A Systematic Review  
*Zhangyan Lyu, China*
- EP04.01-11 AI-based Detection on Low-Dose CT: A Focus on Augmenting Model Performance  
*Soo-Youn Ham, Republic of Korea*
- EP04.01-12 METTL7A Inhibits Cell Proliferation and M2-Like Polarisation of Tumor-Associated Macrophage in Lung Adenocarcinoma  
*Junfan Pan, China*

**EP04.02 Track: Screening and Early Detection - Implementation**

- EP04.02-01 Impact of an Urban Based Lung Cancer Screening Program: Seven Year Follow-up  
*Mary Pasquinelli, USA*
- EP04.02-02 Implementation of an Integrated Lung Cancer Screening Program at a Large Academic Community Health System in the U.S.  
*Jannifer Stromberg, USA*
- EP04.02-03 Cost-Consequence Analysis of Artificial Intelligence Assisted Image Reading in Lung Cancer Screening  
*Harriet Lancaster, Netherlands*
- EP04.02-04 Screening Success: A Review of Outcomes from Lehigh Valley Health Network's Multi-Disciplinary Lung Cancer Screening Program  
*Timothy Johnson, USA*

**EP04.04 Track: Screening and Early Detection - Nodule Management**

- EP04.04-01 Delay in Lung Cancer Diagnosis as a result of being Diagnosed as Pulmonary Tuberculosis in Riau Province  
*Ananda Aulia, Indonesia*
- EP04.04-02 Incidental Lung Nodule Identification and Subsequent Diagnosis of Lung Cancer in a University Hospital in Hong Kong  
*Lynn Yim-Wah Shong, China*
- EP04.04-03 Impact of a Lung Nodule Program in a Tertiary Care Academic Center in the United States  
*Hari Keshava, USA*
- EP04.04-04 Relevance of AI (qCT) In Automated Progression Monitoring of Pulmonary Nodules in Follow-up Lung CT Scans  
*Rohitashva Agrawal, India*
- EP04.04-05 Ten-year CTNB Data Indicate Its Usefulness and Safety, Especially Salvage Situation after Bronchoscopy without Diagnosis  
*Yuki Misumi, Japan*
- EP04.04-06 Low-Dose CT Iterative Reconstructions can Impact Lung Nodule Measurements and Type Classification  
*Harriet Lancaster, Netherlands*
- EP04.04-07 The Frequency of Incidental Lung Cancer Detected in Thorax CT During the COVID-19 Pandemic Process in Turkey  
*Berna Komurcuoglu, Turkey*

**EP04.05 Track: Screening and Early Detection - Program Design**

- EP04.05-01 Comparison of Two Enrolment Criteria in Lung Cancer Screening Pilot Project in Estonia  
*Tanel Laisaar, Estonia*
- EP04.05-02 Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening  
*Raymond Osarogiagbon, USA*
- EP04.05-03 Perspectives of Potentially Eligible Indigenous Māori on a Lung Cancer Screening Programme - A Qualitative Study  
*Kate Parker, New Zealand*

- EP04.05-04 **Impact of Magnitude of Lung Cancer Screening Benefit on Uptake**  
*David Yankelevitz, USA*
- EP04.05-05 **Singapore Lung Cancer Screening through Integrating CT with Other Biomarkers (SOLSTICE), A Single Arm Lung Cancer Screening Study**  
*Gillianne Lai, Singapore*
- EP04.05-06 **Centralized Shared Decision Making in Lung Cancer Screening: Unexpected Consequences**  
*David Yankelevitz, USA*
- EP04.05-07 **Improved Efficiency with Lungflag vs Opportunistic Selection in a Theoretical East Asian Lung Cancer Screening Program**  
*Eran Netanel Choman, Israel*

**EP04.06 Track: Screening and Early Detection - Recruitment + Screening Uptake**

- EP04.06-01 **Compliance with Lung Cancer Screening Guidelines Among At-Risk Patients at a Rural Teaching Hospital in West Texas**  
*Kavya Bharathidasan, USA*
- EP04.06-02 **Multimodal Intervention Strategies to Improve Lung Cancer Screening for Women Undergoing Breast Screening**  
*Lye-Yeng Wong, USA*
- EP04.06-03 **Qualitative Study Using Focus-Group Interviews on Cognition of Lung Cancer Screening and Symptom**  
*Minji Seo, Republic of Korea*
- EP04.06-04 **Impact of a Navigational Program on Lung Cancer Screening at a Community Health Center Serving an Urban Diverse Population**  
*Hina Khan, USA*

**EP04.07 Track: Screening and Early Detection - Others**

- EP04.07-01 **Message from the Patients: What If I Wasn't COVID 19**  
*Cengiz Gebitekin, Turkey*

**EP05.01 Track: Pulmonology and Staging**

- EP05.01-01 **An Analysis of Lymph Node Metastasis Patterns in Surgical Cases of Non-small-Cell Lung Cancer**  
*Miyuki Abe, Japan*
- EP05.01-02 **Cryobiopsy for Peripheral Pulmonary Lesions Using a 1.1 mm Cryoprobe and Guide Sheath without Fluoroscopy: The Initial 400 Cases**  
*Dongil Park, Republic of Korea*
- EP05.01-03 **Efficacy of Artificial Intelligence and Deep Learning Predicting NO Status**  
*Gizem Özçibik Isik, Turkey*
- EP05.01-04 **A Retrospective Study on the Efficacy and Safety of Flexible Bronchoscopy in Elderly Patients with Suspected Primary Lung Cancer**  
*Zentaro Saito, Japan*
- EP05.01-05 **Predictive Factors for Hemoptysis Following CT-guided PCNB: The Role of Post-procedure CT Findings and Cough after Biopsy**  
*Green Hong, Republic Of Korea*

- EP05.01-06 **Stepwise Progression of Invasive Mucinous Adenocarcinoma Based on the Radiological and Biological Characteristics**  
*Eisuke Goto, Japan*
- EP05.01-07 **Propective Study: Usefulness of D-Dimer Determination for Thromboembolic Disease Screening in Patients with Metastatic Lung Cancer**  
*Teresa García Manrique, Spain*
- EP05.01-08 **Observation of Peripheral Airways Using Ultra-Thin Fiberscope**  
*Tomonari Kinoshita, Japan*
- EP05.01-09 **Lung Cancer in Combined Pulmonary Fibrosis and Emphysema Syndrome Patients. A Complication or a Comorbidity?**  
*Jolanda Nikolla, Albania*
- EP05.01-10 **Multi-scale Generator with Channel-wise Mask Attention to Generate Synthetic Contrast-enhanced Chest Computed Tomography**  
*Yun-Gyoo Lee, Republic of Korea*
- EP05.01-11 **Lung Cancers Diagnosed in a Retrospective Cohort of Lung Nodule Patients in Singapore**  
*Mamta Ruparel, Singapore*
- EP05.01-12 **A Retrospective Audit of Lung Nodules with Validation of the Brock Tool in a Singaporean Cohort**  
*Mamta Ruparel, Singapore*
- EP05.01-13 **Time to Lung Cancer Diagnosis and Treatment in the Era of the COVID-19 Pandemic**  
*Melinda Hsu, USA*
- EP05.01-14 **Survival in Patients with Malignant Pleural Effusion Treated with a Tunneled Pleural Catheter Compared to the Lent Prognostic Score Scale**  
*Rafael Lopez-Castro, Spain*
- EP05.01-15 **Prognosis in Terms of Invasive Non-mucinous Adenocarcinoma Grading System**  
*Toshimasa Okazaki, Japan*
- EP05.01-16 **Re Evaluation of a Larger Sample: Anatomical Variation Analysis of Left Upper Pulmonary Based on 3Dreconstruction of Chest CT**  
*Youjun Deng, China*

**EP06.01 Track: Pathology and Biomarkers - Artificial Intelligence for Pathology**

- EP06.01-01 **Concordance Between Generative AI GPT-4 and NCCN Guidelines: Biomarker-Driven Treatment Strategies in NSCLC**  
*Hye Sung Kim, USA*
- EP06.01-02 **A Circulating Tumor Cell-based Artificial Neural Network of Patients with Advanced Non-Small Cell Lung Cancer**  
*Xuyu Gu, China*
- EP06.01-03 **Evaluation of Unstained Cytology Slides for Artificial Intelligence Rapid On-Site Evaluation**  
*Eric Flenaugh, USA*
- EP06.01-04 **Deep Learning Based Quality Assessment of DAPI Stained Nuclei Images Obtained from Routine FISH Test for Lung Cancer**  
*Tae-Jung Kim, Republic of Korea*

**EP06.02 Track: Pathology and Biomarkers - Biomarkers for Immuno-oncology**

- EP06.02-01 **Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: A Real-World Australian Perspective**  
*Sarita Prabhakaran, Australia*
- EP06.02-02 **Enrichment for PD-L1 High Tumors in AXL-Expressing Advanced Non-small Cell Lung Cancer (NSCLC)**  
*Muhammad Awidi, USA*
- EP06.02-03 **PD-L1 Expressions in Non-small Cell Lung Cancer and its Correlation with Imaging Findings**  
*Naoko Shigeta, Japan*
- EP06.02-04 **The Relationship between Pathologic and Molecular Characteristics and PD-L1 Expression in Surgically Resected Non-small Cell Lung Cancer**  
*Atsushi Ito, Japan*
- EP06.02-05 **Agreement Among Programmed Cell Death Ligand-1 Immunohistochemistry Results Using 73-10, 22C3 and 28-8 Antibodies for Lung Cancer**  
*Tomohito Saito, Japan*
- EP06.02-06 **Pan-cancer Analyses Reveal Immune Infiltration and Clinical Outcomes of IL7R**  
*Jiafeng Liang, China*
- EP06.02-07 **Tertiary Lymphoid Structures Predict Clinical Outcomes of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC**  
*Xinying Xue, China*

**EP06.03 Track: Pathology and Biomarkers - Genetic Biomarkers**

- EP06.03-01 **Genetic Characterization of Driving Metastasis in TP53-Mutant Non-small Cell Lung Cancer Patients**  
*Jun Lu, China*
- EP06.03-02 **Elucidating Tumor Heterogeneity from Spatially Resolved Transcriptomics in ALK-Rearranged Non-small Cell Lung Cancer**  
*JungHan Oh, Republic of Korea*
- EP06.03-03 **Oncogenic Drivers of Pulmonary Invasive Mucinous Adenocarcinoma, Detected by Trusight Oncology 500**  
*Kanako Shinada, Japan*
- EP06.03-04 **Molecular Alterations in Non-Small Cell Lung Cancer Arising in Emphysematous and Fibrotic Lungs**  
*Yinghan Hsu, Canada*
- EP06.03-05 **EGFR Exon 20 Insertion Mutations in NSCLC: The Need for Accurate Naming Conventions and Implications for Personalized Therapy**  
*Jieun Park, Republic of Korea*
- EP06.03-06 **Clinical Impact of EGFR vs KRAS Mutations in Multifocal Lung Adenocarcinoma**  
*Jiahao Jiang, USA*
- EP06.03-07 **Clinical Impact of Next-Generation Sequencing in KRAS-Mutated Non-Small Cell Lung Cancer Patients: a Single-Center Experience**  
*Emmanouil Panagiotou, Greece*

- EP06.03-08 **Clinical Study to Molecularly Profile Filipino Lung Adenocarcinoma**  
*Francisco Heralde, Philippines*
- EP06.03-09 **Characteristics of Insufficient Samples for EGFR Mutation Testing at the Lung Center of the Philippines**  
*Francisco Heralde, III, Philippines*
- EP06.03-10 **HER3 Expression in Archived Tissue Samples from Patients with NSCLC Across Various Genomic Subtypes and Characteristics**  
*Ross Soo, Singapore*
- EP06.03-11 **Characterization of KRAS Mutations in Black Patients with NSCLC at an Urban Academic Medical Center**  
*Danielle Dressler, USA*
- EP06.03-12 **Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions in HER1 (EGFR) and HER2 (ERBB2)**  
*Amanda Gibson, Canada*
- EP06.03-13 **HRR Gene Mutations- A New Biomarker for Precision Genomics Based Testing in Metastatic Lung Cancer**  
*Madhu Nagaraj, India*
- EP06.03-14 **Genomic Alterations in Advanced Lung Cancer Patients Compared via CGP and Hotspot Panel Test in a Bangladeshi Tertiary Hospital**  
*Qamruzzaman Chowdhury, Bangladesh*
- EP06.03-15 **Predicting ROS1 Fusions and Targetable Mutations in Non-small Cell Lung Cancer through H-score Pathological Analysis**  
*Ghassen Soussi, France*
- EP06.03-16 **Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations**  
*Ebaa Al-Obeidi, USA*
- EP06.03-17 **The Prognostic Impact of Postoperative EGFR Mutation Status in Lung Cancer Patients with Stage II - III**  
*Shota Nakamura, Japan*
- EP06.03-18 **Atlas: Italian Knowledge Based Database for Biomarkers Analysis In NSCLC Patients**  
*Umberto Malapelle, Italy*
- EP06.03-19 **Genomic Landscape of Non-Small Cell Lung Cancer in the Republic of Ireland**  
*Rachel Keogh, Ireland*
- EP06.03-20 **Molecular Testing of Pulmonary Adenosquamous Cell Carcinoma for EGFR Mutation and ALK Gene Rearrangement**  
*Goohyeon Hong, Republic Of Korea*
- EP06.03-21 **Usefulness of Immunohistochemistry for the Detection of BRAFV600E in Lung Cancer: A Multicenter Retrospective Study in China**  
*Pei Yuan, China*
- EP06.03-22 **Implementing Next Generation Sequencing for Lung Cancer Patients in Mexico: A Real-World Study from Puebla**  
*Iván Romarico González-Espinoza, Mexico*

EP06.04	Track: Pathology and Biomarkers - Liquid Based Biomarkers
EP06.04-01	Challenge to Detect CTC-derived EGFR Mutation of Non-small Cell Lung Carcinoma by Unique Blood-Filtration Device <i>Hitoshi Dejima, Japan</i>
EP06.04-02	FLUIDIndia: Liquid "First" Approach is a "Solid" Solution in NSCLC <i>Ullas Batra, India</i>
EP06.05	Track: Pathology and Biomarkers - Pathology
EP06.05-01	Molecular, Clinicopathological Characteristics of Thoracic SMARCA4-deficient Undifferentiated Malignant Tumor -5 Cases Review <i>Yu-Deok Choi, Republic of Korea</i>
EP06.05-02	Accuracy of Postoperative Thoracic Malignancy Diagnosis in National Respiratory Center Persahabatan Hospital <i>Evi Ho, Indonesia</i>
EP06.05-03	Subpleural Cystic Mesenchymal Neoplasm with Endometrial-type Stromal Proliferation: A Report of 3 Cases <i>Peter Illei, USA</i>
EP06.05-04	SMARCA4/BRG1 Deficient Thoracic Neoplasms: Spectrum Encompassing Carcinomas to Undifferentiated Tumors <i>Arshi Tandon, India</i>
EP06.05-05	Molecular Characteristics of Lung Signet Ring Cell Carcinoma in the Chinese Population <i>Shirong Zhang, China</i>
EP06.05-06	Distant Metastasis Pattern and Baseline Clinicopathological Features from a Real-World KRAS G12C Mutant Cohort of Advanced NSCLC Patients <i>Anna Cecilia Bettini, Italy</i>
EP06.05-07	Non Small Cell Lung Cancer Associated to Dipnech: A Clinico-Pathological Analysis of 32 Cases <i>Filippo Lococo, Italy</i>
EP06.05-08	Efficacy of Preoperative Biopsy in Predicting the Newly Proposed Histologic Grade of Resected Lung Adenocarcinoma <i>Seiyu Ohtani, Japan</i>
EP06.05-09	Computational Pathology-Based Assessment of cMET IHC Expression for Patient Selection in the Treatment of MET Overexpressing NSCLC <i>Simon Christ, Germany</i>
EP06.05-10	Clinical Value of Baseline Plasma Epstein-Barr Virus DNA in Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma <i>Ying Liang, China</i>
EP06.05-11	Immunohistochemical Features in Tissue Microarray in Pleomorphic Carcinoma of the Lungs <i>Won-Il Choi, Republic of Korea</i>
EP06.05-12	Histopathologic Changes of the Perioperative Pirfenidone Therapy in Lung Cancer with Idiopathic Pulmonary Fibrosis <i>Hodaka Oeda, Japan</i>
EP06.05-13	Validation of the IASLC Grading System of Invasive Adenocarcinoma of the Lung in Small Volume Center <i>Kisung Park, Republic of Korea</i>

EP06.05-14	Twelve Cell Death Patterns-Related Classification of the Immune Microenvironment and Prognosis Prediction of LUSC <i>Xiaorong Dong, China</i>
EP06.05-15	STAS and Expression of EMT-markers in Surgically Resected Lung Pleomorphic Carcinomas <i>Renata Langfort, Poland</i>
EP06.06	Track: Pathology and Biomarkers - Prognostic Biomarkers
EP06.06-01	Insulin Like Growth Factor 2 mRNA Binding Protein3 is a Novel Post-Transcriptional Regulator of Lung Adenocarcinoma Malignancy <i>Xuequan Wang, China</i>
EP06.06-02	Correlation Between Vitamin C and CRP Serum Levels in Non Small Cell Lung Cancer Patient Among Sumatera Utara Population <i>Elizabeth Napitupulu, Indonesia</i>
EP06.06-03	The Expression of MIR-320B in Extracellular Vesicles as a Prognostic factor for Non-small Cell Lung Carcinoma <i>Wily Ariawan, Indonesia</i>
EP06.06-04	The Expression of MIR-320B in Extracellular Vesicles as a Prognostic Factor for Non-small Cell Lung Carcinoma <i>Wily Ariawan, Indonesia</i>
EP06.06-05	Circular RNA hsa_circ_0067705 Expression as a Potential Diagnostic Biomarker for Malignant Pleural Effusion <i>Raghda Taleb, Egypt</i>
EP06.06-06	Plasma Extracellular Vesicle miR-10b-5p as a Biomarker for Progressivity, Survivorship and Treatment Response in NSCLC Patients <i>Jaka Pradipta, Indonesia</i>
EP06.06-07	Surveying for Lung Cancer after Idiopathic Pulmonary Fibrosis at Pham Ngoc Thach Hospital - Viet Nam in 5 year (2017 - 2021) <i>Nguyen Lam, Viet Nam</i>
EP06.06-08	Comparison of RICTOR FISH and Rictor Immunohistochemistry in Lung Squamous Cell Carcinoma <i>Andras Khor, USA</i>
EP06.06-09	Clinical Significance of the Presence of MECA-79-Positive Tumor Cells in Pathological Stage IA Invasive Adenocarcinoma of the Lung <i>Tomohito Saito, Japan</i>
EP06.06-10	Cancer-Associated Fibroblasts and Estrogen Receptor Beta in Lung Cancer with Idiopathic Pulmonary Fibrosis <i>Eiji Nakajima, Japan</i>
EP06.06-11	Expression of miR-30a-5p in Expression of Mir-30A-5P in Extracellular Vesicle as a Prognostic Biomarker for Non Small Cell Lung Cancer Therapy <i>Mariska Pangaribuan, Indonesia</i>
EP06.06-12	EBUS as a Novel Procedure for Microbiome Collection and Analysis in NSCLC <i>Anna Mclean, Australia</i>
EP06.06-13	Fibronectin Promotes Tumor Angiogenesis and Progression of Non-small-Cell Lung Cancer <i>Guanghui Gao, China</i>

- EP06.06-14 High Circulating Activin a Plasma Level Is Associated with Advanced Tumor Stage and Poor Prognosis in Lung Squamous Cell Cancer Patients  
*Mir Alireza Hoda, Austria*
- EP06.06-15 Epigenetic Silencing of MYO1E in a US Veterans Cohort with Lung Adenocarcinoma and the Effect on Overall Survival  
*Kathleen Kennedy, USA*
- EP07.01 Track: Early-Stage Non-small Cell Lung Cancer - Best Practice**
- EP07.01-01 Nomogram for Predicting Prognosis and Adjuvant Chemotherapy Benefits in Early-stage Invasive Mucinous Lung Adenocarcinoma  
*Hua He, China*
- EP07.01-02 Gender Differences in Postoperative Symptoms of Lung Cancer and its Influencing Factors  
*Jia Liao, China*
- EP07.01-03 Perioperative Outcomes and Strategies for Pleomorphic Carcinoma in Lung  
*Aki Kobayashi, Japan*
- EP07.01-04 Factors Affecting Survival in YPT1N01M0 Non Small Cell Lung Cancer Patients  
*Gizem Özcibik Isik, Turkey*
- EP07.01-05 A Study of the Characteristics of Lung Cancer Surgery Cases in the Elderly and the Usefulness of the Japanese NCD Risk Calculator  
*Teruhisa Kawaguchi, Japan*
- EP07.01-06 Lead-Time Bias in Surgically Resected Non-Small Cell Lung Cancer (NSCLC) Diagnosed Through Different Pathways of Care  
*Raymond Osarogiagbon, USA*
- EP07.01-07 Comparison of Surveillance with Contrast Chest CT and Non-contrast Chest CT Among who Survived 2 Years after Curative Resection for Lung Cancer  
*Bubse Na, Republic of Korea*
- EP07.01-08 Development of a Shared Decision-Making Tool for Adjuvant Treatment for Patients with Resected Non-Small Cell Lung Cancer  
*Konstantinos Leventakos, USA*
- EP07.01-09 Can the Use of New Haemostatic Agent Improve Short Term Outcomes of Surgically Treated Non-small Cell Lung Cancer Patients?  
*Sara Ricciardi, Italy*
- EP07.01-10 Risk Assessment of Severe Pulmonary Complications Leading to Death or Oxygen Therapy After Lung Resection in Patients with Primary Lung Cancer  
*Shinji Otani, Japan*
- EP07.01-11 Ablation of Early-Stage Non-Small Cell Lung Cancer in Patients with Interstitial Lung Disease: A Multicenter Retrospective Cohort Study  
*Florian Fintelmann, USA*
- EP07.01-12 A Retrospective Study on the Methods of Covering Bronchial Stump/ Anastomotic Site to Avoid the Bronchopleural Fistula after Lung Cancer Surgery  
*Tomohiro Habu, Japan*
- EP07.01-13 Definitive Chemoradiation versus Radiation Alone for Stage II Non-Small Cell Lung Cancer. A National Cancer Database Analysis  
*Janakiraman Subramanian, USA*

- EP07.01-14 Assessing Morphometric Complexity in Lung Parenchyma of NSCLC Patients with IPF Undergoing Radiotherapy  
*Jeongeun Hwang, Republic of Korea*
- EP07.01-15 Utility of Bronchus-First Right Upper Lobectomy as a Routine Technique  
*Takahiro Utsumi, Japan*
- EP07.01-16 The Relationship of FDG PET-SUVm and Glucose Metabolism and Contribution to Early-Stage Non-Small Cell Lung Cancer Survival  
*Kemp Kernstine, USA*
- EP07.01-17 Identification of the Inter Segmental Area by Indocyanine Green Fluorescence Navigated Method During Thoracoscopic Segmentectomy  
*Fumiaki Watanabe, Japan*
- EP07.01-18 Adjuvant Chemotherapy is Less Effective in Non Small Cell Lung Cancer Patients Rated Undernourished by CONUT Score  
*Ken Onodera, Japan*
- EP07.01-19 Factors Affecting Postoperative Nausea and Vomiting in Surgical Patients with Non-Small Cell Lung Cancer  
*Satomi Imamura, Japan*
- EP07.01-20 Perioperative and Long-Term Outcomes of Fissureless Fissure-Last Lobectomy in Patients with Non-small Cell Lung Cancer  
*Hayato Nanami, Japan*
- EP07.01-21 A 22 to 23G Intraoperative Needle Biopsy Does Not Affect Recurrence of Preoperatively Undiagnosed Stage 1 Lung Cancer  
*Yoshito Imamura, Japan*
- EP07.01-22 Identifying the Optimal Number of Lymph Node Stations for Improving Survival in Resections for Non-small Cell Lung Cancer  
*Matthew Smeltzer, USA*
- EP07.01-23 Stereotactic Body Radiation Therapy for Patients with Early-Stage Non-small Cell Lung Cancer Inoperable  
*Luan Pham, Viet Nam*
- EP07.01-24 Surgical Treatment of Lung Cancer in Patients Over the Age of 75 Years: Single Cancer Centre Experience  
*Oleg Pikin, Russian Federation*
- EP07.01-25 Implementation and Safety of a Same-day Discharge Program for Minimally-invasive Pulmonary Resection  
*Patrick Villeneuve, Canada*
- EP07.01-26 Is Chemical Venous Thromboembolism Prophylaxis Necessary After Lung Cancer Resection? A 10-year T-ERAS Experience  
*Ju Ae Park, USA*
- EP07.01-27 The Impact of Comorbidities on Exercise Level after Treatment for Early-Stage Lung Cancer Patients  
*Jiafang Zhang, USA*
- EP07.01-28 Local Control & Toxicity Results of Stereotactic Body Radiotherapy in Central Lung Tumors  
*Serap Akyürek, Turkey*
- EP07.01-29 What is a Risk Factor for Postoperative Home Oxygen Therapy in Primary Lung Cancer Patients?  
*Takahiro Yamanaka, Japan*

## POSTER SESSIONS - ELECTRONIC POSTERS

- EP07.01-30 **Predictors of Poor Quality of Life Following Lung Cancer Surgery**  
*Anna McGuire, Canada*
- EP07.01-31 **Preoperative Respiratory Assessment Predicts Post-Operative Survival in Stage IA Non-small Cell Lung Cancer**  
*Mototsugu Watanabe, Japan*
- EP07.01-32 **Long Term Outcomes beyond Five Years after Pulmonary Resection for Non-small Cell Lung Cancer**  
*Tetsuya Mizuno, Japan*
- EP07.01-33 **Recurrence Patterns and Prognostic Factors for Relapse in Operated Lung Cancers**  
*Berna Komurcuoglu, Turkey*
- EP07.02 Track: Early-Stage Non-small Cell Lung Cancer - New Technology and Innovations**
- EP07.02-01 **Evaluation of the Efficacy of Oral Bacterial Lysates in Patients with High-risk Lung Nodules Detected by CT Screening**  
*Dawei Yang, China*
- EP07.02-02 **Impact of Neoadjuvant Immunotherapy on Surgical Management for Non-small Cell Lung Cancer: A Multi-center Survey of Current Practice from China**  
*Han Wu, China*
- EP07.02-03 **High-Dose Rate Endobronchial Brachytherapy with Palliative and Definitive Intent at a Tertiary Care Hospital**  
*Meng Welliver, USA*
- EP07.02-04 **The Prediction of Pathological Pleural Invasion of Lung Cancer by Artificial Intelligence Image Analysis**  
*Wakako Nagase, Japan*
- EP07.02-05 **A Three-Dimensional Computed Tomography Analysis of Residual Lung Volume Changes after Segmentectomy for Non-small-Cell Lung Cancer**  
*Miyuki Abe, Japan*
- EP07.02-06 **MIDRIXNEO-LUNG: Safety and Immunogenicity of a Neoantigen-Presenting Autologous Dendritic Cell Therapy in Resected NSCLC Patients**  
*Karim Vermaelen, Belgium*
- EP07.02-07 **Prospective Study of Hypofractionated Proton Therapy for Inoperable Early Stage Non-small Cell Lung Cancer**  
*Kyungmi Yang, Republic of Korea*
- EP07.02-08 **Comparison of ICG and Methylene Blue in Preoperative Dye Marking Localization of Pulmonary Nodules Under the Guidance of ENB**  
*Yong-Bin Lin, China*
- EP07.02-09 **Hypofractionated Radiation Therapy vs Stereotactic Body Radiation Therapy for Ultra-Central Lung Tumors**  
*Rui Song, USA*
- EP07.02-10 **Adjuvant Chemotherapy with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin for Stage IB Non-small Cell Lung Cancer**  
*Yamato Motooka, Japan*

## POSTER SESSIONS - ELECTRONIC POSTERS

- EP07.02-11 **Navigational Bronchoscopy: Driving to the Nodule Drives Your Patients to Earlier Stage**  
*Patrick Ross, USA*
- EP07.02-12 **The Role of Online MR-guided Multi-Fraction Stereotactic Ablative Radiotherapy in Lung Tumors**  
*Chukwuka Eze, Germany*
- EP07.02-13 **Utilization of Real-time MRI-guided Stereotactic Ablative Body Radiotherapy in NSCLC, One Step forward Precise Targeting in Radiotherapy**  
*Yoo Kang Kwak, Republic of Korea*
- EP07.02-14 **Image-Guided Thermal Ablation of Early-Stage Non-small Cell Lung Cancer; Five-Year Outcome**  
*Soheil Kooraki, USA*
- EP07.02-15 **Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers**  
*Jamie Feng, Canada*
- EP07.02-16 **Localization of Lung Nodules by Electromagnetic Navigation Bronchoscopy-Guided Dye Marking: Procedural Outcomes and Learning Curve**  
*Deog Gon Cho, Republic of Korea*
- EP07.02-17 **The Utility of Postoperative ctDNA Detection in Guiding Adjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer**  
*Bolin Wang, China*

**EP07.03 Track: Early-Stage Non-small Cell Lung Cancer - Limited Resections and Minimally Invasive Approaches**

- EP07.03-01 **Meeting the Quality Metric for Minimum Lymph Node Harvest for Robotic Lobectomy for Lung Cancer**  
*Jobelle Joyce Anne Baldonado, USA*
- EP07.03-02 **Pulmonary Ligament Approach for Robot-Assisted S9 or S9 and 10 Segmentectomy**  
*Mariko Fukui, Japan*
- EP07.03-03 **Uniportal Video-Assisted Thoracoscopic Surgery Simple Segmentectomy Versus Complex Segmentectomy in Lung Cancer Patients**  
*Youngkyu Moon, Republic of Korea*
- EP07.03-04 **Non-Small Cell Lung Cancer in Obese Patients: Comparison of Open, Robotic and Videothoracoscopic Surgery. A Multicenter Retrospective Series**  
*Andrea Bille, UK*
- EP07.03-05 **Oncological Outcomes After Uniportal Versus Multiportal Thoracoscopic Lobectomy for Lung Cancer Patients**  
*Wei Dai, China*
- EP07.03-06 **Challenges in Robotic Lobectomy of the Lung Through the Anterior Approach**  
*Atsushi Osoegawa, Japan*
- EP07.03-07 **Negative Impacts of Mediastinal Lymph Node Dissection Forstage I Ground Glass Opacity Pulmonary Lesions**  
*Jimin Lee, Republic of Korea*
- EP07.03-08 **Impact of Tumor Location on Surgical Margin in Segmentectomy and Wedge Resection**  
*Atsushi Kosuge, Japan*

- EP07.03-09 **A Minimally Invasive Open Surgery Approach Is Superior to VATS with Respect to Intraoperative Outcomes during Lung Cancer Surgery**  
*Satoshi Shiono, Japan*
- EP07.03-10 **Effects of Preoperative Diabetes Mellitus on Postoperative Outcomes After Robotic-Assisted Video-Thoroscopic Pulmonary Lobectomy**  
*Eric Toloza, USA*
- EP07.03-11 **Effects of Intraoperative Trainees on Outcomes after Robotic-Assisted Pulmonary Lobectomy**  
*Eric Toloza, USA*
- EP07.03-12 **Early PROs After Uniportal Thoroscopic Lobectomy vs Da Vinci Robotic-assisted Thoroscopic Lobectomy**  
*Kaixin Zhang, China*
- EP07.03-13 **Comparison Of Patient-Reported Outcomes for Early-Stage Lung Cancer Patients Underwent Thoroscopic Segmentectomy Versus Lobectomy**  
*Xin Gao, China*
- EP07.03-14 **Effect of Lymph Node Dissection on Recurrence and Survival Following Thoroscopic Segmentectomy for Early-Stage Non-small Cell Lung Cancer**  
*René Petersen, Denmark*
- EP07.03-15 **Nodal Upstaging in Uniportal VATS Lobectomy for Early-Stage Lung Cancer: Is It Fair?**  
*Riccardo Orlandi, Italy*
- EP07.03-16 **Early PROs After Thoroscopic Segmentectomy Versus Wedge Resection for Small-sized Peripheral NSCLC**  
*Yingzhi Zhao, China*
- EP07.03-17 **Robotic Lung Cancer Program: Initial Experience and Results**  
*Daniel Brandao, Brazil*

**EP07.04 Track: Early-Stage Non-small Cell Lung Cancer - Progress in Pathology**

- EP07.04-01 **Free Circulating and Extracellular Vesicles-Derived microRNA as Prognostic Biomarkers in Resected Early-Stage NSCLC: RESTING Study Results**  
*Paola Ulivi, Italy*
- EP07.04-02 **Real-World Data Based on EGFR Mutation Status in Early-Stage NSCLC**  
*Ji Hyung Hong, Republic of Korea*
- EP07.04-03 **Analyze Gene Changes Characteristics of MSLAs in Genomic Study**  
*Kewei Ma, China*
- EP07.04-04 **High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma**  
*Cameron Fick, USA*
- EP07.04-05 **Spread Through Air Spaces in Non-small Cell Lung Cancer. Clinical and Pathological Associations**  
*Virginia Calvo de Juan, Spain*
- EP07.04-06 **ALK Rearrangement Is Associated with Early Lymphatic Spread in Resected LUAD with Negative Preoperative Mediastinal Staging**  
*Filippo Tommaso Gallina, Italy*

- EP07.04-07 **Early-Stage Low Malignant Potential Adenocarcinomas: A Histological Category with a Significantly Better Prognosis**  
*Filippo Lococo, Italy*
- EP07.04-08 **Immune Cell States as Predictors of Survival in Surgically Treated Stage I Non-small Cell Lung Cancer (NSCLC)**  
*Laura Sellmer, Germany*
- EP07.04-09 **Pleural CEA and SUVmax as Predictors of Visceral Pleural Invasion in Clinical TINOMO Lung Adenocarcinoma**  
*GaYoung Yoo, Republic of Korea*
- EP07.04-10 **Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center**  
*Joseph Fuchs, USA*
- EP07.04-11 **Clinicopathological Features and Postoperative Prognosis of Bubble-like Appearance Type Lung Adenocarcinoma**  
*Kotaro Murakami, Japan*
- EP07.04-12 **Comparison of Pathologic Outcomes Following Neoadjuvant Regimens in Resectable Locally Advanced Non-Small Cell Lung Cancer**  
*Nicholas Wells, USA*
- EP07.04-13 **Long-term Prognostic Impact of EGFR Mutations on Resected Early-stage Lung Cancer**  
*Takahiro Suzuki, Japan*
- EP07.04-14 **Pathologic Risk Factors for Recurrence in Early Stage Invasive Lung Adenocarcinoma with Tumor Spread through Air Spaces**  
*Eunjue Yi, Republic of Korea*
- EP07.04-15 **Diagnosis, Treatment Patterns and Outcomes in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in China**  
*Shun Lu, China*
- EP07.04-16 **Occult Lymph Node Metastasis Is Not a Favorable Factor for Resected NSCLC Patients**  
*Jing-Sheng Cai, China*
- EP07.04-17 **Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma**  
*Dawei Yang, China*
- EP07.04-18 **Factors Associated with Postoperative Recurrence in Early NSCLC with EGFR Mutation: Analysis of Korean National Population Data**  
*Jeong Uk Lim, Republic of Korea*
- EP07.04-19 **Clinical and Molecular Profile and Risk Factors of Stage IA NSCLC Relapsing After Radical Resection**  
*Pietro Bertoglio, Italy*
- EP07.04-20 **Identification of Tumor Microenvironment and Prognosis Risk Prediction Through Proteomics Analysis in Stage I Lung Adenocarcinoma**  
*Hsuan-Yu Chen, Taiwan*
- EP07.04-21 **Lymphatic Vascular Invasion: Diagnostic Variability and Overall Survival Impact on Patients Undergoing Surgical Resection of NSCLC**  
*Kemnasom Nwanwene, USA*
- EP07.04-22 **Current Biomarker Testing Practices for Early Stage Non-small Cell Lung Cancer (NSCLC) In Community and Academic Centers in the US**  
*Matthew Smeltzer, USA*



## POSTER SESSIONS - ELECTRONIC POSTERS

- EP07.04-23 **Telomerase-Based Circulating Tumor Cell Detection for the Treatment Response Prediction in Patients with Non-small-Cell Lung Cancer**  
*Kazuaki Hoshi, Japan*
- EP07.04-24 **Histopathologic Fate of Resected Pulmonary Pure Ground Glass Nodule: A Systematic Review and Meta-Analysis**  
*Jimin Lee, Republic of Korea*
- EP07.04-25 **Construction of Genome Atlas for Lung Nodule and Molecular Insight into Lung Adenocarcinoma Development in Chinese Population**  
*Wenhua Liang, China*
- EP07.04-26 **Real-World Biomarker Testing and Treatment Patterns Identified Using Machine Learning in Early Non-small Cell Lung Cancer**  
*Jay Lee, USA*
- EP07.04-27 **Prevalence of Driver Gene Mutation Testing in Resected Early-Stage Lung Adenocarcinomas (LUAD): Implications for Perioperative Therapy**  
*Wei Wang, China*
- EP07.04-28 **Low O-GlcNAcase Expression Is Associated with Poor Prognosis in Surgically Resected Early-Stage Lung Adenocarcinoma**  
*Wei Wang, China*
- EP07.04-29 **Hyperspectral Multiplex Immunohistochemistry and Recurrence in Resected Early Stage Non-small Cell Lung Cancer**  
*Anna McGuire, Canada*
- EP07.04-30 **Analysis of Radiologic-Pathologic Correlation for Subsolid Lung Adenocarcinoma Using the Whole-Mount Section Technique: A Prospective Study**  
*Chaoqiang Deng, China*

**EP07.05 Track: Early-Stage Non-small Cell Lung Cancer - Pushing the Boundaries**

- EP07.05-01 **Postoperative Recurrence Pattern and the Role of Adjuvant Therapy in Radiological Solid-Predominant Part-Solid Lung Adenocarcinoma**  
*Yang Wo, China*
- EP07.05-02 **NEOEAST: A Phase II Study of Ensartinib as Neoadjuvant Therapy for Stage II-IIIb ALK-rearranged Non-small Cell Lung Cancer**  
*Fang-Liang Lu, China*
- EP07.05-03 **Neoadjuvant Chemotherapy or Chemo-IO in Resectable KRAS-Mutated Non-small Cell Lung Cancer (NSCLC) Patients: Single Center Experience**  
*Kaiwen Wang, USA*
- EP07.05-04 **CDDP/TS1 Followed by Maintenance TS1 as Adjuvant Chemotherapy in Completely Resected Stage II-IIIa Non-Small Cell Lung Cancer**  
*Kosuke Fujino, Japan*
- EP07.05-05 **Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions**  
*Haitao Ma, China*
- EP07.05-06 **Minimal Residual Lesion Might Predict Adequate Cycles for Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer**  
*Dong Lin, China*

## POSTER SESSIONS - ELECTRONIC POSTERS

- EP07.05-07 **Real-World Outcomes of Adjuvant Cisplatin/Vinorelbine vs Cisplatin/Pemetrexed in Resected Non-Squamous NSCLC**  
*Samantha Low, UK*
- EP07.05-08 **Application of Neoadjuvant Chemoimmunotherapy in A Specific Group of Stage IB NSCLC**  
*Bengang Hui, China*
- EP07.05-09 **Oncologic Outcomes of Stereotactic Body Radiotherapy in Early-Stage Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease**  
*Young Seob Shin, Republic of Korea*
- EP07.05-10 **Efficacy and Safety of Aumolertinib in Stage IB-IIIa NSCLC after R0 Resection and the Correlation between Efficacy and Postoperative MRD Status**  
*Sheng Li Yang, China*
- EP07.05-11 **Efficacy and Safety of Osimertinib Therapy in High-Risk Stage I EGFRm NSCLC After R0 Resection(OSTAR): A Prospective, Single-Arm Study**  
*Dongsheng Yue, China*
- EP07.05-12 **The Impact of COVID-19 on Both the Diagnosis and Surgical Outcomes of Lung Cancer in Korea**  
*Sumin Shin, Republic of Korea*
- EP07.05-13 **The Efficacy of Neoadjuvant Chemoimmunotherapy versus Neoadjuvant Chemotherapy in Resectable NSCLC, a Comparison Research from Real World**  
*Xinying Xue, China*
- EP07.05-14 **HRQoL with Adjuvant Aumolertinib in Patients with Resected Stage IB-IIIa EGFR Mutant Non-small Cell Lung Cancer**  
*Weidong Hu, China*
- EP07.05-15 **Prognostic Factors in Non-Small-Cell Lung Cancer Treated with Chemoimmunotherapy or Chemotherapy: A Real-World Data Study**  
*Ayah Bani Mostafa, Jordan*
- EP07.05-16 **MPR and pCR Rates after Neoadjuvant Chemo-immunotherapy for Stage III Non-small Cell Lung Cancer**  
*Yana Akhmediyarova, Russian Federation*
- EP07.05-17 **Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial**  
*Yi-Yang Wang, China*
- EP07.05-18 **Spontaneous Ventilation Video-assisted Thoracoscopic Surgery for Super-elderly NSCLC Patients: a Noninferiority Study.**  
*Yulin Zhao, China*

**EP08.01 Track: Local-Regional Non-small Cell Lung Cancer - Biomarkers**

- EP08.01-01 **Subtyping EGFR-mutated NSCLC Patients with Adjuvant TKIs or Chemotherapy Using Deep Radiomic Signatures**  
*Yi-Fan Qi, China*
- EP08.01-02 **Single-Cell RNA Sequencing Reveals Unique Immune Landscape in Rare-Mutant Non-small Cell Lung Cancer Undergoing Chemo-Immunotherapy**  
*Rui Fu, China*
- EP08.01-03 **Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy**  
*Ashley Horne, UK*

EP08.02	Track: Local-Regional Non-small Cell Lung Cancer - Multimodality Therapy
EP08.02-01	Parameters of FDG PET/CT Predicting Pathological Response to Neoadjuvant Immunotherapy in Stage II/III Non-small Cell Lung Cancer Patients <i>Eun Seong Lee, Republic of Korea</i>
EP08.02-02	Real World Chemoradiotherapy Outcomes for Frail Older Adults with Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) <i>Nicole Pringle, Australia</i>
EP08.02-03	Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) <i>Nicole Pringle, Australia</i>
EP08.02-04	Real-World Disease-Free Survival (DFS) in Non-metastatic Non-small Cell Lung Cancer (NSCLC): A German I-O Optimise Analysis <i>Melinda J Daumont, Belgium</i>
EP08.02-05	Neoadjuvant Immunochemotherapy Combined with Probiotic Supplements in Stage IIB-III B NSCLC: A Real-World Prospective Study <i>Min Li, China</i>
EP08.02-06	Neoadjuvant Therapy, Still a Contraindication to VATS Lobectomy or is it a New Indication? <i>Cengiz Gebitekin, Turkey</i>
EP08.02-07	FDG PET Scan Based Response Assessment in Non-small Cell Lung Cancer Treated with Chemoradiotherapy and Neoadjuvant Chemotherapy <i>Aftab Ahmad, India</i>
EP08.02-08	Lymphovascular Invasion Prediction with CT images in Patients with Non-small Cell Lung Cancer (NSCLC) <i>Misuk Lee, Republic of Korea</i>
EP08.02-09	Comprehensive Assessment of Pulmonary Function in Patients Receiving Radical (Chemo)Radiotherapy for Carcinoma Lung <i>Sam David, India</i>
EP08.02-10	Clinicopathological Analyses for Predicting Survival After Salvage Surgery for Initially Unresectable Lung Cancer <i>Naoyuki Oka, Japan</i>
EP08.02-11	Dosimetric Contribution of LAD Sparing Radiotherapy Plan in Patients with Postoperative Lung Cancer <i>Serap Akyürek, Turkey</i>
EP08.02-12	Dosimetric Contribution of LAD Artery Sparing RT Plan in Lung Cancer Patients who Received Definitive RT <i>Serap Akyürek, Turkey</i>
EP08.02-13	Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer <i>Yuki Akazawa, Japan</i>
EP08.02-14	Prognostic Role of Baseline PET/CT Parameters in Frail Patients with Inoperable Node-Positive Stage IIB-IIIC/Recurrent NSCLC <i>Chukwuka Eze, Germany</i>
EP08.02-15	Moderately Hypofractionated PET/CT-Based Thoracic Radiotherapy in Elderly and Multimorbid Patients with Stage II/III NSCLC <i>Chukwuka Eze, Germany</i>

EP08.02-16	Higher Radiation Dose to Immune Cells is a Negative Prognostic Factor in Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) <i>Nikhil Yegya-Raman, USA</i>
EP08.02-17	Comparison of Long-term Survival of Patients With Locally Advanced Lung Cancer After Video-Assisted Thoracoscopic Surgery Versus Thoracotomy <i>Xing Wei, China</i>
EP08.02-18	The Value of Combined Immunotherapy in Neoadjuvant Regimen for Patients with Resectable Non-small Cell Lung Cancer <i>Yu Tian, China</i>
EP08.02-19	Correlation of Quantified Metabolic Activity with Gross Tumor Volume in Patients with Non-small Cell Lung Cancer <i>Danijela Scepánovic, Slovakia</i>
EP08.02-20	A Prospective Study of Gallium-68 Ventilation and Perfusion PET/CT Before, During, and After Radiotherapy in Patients with NSCLC <i>Neil Wallace, Australia</i>
EP08.02-21	Robot-Assisted Thoracic Surgery for Locally Advanced Non-small Cell Lung Cancer in a Japanese Single Institution <i>Ryuichi Waseda, Japan</i>
EP08.02-22	Survival Outcome Comparison of Stage III and IV NSCLC Patients in Latvia and Israel: An Analysis of Treatment Approaches <i>Laila Roisman, Israel</i>
EP08.02-23	Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC? <i>Michael MacManus, Australia</i>
EP08.02-24	Neoadjuvant Immune Checkpoint Inhibitor plus Chemotherapy for Resectable Non-small Cell Lung Cancer in Real World <i>Cheng Chen, China</i>
EP08.02-25	A Case of Persistent Complete Response To Personalized Osimertinib and Concurrent Chemoradiation for Stage IIIC EGFRm NSCLC <i>Victor Ho Fun Lee, Hong Kong</i>
EP08.02-26	Clinical Outcome of Neoadjuvant of Tislelizumab Plus Chemotherapy for Chinese Locally Advanced NSCLC Patients <i>Yongsheng Wang, China</i>
EP08.02-27	Trimodality Treatment of Superior Sulcus non-Small Cell Lung Cancer. An Institutional Series of 47 Consecutive Patients <i>Robert Dziedzic, Poland</i>
EP08.02-28	Do We Have to Offer Postoperative Radiotherapy in Resected Pathologic N2 Non-small Cell Lung Cancer with Extranodal Extension? <i>Changhoon Song, Republic of Korea</i>
EP08.02-29	Is Moderate-intensity Stereotactic Body Radiation Therapy for Ultra-central Lung Tumor a Feasible Option? <i>Chai Hong Rim, Republic of Korea</i>
EP08.02-30	Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120) <i>Mauro Zukin, Brazil</i>
EP08.02-31	Long-Term Efficacy and Safety of Tislelizumab Plus Chemotherapy as Neoadjuvant/Adjuvant Therapy for IIB-III NSCLC: A Retrospective Study <i>Yang Cheng, China</i>

## POSTER SESSIONS - ELECTRONIC POSTERS

- EP08.02-32** Optimal Planning Target Volume Margins for Spirometer-Based DIBH Radiotherapy for Lung Cancer  
*Noriko Kishi, Japan*
- EP08.02-33** Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Unresectable Locally Advanced Non-small Cell Lung Cancer  
*Leilei Wu, China*
- EP08.02-34** Evaluation of Treatment Strategies for Patients with Stage IIIA Non-small Cell Lung Cancer in the Immunotherapy Era  
*Amy Alabaster, USA*
- EP08.02-35** Prognostic Impacts of Lymphovascular Invasion of Resected Lung Adenocarcinoma after Induction Chemoradiotherapy  
*Takafumi Kabuto, Japan*
- EP08.02-36** Long Term Patient Reported Outcomes in Non Small Cell Lung Cancer Patients Who Underwent Pneumonectomy  
*Gizem Özçibik Isik, Turkey*
- EP08.02-37** Definitive Hypofractionated Radiation Therapy with or without Immunotherapy for Stage IIb-III NSCLC: An Institutional Experience  
*Benjamin Hopkins, USA*
- EP08.02-38** No Benefit for Extending Neoadjuvant Targeted Therapy Exposure Time in Resectable EGFR Mutation Non-small Cell Lung Cancer  
*Nan Wu, China*
- EP08.02-39** Dosimetric Comparison of Free-Breathing versus Respiratory Motion-managed Radiotherapy with 4D-CT Based VMAT in Lung Cancer  
*Sureyya Sarihan, Turkey*
- EP08.02-40** Management of Inoperable Locally Advanced Stage III ALK fusion Positive NSCLC: A Retrospective Multi-institutional Analysis  
*Shun Lu, China*

**EP08.03** Track: Local-Regional Non-small Cell Lung Cancer - Novel Therapies and Trials

- EP08.03-01** Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials  
*Roberto Serna Blasco, Spain*
- EP08.03-02** Nivolumab Plus Ipilimumab in Relapsed Stage III Non-small Cell Lung Cancer After Durvalumab Following Chemoradiotherapy  
*Takaaki Tokito, Japan*
- EP08.03-03** S-1 and CDDP with Concurrent TRT followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI  
*Shigeru Tanzawa, Japan*
- EP08.03-04** MicroDurva: A Prospective Study to Investigate the Role of Microbiome in Predicting the AEs from Durvalumab in Post-CCRT NSCLC Patients  
*Jun Zhang, USA*
- EP08.03-05** Role of DCE MRI in Predicting Treatment Response to Induction Immunochemotherapy in Locally Advanced NSCLC Patients  
*DaQuan Wang, China*

## POSTER SESSIONS - ELECTRONIC POSTERS

**EP08.04** Track: Local-Regional Non-small Cell Lung Cancer - Toxicities of Multimodality Therapy

- EP08.04-01** Predictors and Outcomes of Pneumonitis in Non-small Cell Lung Cancer Patients Treated with Consolidative Durvalumab  
*Chloe Lim, Canada*
- EP08.04-02** Evaluating Safety Profiles of Radiation-Related Toxicities in Thoracic Re-Irradiation  
*Rohan Patel, USA*
- EP08.04-03** Acute Postoperative Pain is the Most Severe at the Site of Chest Tube Insertion in Multiportal Video-assisted Thoracoscopic Surgery  
*Yoshifumi Sano, Japan*
- EP08.04-04** Development of a Risk Score to Predict Postoperative Complications in Patients with Non-small Cell Lung Cancer  
*Makhmudbek Mallaev, Switzerland*

**EP09.01** Track: Metastatic Non-small Cell Lung Cancer - Local Therapies - Effects of Local Therapies in Metastatic NSCLC

- EP09.01-01** Feasibility and Survival Outcomes of "Salvage Surgery" for Initially Clinical Stage IV Non-small Cell Lung Cancer  
*Tomoyuki Hishida, Japan*
- EP09.01-02** Clinical Outcome of Palliative Thoracic Radiotherapy in Advanced Lung Cancer in the Modern Era - A Single Institution Experience  
*Tsz Yeung Kam, China*
- EP09.01-03** Hypofractionated Radiotherapy for Elderly Lung Cancer Patients  
*Jeong Won Lee, Republic of Korea*
- EP09.01-04** Surgical Treatment in Non-small Cell Lung Cancer with Pulmonary Oligometastasis; 26 Years of Experience in a Single Center  
*Cengiz Gebitekin, Turkey*
- EP09.01-05** Is Palliative Thoracic Radiation Beneficial in Stage IV Non-small Cell Lung Cancer (NSCLC) in the Era of Modern Systemic Therapy?  
*Tithi Biswas, USA*
- EP09.01-06** Outcomes of Surgical Treatment for Stage IV Non-Small Cell Lung Cancer (NSCLC) in a Population-Based Cohort  
*Raymond Osarogiagbon, USA*
- EP09.01-07** Reverse Endobronchial Y-stent Implantation in Selected Cases of the Malignant Central Airway Obstruction  
*Jaroslław Pieróg, Poland*

**EP09.02** Track: Metastatic Non-small Cell Lung Cancer - Local Therapies - Integration of Local Therapies With Systemic Therapies

- EP09.02-01** Combination Of EGFR-TKIs And Radiotherapy In Stage IV LUAD  
*Shuai Liang, China*
- EP09.02-02** Stereotactic Body Radiotherapy Synergizes Immunotherapy in Advanced or Recurrent NSCLC: A Single-center Experience  
*Dan Yao, China*

## POSTER SESSIONS - ELECTRONIC POSTERS

- EP09.02-03 A Phase II Study on Aggressive Local Consolidative Therapy in Combination with Chemotherapy for Oligometastatic NSCLC: TORG1529  
*Takaaki Tokito, Japan*
- EP09.02-04 Operative and Mid-Term Oncologic Outcomes of the Surgery as a Form of Local Consolidation for Oncogenic-Driven Advanced NSCLC  
*Byung Jo Park, Republic of Korea*
- EP09.02-05 Fibrates Enhances Radiotherapy Efficacy by Elevating HDL Levels to Induce Tumor Cell Ferroptosis in NSCLC with Brain Metastasis  
*Xiaorong Dong, China*
- EP09.02-06 Long-term Efficacy of Tumor Treating Fields (TTFields 150 kHz) in Metastatic NSCLC: A Case Report  
*Izabela Chmielewska, Poland*

**EP09.03 Track: Metastatic Non-small Cell Lung Cancer – Local Therapies- Oligometastatic NSCLC**

- EP09.03-01 Outcomes of Extracranial SBRT for Induced Oligopersistent and Oligoprogressive NSCLC Combined with Novel Systemic Therapies  
*Philip Blumenfeld, Israel*
- EP09.03-02 Local Ablation Induces Abscopal Effects and Improves the Efficacy of Continuous ICIs in Advanced NSCLC Patients with Oligo-progression  
*Leilei Wu, China*

**EP09.04 Track: Metastatic Non-small Cell Lung Cancer – Local Therapies - Predictive and Prognostic Biomarkers**

- EP09.04-01 Prognostic Factors for Patients With KRAS Mutated Non-small Cell Lung Cancer and Brain Metastases  
*Simon Ekman, Sweden*
- EP09.04-02 Preoperative Circulating Tumor DNA Status Predicts Pathological Response in Advanced Non-small Cell Lung Cancer  
*Rui Fu, China*
- EP09.04-03 Survival of Non-small Cell Lung Cancer with and without Brain Metastasis - Shifting to a Merging Survival Curves Era  
*Itamar Averbuch, Israel*

**EP09.05 Track: Metastatic Non-small Cell Lung Cancer – Local Therapies - Toxicity of Local Therapies**

- EP09.05-01 Ionizing Radiation Induces Vascular Smooth Muscle Cell Senescence through Activating NF- $\kappa$ B/CTCF/p16 Pathway  
*Fan Tong, China*
- EP09.05-02 Changes in Pulmonary Function Following Single and Multi-Fraction Stereotactic Body Radiotherapy for Pulmonary Oligometastatic Disease  
*Nicholas Bucknell, Australia*

**EP10.01 Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy**

## POSTER SESSIONS - ELECTRONIC POSTERS

- EP10.01-01 DDR1 Mediated Glycolysis Regulates the Synergistic Effect of Anlotinib and Docetaxel in Lung Cancer  
*Xueqin Chen, China*
- EP10.01-02 Chemotherapy Outcomes in EGFR-TKI Resistant Patients: A Comparison of Common and Uncommon EGFR Mutation Subtypes  
*Jeng Shiuan Tsai, Taiwan*
- EP10.01-03 A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC  
*Alexander Drilon, USA*
- EP10.01-04 First-Line Treatment for Driver-Gene Negative Metastatic Lung Adenocarcinoma with MPE: A Multicenter Retrospectively Study  
*Yuanyuan Zhao, China*
- EP10.01-05 Retrospective Analysis of Real-World Treatment Patterns and Survival Outcomes for Non-small Cell Lung Cancer Patients in Thailand  
*Sajjai Supaattagorn, Thailand*
- EP10.01-06 Predictors of Survival for Docetaxel as a Subsequent Line after Progression to Platinum-Based Chemotherapy and Immunotherapy  
*Virginia Calvo de Juan, Spain*
- EP10.01-07 Clinical Features and Outcome Evaluation of Patients with Non-small-Cell Lung Cancer: A Single Center Study  
*Andree Kurniawan, Indonesia*
- EP10.01-08 Relationship Between Age and Chemotherapy Regimen for Elderly Patients with Advanced Lung Cancer  
*Ritsuya Shiiba, Japan*
- EP10.01-09 Added Serum Albumin to Lung-mol GPA Score Improves Prediction of Overall Survival in Non-small Cell Lung Cancer Patients with Brain Metastasis  
*Chudanun Pinthaya, Thailand*
- EP10.01-10 Retrospective Study on Outcomes and Treatment Options for Patients with NSCLC Progression After Treatment with Durvalumab  
*Bushra Shariff, USA*
- EP10.01-11 Efficacy of Intraventricular Chemotherapy with Pemetrexed for Leptomeningeal Metastasis from Lung Adenocarcinoma: A Retrospective Study  
*ShenCun Fang, China*
- EP10.01-12 Patterns of Systemic Anti-Cancer Therapy & Overall Survival of Stage IV NSCLC at Tertiary General Hospital  
*Wulyo Rajabto, Indonesia*
- EP10.01-13 Evaluating Osimertinib Induced Pneumonitis in EGFR Advanced Lung Cancer in a Real World Clinical Practice  
*Shawn Ali, USA*
- EP10.01-14 Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis  
*Marko Jakopovic, Croatia*
- EP10.01-15 Sarcopenia as a Predictive Factor of Carboplatin Toxicity in Patients with Advanced Non-small Cell Lung Cancer  
*Jenny Turcott, Mexico*

- EP10.01-16 Relationship Between Impaired Fasting Glucose and Prognosis of the Disease in Patients with Advanced Stage Non-small Cell Lung Cancer  
*Berna Komurcuoglu, Turkey*
- EP10.01-17 Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China  
*Yan Wang, China*

**EP11.01 Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy - Biomarker**

- EP11.01-01 Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study  
*Alessandro Leonetti, Italy*
- EP11.01-02 A Multicenter Study of the Association between TTF-1 and Immunochemotherapy in Lung Adenocarcinoma  
*Nanami Yamasaki, Japan*
- EP11.01-03 Neutrophil to Lymphocyte Ratio in Patients Treated with Immunotherapy After Progression on Chemotherapy  
*Marko Jakopovic, Croatia*
- EP11.01-04 Does Tumor Microvessel Density Predict Response to Immune Checkpoint Inhibitors in Metastatic Non-small Cell Lung Cancer?  
*Akif Turna, Turkey*
- EP11.01-05 ICTIS: A Novel Scoring System to Assess the Inclusivity of Metastatic Non-small Cell Lung Cancer Immunotherapy Trials  
*Nagashree Seetharamu, USA*
- EP11.01-06 SPD-CD40L Prevents Tumor Growth via Recruitment of Immune Cells to the Tumor Microenvironment  
*Gregory Holt, USA*
- EP11.01-07 Low NLR Predicted Overall Survival Benefit of Pembrolizumab and Chemotherapy Combination in Patients with NSCLC and Low PD-L1 Expression  
*Chian-Wei Chen, Taiwan*
- EP11.01-08 GSDME-dependent Pyroptosis Affects the Prognosis and Response to Immunotherapy in Lung Adenocarcinoma  
*Peijun Cao, China*
- EP11.01-09 Study on Biomarkers for Predictive the Clinical Efficacy of Non-small Cell Lung Cancer Immunotherapy  
*Tong Cui, China*
- EP11.01-10 Immune Checkpoint Inhibitors in the Treatment of Non-small Cell Lung Cancer: Does Histology Matter?  
*Khalil Choucair, USA*
- EP11.01-11 Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors  
*Yoshiro Nakahara, Japan*
- EP11.01-12 Prediction of NSCLC Immunotherapy Outcomes Across Multiple Clinical Indicators  
*Shanshan Xiao, China*
- EP11.01-13 The Value of PD-L1 in Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Receiving Immunotherapy  
*Yasi Xu, China*

**EP11.02 Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy - Prospective**

- EP11.02-01 Nivolumab as Maintenance Therapy Following Platinum-Based Chemotherapy in EGFR-mutant Lung Cancer Patients After TKI Failure  
*Jiwon Kim, Republic of Korea*
- EP11.02-02 Phase I Study of Epacadostat in Combination with Sirolimus in Solid Tumors and PK Data  
*Chao Huang, USA*
- EP11.02-03 First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis  
*Tianqing Chu, China*
- EP11.02-04 Efficacy and Safety of Camrelizumab plus Famitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer  
*Ming Gao, China*
- EP11.02-06 Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS  
*Baohui Han, China*
- EP11.02-07 Dostarlimab + CT vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC: Asian Subgroup Analyses of the PERLA Trial  
*Dae Ho Lee, Republic Of Korea*
- EP11.02-08 Predictive Toxicity and Response to Immunotherapy in Patients with Metastatic Non-small Cell Lung Cancer (IMMUNOPREDICT)  
*Jessica Nguyen, France*
- EP11.02-09 Rh-endostatin Combined With PD-1 Inhibitors as First-line Treatment for EGFR/ALK-Negative, Non-squamous NSCLC  
*Dong Wang, China*
- EP11.02-10 Efficacy and Safety of Combining Envafolelimab with Endostar in Advanced NSCLC: A Multi-Center Prospective Study (Endouble)  
*Xiaodong Jiang, China*

**EP11.03 Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy - Retrospective**

- EP11.03-01 Real World Outcomes of Immunotherapy for Treatment of Advanced Stage NSCLC in Jordan  
*Taher Abu Hejleh, Jordan*
- EP11.03-02 Characterizing Neurologic Immune-related Adverse Events Using Consensus Disease Definitions  
*Aliyah Pabani, Canada*
- EP11.03-03 Patient-Reported Fatigue in Lung Cancer Patients Undergoing Immunotherapy: A Real-life Study  
*Mariana Picado, Portugal*
- EP11.03-04 Multi-Institutional Retrospective Study for the Efficacy of ICIs plus Platinum-Based Chemotherapy for EGFR Mutated NSCLC  
*Shunichi Kataoka, Japan*
- EP11.03-05 Molecular Characterization and Prognosis of Patients with KRAS Mutant Non-small Cell Lung Cancer  
*Laura Gutiérrez Sainz, Spain*

- EP11.03-06 Prognosis of Immunotherapy plus Whole Brain Radiotherapy for Non-small Cell Lung Cancer Patients with Brain Metastases  
*Shilan Luo, China*
- EP11.03-07 Long-term Outcomes and Toxicity in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy Containing Regimens  
*Meghana Maddula, Australia*
- EP11.03-08 Multicenter Pharmacokinetic Study of Pembrolizumab for Non-small Cell Lung Cancer in Older Adults Aged Over 75 Years  
*Hidehito Horinouchi, Japan*
- EP11.03-09 Profile of Patients with NSCLC Who Benefit from Immunochemotherapy. Real-World Data from the Multicenter Polish Lung Cancer Group Study  
*Magdalena Knetki-Wróblewska, Poland*
- EP11.03-10 Similar Efficacy Observed for Frontline Immunotherapy in Ethnic-Minority Patients with Metastatic NSCLC  
*Matthew Lee, USA*
- EP11.03-11 Site-Specific Response Patterns in Patients with Advanced NSCLC Treated with First-Line Systemic Therapy  
*Lauren Brown, Australia*
- EP11.03-12 Combing Immune Checkpoint Inhibitors with Radiotherapy in Advanced Non-small Cell Lung Cancer  
*Yongmei Liu, China*
- EP11.03-13 Real-World Efficacy of Atezolizumab in Patients with Previously Treated Advanced NSCLC in Spain - TRACKER Study  
*Enric Carcereny, Spain*
- EP11.03-14 The Economic Burden of Lung Cancer (NSCLC) In the County of Gävleborg - Sweden  
*Hirsh Koyi, Sweden*
- EP11.03-15 Sarcopenia is a Poor Predictive Prognostic Factor for Non-small Cell Lung Cancer Patients who were Treated with Immune Check Point Inhibitors  
*Sung Yong Lee, Republic of Korea*
- EP11.03-16 Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody  
*Zentaro Saito, Japan*
- EP11.03-17 Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials  
*Ben Ponvilawan, USA*
- EP11.03-18 Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: Less Is More?  
*Mariola Blanco Clemente, Spain*
- EP11.03-19 Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations  
*Tianqing Chu, China*
- EP11.03-20 Real World Experience of First Line Pembrolizumab for Non-small Cell Lung Cancer (NSCLC) at a Tertiary Centre  
*William Mullally, Australia*
- EP11.03-21 Incidence of Cardiotoxicity in Patients Treated for Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors  
*Luis Raez, USA*

- EP11.03-22 Proton Pump Inhibitors' Impact on the Effectiveness of Immune Checkpoint Inhibitors in Metastatic Non-small Cell Lung Cancer  
*Luis Raez, USA*
- EP11.03-23 Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: A Network Meta-analysis  
*Adam Lee, UK*
- EP11.03-24 The Efficacy of Immunotherapy and Chemoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC)  
*Tony Cheung, USA*
- EP11.03-25 A Novel Approach for Personalized Strategy of Cancer Immunotherapy with Pattern Identification: From the Results of the HARMONY Study  
*Mi-kyung Jeong, Republic of Korea*
- EP11.03-26 Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression  
*Kaushal Parikh, USA*
- EP11.03-27 Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced Lung Cancer with KRAS Mutation in China  
*Fengnan Wang, China*
- EP11.03-28 Real World Outcomes after Chemotherapy and Immunotherapy in Patients with Metastatic Non-small Cell Lung Cancer in Europe  
*Ticiana Leal, USA*
- EP11.03-29 Immunotherapy and Overall Survival in Advanced NSCLC: A Systematic Review of Randomised Trials  
*Shalini Subramaniam, Australia*
- EP11.03-30 What Are Favorable Clinicopathological Factors and Types of Therapy for Postoperatively Recurrent NSCLC Patients?  
*Yuki Matsumura, Japan*
- EP11.03-31 Quantification of Interstitial Lung Abnormality Using Deep Learning in Cancer Patients who Underwent Immune Checkpoint Inhibitors  
*Eun Young Kim, Republic of Korea*
- EP11.03-32 Dose the Histological Subtype of NSCC-NOS Affect the Efficacy of 1st-Line PD-1/PD-L1 Inhibitors with or without Chemotherapy?  
*Tatsuya Hirano, Japan*
- EP11.03-33 Prognostic Value of Body Mass Index and Serum Lipid for First-line Immunotherapy in Patients with Advanced NSCLC: A Retrospective Study  
*Yanxin Sun, China*
- EP11.03-34 Clinical Impact of Immune Checkpoint Inhibitors Following Platinum Chemotherapy in Advanced or Metastatic Non-small Cell Lung Cancer Patients  
*Sang Chul Lee, Republic of Korea*
- EP11.03-35 Impact of KRAS Mutation Subtype and Comutations across PD-L1 Levels in aNSCLC Patients Treated with (Chemo)Immunotherapy  
*Jessica Bauman, USA*
- EP11.03-36 Clinical Outcomes of Immunotherapy with or without Radiation in Advanced Lung Cancer: a Real-World, Retrospective Study  
*Jiafeng Liang, China*

## POSTER SESSIONS - ELECTRONIC POSTERS

- EP11.03-37 Efficacy and Safety of Chemotherapy Plus Immunotherapy and Recombinant Human Endostatin in Advanced Non-small Cell Lung Cancer  
*Shan Su, China*
- EP11.03-38 Comparison of Real-World Outcomes in aNSCLC Patients Receiving 1L Immunotherapy Alone or in Combination with Chemotherapy  
*Sun Min Lim, Republic of Korea*
- EP11.03-39 Platinum/Taxane Versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers that Progressed on Platinum Doublets and Anti-PD1/PD-L1  
*Kang Qin, USA*
- EP11.03-40 An Observational Study to Identify Selection Criteria for Initiation of Different First Line Treatment Options in NSCLC Patients  
*Adam Sierakowiak, Sweden*
- EP11.03-41 Successful Treatment with Pembrolizumab Alone for SMARCA4-deficient Lung Sarcomatoid with a High-TMB and PD-L1(+) A Case Report  
*Youjun Deng, China*
- EP11.03-42 Superior Effectiveness of PD-1 Inhibitor Plus Chemotherapy vs Bevacizumab Plus Chemotherapy for NSCLC with Brain Metastases  
*Li Kun Chen, China*

**EP11.04 Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy - TIPS**

- EP11.04-01 Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-small Cell Lung Cancer  
*Yongsheng Wang, China*

**EP12.01 Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy - EGFR/HER2**

- EP12.01-01 The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm who were Intolerant to Osimertinib: A Retrospective Clinical Study  
*Longhua Sun, China*
- EP12.01-02 NGS Reveals Convergent Acquired Resistance and Newly Emerging Driver Involving MET Alterations in NSCLC: A Case Report  
*Chek Kun Tan, Singapore*
- EP12.01-03 Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study  
*Tomoki Tamura, Japan*
- EP12.01-04 Clinical Features and Progression Free Survival of Lung Adenocarcinoma Patients with EGFR Sensitizing Mutations with Dose Reduction of Afatinib  
*Widya Angasreni, Indonesia*
- EP12.01-05 Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR+) Metastatic Non-small Cell Lung Cancer (NSCLC) Real-World Patients  
*Blanca Távora, Spain*
- EP12.01-06 Metastatic NSCLC with G719X/S781I EGFR-mutations with Acquired BRAF V600E Mutation - Response to Osimertinib, Dabrafenib and Trametinib  
*Edyta Urbanska, Denmark*

## POSTER SESSIONS - ELECTRONIC POSTERS

- EP12.01-07 Brigatinib Restores Disease Control at Second Progression on Osimertinib in Metastatic EGFR ex19del Mutated NSCLC with Acquired EML4-ALK Fusion  
*Edyta Urbanska, Denmark*
- EP12.01-08 Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/G724S Mutation  
*Xin Lyu, China*
- EP12.01-09 Predictive and Prognostic Value of Early Skeletal Muscle Loss During First-Line EGFR-TKIs for Advanced Lung Adenocarcinoma  
*Xin Nie, China*
- EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer  
*Fiona Desland, USA*
- EP12.01-11 Efficacy of Amivantamab in a Patient with EGFR ex20ins Lung Adenocarcinoma with Symptomatic Pleural Effusion after Platinum Doublet Failure  
*Javier Baena, Spain*
- EP12.01-12 Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study  
*Ruei-Lin Sun, Taiwan*
- EP12.01-13 Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC  
*Nabil Dorkhom, Netherlands*
- EP12.01-14 First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases  
*Li Zang, China*
- EP12.01-15 Aumolertinib Combination SBRT Treated EGFR Co-mutation Patients with Symptomatic Brain Metastases: A Case Report  
*Xiaojuan Zhang, China*
- EP12.01-16 The Safety and Efficacy of Aumolertinib in Advanced EGFR-Mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment  
*Qinhong Zheng, China*
- EP12.01-17 Association of CYP450 and Drug Efflux Transporters Polymorphism Influence Outcomes of Thai Non-small Cell Lung Cancer Treated with Osimertinib  
*Teerapat Majam, Thailand*
- EP12.01-18 Validation of the ALK-Brain Prognostic Index (ALK-BPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases  
*Georgios Tsakonas, Sweden*
- EP12.01-19 Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib  
*Enguo Chen, China*
- EP12.01-20 Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins)  
*Andrés Aguilar, Spain*
- EP12.01-21 A Case of Brain Metastases from Lung Cancer with Epilepsy and ECOG Score of 4 Successfully Treated with Aumolertinib  
*Jing Quan Zhao, China*

- EP12.01-22 **Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC**  
*Amanda Gibson, Canada*
- EP12.01-23 **Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report**  
*Kijjakom Thanasombunsukh, Thailand*
- EP12.01-24 **High-Dose Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC with Meningeal Symptoms as the First Symptom**  
*Wei Wang, China*
- EP12.01-25 **Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results**  
*Shencun Fang, China*
- EP12.01-26 **Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations**  
*ShenCun Fang, China*
- EP12.01-27 **Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer**  
*Tae Won Jang, Republic of Korea*
- EP12.01-28 **A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases Including Brain Metastasis**  
*Xiu Shan, China*
- EP12.01-29 **Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib**  
*Jian Chun Duan, China*
- EP12.01-30 **Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and Leptomeningeal Metastasis**  
*Yun Fan, China*
- EP12.01-31 **Updated First-line Osimertinib in Asian Patients with Advanced EGFR-mutated Lung Cancer**  
*Wan Ling Tan, Singapore*
- EP12.01-32 **Intracranial Complete Remissions and Long-Term Response in a EGFR-positive NSCLC Patient with Brain Metastases: Case Report**  
*Hao Ran Su, China*
- EP12.01-33 **Liquid Biopsy Reduce Time to Treatment for Patients with EGFR Mutated Advanced Nonsquamous Non-small Cell Lung Cancer: A Mexican Unit Experience**  
*Saul Campos-Gomez, Mexico*
- EP12.01-34 **Autopsy and Next Generation Sequencing Report of First-Line Treatment with Osimertinib for EGFR-Mutated Squamous Cell Carcinoma of the Lung**  
*Tadashi Nishimura, Japan*
- EP12.01-35 **Skin Toxicity Associated with Targeted and Immune Therapies in Stage IV Lung Cancer Patients: A 14-year Cohort**  
*Ping Yang, USA*
- EP12.01-36 **Heart Failure Incidence and Mortality With EGFR TKIs in Patients with NSCLC: Targeted Literature Review**  
*Bilal Khokhar, USA*

- EP12.01-37 **Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations**  
*Tao Tao, China*
- EP12.01-38 **Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype**  
*Ying Liu, USA*
- EP12.01-39 **Therapeutic or Prophylactic Targeting C797S in EGFR Mutant Lung Adenocarcinoma**  
*Xu-Hui Guan, China*
- EP12.01-40 **The Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastases**  
*Qian Shao, China*
- EP12.01-41 **Osimertinib beyond Progression in Patients with EGFR Mutated Non-small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib.**  
*Amin Benyounes, USA*
- EP12.01-42 **Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort**  
*Heather Halperin, Canada*
- EP12.01-43 **Case Report of Short-Term Gefitinib Induced IgA Nephropathy and Tubulointerstitial Nephritis in a Patient with Non-small Cell Lung Cancer**  
*Jieun Yang, Republic of Korea*
- EP12.01-44 **A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib**  
*Yan Chen, China*
- EP12.01-45 **Real-World Outcomes of Health-Related Quality-of-Life(HRQoL) In Advanced Non-small Cell Lung Cancer Patients Treated with Aumolertinib**  
*Jisheng Li, China*
- EP12.01-46 **L858R Exon 21 Mutation Is Associated with a Higher Risk of Brain Metastases in Patients with NSCLC Treated with TKI**  
*Oscar Arrieta, Mexico*
- EP12.01-47 **Lazertinib in Pretreated Epidermal Growth Factor Receptor T790M-Mutated Advanced Non-small Cell Lung Cancer: A Real-World Multicenter Study**  
*Beung-chul Ahn, Republic of Korea*
- EP12.01-48 **A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases**  
*Xiaojuan Zhang, China*
- EP12.01-49 **Molecular Characteristics and Response to TKIs in NSCLC Patients with EGFR Exon 19 Insertions**  
*Yang Shao, China*
- EP12.01-50 **Real-World Characteristics and Outcomes of ERBB2-Mutant Non-small Cell Lung Cancer in Latin America Patients**  
*Helano Freitas, Brazil*
- EP12.01-51 **Clinical Significance of Chronic Interstitial Pneumonia Induced by EGFR-TKI Administration**  
*Yuki Sato, Japan*
- EP12.01-52 **A Multi-Center Observational Study of Effectiveness and Safety of First Line Afatinib in Major Uncommon EGFR mutated NSCLC**  
*Anh Le, Viet Nam*



- EP12.01-53 The Contribution of Compound EGFR Mutations and Other Co-mutations to Efficacy of EGFR TKI in Lung Adenocarcinoma  
*Se Hyun Kwak, Republic of Korea*
- EP12.01-54 Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam  
*Chau Pham, Viet Nam*
- EP12.01-55 Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)  
*Gen Lin, China*
- EP12.01-56 Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases  
*Yi-Bin Li, China*
- EP12.01-57 Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report  
*Cheng Chen, China*
- EP12.01-58 Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment  
*Qiang Wu, China*
- EP12.01-59 Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC)  
*Boris Pfeiffer, Germany*
- EP12.01-60 An Observational Study Analyzing Progression Free Survival of Patients With EGFR Mutant NSCLC Treated with Osimertinib in South Carolina  
*Michael Pavy, USA*
- EP12.01-61 Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer  
*Andres Cardona, Colombia*
- EP12.01-62 Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib  
*Kensuke Kanaoka, Japan*
- EP12.01-63 Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study  
*Biao Yao, China*
- EP12.01-64 Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review  
*Shirish Gadgeel, USA*
- EP12.01-65 Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC  
*Andres Cardona, Colombia*
- EP12.01-66 Long Survival in LM NSCLC Treated with Aumolertinib and Metronomic Intrathecal Pemetrexed under Dynamic Detection of CSF ctDNA  
*Zhao Dai, China*
- EP12.01-67 A Real World Cohort Study of First Line Afatinib in Patients with EGFR Mutant Advanced Non-small Cell Lung Cancer in Vietnam  
*Phuong Pham, Vietnam*

- EP12.01-68 Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases  
*Qingqing Zhu, China*
- EP12.01-69 Response Evaluation of Newly Diagnosed EGFR Mutated NSCLC in Tertiary Referral Cancer Center in Jakarta-Indonesia  
*Devi Amelia, Indonesia*
- EP12.01-70 Anlotinib Combined with Osimertinib Reverses Acquired Osimertinib Resistance in NSCLC by Targeting the c-MET/MYC/AXL Axis  
*Zhaoxia Wang, China*
- EP12.01-71 Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure  
*Shencun Fang, China*
- EP12.01-72 Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results  
*Shencun Fang, China*
- EP12.01-73 Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy  
*Feng Luo, China*
- EP12.01-74 Increased Progression Free Survival of Patients with EGFR Positive Mutation NSCLC Treated with Afatinib in Regard to Toxicity  
*Suryanti Pratiwi, Indonesia*
- EP12.01-75 Good Results of Osimertinib in a Patient with EGFR (L861Q) and MET Amplification NSCLC: A Case Report  
*Iván Romarico González-Espinoza, Mexico*
- EP12.01-76 Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/ Mobocertinib) in EGFRm+ NSCLC  
*Nir Peled, Israel*
- EP12.01-77 Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area  
*Jiagang Feng, China*

### EP12.02 Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy - FUSIONS

- EP12.02-01 Novel-Acquired KANK1-ALK Fusion in An Advanced Lung Adenocarcinoma Responds to Alectinib: A Case Report  
*Quanying Tang, China*
- EP12.02-02 Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ mNSCLC Receiving ALK TKIs  
*Hannah Le, USA*
- EP12.02-03 Judith Tam ALK Lung Cancer Research Initiative  
*Angel Qin, USA*
- EP12.02-04 The Response to First-line Therapies in Stage IV RET Fusion-Positive Non-small Cell Lung Cancer: a Multi-center Retrospective Study in China  
*Aiqin Gao, China*
- EP12.02-05 PD-L1 Expression Status Was Not Associated with Efficacy of Alectinib in Patients with ALK-positive Lung Cancer  
*Xinyu Liu, China*

## POSTER SESSIONS - ELECTRONIC POSTERS

- EP12.02-06 **Comparative Efficacy and Safety of Lorlatinib vs Alectinib and Brigatinib Using Matching Adjusted Indirect Comparisons (MAIC)**  
*Christine Garcia, USA*
- EP12.02-07 **The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real-world Experience in Taiwan**  
*Xuet Yit Chen, Taiwan*
- EP12.02-08 **Frequency and Outcomes of Leptomeningeal Metastases in Patients with Fusion-Positive Lung Cancers**  
*Monica Chen, USA*
- EP12.02-09 **Prevalence and Treatment of Advanced NSCLC patients with REarranged During Transfection [RET]-fusion at a South Korean Centre**  
*Shinkyoo Yoon, Republic of Korea*
- EP12.02-10 **Personalizing Care for Patients with Advanced ALK+ NSCLC through a Blended Continuing Education and Quality Improvement Initiative**  
*D. Ross Camidge, USA*
- EP12.02-11 **Sequencing Patterns and Treatment Effectiveness in ALK-positive aNSCLC Following First-Line Alectinib or Brigatinib**  
*Jessica Bauman, USA*
- EP12.02-12 **Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+ NSCLC**  
*Shun Lu, China*

**EP12.03 Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy - Other**

- EP12.03-01 **Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy**  
*Michelle Dean, Canada*
- EP12.03-02 **Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)**  
*Luna Zhan, Canada*
- EP12.03-03 **A Case of Successful Desensitization Treatment with Tepotinib after Tepotinib-Induced Rash**  
*Takahiro Baba, Japan*
- EP12.03-04 **Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib.**  
*Leonardo Rojas, Colombia*
- EP12.03-05 **How Advanced Lung Cancer Patients Receiving Immuno or Targeted Therapy Label Themselves and How Community Organizations Can Support Them**  
*Paul Wheatley-Price, Canada*
- EP12.03-06 **A Retrospective Analysis on the Lung Cancer Specimens for Multi-CDx System in Keio University Hospital**  
*Ayaka Saito, Japan*
- EP12.03-07 **A Case Report of Sustained Survival of NSCLC Treated with Combination of Cell Therapy and Immunotherapy**  
*Francisco Heralde, III, Philippines*

## POSTER SESSIONS - ELECTRONIC POSTERS

**EP13.01 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Biomarkers and Radiomics**

- EP13.01-01 **pN Stage Predicts Survival Benefits of Postoperative Radiotherapy in Combined Small Cell Lung Cancer Patients after Surgery**  
*Wei Zhang, China*
- EP13.01-02 **Patient-Specific Factors as Prognostic Biomarkers in Extensive Disease SCLC**  
*Romana Wass, Austria*
- EP13.01-03 **Does Oligometastases state exist in patients of Small Cell Lung Cancer? - A Small Retrospective Analysis from a Tertiary Cancer Centre**  
*Renu Nabariya, India*
- EP13.01-04 **Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer with an Emphasis on Oligo-Progressive Disease**  
*Hakyoun Kim, Republic of Korea*
- EP13.01-05 **Survival Characteristics in SCLC Patients Receiving Atezolizumab and Etoposide-Carboplatin**  
*Mi-Hyun Kim, Republic of Korea*
- EP13.01-06 **Prognostic impact of Neutrophil-to-Lymphocyte Ratio (NLR) For Extensive-Stage Small Cell Lung Cancer (ES-SCLC)**  
*Masashi Ishihara, Japan*
- EP13.01-07 **Immunohistochemical Classification of Patients with Small Cell Lung Cancer - A Single Center Study**  
*Chi-Lu Chiang, Taiwan*
- EP13.01-08 **Stratified Control Study Of Neuroendocrine Differentiation and Potential Clinicopathologic Markers**  
*Li Liu, China*
- EP13.01-09 **Single-Cell RNA Sequencing Reveals Immune Microenvironment of Small Cell Lung Cancer-associated Malignant Pleural Effusion**  
*Shuyan Wang, China*
- EP13.01-10 **Mitotic Counts and Phospho-Histone H3 Index in Grading Pulmonary Neuroendocrine Tumors: Assessment of Interobserver Variability and Utility**  
*Somagattu Sushmitha, India*
- EP13.01-11 **Study of NLI Use in the First Line of Atezolizumab Plus Chemotherapy**  
*Ruth Alvarez Cabellos, Spain*
- EP13.01-12 **Validation of LIPI index in SCLC**  
*Ruth Alvarez Cabellos, Spain*
- EP13.01-13 **Prognostic Nutritional Index-Based Immune Risk System for Prognosis and Immunotherapy Response Prediction in Small Cell Lung Cancer**  
*Chaoqiang Deng, China*

**EP13.02 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Case Report**

- EP13.02-01 Minimally Invasive Surgery for Endobronchial Small Cell Lung Carcinoma Following Neoadjuvant Chemotherapy  
*Konstantinos Konstantinidis, Greece*
- EP13.02-02 Dynamic Transition of Molecular Subtypes in Relapsed Small Cell Lung Cancer Treated with Multimodal Therapy  
*Kengo Yasuda, Japan*
- EP13.02-03 Entrectinib Amazing Efficacy in a Case of Lung Atypical Carcinoid with NTRK Gene Fusion  
*Hui Shi, China*

**EP13.03 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - First Line Therapy**

- EP13.03-01 Correlation of Immune-Related Adverse Events to Efficacy of PD-1/PD-L1 Inhibitors in Small Cell Lung Cancer: A Multi-center Retrospective Study  
*Yuping Sun, China*
- EP13.03-02 Improved Long-Term Survival and Less Chemotherapy in Extended-SCLC Patients: A Real-World Study in the Immunotherapy Era  
*Lorenzo Calvetti, Italy*
- EP13.03-03 RWD of Atezolizumab Plus Chemotherapy in First Line SCLC  
*Ruth Alvarez Cabellos, Spain*
- EP13.03-04 A Single Arm Phase II Study of Tislelizumab Plus Anlotinib as Maintenance Therapy in Patients with Extensive-stage Small Cell Lung Cancer  
*YK Shi, China*
- EP13.03-05 Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study  
*Fanming Kong, China*
- EP13.03-06 Small Cell Lung Cancer Immune Related Adverse Events, Survival Impacts  
*John Hunting, USA*
- EP13.03-07 Real-World Analysis of ICI Efficacy in ES-SCLC Patients with and without Brain Metastases: A Call for Inclusion in Clinical Trials  
*Yuanzhen Cao, USA*
- EP13.03-08 Developing Strategies for Delivery of Patient-Centered Care for Small Cell Lung Cancer  
*Jennifer King, USA*
- EP13.03-09 Outcomes of ES-SCLC Patients Treated with Platinum Doublet and Immunotherapy: A Western Australia Retrospective Review  
*Joann Lee, Australia*
- EP13.03-10 The Survival Analysis of Immunotherapy in a Real-Word Cohort of Women Patients with Extensive-Stage Small Cell Lung Cancer  
*Yuling He, China*
- EP13.03-11 Clinical Effectiveness of First-Line Immunotherapy in Small Cell Lung Cancer  
*Matthew Lee, USA*
- EP13.03-12 Prophylactic Cranial and Consolidation Thoracic Radiation in Extensive Stage Small Cell (ES-SCLC) Lung Cancer in the Chemo-immunotherapy Era  
*Tithi Biswas, USA*

- EP13.03-13 Clinical Response of Tislelizumab Combined with Chemotherapy in Stage IV Small Cell Lung Cancer: A Retrospective Study  
*Cheng Chen, China*
- EP13.03-14 A Comparative Analysis Between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients  
*Luca Marzano, Sweden*
- EP13.03-15 Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC  
*Chu Qian, China*

**EP13.04 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - LS-SCLC**

- EP13.04-01 Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer  
*Tae Hoon Lee, Republic of Korea*
- EP13.04-02 Characterization of Limited-Stage Small Cell Lung Cancer: Molecular Subtypes, Tumor Microenvironment and Clinical Follow-up  
*Guoping Cai, USA*
- EP13.04-03 The Impact of PCI on the Prognosis of Limited-stage SCLC Patients in the Era of MRI Surveillance  
*Xiao Hu, China*
- EP13.04-04 Preliminary Results of a Prospective Trial of Hypofractionated Radiotherapy Versus Hyperfractionated Radiotherapy for Limited-stage SCLC  
*Xiao Hu, China*
- EP13.04-05 Outcomes of Limited-Stage Extrapulmonary Small Cell Carcinoma and Small Cell Lung Cancer  
*Daniel Liem, Australia*

**EP13.05 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - NETs**

- EP13.05-01 Early ctDNA Changes and Clinical Outcomes in Extensive Stage Small Cell Lung Cancer Patients on Nivolumab and Temozolomide  
*Jinesh Gheeya, USA*
- EP13.05-02 Temozolomide-associated Hypermutation and Response to Immunotherapy in Advanced Pulmonary Neuroendocrine Tumors  
*Wieneke Buikhuisen, Netherlands*
- EP13.05-03 A Comparison of the Outcomes of Pulmonary versus Extrapulmonary Extensive Stage Small Cell Carcinoma  
*Emily Chen, Australia*
- EP13.05-04 Real-world Efficacy of PD-1/PD-L1 Inhibitors in Patients with Advanced Pulmonary Neuroendocrine Carcinoma  
*Yun Fan, China*
- EP13.05-05 Comparative Study of LCNEC and LCLC of the Lung Pathologically Diagnosed by Surgical Resection Specimens  
*Junxi Xu, China*
- EP13.05-06 Effects and Outcomes Analysis of Immunotherapy for Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma  
*Tianqing Chu, China*

**EP13.06 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Preclinical**

- EP13.06-01 Anlotinib Promotes the Phagocytosis and M1 Polarization of Macrophages through Inhibiting CD47 via NF- $\kappa$ B Pathway in SCLC  
*Haihua Yang, China*
- EP13.06-02 hSSB1 is Elevated and a Potential Target for Therapy in SCLC  
*Amila Suraweera, Australia*
- EP13.06-03 Real-World Outcomes in Patients with 3rd-Line Extensive Stage Small Cell Lung Cancer  
*Jair Bar, Israel*
- EP13.06-04 Radiotheranostics targeting Delta-Like Ligand 3 Expressing Small-Cell Lung Cancers  
*Salomon Tendler, USA*
- EP13.06-05 Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer  
*Xiaorong Dong, China*
- EP13.06-06 Exploratory Clinical Study of Anlotinib Combined with Concurrent Chemoradiotherapy in the Treatment of Small Cell Lung Cancer (SCLC)  
*Fujun Yang, China*

**EP13.07 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Relapse and Salvage Therapy**

- EP13.07-01 Understanding Real-Life Response to Lurbinectedin as Second Line Therapy in Patients with Extensive Stage Small-Cell Lung Cancer  
*Katherine Curt, USA*
- EP13.07-02 Is Concept of Continuous Immunotherapy Beyond Progression Effective in Small Cell Lung Cancer?  
*Ken Yamamoto, Japan*
- EP13.07-03 Treatment Patterns and Outcomes in Recent US Clinical Practice for SCLC Patients After Two Prior Lines of Therapy  
*Hossein Borghaei, USA*
- EP13.07-04 Immune Activation Effect of Different Irradiated Sites and Survival in ES-SCLC Patients Treated with Radioimmunotherapy: A Real-World Analysis  
*Min Wu, China*
- EP13.07-05 RYZ101 (Ac-225 DOTATATE) Opportunity Beyond GEP-NETs: Preclinical Efficacy in Small Cell Lung Cancer  
*Ye Yuan, USA*
- EP13.07-06 Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients  
*Jose Manuel Trigo, Spain*
- EP13.07-07 Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others  
*Faran Polani, USA*
- EP13.07-08 Canadian Consensus Recommendations: Use of Radiation Therapy Among Patients with ES-SCLC Receiving Immunotherapy  
*Alexander Sun, Canada*

- EP13.07-09 The Role of Radiotherapy in Extensive-Stage Small Cell Lung Cancer After Durvalumab-Based Immunochemotherapy: A Retrospective Study  
*Xiaorong Dong, China*
- EP13.07-10 A Study of Sintilimab Combined with Anlotinib and Chemotherapy as Second-Line or Later Therapy in Extensive-Disease Small Cell Lung Cancer  
*Zhejiang Wang, China*
- EP13.07-11 Efficacy and Safety of Antiangiogenic Therapy plus Immunotherapy as Later-line Treatment for Small Cell Lung Cancer  
*Yutao Liu, China*

**EP14.01 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Mesothelioma**

- EP14.01-01 Does Delaying Surgery Following Induction Chemotherapy Compromise Survival in Patients with Malignant Pleural Mesothelioma?  
*Lye-Yeng Wong, USA*
- EP14.01-02 Treatment Response in Malignant Pleural Mesothelioma Patients Can Be Predicted by Exhaled Breath Analysis  
*Kevin Lamote, Belgium*
- EP14.01-03 Cytologic Predictors and Novel Markers of Malignant Mesothelial Proliferation (Mesothelioma) in Pleural Effusion  
*Patrizia Viola, UK*
- EP14.01-04 Risk Factors Influencing Postoperative Pleural Empyema in Patients with Pleural Mesothelioma after Multimodal Therapy  
*Sven Hillinger, Switzerland*
- EP14.01-05 Neo-Adjuvant Immunotherapy in Malignant Pleural Mesothelioma: Report on Three Cases Treated in a Single Institution  
*Pierluigi Novellis, Italy*
- EP14.01-06 Multimodal Treatment in Malignant Pleural Mesothelioma: An Institutional Experience of 432 Patients over a 29 Year Period  
*Mir Alireza Hoda, Austria*
- EP14.01-07 Patients Who Undergo Surgery Survive Longer than Those Who Refuse Surgery  
*Akifumi Nakamura, Japan*
- EP14.01-08 Low Ki-67 Positive Index is a Prognostic Factor for Better Survival Outcomes of Patients treated with Intracavitary Cisplatin-Fibrin  
*Michaela Kirschner, Switzerland*
- EP14.01-09 Clinical Significance of BAP1 Expression in Malignant Mesothelioma Treated with Ipilimumab and Nivolumab  
*Sook-hee Hong, Republic of Korea*
- EP14.01-10 Feasibility of Near-Infrared Fluorescence-Guided Robotic-Assisted Minimally Invasive Esophagectomy with Indocyanine Green Dye  
*Yogita S. Patel, Canada*
- EP14.01-11 Three-port Robot-assisted Thoracoscopic Surgery for Mediastinal Tumor with "Confronting View" at Our Hospital  
*Yosuke Hamada, Japan*
- EP14.01-12 Forced Vital Capacity Is a Strong Predictor for Postoperative Survival of Patients with Malignant Pleural Mesothelioma  
*Masaya Yotsukura, Japan*

- EP14.02 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Thymic Malignancy**
- EP14.02-01 **Neoadjuvant Immune Checkpoint Inhibitor-Based Therapy Followed by Resection for Locally Advanced Thymic Malignancies**  
*Xiuxiu Hao, China*
- EP14.02-02 **Preoperative Steroid Pulse Therapy for Invasive Thymoma**  
*Janna Berg, Norway*
- EP14.02-03 **Open Versus Video-Assisted and Robotic-Assisted Thymectomy for the Treatment of Thymic Neoplasms**  
*Bright Huo, Canada*
- EP14.02-04 **Identification of Risk Factors for Postoperative Acute Exacerbation of Myasthenia Gravis after Total Thymectomy**  
*Kyohei Masai, Japan*
- EP14.02-05 **Mid-Long Term Results of 3-Port Thoracoscopic Thymectomy for Masaoka Stage I-II Thymoma without Combined Resection of Surrounding Organs**  
*Reo Ohtsuka, Japan*
- EP14.02-06 **Mixed Feelings about Mixed Thymomas**  
*Florit Marcuse, Netherlands*
- EP14.02-07 **Atypical Response to Metronomic Chemotherapy in a Patient with Advanced Thymoma**  
*Javier Baena, Spain*
- EP14.02-08 **The Significance and Risk Factors of Lymph Node metastasis in Thymic Malignancies: A Large Population-based Database Analysis**  
*Kunpang Xu, China*

- EP14.03 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Other Thoracic Malignancy**
- EP14.03-01 **Is Subxiphoid Uniportal Video-Assisted Thoracoscopic Mediastinal Surgery Safe, Minimally Invasive, and Radical?**  
*Yu Mori, Japan*
- EP14.03-02 **The Impact of Expanded Indication of Robot-Assisted Thoracic Surgery for Mediastinal Tumors**  
*Taketo Kato, Japan*
- EP14.03-03 **Pulmonary Blastoma is Successfully Treated with Immunotherapy and Targeted Therapy**  
*Yongmei Liu, China*
- EP14.03-04 **Rare but Aggressive: A Case of Primary Pulmonary Synovial Sarcoma**  
*Jennifer Duke, USA*
- EP14.03-05 **Implant Associated Squamous Cell Carcinoma: An Emerging Chest Wall Malignancy**  
*Mark Clemens, USA*
- EP14.03-06 **PULS - An International Collaboration for Collection and Assessment of Data from Patients with PUL Monary Artery Sarcoma**  
*Isabelle Opitz, Switzerland*
- EP14.03-07 **Three Cases of Mediastinal Teratoma Resulting in Thoracic Perforation**  
*Masakazu Takayama, Japan*

- EP14.03-08 **Pulmonary Metastasis of Dermatofibrosarcoma Protuberans of the Scalp: A Challenging Mesenchymal Tumor**  
*Ananda Aulia, Indonesia*
- EP14.03-09 **Expression of Fibroblast Activation Protein in Intrathoracic Solitary Fibrous Tumor**  
*Toru Kimura, Japan*
- EP14.03-10 **Ebstein-Barr Virus-Associated Pulmonary Lymphomatoid Granulomatosis with Trigeminal Nerve Involvement**  
*Ba Nguyen, USA*
- EP14.03-11 **Lung Epithelioid Hemangioendothelioma with Paraneoplastic Nail Clubbing and Hypertrophic Osteoarthropathy**  
*Ba Nguyen, USA*
- EP14.03-12 **Anastomosing Hemangioma of Mediastinum and Pleura Mimicking Chest Malignancy**  
*Ba Nguyen, USA*

- EP14.04 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Clinical**
- EP14.04-01 **BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma**  
*Caleb Smith, USA*
- EP14.04-02 **Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients (p)**  
*Susana Cedres, Spain*

- EP15.01 Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Nursing and Allied Health**
- EP15.01-01 **Can Nurses Successfully Do Patient Advocacy: Need in Resource Poor Settings**  
*S Pal, India*

- EP15.02 Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Palliative Care**
- EP15.02-01 **Improving the Lives of Patients Diagnosed with Lung Carcinoma: The Holistic Power of Palliative Care**  
*Goran Stojanovic, Serbia*
- EP15.02-02 **Starting Early Palliative Care for Lung Cancer as Soon as Possible: Lesson Learned from Resource-limited Setting in Indonesia**  
*Muhammad Ilham Rakasiwi, Indonesia*

- EP15.03 Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Supportive Care**
- EP15.03-01 Technology Based Cancer Care In Rural India, An Ngo Based Approach  
*Nabanita Mandal, India*
- EP15.03-02 Implementation of an Interdisciplinary Distress Assessment and Response Program for Family Caregivers  
*Nazanin Nouriany, Canada*
- EP15.03-03 Assessment of the Multidisciplinary Onco-thoracic Consultation Meeting of the University Hospital Center of Tangier  
*Yassine Sbaiti, Morocco*
- EP15.03-04 Unscheduled Hospitalizations in Patients with Lung Cancer as a Frailty Event  
*Javier de Castro, Spain*

- EP16.01 Track: Patient Advocacy**
- EP16.01-01 Virtual Educational Patient Meetings Empower, Unite Small Cell Lung Cancer Patients  
*Dusty Donaldson, USA*
- EP16.01-02 A Brief History of Lung Cancer in Canada: Care, Contributions and Challenges  
*Stéphanie Mercier, Canada*
- EP16.01-03 Optimizing Treatment Outcomes for L858R EGFR+ NSCLC  
*Jo Monsen, Norway*
- EP16.01-04 Standardized Screening of Thoracic Oncology Patients for Clinical Trial Eligibility Increases Enrollment  
*Daniel Gomez, USA*
- EP16.01-05 Creation of Mental Health Support Materials for People with Lung Cancer and Healthcare Providers (HCPs)  
*Shani Shilo, Israel*

- EP17.01 Track: Global Health, Health Services, and Health Economics - Digital Solutions**
- EP17.01-01 The Lung Cancer Clinical Quality Data Platform (LUCAP): Results from a Western Australia Pilot Study  
*Jessica Nash, Australia*
- EP17.01-02 Data Mining to Build Metrics. A Feasible Assessment of Quality of Care for Stage III Non-small Cell Lung Cancer (NSCLC).  
*Virginia Calvo de Juan, Spain*
- EP17.01-03 Proposing Relevant Diagnosis Associated with Lung Cancer Based on Prior Diagnosis: Implementing Apriori Algorithm  
*So Yeon Kim, Republic of Korea*
- EP17.01-04 Lung Cancer Information System: Enabling Precision Oncology through Informatics  
*Madhusmita Behera, USA*
- EP17.01-05 Lung Cancer (Internet-Based) Delphi (LuCiD): a Delphi Consensus to Develop Australasian Thoracic Oncology Quality Indicators  
*Jessica Nash, Australia*

- EP17.02 Track: Global Health, Health Services, and Health Economic - Health Care Utilization**
- EP17.02-01 Concordance on Treatment Recommendations from Multidisciplinary Tumor Boards -Data from Driver-Mutated Lung Cancer in Focus  
*Julia Roeper, Germany*

- EP17.03 Track: Global Health, Health Services, and Health Economics - Health Economics**
- EP17.03-01 Quantitative Findings from a Survey of Health Insurance in Patients Diagnosed as Advanced Lung Cancer in Japan  
*Katsuhito Kinoshita, Japan*
- EP17.03-02 Utilities Used in HTAs in mNSCLC Following Progression on or After Platinum-Based Chemotherapy  
*Cloe Ying Chee Koh, USA*
- EP17.03-03 Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer  
*Congling Gu, China*
- EP17.03-04 The Economic Evaluation of The protein-Based Lung Cancer Biomarker Panel (LCBP): Evidencebased Onamulticenter Clinicaltrialin China  
*Dawei Yang, China*

- EP17.04 Track: Global Health, Health Services, and Health Economics - Real World Data**
- EP17.04-01 The Impact of the Emergency Presentation of Patients Diagnosed with Lung Cancer on Treatment Outcomes in Wales  
*Lydia Guhaniyogi, UK*
- EP17.04-02 Global, Regional, National Burden of Lung Cancer Attributable to High Fasting Plasma Glucose  
*Minmin Wang, China*
- EP17.04-03 Lung Cancer Care in Singapore: A review of the Healthcare Registry, 2013-2020  
*Jia Li Low, Singapore*
- EP17.04-04 Survival Rate of Untreated Lung Cancer Patients at Dr. (H.C) Ir. Soekarno Hospital Bangka  
*Liyah Giovana, Indonesia*
- EP17.04-05 Research and Analysis on the Situation of Prevention and Treatment Capability of Cancer in County of China  
*Chi Du, China*
- EP17.04-06 Clinical Outcomes and Lack of Health Equity in Minority Patients with Unresectable Non-small Cell Lung Cancer (NSCLC) Treated with Durvalumab  
*Luis Raez, USA*
- EP17.04-07 Lung Stereotactic Body Radiation Therapy in a Developing Country: Patterns of Safety and Treatment Toxicities  
*Renne Augusto Bart Aguiar, Brazil*

POSTER SESSIONS - **ELECTRONIC POSTERS**

EP17.04-08 **Changing Lung Cancer Incidence Trends and Risk Patterns Among Asian Americans in Los Angeles County, California, USA**  
*Lihua Liu, USA*

**EP17.05** **Track: Global Health, Health Services, and Health Economics - Supportive Care**

EP17.05-01 **The Supportive Care Needs of Advanced Lung Cancer Patients Receiving Immuno and Targeted Therapy at Different Stages of the Disease Trajectory**  
*Paul Wheatley-Price, Canada*

**EP17.06** **Track: Global Health, Health Services, and Health Economics - COVID 19**

EP17.06-01 **COVID-19 Long-Lasting Effect on Lung Cancer Diagnoses in Italy: Update of the Real-World Multicenter COVID-DELAY Study**  
*Giulia Mentrasti, Italy*



**7** GENERAL  
INFORMATION



2023 North America  
Conference on  
Lung Cancer

DECEMBER 1-3, 2023 | CHICAGO, ILLINOIS

# Elevate Your Lung Cancer Expertise!

EARLY REGISTRATION CLOSES OCTOBER 23, 2023

#NACLC23

Register  
Now!



Discover cutting-edge education, breakthroughs, and connections at the IASLC North America Conference on Lung Cancer!

- Insightful & innovative tumor boards
- Networking with top experts
- Dynamic sessions on prevention & screening, multimodality care, and more
- Inspiring oral abstracts and posters

ELEVATE YOUR UNDERSTANDING | IGNITE COLLABORATION

Shape the future of lung cancer care at NACLC!

# MEET THE EDITOR

**JTO**  
CLINICAL AND  
RESEARCH  
REPORTS

*Now indexed in PubMed Central!*



September 11 | 2-3 PM SGT  
Room 327

**Editor-in-Chief:** Emily Stone, MBBS, PhD, FRACP,  
St. Vincent's Hospital, Sydney and School of Clinical Medicine,  
UNSW, Sydney, Australia.

Join JTO CRR Editor-in-Chief Emily Stone, MBBS, PhD, FRACP, for a Meet-the-Editor session during WCLC 2023. This session is open to all WCLC attendees.

Also plan to visit the IASLC booth in the exhibit hall to learn more about the journals, including how to become a reviewer.



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER  
*Conquering Thoracic Cancers Worldwide*



[jtocrr.org](http://jtocrr.org)



## 07 GENERAL INFORMATION

Supporters and Exhibitors

### Conference Supporters

Diamond Level



Gold Level



Silver Level



Bronze Level



## 07 GENERAL INFORMATION

Supporters and Exhibitors

### Conference Supporters

Networking Break Supporter



Presenting Supporter



Charging Station / Recharge Bar Supporters



Collaborative Meeting Space Supporter



Water Stations Supporter



IASLC 2023 Official Virtual Platform Supporter



IASLC Patient Advocacy Lounge Supporters



Faculty Networking Dinner Supporter




Activation Area Supporter



## 07 GENERAL INFORMATION

### Exhibitor Information

## Exhibit Floorplan



#### EXHIBIT HALL FEATURES:

- ✔ Recharge Bar / Charging Station
- ✔ Collaborative Meeting Lounge
- ✔ Food & Beverages
- ✔ Business Center

#### LEGEND:

- Barista Bar
- Food & Beverage

## 07 GENERAL INFORMATION

### Exhibitor Information

## Exhibitor Listings

#### Exhibitors By Name

Abbvie	A105
Act Genomics	A119
Amgen	B111
Arcus Biosciences	A109
ASCO	D159
AstraZeneca	D101
BeiGene	D125
BMS	A117
Boehringer Ingelheim International GmbH	C125
Burning Rock DX	A130
Coreline Soft	A115
Daiichi Sankyo, Inc.	B105
Erbe Singapore	D161
ESTS	Tabletop #1
Gilead Sciences, Inc	D131
Global Lung Cancer Coalition	Tabletop #2
GSK	B103
Guardant	D140
IASLC Booth	A137
IASLC Membership Lounge	A122
IASLC Patient Advocacy Lounge	A120
Janssen Asia Pacific	C113
Korean Association for Lung Cancer	Tabletop #3
MSD	C131
NGeneBio Co, Ltd	A118
Olympus	D160
Pfizer Oncology	C147
Regeneron (Commercial)	C119
Regeneron (Medical)	A101
Roche (Exhibit)	C101
Roche (Meeting)	D147
Sanofi	B101
Scanlan International	A114
Seagen	A131

#### Exhibitors By Booth Number

Regeneron (Medical)	A101
Abbvie	A105
Arcus Biosciences	A109
Scanlan International	A114
Coreline Soft	A115
BMS	A117
NGeneBio Co, Ltd	A118
Act Genomics	A119
IASLC Membership Lounge	A120
IASLC Patient Advocacy Lounge	A122
Burning Rock DX	A130
Seagen	A131
IASLC Booth	A137
Sanofi	B101
GSK	B103
Daiichi Sankyo, Inc.	B105
Amgen	B111
Roche (Exhibit)	C101
Janssen Asia Pacific	C113
Regeneron (Commercial)	C119
Boehringer Ingelheim International GmbH	C125
MSD	C131
Pfizer Oncology	C147
AstraZeneca	D101
BeiGene	D125
Gilead Sciences, Inc	D131
Guardant	D140
Roche (Meeting)	D147
ASCO	D159
Olympus	D160
Erbe Singapore	D161
ESTS	Tabletop #1
Global Lung Cancer Coalition	Tabletop #2
Korean Association for Lung Cancer	Tabletop #3

**07 GENERAL INFORMATION**

## Exhibitor Information

**BOOTH A105****abbvie****Abbvie**

Abbvie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at [www.abbvie.com](http://www.abbvie.com). Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

[www.abbvie.com](http://www.abbvie.com)

**BOOTH A119**

**Act Genomics**

ACT Genomics is an innovation-driven cancer solution provider with offices in Taipei, Hong Kong, Singapore, Tokyo, Bangkok and Wales (UK). With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team, and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we "Turn Genomics into Action".

[www.actgenomics.com](http://www.actgenomics.com)

**BOOTH B111****AMGEN****Amgen**

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies and has reached millions of patients globally.

[www.amgen.com](http://www.amgen.com)

**BOOTH A109****ARCUS  
BIOSCIENCES****Arcus Biosciences**

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. The company has six investigational medicines in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2a. For more information about its clinical and pre-clinical programs, follow us on Twitter.

[www.arcusbio.com](http://www.arcusbio.com)

**BOOTH D159**

**ASCO**

The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are multidisciplinary, global oncology organizations. Through research, education, and promotion of the highest quality, equitable patient care, members work to create a world where cancer is prevented or cured, and every survivor is healthy.

[www.asco.org](http://www.asco.org)

**BOOTH D101**

**AstraZeneca**

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company's focus is on some of the most challenging cancers. Through persistent innovation, AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

[www.astrazeneca.com](http://www.astrazeneca.com)

**BOOTH D125**

**BeiGene**

BeiGene is a global biotechnology company with a mission to ensure medicines are accessible to people facing cancer and life-threatening diseases, wherever they live. Our founding belief is that there is a better way to bring medicines to patients around the world. As a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. United by a sense of urgency and a commitment to reach far more patients around the world Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Basel, Beijing and Cambridge, Mas., yet this is just the beginning. That's why we say, "Cancer has no borders, and neither do we."

[www.beigene.com](http://www.beigene.com)

## BOOTH C125



## Boehringer Ingelheim International GmbH

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

[pro.boehringer-ingelheim.com/inoncology](http://pro.boehringer-ingelheim.com/inoncology)

## BOOTH A117



## Bristol Myers Squibb

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients' lives through science.

[www.bms.com](http://www.bms.com)

## BOOTH A130



## Burning Rock Dx

Burning Rock Dx (NASDAQ: BNR) is committed to providing NGS-based testing for cancer patients, biomarker detection and companion diagnostic development services to pharmaceutical partners, and NGS-based multi-cancer early detection testing. We focus on providing tumor genomic data solutions, clinical trial solutions, integrated CDx development, and precision patient recruitment for pharmaceutical companies, thereby efficiently facilitating the entire process of anti-cancer drug development.

[us.brbiotech.com](http://us.brbiotech.com)

## BOOTH A115



## Coreline Soft

Coreline Soft is a leading AI solution company specializing in CT image analysis. Our flagship product, aview, offers a range of innovative solutions for lung cancer screening and other pulmonary diseases. With global recognition and partnerships with prestigious medical institutions, Coreline is revolutionizing the field of CT imaging, empowering medical professionals, and enhancing early detection of cancer worldwide.

[www.corelinesoft.com](http://www.corelinesoft.com)

## BOOTH B105



## Daiichi Sankyo, Inc.

With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

[www.daiichisankyo.com](http://www.daiichisankyo.com)

## BOOTH D161



## Erbe

As a family-owned and operated business, Erbe develops, manufactures and markets surgical systems for professional use in various medical disciplines all over the world. Erbe technology leads the market in many countries and is therefore an inherent part of the working processes in the OR. The products are thus helping to provide the best possible treatment for patients. The portfolio comprises devices and instruments for electrosurgery, thermofusion, plasmasurgery, cryosurgery and hydrosurgery. By combining these technologies, innovative applications become possible, particularly in general surgery, gastroenterology, gynecology, pulmonology and urology. Erbe employs more than 1000 people worldwide, over 650 of them in Germany. Approx. 170 employees work in research and development. The intensive collaboration with renowned users from medical schools and hospitals is the key to success with which Erbe successfully furthers developments in medicine.

[de.erbe-med.com](http://de.erbe-med.com)

## TABLETOP #1



## ESTS

ESTS is the largest international general thoracic surgery organisation with more than 1650 members from all continents. The Society's mission is to improve quality in the specialty, from clinical and surgical management of patients to education, training and credentialing of thoracic surgeons worldwide. The 32nd European Conference on General Thoracic Surgery will be held 26-28 May 2024, Barcelona, Spain.

## BOOTH B131



## Gilead Sciences, Inc

Gilead and Kite Oncology are creating the future of oncology. From ADCs and small molecules to cell therapy, our R&D programs and partnerships are focused on helping to bring more life to people with cancer and changing the way cancer is treated.

[www.gilead.com](http://www.gilead.com)

## TABLETOP #2

## Global Lung Cancer Coalition



The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

[www.lungcancercoalition.org](http://www.lungcancercoalition.org)

## BOOTH B103

## GSK



GSK is committed to maximising patient survival through transformational medicines. GSK's oncology pipeline is focused on immuno-oncology, tumour cell targeting therapies and synthetic lethality.

Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, and antibody-drug conjugates, either alone or in combination.

[www.gsk.com](http://www.gsk.com)

## BOOTH D140

## Guardant Health



Guardant Health AMEA is a wholly owned subsidiary of Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for patients with advanced-stage cancer, and Guardant Reveal™ for patients with early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. Follow us on LinkedIn, Twitter and Facebook.

[www.guardanthealthamea.com](http://www.guardanthealthamea.com)

## BOOTH C113



## Janssen Asia Pacific

At Janssen Oncology, we have a bold vision – the elimination of cancer. This is what drives us to push the boundaries of science to help patients live cancer-free for longer than ever before. On the back of 30 years of innovation in oncology<sup>1</sup>, our first-in-class therapies in solid tumors and hematological malignancies have extended lives and established new standards of care. Yet we continue to pursue every avenue to suppress, destroy and ultimately eliminate cancer – seeking not just incremental, but monumental change as we concentrate on where we can make the biggest difference. It is this focus on the needs of patients and their families that has propelled us to be among the top 5 and fastest growing oncology companies globally<sup>1</sup>, with no less than ten transformational therapies approved in the last decade. We focus on making hope and possibility a reality. Harnessing cutting-edge research platforms for personalized medicines, we continue to pursue the most compelling science to give an increasing number of people more time to live well, live longer and live cancer-free. At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism and Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Janssen Asia Pacific, a division of Johnson and Johnson International (Singapore) is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

[www.janssen.com](http://www.janssen.com)

## TABLETOP #3



## Korean Association for Lung Cancer

The Korean Association for Lung Cancer (KALC) has been based in Korea since 2000, and we are currently working to promote collaborative research and multidisciplinary approaches to cure lung cancer and identify and support creative and innovative lung cancer research. Furthermore, we establish guidelines and propose policies for lung cancer prevention, diagnosis, and treatment, and provide evidence-based information about lung cancer for our members and the general public. In accordance with our working statements, we organize the KALC International Conference annually in which we endeavor to share the latest advances in research, together with our developing theories on lung cancer. The conference format involves up-to-the-minute lectures and presentations followed by in-depth discussions between lecturers and attendees. We believe this conference will provide an optimal experience for all participants to learn, share, and discuss the very latest information obtained from their research. (\* KALC 2023: Nov. 30 - Dec. 1, 2023, Seoul, Korea)

[www.kalcic.or.kr](http://www.kalcic.or.kr)

## BOOTH C131



## MSD

At MSD, our goal is to translate breakthrough science into innovative oncology medicines. As part of our focus on cancer, MSD is committed to clinical research with one of the largest development programs in the industry.

[www.msd.com](http://www.msd.com)

## BOOTH A118

## NGeneBio



NGeneBio Co., Ltd. provides precision diagnostic solution that combines diagnostics and big data technology.

NGS cancer panel received 26 Patents and has a worldwide sales network in over 20 countries. NGeneBio is a leading global provider in the precision diagnostic industry.

[www.ngenebio.com](http://www.ngenebio.com)

## BOOTH D160

## Olympus



At Olympus, we focus on improving patient care quality. We do this through developing and designing world-leading, clinically advanced, precision technologies and services. We care about achieving the best results in lung cancer diagnosis, and our passion has translated into our portfolio of minimally invasive lung cancer solutions to help tackle this devastating disease today and in the future.

[www.olympus.com.sg](http://www.olympus.com.sg)

## BOOTH C147

## Pfizer Oncology



At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

[www.pfizer.com](http://www.pfizer.com)

## BOOTH C119 (COMMERCIAL) | BOOTH A101 (MEDICAL)

## Regeneron



Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.

[www.regeneron.com](http://www.regeneron.com)

## BOOTH C101 &amp; D147

## Roche



Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

**Roche in Oncology:** Our mission has been to turn science into breakthroughs to deliver better outcomes for everyone facing a cancer diagnosis. Today, we're studying treatments for a wide array of cancers, with nearly 150 ongoing clinical trials and 22 breakthrough therapy designations in oncology. Our research is backed by our investment of over 13B CHF in R&D, more than any other healthcare company in the world. We are committed to personalising cancer care for all patients and continue to focus on developing innovative medicines across various types of haematologic malignancies and solid tumours. We are leveraging multiple treatment approaches, including targeted therapies, cancer immunotherapies, cell and gene therapies, and next generation vaccines, and bringing innovation into earlier stages of disease to maximise a chance of cure.

[www.roche.com](http://www.roche.com)

## BOOTH B101

## Sanofi



We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi's Specialty Care business is committed to meeting significant unmet medical needs. In oncology, we are building on a rich legacy with a strong pipeline and a continued commitment to contribute meaningful solutions for patients with cancer. Through rigorous drug discovery and development rooted in cutting-edge science and innovative technologies, we are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

[www.sanofi.com](http://www.sanofi.com)

BOOTH A114



Scanlan International

Celebrating Over 100 Years and Our Journey Continues! Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Proudly crafting Scanlan® LEGACY Needle Holders and Forceps; featuring our new revolutionary Scan- II™ handle design. Full line Scanlan® VATS instruments including D'Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps and Khan Decortication Grasper.

[www.scanlaninternational.com](http://www.scanlaninternational.com)

BOOTH A131



Seagen

Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors.

[www.seagen.com](http://www.seagen.com)



2023 North America  
Conference on  
Lung Cancer

DECEMBER 1-3, 2023 | CHICAGO, ILLINOIS

# SUBMIT YOUR ABSTRACTS

Abstract  
Submission  
Deadline:  
October 3, 2023



## #NACLC23

Showcase your research and contribute to discussions that will shape the future of treatments in lung cancer and thoracic malignancies.

**07 GENERAL INFORMATION**

Industry Sponsored Symposia

**Saturday, September 9, 2023****10:45 - 11:45** **IS01: Industry Sponsored Symposium by Abbvie: The Expanding Role of Precision Medicine with Antibody Drug Conjugates in NSCLC****ROOM: 405C, LEVEL 4** Refreshments Provided

Chair: Ross Camidge, USA

- 10:45** **Introduction and Opening Remarks**  
Ross Camidge, USA
- 10:50** **Current NSCLC Treatment Landscape and Expanding Treatment Options with Antibody Drug Conjugates**  
David Planchard, France
- 11:00** **Getting to Know ADCs: Differentiating Composition and Mechanisms of Action**  
David Planchard, France
- 11:10** **Latest Evidence and Ongoing Trials of ADCs**  
David Planchard, France
- 11:20** **c-Met Overexpression a Novel Target in NSCLC**  
Umberto Malapelle, Italy
- 11:30** **Integrating ADCs with Novel Biomarkers into Clinical Practice: Practicalities, Challenges, and Future Directions**  
Umberto Malapelle, Italy
- 11:40** **Discussion/Questions**

**13:15 - 14:15** **IS05: Industry Sponsored Symposium by Sanofi: Hitting the Mark: Emerging Biomarkers in Advanced NSCLC****ROOM: 405C, LEVEL 4** Refreshments Provided

Chair: Benjamin Besse, France

- 13:15** **Welcome and Overview of the Current Treatment Landscape in Advanced NSCLC: Where Are We Headed?**  
Benjamin Besse, France
- 13:20** **The Role of Emerging Biomarkers in Advanced NSCLC**  
Mari Mino-Kenudson, USA
- 13:40** **Clinical Developments with ADCs in Advanced NSCLC**  
Benjamin Besse, France
- 14:00** **Group Discussion**

**14:30 - 15:30** **IS07: Industry Sponsored Symposium by Janssen: Academy for Cancer Education (ACE) Asia Pacific Lung Cancer Symposium: Emerging Strategies in EGFR Driver Mutation-based Management of Advanced Non-small Cell Lung Cancer (NSCLC)****ROOM: 405B, LEVEL 4**

Chair: Caicun Zhou, China

- 14:30** **Welcome and Introductions**  
Caicun Zhou, China
- 14:35** **Where the Road May Lead in the Management of Patients with EGFR Exon 20 Insertion Mutations**  
Darren Lim, Singapore
- 14:50** **The Way Forward in Managing Common EGFR Mutations**  
Hiroaki Akamatsu, Japan
- 15:10** **One for the Road: Panel Discussion and Best Practice Sharing**
- 15:25** **Meeting Close**  
Caicun Zhou, China

**14:30 - 15:30** **IS08: Industry Sponsored Symposium by Boehringer Ingelheim: Past, Present, and Future of Personalized Care in Lung Cancer: HER2 and DLL3 Targeted Therapies in Focus****ROOM: 405A, LEVEL 4**

Chair: Byoung Chul Cho, Republic of Korea

- 14:30** **Welcome and Introduction of Speakers**  
Byoung Chul Cho, Republic of Korea
- 14:32** **The Past: A Brief History of Personalized Therapy in Lung Cancer**  
Herbert Loong, Hong Kong
- 14:47** **Improving the Present: Selective HER2 TKI in NSCLC**  
Byoung Chul Cho, Republic of Korea
- 15:02** **Advancing Towards the Future: Targeting DLL3 in SCLC**  
Yasushi Goto, Japan
- 15:25** **Panel Discussion and Audience Q&A**
- 15:30** **Key Take-aways and Closing Remarks**



## Industry Sponsored Symposia - SATURDAY, SEPTEMBER 9

**15:45 - 16:45** IS10: Industry Sponsored Symposium by Pfizer: Maximising the Potential in ALK+ NSCLC: Enhancing Outcomes and Improving Patient Care

**ROOM: 405C, LEVEL 4**

 Refreshments Provided

Chair: Tony Mok, Hong Kong

**15:45** Welcome and Introduction

Tony Mok, Hong Kong

**15:50** Updates in the 1L ALK+ NSCLC Treatment Landscape

Tony Mok, Hong Kong

**16:08** Contemporary Strategies Beyond 1L ALK TKIs

Yi-Long Wu, China

**16:21** Managing Adverse Events in ALK+ NSCLC

Narjust Florez (Duma), USA

**16:36** Future Directions in ALK+ NSCLC Care

Tony Mok, Hong Kong



**2023 HOT TOPIC IN BASIC & TRANSLATIONAL SCIENCE:  
RESISTANCE TO IO IN NSCLC**

**NOVEMBER 10-12, 2023 | BRUSSELS, BELGIUM**

# REGISTER NOW!

Chairs:



Joachim Aerts, MD, PhD  
Netherlands



Roberto Ferrara, MD  
Italy



Kellie Smith, PhD  
United States

The clinical application of the immune checkpoint inhibitors (ICIs) that target PD-1, PD-L1, and CTLA-4 have shown significant and durable survival increases for a subset of patients with advanced NSCLC. However, the challenge in the usage of ICIs in lung cancer remains in understanding the biology of resistance, including predictive biomarkers beyond PD-L1 expression and the factors controlling either de novo or acquired resistance. Join us to discuss and present new and emerging data on immunoresistance in NSCLC!

In-person registration for IO 2023 is limited - don't miss your opportunity to attend this exceptional meeting!

[www.IASLC.org/IO23](http://www.IASLC.org/IO23) | #IO23

Scan the QR code to Register Today!



**SATELLITE CME SYMPOSIUM**

**12:00 - 13:00** IS03: Satellite CME Symposium by PVI, PeerView Institute for Medical Education, Supported by Gilead: A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment with TROP2-Targeting ADCs and Rational Combinations

**ROOM: 405A, LEVEL 4**

Refreshments Provided

ACCME Accredited by Other Provider

Chair: Stephen Liu, USA

- 12:00** Welcome and Introduction  
*Stephen Liu, USA*
- 12:05** MasterClass 1: Comprehending the Fundamental Concepts of ADCs and TROP2 in Lung Cancer  
*All*
- 12:20** MasterClass 2: Unleashing the Potential of TROP2-Targeting ADCs and Rational Combinations  
*All*
- 12:35** Practicum: Integrating TROP2-Targeting ADCs Into the Treatment Landscape of Lung Cancer  
*All*
- 12:50** Summary and Audience Q&A

**SATELLITE CME SYMPOSIUM**

**15:45 - 16:45** IS09: Satellite CME Symposium by Medscape Oncology Global, Supported by Lilly: Unlocking the Power of Genomic Testing in NSCLC: Implementing Personalized Therapy to Impact Outcomes

**ROOM: 406, LEVEL 4**

Refreshments Provided

ACCME Accredited by Other Provider

Chair: James Chih-Hsin Yang, Taiwan

- 15:45** Welcome and Introduction of Speakers  
*James Chih-Hsin Yang, Taiwan*
- 15:50** Genomic Testing in NSCLC: Tailoring the Appropriate Testing Methodology to Treatment Goal  
*Fernando Lopez-Rios, Spain*
- 16:05** Optimizing Integration of Molecular Testing in the Clinics: Applying the Guidelines  
*Justin Gainor, USA*
- 16:20** Personalizing Therapy in NSCLC With a Rare Molecular Alteration: Clinical Cases
- 16:40** Q&A Session and Concluding Remarks

# LUNG CANCER CONSIDERED



IS AVAILABLE IN MANY LANGUAGES!

ESPAÑOL FRANÇAIS

ΕΛΛΗΝΙΚΑ العربية تىربى

DEUTSCH NEDERLANDS

MAGYAR 普通话 日本語

한국인 ITALIANO POLSKI

Join us in listening to our award winning content on your favorite app.



Find new podcast episodes here.



Lung Cancer Considered is funded in part by:  
AstraZeneca, Daiichi-Sankyo, Genentech, and Takeda



## Sunday, September 10, 2023

### Industry Sponsored Symposia

**13:45 - 14:45** **IS12: Industry Sponsored Symposium by AstraZeneca: The Road Ahead: Navigating Developments in Resectable NSCLC**

**ROOM: 405B, LEVEL 4**

 Refreshments Provided

Chair: Roy Herbst, USA

- 13:45** **Welcome and Introduction**  
*Roy Herbst, USA*
- 13:48** **Optimising Outcomes in Resectable NSCLC for Patients with Actionable Mutations**  
*Roy Herbst, USA*
- 14:01** **Exploring IO Treatment Options in Patients with Resectable NSCLC Without Actionable Mutations**  
*David Harpole, USA*
- 14:14** **Neoadjuvant, Adjuvant, or Perioperative? That is the Question!**  
*Jarushka Naidoo, Ireland*
- 14:27** **Expert Panel Discussion and Q&A**

**13:45 - 14:45** **IS13: Industry Sponsored Symposium by Amgen: Transforming Care for Patients with Advanced Lung Cancer**

**ROOM: 405C, LEVEL 4**

 Refreshments Provided

Chair: Ferdinandos Skoulidis, USA

- 13:45** **Novel Targets in Lung Cancer: What Does the Future Hold?**  
*Ferdinandos Skoulidis, USA*
- 13:50** **Current and Future Directions of KRASG12C Inhibitors in Advanced NSCLC**  
*Alessandra Curioni-Fontecedro, Switzerland*
- 14:10** **Re-shaping SCLC Treatment in the Immune-Oncology Era**  
*Taofeek Owonikoko, USA*
- 14:30** **Panel Discussion and Q&A**
- 14:40** **Summary and Close**  
*Ferdinandos Skoulidis, USA*

**18:30 - 19:30** **IS14: Industry Sponsored Symposium by MSD: Reaching New Heights: Building on the Foundation of Immuno-Oncology**

**ROOM: 405B, LEVEL 4**

 Refreshments Provided

Chair: Marina Garassino, USA

- 18:30** **Welcome - Audience Poll Question Practice**  
*Marina Garassino, USA*
- 18:35** **Paradigm Shifts in Early Stage NSCLC Treatment**  
*Marina Garassino, USA*
- 18:55** **Raising the Bar in 1L NSCLC - What's Coming?**  
*Alfredo Addeo, Switzerland*
- 19:10** **Moving the Needle in Mesothelioma**  
*Corey Langer, USA*
- 19:25** **Summary and Close**  
*Marina Garassino, USA*

**18:30 - 19:30** **IS15: Industry Sponsored Symposium by Novocure: A Spotlight on Tumor Treating Fields in Thoracic Oncology**

**ROOM: 405C, LEVEL 4**

 Refreshments Provided

Chair: Sanjay Popat, UK

- 18:30** **Welcome and Introduction**  
*Sanjay Popat, UK*
- 18:35** **From MoA to Clinical Efficacy with TTFIELDS Therapy**  
*Rachel Grossman, Israel*
- 18:50** **Building Evidence for TTFIELDS Therapy in Thoracic Oncology**  
*Joachim Aerts, Netherlands*
- 19:10** **Discussion and Q&A**
- 19:25** **Close**  
*Sanjay Popat, UK*

# Sunday, September 10, 2023

Satellite CME Symposia

## SATELLITE CME SYMPOSIUM

**13:45 - 14:45** IS11: Satellite CME Symposium by PeerVoice, Supported by Daiichi Sankyo, Inc.: Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?

**ROOM: 406, LEVEL 4**

Refreshments Provided

ACCME Accredited by Other Provider

Chair: *Wong Seng Weng, Singapore*

**13:45** **Welcome and Introduction**  
*Wong Seng Weng, Singapore*

**13:48** **What Now? Assessing Current Approaches to Managing Progressive EGFR-Mutant NSCLC**  
*Wong Seng Weng, Singapore*

**14:03** **What Next? Future Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy**  
*Pasi A. Jänne, USA*

**14:18** **What Can We Do Today vs Tomorrow? Optimizing Patient Outcomes Following TKI and Chemotherapy**  
*Solange Peters, Switzerland*

**14:33** **“Ask the Faculty” and Take-Home Messages**

## SATELLITE CME SYMPOSIUM

**18:30 - 19:30** IS16: Satellite CME Symposium by AGILE, Supported by Merck KGaA: MET Inhibition in Metastatic NSCLC “In the Spotlight”

**ROOM: 406, LEVEL 4**

Refreshments Provided

ACCME Accredited by Other Provider

Chair: *Paul Paik, USA*

**18:30** **Welcome and Introduction**  
*Paul Paik, USA*

**18:33** **Have You MET Gene Aberrations in NSCLC?**  
*Keith Kerr, UK*

**18:38** **Panel Discussion and Q&A**

**18:46** **Have You MET the New Molecular-Driven Therapies in NSCLC?**  
*Paul Paik, USA*

**18:56** **Panel Discussion and Q&A**

**19:04** **Have You MET NSCLC in Clinical Practice?**  
*Ross Camidge, USA*

**19:14** **Panel Discussion and Q&A**

**19:22** **Our Message Worth Sharing: Key Takeaways**  
*Paul Paik & Ross Camidge, USA*

**19:28** **Closing Remarks**  
*Paul Paik, USA*

# Join the IASLC Today!



Scan the QR code & enter

**WCLCNewMember2023**

to receive half off membership dues for one year.



INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

Staging



Patient Advocacy



Publication

Podcasts

Networking



Scientific Expertise



ILCN



IASLC Meeting Discounts

Research & Education

Grant Opportunities



Memberships

IASLC Journals

Committees



## Monday, September 11, 2023

### Industry Sponsored Symposia

**13:15 - 14:15** **IS17: Industry Sponsored Symposium by Daiichi Sankyo, Inc.: ADCs in Lung Cancer: Where We Are and Where We Are Going**

**ROOM: 406, LEVEL 4**

 Refreshments Provided

Chair: Sandip Patel, USA

- 13:15** **Introduction**  
Sandip Patel, USA
- 13:20** **ADCs in the Advanced NSCLC Treatment Landscape**  
Sandip Patel, USA
- 13:45** **Implications of Emerging Data for SCLC**  
Myung-Ju Ahn, Republic of Korea
- 14:00** **Panel Discussion and Q&A**

**13:15 - 14:15** **IS18: Industry Sponsored Symposium by AstraZeneca: Tailoring Treatment in Metastatic NSCLC: Advances in Targeted Therapy and Post-progression Treatment Options**

**ROOM: 405B, LEVEL 4**

 Refreshments Provided

Chair: Ross Soo, Singapore

- 13:15** **Welcome and Introductions**  
Ross Soo, Singapore
- 13:18** **Overview of the Current Patient Journey and Treatment Paradigm for Metastatic NSCLC**  
Ross Soo, Singapore
- 13:23** **Emerging First-line Treatment Strategies for Patients with EGFRm NSCLC**  
Chee Lee, Australia
- 13:38** **Panel Discussion and Q&A**  
All
- 13:48** **Post-progression Treatment Options in Patients with Metastatic NSCLC**  
Julia Rotow, USA
- 14:03** **Panel Discussion and Q&A**
- 14:13** **Summary and Close**  
Ross Soo, Singapore

**13:15 - 14:15** **IS19: Industry Sponsored Symposium by Regeneron and Sanofi: The Path to Optimizing Immunotherapy in Advanced NSCLC**

**ROOM: 405C, LEVEL 4**

 Refreshments Provided

Chair: Daniel Tan, Singapore

- 13:15** **Introduction**  
Daniel Tan, Singapore
- 13:20** **Navigating the Treatment Pathway: Harnessing Biomarkers to Guide Therapeutic Decisions**  
Daniel Tan, Singapore
- 13:30** **At a Cross-roads: Monotherapy Versus Combination Therapy Treatment Considerations**  
Natasha Leighl, Canada
- 13:50** **The Way Forward: Remaining Unmet Needs and Future Directions in Advanced NSCLC**  
Ticiana Leal, USA
- 14:05** **Discussion and Close**

**19:00 - 20:00** **IS20: Industry Sponsored Symposium by GSK: Tackling Unmet Needs for Patients With NSCLC: Latest Scientific Advances & Investigational Approaches**

**ROOM: 405B, LEVEL 4**

 Refreshments Provided

Chair: Koichi Goto, Japan

- 19:00** **Introduction**  
Koichi Goto, Japan
- 19:05** **Unmet Need in Advanced NSCLC and the Requirement for New Combinations**  
Koichi Goto, Japan
- 19:20** **Novel Checkpoint Combinations for Advanced NSCLC**  
Ben Solomon, Australia
- 19:35** **Looking Beyond Checkpoints for NSCLC Brain Metastases**  
Lizza Hendriks, Netherlands
- 19:50** **Panel Discussion and Q&A**

**19:00 - 20:00** **IS22: Industry Sponsored Symposium by Daiichi Sankyo, Inc.: Taking Aim at HER2-Driven NSCLC**

**ROOM: 406, LEVEL 4**

 Refreshments Provided

Chair: Stephanie Saw, Singapore

- 19:00** **Welcome and Introduction**  
Stephanie Saw, Singapore
- 19:05** **Understanding the Role of HER2-alterations in NSCLC**  
Yasushi Yatabe, Japan
- 19:15** **Targeting Treatments for Patients with HER2-mutant Tumours**  
Hossein Borghaei, USA
- 19:40** **Future Outlook and Possibilities in HER2-mutant NSCLC**  
Stephanie Saw, Singapore
- 19:45** **Panel Discussion and Q&A**
- 19:55** **Wrap-up and Close**  
Stephanie Saw, Singapore

## Monday, September 11, 2023

Satellite CME Symposia

### SATELLITE CME SYMPOSIUM

**19:00 - 20:00** IS21: Satellite CME Symposium by Med Learning Group, Supported by Regeneron Pharmaceuticals: Applying Multidisciplinary Expertise and Heterogeneous Skills in Clinical Practice: Transforming Non-Small Cell Lung Cancer Treatment with Immunotherapy

**ROOM: 405C, LEVEL 4** Refreshments Provided ACCME Accredited by Other Provider

Chair: David Carbone, USA

**19:00 Introduction**

David Carbone, USA

**19:05 Clinical Practice Guidelines - Immunotherapy in Advanced NSCLC**

David Carbone, USA

**19:15 Evolving Immunotherapy Agents - Transforming Lung Cancer Care**

David Planchard, France

**19:30 The Relevance of Biomarkers in NSCLC**

David Carbone, USA

**19:40 Immunotherapy Related Adverse Events - NSCLC**

David Planchard, France

**19:50 Case-Based Discussion**

All

**19:55 Conclusions and Q&A**

All

## Tuesday, September 12, 2023

Satellite CME Symposia

### SATELLITE CME SYMPOSIUM

**13:15 - 14:15** IS23: Satellite CME Symposium by PVI, PeerView Institute for Medical Education, Supported by Daiichi Sankyo, Inc.: Taking Aim With the Next Wave of Antibody-Drug Conjugates in NSCLC: Rational Strategies for Addressing the Unmet Needs of Diverse Patient Populations With TROP2- and HER3-Targeting Therapies and Other ADC-Based Regimens

**ROOM: 406, LEVEL 4** Refreshments Provided ACCME Accredited by Other Provider

Chair: Melissa Johnson, USA

**13:15 Introduction: Recognizing Current Gaps and Opportunities for Improvement With Novel ADCs in Lung Cancer**

Melissa Johnson, USA

**13:20 Getting to Know ADCs as the Next Frontier in Precision Lung Cancer Care: Foundational Concepts**

All

**13:30 Focus on ADCs Targeting HER3, TROP2, and Others in Lung Cancer: Latest Evidence and Ongoing Trials**

All

**13:50 How to Leverage Research on ADCs Targeting HER3, TROP2, and Others to Accelerate Progress in the Clinic: Practicalities, Challenges, and Future Directions**

All

**14:05 Audience Q&A, Reflections, and Conclusions**

All

# WEBINARS



Webinars are an important part of IASLC's offerings—providing education and insight to those in the thoracic cancer community.

Attendees represent

multiple specialties, and geographical regions, and are IASLC members, patients, and non-members. Our webinars address topics of interest, professional practice gaps, and provide competency-based learning.



Scan the QR Code to Learn More.



# MICROLEARNING

We are thrilled to introduce the Microlearning Insights Series—a fresh and exciting approach to education tailored to modern learners' needs. We at IASLC firmly believe that short-form education can be highly effective in keeping up with the rapid changes in knowledge. As a testament to this, we are thrilled to introduce our Insights Conference coverage, which aims to spread key topic points from sessions and abstracts discussed in various meetings across the globe. We're confident that this new method of learning will be a game-changer for many eager learners out there!

**NEW!**  
Microlearning  
Insights  
Series

**07 GENERAL INFORMATION**

## Opening Hours and Other Conference Information

**REGISTRATION | DELEGATE HELP DESK | VIRTUAL PLATFORM HELP DESK**

📍 Level 3 Concourse

<b>Friday, September 8</b>	15:00 – 19:00	<b>Monday, September 11</b>	07:00 – 17:00
<b>Saturday, September 9</b>	07:00 – 20:30	<b>Tuesday, September 12</b>	07:00 – 14:00
<b>Sunday, September 10</b>	07:00 – 16:30		

**SPEAKER READY ROOM & LOUNGE**

📍 320, Level 3

<b>Friday, September 8</b>	15:00 – 19:00
<b>Saturday, September 9</b>	07:00 – 20:30
<b>Sunday, September 10</b>	07:00 – 16:30
<b>Monday, September 11</b>	07:00 – 17:00
<b>Tuesday, September 12</b>	07:00 – 15:45

**PRESS & MEDIA WORK ROOM**

📍 328, Level 3

<b>Saturday, September 9</b>	08:00 – 18:00
<b>Sunday, September 10</b>	08:00 – 18:00
<b>Monday, September 11</b>	08:00 – 18:00
<b>Tuesday, September 12</b>	08:00 – 16:00

**PRESS CONFERENCE SCHEDULE**

📍 327, Level 3

<b>Saturday, September 9</b>	13:00 – 14:00
<b>Sunday, September 10</b>	10:35 – 11:30
<b>Monday, September 11</b>	10:05 – 11:00
<b>Tuesday, September 12</b>	10:05 – 11:00

**WELCOME RECEPTION**

📍 Exhibit Hall, 401 – 403, Level 4

<b>Saturday, September 9</b>	20:00 – 21:30
------------------------------	---------------

**POSTER VIEWING RECEPTIONS**

📍 Exhibit Hall, 401 – 403, Level 4

<b>P1 Sunday, September 10</b>	17:30 – 19:30
<b>P2 Monday, September 11</b>	18:00 – 20:00

**EXHIBIT HALL**

📍 401 – 403, Level 4

<b>Saturday, September 9</b>	20:00 – 21:30
<b>Sunday, September 10</b>	10:15 – 19:30
<b>Monday, September 11</b>	09:45 – 20:00
<b>Tuesday, September 12</b>	09:45 – 14:15

**POSTER DISPLAY**

<b>P1 Sunday, September 10</b>	10:00 – 19:30
<b>P2 Monday, September 11</b>	10:00 – 20:00

**POSTER PRESENTERS IN ATTENDANCE**

<b>P1 Sunday, September 10</b>	17:30 – 19:30
<b>P2 Monday, September 11</b>	18:00 – 20:00

**NETWORKING BREAKS** 🍷 Refreshments Provided

📍 Exhibit Hall, 401 – 403, Level 4

<b>Sunday, September 10</b>	10:30 – 11:15
<b>Monday, September 11</b>	10:00 – 10:45
<b>Tuesday, September 12</b>	10:00 – 10:45

**NETWORKING LUNCHES** 🍽️ Lunch Provided

📍 Exhibit Hall, 401 – 403, Level 4

<b>Sunday, September 10</b>	13:45 – 14:45
<b>Monday, September 11</b>	13:15 – 14:15
<b>Tuesday, September 12</b>	13:15 – 14:15

**IASLC AWARD CEREMONY**

📍 405B, Level 4

<b>Saturday, September 9</b>	17:00 – 18:00
------------------------------	---------------

**IASLC BOARD OFFICE HOURS**📍 Exhibit Hall, 401 – 403, Level 4  
Collaborative Meeting Lounge

<b>Sunday, September 10</b>	10:40 – 11:10
<b>Monday, September 11</b>	10:10 – 10:40

**IASLC BUSINESS MEETING**

📍 Nicoll 1, Level 3

<b>Tuesday, September 12</b>	10:00 – 10:45
------------------------------	---------------

**PRESENTER RESOURCES**Please visit [wclc2023.iaslc.org/presenter-resources/](http://wclc2023.iaslc.org/presenter-resources/) for more information on presenter resources.**MEDIA POLICIES**Please visit [wclc2023.iaslc.org/press-media/](http://wclc2023.iaslc.org/press-media/) for more information on press and media policies.**CONTINUING MEDICAL EDUCATION (CME) AND CERTIFICATE OF ATTENDANCE**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates the “other activity” (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 91.00 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Visit [wclc2023.iaslc.org/cme-information/](http://wclc2023.iaslc.org/cme-information/) for more information on how to obtain CME credits and your Certificate of Attendance.

**NURSING / PRAYER ROOM**

IASLC is offering delegates the use of a private nursing room and the use of a multifaith prayer area.

**NURSING ROOM:**

Level 3, Next to Room 323

**PRAYER ROOM:**

Level 3, Across from Room 307

**EMERGENCY SERVICES AND FIRST AID**

Dial 999 for Police or 995 for Fire & Ambulance. In case of fire at the Suntec Singapore Convention & Exhibition Centre, use the stairs and NOT the elevator for exit. Please follow the Suntec Singapore Convention & Exhibition Centre instructions in case of emergency.



## 07 GENERAL INFORMATION

### Virtual Platform

#### VIRTUAL PLATFORM FAQ

Check out our Virtual Platform FAQ for more information and useful tips! Walkthrough videos are available for desktop and mobile device access.



**Virtual Platform Guide:**

<https://wclc2023.iaslc.org/wclc-2023-virtual-meeting-guide/>

**Virtual Platform Link:**

<https://meetingsapp.iaslc.org/event/wclc2023>

#### Virtual Platform Features:


- Full Scientific Schedule
- Abstract Book, Program Book
- Venue and Exhibit Floor Plan
- Presentation Slides and Recordings (Within 24 Hours)
- ePosters (Online View During the Conference) and Downloadable PDFs for all Traditional Posters and ePosters after the Conference
- Opportunity to Create Personalized Calendar
- Networking Features to Connect with Delegates and Faculty
- Notification Alerts



#### DOWNLOAD THE FREE OFFICIAL WCLC 2023 VIRTUAL PLATFORM

The Virtual Platform offers a convenient way to stay up-to-date on the latest Conference information. The platform is available for desktop and mobile devices. All sessions will be audio recorded and made available along with the presentation slides on the Virtual Platform within 24 hours after the session. Abstracts as well as all posters will also be accessible via this Virtual Platform after the Conference.

Log-in details were sent to your registered email. If you need assistance, you can visit the Virtual Platform Help Desk in the registration area or send an email to: [wclc2023-registration@icsevents.com](mailto:wclc2023-registration@icsevents.com).



INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER



# A M A Z I N G C A S E R A C E

Academy mentors work closely with their mentees for a full 9 months leading up to the annual WCLC meeting! During this time, they connect monthly to discuss research projects and hold lectures on professional development topics. This helps mentees grow in their careers and gain valuable insights from experienced professionals in their field.




**The Race is On!  
Vote Now!**

## 07 GENERAL INFORMATION

Venue Floorplans


### Suntec, Singapore - Level 3



## 07 GENERAL INFORMATION

Venue Floorplans

### Suntec, Singapore - Level 4





# 2024 Latin America Conference on Lung Cancer

NOVEMBER 14-16, 2024 | BOGOTÁ, COLOMBIA

# SAVE THE DATE

During LALCA 2024, benefit from wide-ranging and multidisciplinary content including keynote lectures, roundtable discussions, cancer control program and tobacco forums, oral abstract, and poster presentations. You will learn, share knowledge, and network with delegates from across Latin America and the rest of the world including prominent researchers and physicians.



# #LALCA24

When testing reveals a patient with an **NTRK** gene fusion, long response is possible!

## LASTING VICTORY WITH VITRAKVI®<sup>1</sup>

**ONLY VITRAKVI** has demonstrated a median duration of response lasting nearly **3 years** in TRK fusion-positive solid tumors\*

MEDIAN DURATION OF RESPONSE <sup>1</sup>	OVERALL RESPONSE RATE <sup>1</sup>
<b>34.5 MONTH mDOR</b>	<b>72% ORR</b> (95% CI: 65%, 79%)

**STUDY DESIGN**  
Pooled efficacy analysis based on 3 multicenter, open-label, single-arm clinical studies in adult and pediatric patients with TRK fusion cancer.<sup>1</sup>



**IN AN EXPANDED DATA SET OF NTRK GENE FUSION-POSITIVE LUNG CANCER PATIENTS (IRC ASSESSED, N=26)<sup>2</sup>**

**REMARKABLE RESPONSES PROVEN TO LAST IN PATIENTS WITH NSCLC, INCLUDING THOSE WITH BASELINE CNS METASTASES<sup>2</sup>**

- **72% DOR RATE AT 24 MONTHS** IN PATIENTS WITH NSCLC<sup>2</sup>
- **83% ORR** IN PATIENTS WITH NSCLC<sup>2</sup>

Expanded data set included 12 patients with known CNS metastases at baseline (as of July 2021).<sup>2</sup>

**A well-established safety profile that enables long-term treatment in adult patients (N=248)<sup>1</sup>**

- Majority of adverse reactions were Grades 1 and 2<sup>1</sup>
- Low rate (2%) of discontinuation due to treatment-emergent adverse reactions<sup>1</sup>

[VITRAKVI.COM](http://VITRAKVI.COM) TO LEARN MORE

This information has been reviewed according to and is consistent with Singapore Prescribing Information (see Abbreviated Prescribing Information below) and is intended for HCPs only. Prescribing Information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the Prescribing Information and/or the SmPC.

### ABBREVIATED PRESCRIBING INFORMATION

**VITRAKVI® (larotrectinib) 25 mg, 100 mg capsules and 20 mg/ml oral solution.** Indication Vitrakvi is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. **Dosage and administration** Confirm the presence of an NTRK gene fusion in a tumor specimen prior to initiation of treatment with Vitrakvi. Vitrakvi is available as a capsule or oral solution formulation with equivalent oral bioavailability, and may be used interchangeably. The recommended dose of Vitrakvi in adults is 100 mg taken orally, twice daily until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. In pediatric patients (1 month to 18 years) recommended dose is 100 mg/m<sup>2</sup> taken orally, twice daily with a maximum of 100 mg per dose until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. **Contraindications** There is no contraindication to the use of Vitrakvi. **Special warnings and precautions for use** **Neurologic reactions:** neurologic reactions including dizziness, gait disturbance and paresthesia were reported in patients receiving larotrectinib. For the majority of neurologic reactions, onset occurred within the first three months of treatment. Caution patients about driving and using machines, until they are reasonably certain Vitrakvi therapy does not affect them adversely. Withholding, reducing or discontinuing Vitrakvi dosing should be considered, depending on the severity and persistence of these symptoms. **Transaminase elevations:** ALT and AST increase were reported in patients receiving larotrectinib. The majority of ALT and AST increases occurred in the first 3 months of treatment. Monitor liver function before the first dose and monthly for the first 3 months of treatment, then periodically during treatment, with more frequent testing in patients who develop transaminase elevations. Withholding, reducing or discontinuing Vitrakvi dosing should be considered, depending on the severity and persistence of the transaminase elevation. **Interaction with other medicinal products** Avoid co-administration of strong CYP3A4 inhibitors with Vitrakvi (e.g. clarithromycin, grapefruit, grapefruit juice, itraconazole, ketoconazole, voriconazole). If co-administration of a strong CYP3A4 inhibitor cannot be avoided, reduce Vitrakvi dose by 50%. Avoid co-administration of strong CYP3A4 inducers with Vitrakvi (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital and St John's Wort). If co-administration of a strong CYP3A4 inducer cannot be avoided, double the Vitrakvi dose. See PI for full details. **Undesirable effects** The most common adverse drug reactions (≥20%) of Vitrakvi in order of decreasing frequency were fatigue (32%), increased ALT (31%), dizziness (30%), increased AST (29%), constipation (29%), nausea (26%), anaemia (24%) and vomiting (20%). The majority of adverse reactions were Grade 1 or 2. For a full listing of undesirable effects, please refer to the full product insert. **For full prescribing information, please contact:** Bayer (South East Asia) Pte. Ltd. 2, Tanjong Katong Road #07-01, Paya Lebar Quarter 3, Singapore 437161. **Date of revision text:** 5 November 2020.

\*Excluding primary CNS tumours.  
CNS, central nervous system; HCP, healthcare provider; IRC, independent review committee; mDOR, median duration of response; NSCLC, non-small cell lung cancer; NTRK, neurotrophic tyrosine receptor kinase; ORR, overall response rate; SmPC, summary of product characteristics; TRK, tropomyosin receptor kinase.  
References: 1. VITRAKVI [summary of product characteristics], Leverkusen, Germany: Bayer AG; 2022. 2. Dillon A, Lin D, Kummer S, et al. Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. Poster presented at: Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2022; Chicago, IL. Poster 9024.



© 2023 Bayer. All rights reserved. Bayer, the Bayer Cross, and VITRAKVI are registered trademarks of Bayer.  
BP-VIT-ALL-0611- 04/2023  
PP-VIT-SG-0063-1 05/2023





# CREATING HOPE THROUGH INNOVATION

At Eisai, everything we do is guided by a simple principle: patients and their families come first. We spend time with them. We listen and we learn about their lives, their desires and their greatest needs. *We call this human health care or hhc*, giving first thoughts to patients and their families and helping increase the benefits health care provides.

*Our hhc mission* is what drives us to discover innovative solutions and therapies that help address unmet needs within the communities that we seek to serve.



TO LEARN MORE, PLEASE VISIT [WWW.EISAI.COM/US](http://WWW.EISAI.COM/US)

CORP-US2790 ©2023 Eisai Inc. All rights reserved. September 2023



READ HERE

Find WCLC News at [ILCN.org](http://ILCN.org)

Stay informed on all things IASLC at [ILCN.org](http://ILCN.org) – the official news source of the only global association dedicated to the multidisciplinary study of lung cancer.



# FREE WIFI

**GET CONNECTED!**  
We are delighted to offer FREE WIFI for all WCLC 2023 delegates!

NETWORK: [WCLC23\\_FREE\\_WiFi@SuntecSingapore](http://WCLC23_FREE_WiFi@SuntecSingapore)



# Save the Date



2024 World Conference  
on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

# SEE YOU IN SAN DIEGO!

Join us to celebrate the IASLC's  
50th Anniversary at WCLC 2024

[wclc2024.iaslc.org](http://wclc2024.iaslc.org)

